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This work describes investigations into novel fluorescent nanohybrids based on carbon nanomaterials 
for the optical imaging of prostate cancer cells. The synthesis and characterisation of the different 
components of the nanoprobes are described within each chapter. The cellular response of as-prepared 
fluorophores, peptide conjugate and nanoprobes was evaluated in PC-3 cells by optical microscopy 
techniques for the first time. The new fluorescent conjugate synthesised showed targeted behaviour 
towards prostate cancer cells and the functional hybrids showed promising characteristics as synthetic 
scaffolds for future imaging nanomaterials.  
 
Chapter 1 describes the context of this work, including different imaging modalities applied to the 
diagnosis, staging and follow-up of prostate cancer. The use of bombesin as a targeting peptide for 
prostate cancer, and its incorporation in different imaging probes from current state-of the-art is 
discussed. The use of specific imaging probes as thiosemicarbazonato-based species is described, due 
to their current importance in tumour hypoxia detection and multimodality imaging potential. Finally, 
the use of single walled carbon nanotubes as biomedical scaffolds with a special interest in imaging 
applications is reviewed. 
 
Chapter 2 describes synthetic approaches towards novel functional unsymmetrical thiosemicarbazonato 
metal complexes. The synthesis of functional novel thiosemicarbazides and the formation of the 
thiosemicarbazone ligands is reported hereby. Several aromatic dicarbonylic starting materials (other 
than the known acenaphthenequinone) were explored and a panel of new zinc thiosemicarbazonato 
complexes were obtained and characterised spectroscopically. 
 
Chapter 3 contains the synthesis of bifunctional BODIPY derivatives which incorporate a protected 
amino acid residue. The synthetic approach towards new derivatives with fluorescence emission in the 
near-infrared region of the spectra is also reported. 
 
Chapter 4 describes the methodology towards the incorporation of the new carbon nanomaterial 
scaffold. The functionalisation of pristine single walled carbon nanotubes and graphene oxide to 
incorporate linkers in the structure, and the characterisation of the functionalised materials, are given 
hereby.  
 
Chapter 5 contains the synthesis and purification of the targeting peptide and the BODIPY-peptide 
conjugate involved as key components for the novel nanohybrids. Other nanohybrids containing the 
BODIPY or gallium thiosemicarbazonato species are also reported. The behaviour of these compounds 
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in living PC-3 cells was evaluated and the cytotoxicity of a selection of compounds determined, for the 
first time. 
 
Chapter 6 provides a summary of the work carried out during this thesis and some proposals for future 
work arising from the research findings described herein. 
 
Chapter 7 contains detailed experimental details and characterisation data for the compounds described. 
 
The Appendices provide supporting spectroscopic evidence and X-ray diffraction data for the new 
compounds synthesised.
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Chapter 1 : Introduction 
1.1 Overview of molecular imaging techniques applied to prostate cancer 
1.1.1 General considerations of prostate cancer diagnosis 
Prostate cancer (PCa) is the most common type of cancer diagnosed in men, second to lung cancer with 
more than 47,000 new cases in the UK last year, accounting for 13% of all cases.1 The numbers in other 
industrialised countries are similar to the aforementioned with PCa representing 15% of all cancers 
globally although in the US and the EU the percentage increases to 26% and 22% respectively with 
prostate cancer being the second cancer diagnosed among men.2-4 It has been highlighted that ca. 70% 
of the cases of prostate cancer cases worldwide are diagnosed in more developed regions.3 The number 
of cases have significantly increased since the 1990s mainly due to prostate specific antigen (PSA) 
screenings to the population. Considering age groups, prostate cancer is strongly age-dependent with 
more than 50% of the cases diagnosed in men of 70 or over.1 Despite the improvement in diagnosis 
techniques and treatment, prostate cancer still is one of the leading causes of mortality in cancer. This 
disease accounts for 13% of the deaths, being the second cause of death among men and the third overall 
in the UK with more than 10,000 cases per year.1 The death rate predicted in the US is comparable and 
it will be in second place after lung cancer with 9% of all cancer cases.4 
The prostate is a complex organ with glandular and non-glandular parts surrounding the urethra and 
located between the bladder and the pelvic diaphragm and anterior to the rectum (Figure 1.1).5 The 
prostate is generally described to be the size of a walnut but its size can increase with age due to benign 
prostatic hyperplasia (BPH).6 The prostate physiological function is to generate an alkaline fluid 
containing ions (calcium, citrate, phosphate) and a clotting enzyme, among other constituents, that are 
part of semen. The prostatic fluid accounts for 30% of the composition of the semen. It is hypothesised 
that the basic pH of the prostatic fluid has an important role in obtaining the optimal conditions for the 
mobility of sperm.7 
 
Figure 1.1: Representation of the male urogenital system. Figure reproduced from ref. 5 with 
permission from the publisher. 




The denomination of prostate cancer generally refers to prostate adenocarcinoma while other types of 
cancers as sarcomas, small cell carcinomas, neuroendocrine tumours or transitional cell carcinomas are 
rare.8-10 In addition, most cases of PCa are multifocal diseases, meaning that multicentric lesions are 
present in the prostate. Furthermore, the different carcinomas can have different grades and be 
genetically different adding complexity to the identification and treatment of the disease.9, 11 
 
The most common diagnostic methods for prostate cancer are all invasive (i.e. digital rectal examination 
(DRE), trans-rectal ultrasound (TRU), PSA blood tests and needle biopsy). The former can reveal an 
enlargement of the prostate gland and the presence of abnormalities in the prostate anatomy, and patients 
with other conditions as BPH or prostatitis can lead to false positive results. Meanwhile, the use of TRU 
has been relegated to guidance during needle biopsies as the probability of finding the tumour just with 
ultrasound is low.10 After a biopsy of the prostate is conducted, the aggressiveness of a prostate tumour 
may be classified depending on the arrangement of the cells in the prostatic tissue according to the 
Gleason system. This contemplates grades from 1 to 5. In grade 1, the tumorous cells are small, 
distinguishable and with minimal changes while in grade 5, the tumour tissue is composed of planes of 
non-differentiated cells (Figure 1.2). As mentioned above, prostate tumours can be heterogeneous so in 
order to take into account the different zones of the tumour, the grades of the two most representative 
zones are added constituting the Gleason score. The probability of progression of the tumour increases 




Figure 1.2: Representation of the arrangement of cells in a prostate tumour with the Gleason score 
(left) and actual tumour samples (right). Figure reproduced from ref. 12 with permission from the 
publisher. 
 




The routine diagnostic tool for PCa in the last two decades has been the PSA test. The prostate-specific 
antigen is a protein synthesised in healthy prostate, zones with BPH and prostate cancer. It is believed 
to have a role in the viscosity of the semen liquefying specific gel proteins. It is present in the semen in 
concentrations up to 3 ng/mL and in healthy subjects the concentration in blood is negligible. The 
presence of prostate cancer produces an increase in the level of PSA in blood which is the basis of its 
use as a diagnostic tool. Therapeutic measures are generally adopted when a total PSA value of 
4.0 ng/mL in blood is detected although the concentration of PSA tends to increase with age and due to 
other conditions as BPH or prostatitis.13 Despite its wide application, there is a strong controversy on 
massive PSA screening of the men population due to the risk of overdiagnosis. The number of men 
overdiagnosed and overtreated because of early PSA screening has been calculated to be as high as 
40-50% in population where the test was performed.14, 15 The statistics show that the mortality in men 
aged 65 or over is generally not caused due to the presence of localised prostate cancer.16 Men diagnosed 
with PCa who undergo treatment are under risk of suffering serious side effects when the disease could 
not have shown symptoms for years.17 Based on these findings, European and American health agencies 
recommend against the massive screening of the population or the application of the test below the age 
of 60.18, 19  
These results have stimulated the research in novel biomarkers to diagnose and target prostate cancers 
early and in a non-invasive way. 
 
1.1.2 Imaging methods of relevance for prostate cancer diagnosis 
Despite the increase of diagnosed prostate cancer cases there has been a significant decrease in the use 
of imaging techniques with diagnostic purposes.20 The adequacy of the use of imaging is under debate 
in the clinical world as early diagnosed cancers have only a low risk to become metastatic hence imaging 
would be redundant. On the other hand, it has been observed that imaging tests have been underused or 
misused according to health agency guidelines.21-24 Therefore, imaging techniques are being applied to 
patients with more advanced diseases. Thanks to other tests and early diagnosis, imaging techniques can 
be applied to other relevant aspects as a preoperative tool to guide the surgery, localising metastases, 
helping plan, deliver and verify radiation treatments, detail staging or following-up after treatment. New 
imaging methods are also shifting to find out the aggressiveness of the cancer which can be determined 
nowadays only histologically after a biopsy.25  
 
Transrectal ultrasound is based on the emission of sound waves that produce different echoes or 
reflections when crossing different tissues. The detection of tumours is achieved because tumorous areas 
are generally anechoic or hypoechoic with relationship to the surrounding tissue.26 Transrectal 
ultrasound was widely used in the past as the first method of choice to image the prostate because it 
could detect abnormal zones that could not be identified by DRE with a high level of accuracy. However, 




as early diagnostic tests progressed, that accuracy decreased dramatically in asymptomatic cases since 
TRU fails to see the smallest tumours that can be present in the early stages of the disease and other 
conditions can lead to false positives.27 This technique is still widely used as it can provide relevant 
information to measure the volume of the prostate and relate it to PSA levels and also to guide transrectal 
needle biopsies. 
 
X-ray computed tomography (CT) is an imaging technique where X-rays are used to image the subject 
with detectors moving at different angles. The images can be visualised as 2D slices or reconstructed to 
generate a three-dimensional image.28 CT can be used with high spatial and temporal resolution at a 
relatively low cost and it is quantifiable so it can be employed to correct other imaging techniques as 
PET. CT is optimal for bone scanning due to the different contrast between the bones and the 
surrounding tissues. However, it has low sensitivity and a reduced soft-tissue contrast so the use of 
contrast agents becomes a condition to image soft tissue.29 For this reason, CT has limited applicability 
to the diagnosis or staging of prostate cancer and its use is only recommended in patients in the advanced 
stage of the disease.25 Due to the advantages of the technique it could be utilised to detect bone 
metastases although other techniques as bone scanning or magnetic resonance imaging (MRI) have 




Figure 1.3: Example of the use of MRSI for the diagnosis of PCa. A) T2-weighted image of a patient 
with PCa. Normal tissue is marked by the red circle on the left while tumorous tissue corresponds to 
the red circle on the right. B) Spectrum corresponding to normal tissue. C) Spectrum corresponding to 
PCa tissue. D) Slice of the prostate indicating the tumorous tissue. E) Stained sample of normal tissue 
and F) tumorous tissue. Figure reproduced from ref. 37 with permission from the publisher. 




MRI is characterised by a great spatial resolution but low specificity.32 The basis of the technique in 
imaging is equivalent to its application in spectroscopy, consisting in the measurement of the relaxation 
of active nuclei after a radiofrequency pulse in a strong magnetic field, but constructing a three-
dimensional image. This is achieved by the application of magnetic field gradients in the three 
dimensions of space.33 MRI modalities are often classified depending on the relaxation mechanism as 
T1- and T2- weighted imaging. T1 refers to the spin-lattice relaxation that accounts for the relaxation of 
the nuclei by interactions with the environment surrounding the nuclei while T2 refers to the spin-spin 
relaxation which is based on the redistribution of energy among the nuclei in a spin system.33  
 
MRI has not been generally used as a screening tool due to the high costs and low specificity as 
mentioned above.32 Its use in determining the stage of prostate cancer has been studied in more detail 
and technological improvements as the introduction of endorectal MRI probes have been proposed.34, 35 
However, there is still no total agreement about the general applicability of the technique to the screening 
or staging of prostate cancer.35 T2-weighted imaging is generally used in prostate cancer as it can provide 
an excellent resolution when observing the prostate anatomy and where the tumours appear dark.27 
Recently, the application of magnetic resonance spectroscopy (MRS) along with the imaging 
experiments has been explored as a way to identify key metabolites (e.g. citrate, creatine, choline) and 
their concentration to improve the specificity of MRI (Figure 1.3).36, 37 The resonance of citrate at 
2.6 ppm is known to be reduced in PCa while the resonance of choline at 3.2 ppm increases. The ratio 
of choline to citrate constitutes a promising indicator for the presence of prostate cancer tumorous tissue.  
 
 
Figure 1.4: Basic principle of PET imaging and structure of two of the most used radionuclides 
([18F]FDG and [18F]DOPA). An emitted positron during the radionuclide decay is annihilated with an 












Furthermore, contrast agents have also been evaluated to improve the imaging quality of the prostate in 
MRI. Compounds of gadolinium(III) have generally been used in the acquisition of magnetic resonance 
images as T1 contrast agents due to its high magnetic moment generated by its unpaired electrons. The 
research interest in T2 contrast agents is focused in compounds as superparamagnetic iron oxide 
nanoparticles (SPION) or other iron particles.38 Much interest has been attracted by targeted derivatives 
and the application of peptides in this role and they will be discussed in detail in the following section. 
 
Differently, the generation of images by PET is achieved by the detection of a couple of gamma rays 
emitted in opposite directions. The gamma rays are generated by the annihilation of a positron (emitted 
by a radionuclide) and an electron of the surrounding tissue (Figure 1.4). A circular detector measures 
the pair of gamma rays at different positions and angles, allowing to construct a three-dimensional 
image.39  
 
Some of the most common radionuclides used in PET imaging are shown in Table 1.1. Carbon-11, 
nitrogen-13 or oxygen-15 offer the possibility to perform isotopic substitutions in biological metabolites 
hence not altering their structure, biological functions or pharmacokinetics.40 Their short lifetimes, 
however, increase the difficulty towards their application as any synthetic steps must be kept to a 
minimum, nevertheless 11C has been applied to the imaging to the identification of bone metastases as 
11C-acetate or tumours as 11C-choline.41 Fluorine-18 is the radionuclide routinely utilised by substitution 
of hydrogen atoms in biological compounds as in the case of 2-[18F]-fluoro-deoxy-D-glucose ([18F]-
FDG) to study glucose metabolism or 6-[18F]-fluoro-3,4-dihydroxyphenylalanine ([18F]-6-Fluoro-L-
DOPA) to study cerebral dopamine metabolism.42 The comparatively long life-time of fluorine-18 
allows longer synthetic procedures to be performed and the transport from the production site to the 
clinical centre which favours the use of [18F]-FDG, performed routinely in most imaging centres.43 
 
Table 1.1: Properties of selected positron-emitting radionuclides.44 
Nuclide Half-life (min) 
Max. energy 
(MeV) 
Mode of decay 
Max. positron 
range (mm) 
18F 110 0.64 β+ (97%), EC (3%) 2.1 
11C 20.3 0.97 β+ (99%) - 
13N 10 1.20 β+ (100%) - 
15O 2 1.74 β+ (100%) - 
76Br 972 4.0 β+ (57%), EC (43%) - 
124I 60192 2.14 β+ (25%), EC (75%) - 
68Ga 68.1 1.90 β+ (89%), EC (11%) 8.4 
64Cu 762 0.655 β+ (41%), EC (3%) 2.2 
89Zr 4704 0.90 β+ (23%), EC (%) 3.4 




However, the incorporation of 18F into biomolecules still presents a challenge due to its short lifetime in 
the timescale of a chemical synthesis. For this reason, late stage fluorination is attracting much research 
interest.45 In addition, the production of [18F] is still carried out in a cyclotron, a facility that is not readily 
available in all hospitals and research facilities. The use of [18F]-FDG in the imaging of prostate cancer 
has demonstrated little applicability as it has little sensitivity for tumour detection, it cannot distinguish 
prostate tumours from BPH and it gives a strong signal in the bladder when excreted.25, 35, 46  
 
For this reason, the research into the chemistry and biomedical applications of radiometals have attracted 
much attention in recent years. The use of radiometals like [64Cu] or [89Zr], although produced equally 
in a synchrotron, offers a prolonged lifetime compared to fluorine-18 which permits for an easier 
handling and allows the study slower metabolic processes in detail. The use of [68Ga] presents an 
additional advantage that is the production in a generator from the decay of [68Ge] facilitating the use of 
the radionuclide in research and clinical environments. The functionalisation of biomolecules with 
highly selective chelators for Ga(III) has also paved the way to targeted imaging where the radiolabelling 
is generally an efficient final step.47 The use of macrocyclic compounds (DOTA, NOTA) in nuclear 
imaging as chelators for 64Cu or 68Ga has been widely applied.48 However, new species with a higher 
selectivity have been proposed for 64Cu as cyclam derivatives or sarcophagine compounds as well as for 
68Ga as TRAP and NOPO.49 The structures of common chelators can be observed in Figure 1.5. 
 
 
Figure 1.5: Structural representations of common chelators used with 64Cu and 68Ga. Figure adapted 
from ref. 49. 




PET imaging agents including PCa targeting groups are being developed. The prostate-specific 
membrane antigen (PSMA) is a membrane protein found in a higher concentration in PCa tumours, 
especially in advanced stage and metastatic.50 The compounds to target PSMA are specific antibodies, 
ureas and phosphoramidates that can be radiolabelled with a range of nuclei as 64Cu, 89Zr or 68Ga.46, 51 
The gastrin-releasing peptide receptor is another well studied target of prostate cancer. Several examples 




Figure 1.6: Use of a multimodal PET-optical multimodal probe to perform pre-operative imaging and 
assisted surgery. Figure reproduced from ref. 54 with permission from the publisher. 
 
The use of various techniques in multimodality imaging aspires to combine their characteristics to obtain 
the advantages of the combined methods. The interest in multimodal probes with an optical component 
has increased in the recent past as a way to enhance the functionality of an imaging probe and reduce 
the number of tests for the patient. PET/CT and SPECT/CT are being applied together routinely in the 
clinic as a result of the development of scanners incorporating both imaging detector systems.52 More 
recent has been the application of MRI/PET, as a consistent way to get high spatial resolution and 
sensitivity, or MRI/optical combined  for the preoperative assessment and surgery guidance.52 
PET/optical probes allow for imaging in vitro, in vivo and ex vivo of the disease.29, 53 
 
Ideally, a multimodal probe would allow to reveal the regions where the tumour is present in a 
preliminary imaging stage and help the surgeon during the surgery to delimitate the tumour removing 
all affected tissue differentiating it effectively from the healthy tissue (Figure 1.6).54 For this reason, the 
research into probes combining nuclear imaging techniques or MRI with optical techniques is receiving 
increasing attention.53 




The structure of PET/optical probes must contain specific groups for the two modalities. This implies 
the presence of a radioisotope, a chelator group and a fluorophore emitting in the visible or NIR. In a 
few cases, such as acenaphthenequinone bis(thiosemicarbazonato) complexes or BODIPYs, both groups 




Figure 1.7: Structural representations of some commonly used NIR dyes: cyanine compounds (top), 
BODIPY compounds (middle) and squaraine derivatives (bottom) and their general photophysical 
properties. 
 
The application of red and near infrared (NIR) fluorescent dyes in multimodal probes attracts special 
interest due to the advantageous characteristics of this region of the electromagnetic spectrum for 
bioimaging. NIR radiation has deeper penetration abilities in the tissue. Moreover, in the 700 – 1000 nm 
window, the autofluorescence of the tissue is reduced and the absorption of the light, produced because 
of haemoblobin, deoxyhaemoglobin and water, is not that intense.58 The observation of tumours with 
fluorescence imaging agents has been described, especially with NIR dyes.59 Furthermore, the use of 
fluorescence or multimodal imaging agents during surgery has been applied to localise and remove 
lymph nodes suspicious of containing metastatic tissue.60, 61 
 
The structures of commonly used NIR dyes in cancer imaging is depicted in Figure 1.7.   




1.2 Bombesin as a targeting biomolecule for prostate cancer 
The G protein-coupled receptors are a large family of surface protein receptors that convert extracellular 
stimuli into intracellular responses. G protein coupled-receptors share a common structure formed by a 
heptahelical transmembrane unit with three intracellular and three extracellular domains.62 Recently, 
GPCR have attracted increasing attention as pharmacological targets due to their involvement in a 
number of diseases, especially cancer growth, angiogenesis and metastasis being many of them 
overexpressed in tumorous cells.63-65  
 
Bombesin is part of a family of neuropeptides that are agonists of the gastrin releasing peptide receptors 
(GRPR). Bombesin is a tetradecapeptide found in the skin of two frogs of the Alytidae or Discoglossidae 
family (Figure 1.8).66 Its mammalian equivalent, that was isolated from porcine tissue, is the 27 amino 
acids gastrin releasing peptide (GRP).67 Since the identification of bombesin in the 1970s, it arose much 
interest within the scientific community as early studies demonstrated its activity in tissues of smooth 




Figure 1.8: Structural representation of bombesin. 
 
Early activity studies demonstrated that the minimum length of the peptide chain showing biological 
response in tissue corresponded to the heptapeptide from the C-terminal. Furthermore, the tryptophan 
and histidine residues proved to be essential to maintain the activity.68-70  
 
The presence of differentiated receptors for bombesin-like peptides was reported by von Schrenk in 
1989. In this pioneering work, the presence of at least two receptors was established by comparing the 
binding affinities of bombesin/GRP and Neuromedin B in rat oesophagus tissue.71 Later, it was found 
that bombesin/GRP and Neuromedin B presented specific receptors. The receptors for bombesin/GRP 
peptides were cloned and characterised in Swiss 3T3 rodent cells.72,73,74 The same group also 
characterised the Neuromedin B receptor shortly after.75 An additional receptor that did not show great 
affinity for GRP or Neuromedin B was also identified.76,77  




All bombesin-like receptors form part of this group of G protein-coupled receptors and the nomenclature 
varies depending on the source but it can be summarised for the three receptors found in mammals as 
follows, BB1 or Neuromedin B receptor, BB2 bombesin receptor or GRPR and BB3 or orphan 
receptor.78 Bombesin binds with similar affinity to BB1 and BB2 while the affinity of Neuromedin B 
for the BB2 receptor is significantly lower (2 orders of magnitude difference in the nM range).71 Both 
bombesin and Neuromedin B bind with low affinity to BB3. All three are heptahelical transmembrane 
GPCR in the 40-60 kDa range. BB1 and BB2 share 55% of the amino acids in the peptide sequence79 
whereas BB3 shares approximately 50% with the first two.76 Despite the presence of BB1 and BB2 
receptors in many tissues, the ability of bombesin/GRP to bind to both with comparable affinities made 
difficult the differentiation. For this reason, the expression, structure, role in disease and binding 
considerations will be commented for the specific bombesin receptor BB2 or GRPR. The GRP receptor 
in humans is a 384 amino acids protein with a heptahelical transmembrane GPCR structure.79 The 
calculated molecular weight for human GRPR is ca. 60 kDa when the protein is glycosylated.80,81 A 





Figure 1.9: Amino acid sequence of the mice transmembrane gastrin releasing peptide receptor. Key 
amino acids for signalling are represented in black circles. Figure reproduced from ref. 78 with 
permission from the publisher. 
 
The presence of GRPR was widely detected by binding studies over the brain, digestive tract, colon and 
urogenital smooth muscle.82-84 Moreover, the GRP and GRPR have a variety of functions in the 
urological system.67 The numerous expression and roles in healthy tissue of both in the male urogenital 
system are summarised in Figure 1.10. Interestingly, the presence of GRP in the prostate is very limited 
and GRP receptors has been identified but their function is not known.84, 85 







Figure 1.10: Normal functions and presence of GRP and GRPR in the male urological system. Figure 
reproduced from ref. 85 with permission from the publisher. 
 
Besides the numerous physiological functions of bombesin-like peptides and BB2 receptors, their 
presence and overexpression in neoplastic tissues has strongly stimulated the interest in their use as 
targets for theranostics. The research in the roles of GRP and GRPR in cancer cells has evolved along 
with the understanding of the receptor and their agonists. The first examples go back to 1985 where 
bombesin-like peptides were identified to act as autocrine growth factors in small-cell lung cancer (i.e. 
the cell produces the peptide that is secreted and has a function in autoproliferation).86 This hypothesis 
has been extended to other diseases as squamous cell carcinoma of head and neck, neuroblastomas or 
renal cancers.84, 85, 87, 88 In addition, GRP receptors have been found to be overexpressed in a big 
percentage of breast, lung, renal and colorectal cancers and to a lower extent in gastric and pancreatic 
cancers.84, 85 The overexpression of GRPR in prostate neoplastic tissues is significant and has been 
largely demonstrated in the literature by binding assays, polymerase chain reaction (PCR) or 
immunohistochemistry.89-91 The percentage of cases varies with the source and technique applied but it 
always comprehends a significant value. Using PCR expression of the mRNA associated to GRP 
receptors, 63% of prostate carcinomas were found to express the receptor.92 The expression of GRP 
receptors in normal tissue or benign prostatic hyperplasia showed weak or no staining in 90% of the 
cases by immunohistochemistry.90 The expression of GRP receptors at the cellular level was studied by 
real-time reverse transcription PCR in different human cell lines including prostate cancer (LNCap, 
PC-3, 22rv1), human embryonic kidney (HEK), cervical cancer (HeLa), BPH, glioma (SNB19, U373) 
or human osteosarcoma cells (U2OS). 
 




The results showed that the expression was noticeably higher in prostate cancer cell lines (i.e. LNCaP 
(lymph node carcinoma of the prostate) and PC-3 cells) than in any other of the cell lines tested 
(Figure 1.11). The expression on a third PCa cell line (22rv1) was considerably lower. The difference 
between the first two PCa cell lines and the last is that 22rv1 is androgen-dependent so the authors 





Figure 1.11: Relative GRPR expression of different cell lines measured by real-time transcriptase 
chain reaction in different cell lines. Figure reproduced from ref. 94 with permission from the 
publisher. 
 
Additionally, GRP receptors were also overexpressed in advanced stages of prostate cancer as metastatic 
tissue or castration resistant tumours.94, 95 As a result of the latter studies, the detection of the presence 
of this receptor as an indicator of the progression of the disease has been proposed85, 94 showing a good 
correlation with other diagnostic markers as the Gleason score but inconclusive with PSA levels.89 All 
the above characteristics in neoplastic tissues, especially in prostate cancer, converts GRPR and their 
agonists and antagonists as ideal candidates for the diagnostic imaging and potential treatment of these 
diseases. Bombesin constitutes an optimal agonist for GRPR as it is formed by an accessible sequence 
and the affinity for the receptors is maintained when shorter versions of the peptide are used. The [6-14] 
fragment has been extensively radiolabelled with 125I Tyr as the imaging agent that helped to unveil the 
biochemical nature of bombesin-like receptors by binding studies or immuno-radiochemistry in different 
tissues.96, 97 Equally, the [7-14] fragment has been profusely applied to the preparation of drugs and 
imaging agents.98 Other fragments, like the des-Met [7-13] still maintain the biological activity towards 
GRP receptors and have been used as well in the study of anticancer drugs and imaging probes.99, 100 
 
Over the years, a number of examples and radioisotopes have been applied to clinical imaging using 
bombesin-like peptides as targeting agents. All imaging agents can be classified by their modality, 
namely radiolabelled analogues, fluorescent analogues, or multimodal analogues (Table 1.2). 




The use of bombesin or its fragments for imaging has been extensively studied in the literature, focusing 
especially in the preparation of radioimaging probes for PET or SPECT.101 A selection of examples of 
functionalised bombesin peptides for imaging reported in the literature over the past decade are 
discussed below. During the early study of bombesin effects and specifity in vivo, the preferred 
radiolabelled analogue was 125I-TyrBBN. However, iodinated versions of bombesin presented the 
disadvantage of being rapidly decomposed liberating radiotyrosine and defying the selective diagnostic 
purpose depending on the timescale of the imaging experiment.99, 102 Therefore, other radioisotopes have 
been studied and radioanalogues of bombesin obtained (vide infra) although 125I-TyrBBN remained as 
gold standard to evaluate the binding of novel imaging probes.  
 
Table 1.2: Imaging agents including diverse bombesin fragments classified by imaging modality. 
 
Entry Analogue Peptide sequence Radioisotope / dye Linker Ref. 
PET 
1 RP527 Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 99mTc Gly-5ava 103 
2 Pesin Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 69/67/68Ga, 177Lu PEG 104 
3 ATSM-BBN Gln-Trp-Ala-Val-Gly-His-Cha-NLe-NH2 64/67Cu Asp-(Ala)2 105 
OPTICAL 
4 Alexa Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 Alexa fluor 680 (Gly)3 106 
5 FITC Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 FITC - 107 
MULTIMODAL  
6  Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 DOTA / FITC Lys 107 
7 18F-BD-BBN Gln-Trp-Ala-Val-Gly-His-Sta-Leu 18F / BODIPY alkyne 108 
8  Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 18F / BODIPY PEG 109 
 
 
Other derivatives for PET imaging of GRPR positive tumours using 18F have also appeared in the 
literature.110, 111 The entire sequence and the shortened [7-14] version of bombesin have been compared, 
with 18F as a label in a phenyl group at the end of an aminocaproic acid molecule used as a linker. The 
whole sequence showed higher affinity for GRP receptors but was more unstable in vivo that the shorter 
analogue.112 Becaud et al. reported the preparation of a BBN[7-14] derivative that included an aromatic 
group in which 18F was incorporated in moderate radiochemical yields by nucleophilic aromatic 
substitution with a trimethylammonium moiety as the leaving group.113 The same group explored the 
18F labelling strategy in mice bearing prostate GRPR positive tumours with positive targeting to the 
tumour.114  
 







Figure 1.12: Heterodimeric imaging agent to target GRP receptors and integrin receptors in prostate 
cancer. a) Representation of the binding of the imaging agent to the receptors in the membrane. 
b) Structure of the imaging agent. c) Micro PET images in mice at 30, 60 and 120 min where the 
monomer and heterodimer compounds are compared. Tumours are marked by the white arrow. This 
research was originally published in JNM. Z. B. Li, Z. Wu, K. Chen, E. K. Ryu and X. Chen. 
18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging. J Nucl Med. 2008; 49, 453-461. 
© by the Society of Nuclear Medicine and Molecular Imaging, Inc. 
 
Modifications of the [7-14] fragment of bombesin have been reported110, 111 and include several linkers 
to improve uptake115, 116, the formation of heterodimers with RGD117, 118, 119 to expand the targeting 
abilities in prostate tumours (Figure 1.12) or the substitution of the fluorine-18 prosthetic group to favour 
the metabolic processing through the kidneys.120 In most of these examples fluorine-18 was incorporated 
by nucleophilic aromatic substitution but other radiolabelling strategies such as the use of NOTA or 
similar macrocyclic chelators for Al18F110, 121, trimethylamonium fluoride salts or the functionalisation 
with 18F-FDG have been described. The effect of agonists versus antagonists in GRPR bearing tumours 
have been compared and the agonist analogues provided better results in terms of internalisation for 18F 










Figure 1.13: Structure of 68Ga-bombesin probes being evaluated in ongoing clinical trials.122, 123 
 
Despite the current interest in the application of nuclides as 99mTc or 18F, as well as the search of other 
elements like transition metals as 64Cu, some new and intense research effort has been recently dedicated 
to the preparation and optimisation of radioprobes based on 68Ga. This is motivated due to its promise 
of generator availability. The chelation of the radiometal is generally achieved by a macrocylic chelator 
as DOTA or NOTA. However, other examples as bis(thiosemicarbazones), TRAP, NOPO, etc. have 
been described because of their higher selectivity or potential hypoxia detection (Figure 1.5).105, 124 The 
possibilities of radiolabelling one derivative with more than one nuclei are possible thanks to the 
versatility of the chelators. Maecke et al. described a [7-14] fragment of bombesin functionalised with 
a PEG linker and a DOTA chelator that was radiolabelled with 67Ga and 177Lu for SPECT imaging and 
68Ga for PET. The derivative presented a promising tumour uptake although experiments in vivo showed 
an increased uptake in the kidneys and pancreas.104 The dual functionalisation with two targeting groups 
to aim for more than one target has also been explored. The GRP and integrin receptors were targeted 
by the preparation of a bombesin-RGD heterodimer radiolabelled with 68Ga (Figure 1.12). The binding 




affinities were comparable to that of the monomers and the specificity was promising as demonstrated 
by blocking studies.125 A PSMA inhibitor was also incorporated in a heterodimer with a modified 
version of bombesin to bind to the two targets and chelate 68Ga. The different parts of the probe were 
assembled by using click chemistry and the products evaluated in vitro and in vivo, showing good 
binding to the two targets and reduced uptake in the rest of the organs in vivo when compared to the 
monomers.126 Furthermore, at the moment of writing this document, at least 10 clinical trials involving 
bombesin derivatives for imaging purposes in prostate cancer were active over Europe and USA.122, 123 
The vast majority of the ongoing clinical trials involved the use of different bombesin-like peptides, 
functionalised with a variety of chelators and 68Ga as a radioisotope, demonstrating the current interest 
in the application of this radioisotope in clinical imaging. 127-129 A selection of these compounds can be 
observed in Figure 1.13. 
 
 
Figure 1.14: In vitro evaluation of a bimodal bombesin-based imaging probe (entry 8 in Table 1.2). 
A) Confocal imaging of BD-BBN in PC-3 cells (top) along with blocking experiments in which 
bombesin was added in a 100-fold excess (bottom). Hoechst co-localisation experiments are shown in 
the right column. B) Quantification of tumour uptake by fluorescence and gamma counting. Figure 
reproduced from ref. 108 with permission from the publisher. 
B 




The development of fluorescent probes is receiving increasing attention to characterise imaging probes 
in vitro prior to animal experiments and as part of bimodal/multimodal imaging probes. In addition, the 
inclusion of nanomaterials in biomedical research, requires fluorescence experiments to study the 
materials in vitro before their translation to animal models.  
 
The study of the behaviour of a bombesin derivative conjugated with a rhodamine dye was investigated 
by Heckl et al. The uptake of the conjugate was studied in human cancerous and healthy cell lines by 
flow cytometry, confocal microscopy and it proved to be receptor-mediated evolving from membrane 
bound to localised in the cytoplasm over time. The presence of GRP receptors in different cell lines was 
also evaluated comparing the fluorescence intensities of the confocal images.93 Near-infrared dyes are 
another area of great interest as tissue auto-fluorescence is considerably reduced in this area of the 
spectrum (Figure 1.7). Commercial dyes, as AlexaFluor 680, have been studied in vitro in breast cancer 
cells but also for the detection of metastases in mice.106, 130 The commercial derivative IR800 or MPA 
has been coupled to bombesin [7-14] through different linkers and the imaging probes studied in vitro 
and in vivo. In both cases, all prepared derivatives showed uptake in PC-3 cells and PC-3 containing 
tumours but the first highlighted the importance of the nature of the linker as it impacts in the efficiency 
of the binding.131, 132 In addition, the design of multimodal probes is attracting much attention as 
explained in section 1.1. Examples of multimodal probes to target prostate cancer including bombesin 
have been described in the literature.133 Optical / PET derivatives are formed by the functionalisation of 
bombesin with a fluorophore and a chelating group. Fluorescein isothiocyanate (FITC) was conjugated 
to two different chelators (DTPA and DOTA) and to a 7-14 residue through a lysine linker. The position 
of the chelating agent directly to the N-terminus or to the lysine linker affected greatly the binding 
affinity. In this case, no nuclear imaging experiments were reported.107  
 
Another bombesin-based derivative conjugated to a BODIPY took advantage of the fluorine atoms in 
BODIPY dyes that can be exchanged for 18F (Figure 1.14). The preparation of different multimodal 
probes based on BODIPY dyes was reported by Goze et al. including NIR derivatives. The linkage to 
the peptide was conducted by click chemistry and a competitive binding study proved that the final 
product binding efficiency was not affected by the incorporation of the fluorophore.109 Another study 
described the preparation of a similar multimodal probe assembled through click chemistry, in vitro 
imaging in PC-3 cells and in vivo imaging in PC-3 tumour bearing mice. The results proved promising 
although the tumour uptake was low with a high bone uptake that was attributed to free 18F according to 
the authors’ hypothesis. 
  




1.3 Bis(thiosemicarbazonato) complexes in molecular imaging applications 
The thiosemicarbazone moiety (Scheme 1.1) has been known for over a century. The first reports date 
from the early 1900s where the study of these compounds was motivated as a way to identify ketones.134 
The primitive interest in thiosemicarbazones was triggered by the varied biological properties presented 
by this family of compounds (e.g. antiviral, antifugal or antibacterial).135-138 However, the interest in 
bis(thiosemicarbazonato) complexes for medical imaging goes back to the late 1990s when the first 
aliphatic complexes were applied to the imaging of cardiac hypoxia by Fujibayashi.139 This interest has 
been sustained over recent times with some derivatives reaching clinical trials for imaging of lung, 
cervical or rectal cancers.140-142 Despite the good results obtained in patients, the use of aliphatic 
thiosemicarbazonato complexes for hypoxia imaging should be considered with caution as the fate of 
the complex in vivo is not totally understood. The latest results suggesting a prompt decomplexation of 




Scheme 1.1: Thione – thiol equilibrium in thiosemicarbazones. 
 
In the past decade, bis(thiosemicarbazonato) complexes for imaging are gaining attention as multimodal 
probes since the introduction of acenaphthenequinone for the preparation of ligands and complexes by 
Pascu et al.143 The acenaphthene aromatic backbone provides an inherently fluorescent group (weak in 
the ligands and stronger in the complexes where ligand to metal charge transfers (LMCT) and metal to 
ligand charge transfers (MLCT) are possible).144 This yields a versatile chelator able to form complexes 
that can act as multimodal imaging probes. The preparation of acenaphthenequinone 
mono(thiosemicarbazone) ligands and complexes had been reported before in the literature but acting 
as tridentate ligands toward the metal and not applied as imaging agents.136 The chemistry of 
thiosemicarbazones has been extensively reviewed over the past decades with the earliest example in 
1974 in the framework of a compendium of ligands containing nitrogen and sulphur.145 Later, other 
reviews focused exclusively in thiosemicarbazones and the corresponding metal complexes covering 
their coordination chemistry comprehensively.146-149 The role of thiosemicarbazones and their 
complexes in imaging150 and pharmaceuticals151, 152 have also been covered. 
The preferred way to obtain thiosemicarbazones usually involves the reaction of carbonyl-based 
compounds with thiosemicarbazides in ethanolic solutions, using acids as catalysts.153 Other methods as 
using hydrazones, oximes, dithiocarbazides or isothiocyanates have been described.153, 154 The 
carbonylic compounds for the synthesis of bis(thiosemicarbazones) are generally 1,2-disubstituted 
although 1,3-, 1,4- and 1,5-dicarbonylic compounds have been explored.155-157 The synthesis of 




symmetrical bis(thiosemicarbazones) is usually straightforward and the products are obtained in good 
yields although side reactions are known to take place (cyclisations or dimerisations). Therefore, the 
reaction conditions have to be cautiously monitored in order to avoid side reactions or the formation of 
mixture of products difficult to separate.158 Despite being more challenging, the synthesis of 
unsymmetrical derivatives has been reported, being the stepwise condensation of the thiosemicarbazides 
to the dicarbonylic compounds the most successful method. The synthesis of aliphatic 
bis(thiosemicarbazones) for imaging applications was reviewed by Dilworth et al.154  
The wide range of metals that thiosemicarbazones are able to chelate (Table 1.3) makes them 
outstandingly flexible ligands which broadens their chemistry and applications. The synthesis of the 
corresponding complexes generally varies with the thiosemicarbazones and the metallic species but 
generally involves heating the thiosemicarbazone with the metal precursor in the form of halide, acetate, 
etc.149 
 
Table 1.3: Examples of metals forming thiosemicarbazonato complexes.149 
 
Group 5 6 7 8 9 10 11 12 13 14 15 
Element 
        Al   
V Cr Mn Fe Co Ni Cu Zn Ga   
 Mo Tc Ru Rh Pd Ag Cd In Sn  
 W Re   Pt Au Hg Tl Pb Bi 
U           
 
 
Mono(thiosemicarbazones) have different coordination modes to the metal: bidentate, through the N 
and S atoms or tridentate, involving any other donor atoms in the thiosemicarbazone structure 
(Figure 1.15, A and B). The most common coordination mode in bis(thiosemicarbazones) is tetradentate 




Figure 1.15: Selected coordination modes of mono(thiosemicarbazones) (A, B) and 
bis(thiosemicarbazones) (C) to a metal atom. 




The aliphatic family of complexes has been extensively explored for their use in PET imaging, chelating 
mainly 64Cu for the detection of hypoxia in tumours and cardiac ischaemia.159, 160 The hypoxic selectivity 
was related to the lipophilicity and redox potential of the bis(thiosemicarbazonato) complexes so the 
structures were modified by changing the backbone (using 2,3-butanedione, glyoxal or pyruvaldehyde 
as starting materials) and substituents in an effort to adjust these two parameters.161 Experimental data 
such as UV-vis spectra, cyclic voltammetry or pKa values were explored for a series of derivatives 
(Figure 1.16) resulting Cu(II)ATSM the most promising species. Furthermore, other parameters as 




Figure 1.16: Aliphatic family of Cu(II) bis(thiosemicarbazonato) complexes with their standard 
reduction potentials and lipophilicity. E1/2 values expressed in volts vs. Ag/AgCl. E1/2 and log P values 
obained from ref. 163. 
 
However, the insights underlying the behaviour of these complexes and their hypoxia selectivity remain 
under debate. The established mechanism for Cu(II)ATSM hypoxia selectivity agreed over the years 
involved the presence of an equilibrium in the cellular environment between the Cu(II) and Cu(I) 
species. The trigger of hypoxia selectivity was related to the reduction of the Cu(II) complex to the 
negatively charged Cu(I). The latter could not cross the cellular membrane so it protonates and 
dissociates resulting in an accumulation of copper into hypoxic cells or tissues. In normoxic tissues, the 
Cu(II) species was free to cross the cellular membrane and exit the cell. 




The preparation of bis(thiosemicarbazonato) complexes from an aromatic precursor as 
acenaphthenequinone provides a number of advantages when compared to the aliphatic counterparts as 
higher stability in biological media, a greater versatility in the formation of complexes (with other metals 
as Ga(III), Ni(II) or In(III)) and the possibility to function as multimodal probes that can be used either 
in vitro thanks to its fluorescence or in vivo when transmetallated with a radioisotope. Furthermore, the 
fluorescence of these metal complexes provided a new dimension in the study of thiosemicarbazones 
and their complexes in vitro by optical techniques.  
Only a few examples of bis(thiosemicarbazonato) metal complexes could be studied optically in vitro 
prior to the appearance of these complexes. Dilworth et al. reported an inherently fluorescent Zn(II) 
derivative, with the exception of this case, all other examples implied the attachment of a dye molecule 
with the risk of changing the intrinsic properties of the compound. Different groups have been used as 
dyes attached to thiosemicarbazonato complexes as pyrene, BODIPY or stilbene (although in this case, 




Scheme 1.2: General synthesis of acenaphthenequinone bis(thiosemicarbazonato) metal complexes. 
 
The general synthesis of acenaphthenequinone bis(thiosemicarbazonato) complexes is depicted in 
Scheme 1.2. The mono and bis(substituted) ligands can be obtained by heating the diketone and 
thiosemicarbazide in the presence of an acid. The zinc complex can be obtained in a one-pot templated 
process from acenaphthenequinone and an excess of thiosemicarbazide and zinc acetate heating in acetic 
acid for 24 – 30 h. It was found that complexes of other metals could be obtained but optimal conditions 
resulted by transmetallation from the Zn analogue rather than from the ligands or from 
acenaphthenequinone.57, 165  
 
Unsymmetrical acenaphthenequinone derivatives have been prepared from the mono(substituted) ligand 
and thiocarbohydrazide in similar conditions as in the formation of symmetrical Zn(II) complexes 
(Scheme 1.3). Unfortunately, the strategy for the conjugation to a targeting peptide proved 
unsuccessful.166 






Scheme 1.3: Synthesis of unsymmetrical bis(thiosemicarbazonato) acenaphthenequinone complexes 
from the corresponding mono(substituted ligand). 
 
The transmetallation of this family of compounds with 68Ga has been described for a small number of 
derivatives so far but appears to constitute a significant advantage towards the application of these 
complexes in imaging.167 Much research effort is being done in the optimisation of efficient gallium 
chelators as 68Ga has a number of advantages compared to other radionuclides as mentioned earlier. 
 
Furthermore, some of the gallium derivatives (R: allyl) have proved to be hypoxia selective under 
specific conditions in a range of cells.168 In this case, the proposed mechanism of hypoxia selectivity 
proposed for Cu(II)ATSM would not be applicable as Ga(III) cannot be reduced under biological 
conditions. One hypothesis is that the complex gets involved in the iron metabolism pathways that are 
known to change under hypoxia.169, 170 This could be explained due to the capability of gallium of 
mimicking iron metabolism and compete in the binding to enzymes or proteins. The reason why 
biomolecules and living systems cannot distinguish between Fe(III) and Ga(III) is based on their 








1.4 Application of carbon nanomaterials to biomedical imaging: towards 
nanotheranostics design and testing 
Carbon nanomaterials are allotropes of carbon where at least one dimension is measured on the 
nanoscale (<100 nm). The main types of carbon nanomaterials are nanotubes, first described by Iijima 
et al.172, 173 and graphene, a more recent material with the single layer derivative reported in 2004.174 
Other nanoallotropes of carbon are the well-studied fullerenes although several other, nano-dimensional 
members of this family such as carbon dots, nanohorns, nanoonions or nanodiamonds have emerged.175 
In this work we focused on the functionalisation of carbon nanotubes with small molecules and 
biomolecules of relevance to PCa targeting. 
 
Carbon nanotubes can be described as a wrapped graphene sheet with ca. 1 nm diameter and lengths in 
the scale of the hundreds of nm to µm. They can be classified according to the number of carbon 
concentric layers as single walled (SWNT) and multi walled (MWNT). The simplest MWNT are double-
walled nanotubes but the number of layers can be higher with the diameter going up to tens of nm. The 
structure of nanotubes can be described by three parameters: the chiral angle (θ) and two vectors (n,m). 
The variation of the two vectors produces three types of tubes: when the vectors are (n,0) a zigzag 
nanotube is obtained; if the vectors are n = m (n,n) an armchair nanotubes is obtained while if n and m 
are different (n,m) a chiral nanotube is obtained. The construction of a chiral (6,3) nanotube from a 




Figure 1.17: Diagram showing the construction of SWNT from a graphene sheet. 
 




The chirality of the nanotube is determinant for its electrical properties as armchair nanotubes are 
metallic, zigzag are metallic if n is a multiple of 3 and chiral tubes can indistinctively be metallic or 
semiconducting.176 The synthesis of nanotubes with specific chirality has been explored and methods 
exist to obtain a desired chirality.177 SWNT present certain properties that make them unique materials 
as a high surface area, excellent electrical conductivity or high mechanical resistance. For these reasons, 
carbon nanotubes have been applied to composite materials, electronic devices, biosensors, drug 
delivery, cancer treatment or imaging.178 The last part of this section will focus on the applications and 
challenges of SWNT in the bioimaging field although toxicity concerns can be generalised to the 
biomedical field. 
The applications of carbon nanomaterials in biological applications leads to concerns about their 
toxicity. A great number of studies have been published examining the toxicity of these materials in 
vitro and in vivo. The results are occasionally controversial but there are certain widely accepted aspects 
like the strong dependence of the toxicity with a number of factors as dose, shape, impurities, surface 
functionalisation or exposure route of the nanomaterial.179 The modification of the mentioned factors 





Figure 1.18: Summary of the possible outcomes to fibre exposure based on length and biopersistence. 
Figure adapted from ref. 169. 
 
Exposure to carbon nanotubes through inhalation is the main cause of concern towards the use of carbon 
nanotubes in industrial or biomedical environments. Carbon nanotubes can be considered fibres due to 
the large aspect ratio so they could present similar toxicity as asbestos-like materials. According to this 
Fibre exposure 
Deposition 
Short fibres Long fibres 
Effective phagocytosis  
and macrophage clearance 
Cleared 
Non-biopersistent Biopersistent 
Dissolution Incomplete phagocytosis, 









route, inhaled carbon nanotubes of a certain length, diameter and biopersistence can be accumulated in 
the lungs and pleura causing oxidative stress, inflammation, genotoxicity and in the end neoplasia 
(Figure 1.18).180, 181 Different in vitro and in vivo studies have confirmed the biopersistence of pristine 
carbon nanotubes and the described behaviour in pleural tissue.182 However, this response is dependent 
on the form of the carbon nanotubes as fibres and many nanotubes are present in tangles that can be 
regarded as particles so would not present this toxicity. The functionalisation type and degree is another 
important factor, as some functionalisation strategies tend to shorten the carbon nanotubes while others 
enhance the dispersibility making the nanotubes able to be excreted through different routes. In addition, 
the presence of metallic contaminants and defects in the tubes originated during the synthetic process 
can trigger inflammatory responses and must be considered.183 Other routes of exposure like dermal 
absorption or ingestion had been less explored although there is evidence that SWNT can present toxic 
effects as reviewed recently by Ong et al. The authors concluded, however, that more research was 





Figure 1.19: Enzymatic degradation experiments of carboxylated SWNT. A) Photograph of initial 
carboxylated SWNT dispersion and after 10 days of incubation with HRP and H2O2. B) TEM 
micrographs before the incubation and after 3 or 10 days (left to right). Adapted with permission from 
B. L. Allen, G. P. Kotchey, Y. Chen, N. V. K. Yanamala, J. Klein-Seetharaman, V. E. Kagan and A. 
Star, J. Am. Chem. Soc., 2009, 131, 17194-17205. © 2009 American Chemical Society. 
 
Nagai et al. compiled a series of in vitro studies evaluating the uptake properties and toxicity of SWNT 
and MWNT according to their functionalisation, length and diameter. Observing this compilation, it can 
be concluded that pristine single walled carbon nanotubes with small dimensions (< 1 µm length and 
1-5 nm diameter) showed little toxicity in a range of cell types such as cervical cancer cells (HeLa), 
leukemic T-cells (Jurkat) or breast cancer cells (Michigan Cancer Foundation-7, MCF-7). The covalent 
or non-covalent functionalisation helped to the internalisation of the nanotubes that was produced by 
endocytosis or diffusion.185 Regarding the in vivo biodistribution and toxicokinetics of nanotubes, the 




response depended on the properties and functionalisation of the material and the accumulation in an 
organ could be controlled to a certain degree. Elimination in urine was observed to be the main excretion 
route for functionalised CNT while pristine samples have a tendency to accumulate in organs like the 




Scheme 1.4: Functionalisation strategies of pristine SWNT to allow their biomedical application. 
 
Interestingly, oxidised SWNT have been reported to be biodegraded through an enzymatic pathway. 
Several different oxidised SWNT dispersions were incubated in the presence of the horseradish 
peroxidase enzyme (HRP) and hydrogen peroxide. After several weeks, the nanotubes were strongly 
degraded as observed by Raman spectroscopy or TEM (Figure 1.19).187, 188 The fate of the nanotubes in 
vitro and in vivo was also followed, finding indications of biodegradation that can be rationalised based 
on this oxidative mechanism that renders the prospect of using carbon nanotubes as delivery agents able 
to be easily excreted or biodegraded after performing their function.189 In a recent study, the production 
of reactive oxygen species in macrophages was found to be of paramount importance in the 
biodegradability of MWNT.190 In summary, the toxicity of carbon nanotubes depends on the exposure 
route, physicochemical properties as fibre-like shape, length or insolubility in biological media.  
The properties of pristine carbon nanotubes of a certain length make them impossible to eliminate by 
phagocytosis so they accumulate in the tissues triggering inflammation responses. However, the 




physicochemical properties of pristine nanotubes can be dramatically modified by different 
functionalisation methods so the nanomaterial can be physiologically processed and excreted so it does 
not pose a toxicological risk, paving the way to the biomedical applications.  
 
Despite the described potential adverse effects of carbon nanotubes, much research effort has been 
applied to enhance their biocompatibility by covalent or non-covalent functionalisation (Scheme 1.4).191 
SWNT conjugates with biologically active molecules as peptides or antibodies have been used in drug 
delivery, imaging or therapy.192 The applications of SWNT in biomedical imaging is broad and examples 
of functionalised imaging probes with fluorophores and chelators have appeared in the literature applied 
with a variety of imaging techniques as optical, Raman or nuclear imaging (Figure 1.20, Figure 1.21 




Figure 1.20: Structure of SWNT-Pt(IV)-FL probe and fluorescence microscopy images after 2.5 h 
incubation in a) human nasopharyngeal epidemoid carcinoma cells (KB) and b) human testicular 
cancer (Ntera-2) cells. Adapted with permission from S. Dhar, Z. Liu, J. Thomale, H. Dai and S. J. 
Lippard, J. Am. Chem. Soc., 2008, 130, 11467-11476. © 2008 American Chemical Society. 
 




The use of carbon nanomaterials for biomedical purposes has been recently covered in several reviews. 
Dai et al. covered the use of carbon nanotubes, evaluating functionalisation strategies for their 
application in sensing, imaging and drug delivery.193 Prato et al. covered the application of delivery 
probes based on nanotubes for imaging and therapeutics that had reached animal experimentation and 
summarised the concerns over the use of these materials.194 The use of carbon nanomaterials in imaging 
has also been reviewed looking at their applications in fluorescence and Raman imaging195, 196 with a 
comprehensive review by Dai et al. on imaging, focusing especially in NIR, sensing and therapy of 
carbon nanomaterials.197 
 
Due to the nature of this project our interest lies in the use of SWNT for a probe applied to the imaging 
of prostate cancer cells by optical imaging in the visible range with an interest in the NIR-I region of the 




Figure 1.21: Schematic representation of SWNT nanoprobe incorporating a taxoid drug.198 
 
The covalent functionalisation of SWNT with chelator groups or its filling with radionuclides has 
attracted interest since the beginning of the exploration of carbon materials as biomedical probes. 
Nuclear imaging allows us to follow the fate of the material in vivo and to evaluate its clearance from 
the body. Several radionuclides as 86Y and 111In have been attached covalently to functionalised SWNT 
using DOTA or DTPA chelator.199 Other probes used in targeted approaches including antibodies with 
DOTA chelated 225Ac for treatment and 89Zr for imaging have been reported.200, 201 
 






Figure 1.22: Structure of a carbon nanotube multimodal probe for MRI/SPECT imaging decorated 
with SPION and incorporating 99mTc as radionuclide. a) In vivo imaging comparing the biodistribution 
of the nanoprobe and the 99mTc chelated agent in mice. b) Biodistribution of the nanoprobe and c) the 
99mTc chelated agent. d) Blood clearance profile of the radioprobe and nanoprobe. Figure reproduced 
from ref. 202 with permission from the publisher. 
 
The covalent functionalisation of carbon nanotubes with fluorophores that allows to follow the 
nanomaterial in vitro by optical microscopy have been profusely reported in the literature. Specifically 
for SWNT, the attachment of different fluorophores to study the cellular uptake has been described. 
Fluorescein isocyanate have been employed as a commercially available dye and linked to SWNT 
functionalised through 1,3-dipolar cycloadditions.203, 204 In other case, functionalised SWNT with 
fluorescein were used to evaluate the in vitro inflammatory response.205 However, in most cases, the 
preparation of the imaging probe was conducted attempting to introduce an additional moiety acting as 




a target or drug. Lippard et al. described the preparation of a targeted anticancer drug system anchored 
to SWNT. The nanoprobe incorporated a folate receptor to target KB tumour cells, a fluorescein 
fluorophore and a Pt(IV) compound based on cis-platin. The anticancer drug improved its efficacy 
supported on the SWNT.206 The structure of the probe and the corresponding in vitro imaging can be 
observed in Figure 1.20. 
 
In a similar manner, Ojima et al. combined a biotin targeting molecule, a taxoid drug and a fluorescein 
group through a double functionalisation route (oxidation and 1,3-dipolar cycloaddition) into a SWNT 
based nanoprobe (Figure 1.21). The conjugate showed promising cytotoxicity and selectivity for cancer 
cell lines.198 The multiple functionalisation of SWNT can be further extended and triple functionalised 
derivatives have been achieved by combining covalent and non-covalent functionalisation.207 In this 
way, oxidised SWNT were modified covalently to attach fluorescein and a targeting antibody while the 
drug doxorubicin was adsorbed onto the surface.208 
 
The description of multiple functionalisation strategies and the development of nanoparticles as contrast 
agents has facilitated the development of multimodal imaging probes. In this way, nanotubes can be 
functionalised with magnetic particles for MRI, radionuclides for nuclear imaging and fluorophores for 
optical or photoacoustic imaging and different imaging modalities like MRI/SPECT (Figure 1.22)202, 
Raman/photoacoustic/MRI209, or SPECT/optical210 can be achieved.  





The aim of this thesis is to obtain a probe able to be used in the imaging of prostate cancer with attention 
to possible multimodal applications by functionalisation of carbon nanomaterials.  
The design elements envisage that a new nanoprobe can be devised, which can be composed of a carbon 
nanomaterial, a linker molecule, a fluorophore and a prostate cancer targeting molecule as depicted in 




Figure 1.23: Representation of a potential imaging probe based on carbon nanotubes. 
 
 
The Objectives are: 
- Synthesis of a functional fluorophore capable to be coupled with the targeting molecule and/or 
nanomaterial. The chemistry of acenaphthenequinone bis(thiosemicarbazonato) metal 
complexes will be especially considered due to their multimodal properties and potential 
hypoxia selectivity. 
 
- Covalent functionalisation of carbon nanomaterials, with emphasis in SWNT, and introduction 
of linker groups to allow the coupling with the fluorophore and targeting molecule moieties. 
 
- Synthesis of a fragment of the peptide bombesin to act as targeting molecule toward prostate 
cancer cells. 
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Chapter 2 : Synthesis of functionalised thiosemicarbazonato metal 
complexes 
2.1 Overview 
The chemistry of bis(thiosemicarbazonato) complexes has been under investigation over the past 
decades, mainly with a focus on the alkylic family that yielded the agent Cu(II) diacetyl-bis(N4-
methylthiosemicarbazone) (CuATSM).1, 2 CuATSM has demonstrated to be an important probe for the 
detection of tumour hypoxia and has been evaluated in several clinical studies, especially applied to lung 
cancer.3-5 However, the weak or lack of fluorescence of the alkylic family implied the attachment a 
fluorophore to the bis(thiosemicarbazonato) core in order to visualise their response in vitro thus 
modifying considerably the structure and pharmacokinetics of the original complexes. 
Acenaphthenequinone-based ligands offer an aromatic backbone inherently fluorescent that presents a 
fluorescence intensity increase when the metal is chelated to form the complex. 
 
The chemistry and biological properties of acenaphthenequinone bis(thiosemicarbazonato) complexes 
have been explored by the Pascu and Dilworth groups over the last 10 years to develop multimodal 
imaging agents with interesting properties for the potential diagnosis of cancerous diseases.6 
Furthermore, the finding of hypoxia selectivity in Ga(III) acenaphthenequinone 
bis(thiosemicarbazonato) complexes under certain in vitro conditions, certainly maintains the interest in 
these derivatives. The compounds in this family would provide a readily available hypoxia-focused 




Figure 2.1: Proposed structure for an unsymmetrical metal complex with orthogonal functional 
groups. 
 
While a variety of thiosemicarbazone substituents (alkyl, allyl, aryl) and metallic species (Zn(II), Ni(II), 
Cu(II), Ga(III)) have been explored for acenaphthenequinone-based compounds, their chemistry has 
been limited to symmetrical bis(substituted) derivatives, and the introduction of functional groups has 
been subjected to little exploration. The introduction of functional groups to obtain unsymmetrical 




derivatives is challenging in the chemistry of acenaphthenequinone bis(thiosemicarbazones) as the 
rigidity and planarity of the system does not allow for free rotation around the CO-CO bond, permitted 
when 2,3-butanedione, glyoxal or pyruvaldehyde are used as starting materials, making the preparation 
of unsymmetrical ligands relatively easy in the case of the aliphatic family.  
The aim of the work presented in this chapter was to develop unsymmetrical acenaphthenequinone 
bis(thiosemicarbazonato) metal complexes able to be introduced in the desired nanoprobe (see 
Figure 1.23). The design showed in Figure 1.23 implies the existence of two orthogonal functional 
groups able to react with the nanomaterial and the targeting molecule (Figure 2.1). 
 
2.2 Synthesis of functional thiosemicarbazides and mono(thiosemicarbazone) ligands 
The first step towards the synthesis of functional unsymmetrical bis(thiosemicarbazonato) metal 
complexes was the preparation of the corresponding functional thiosemicarbazides in order to obtain the 
ligands. As depicted in Figure 2.1, the introduction of protected amines in the design plan is a reasonable 
starting point as the use of similar derivatives has been previously described in thiosemicarbazone 
chemistry found in the literature.7, 8 The synthesis of an aliphatic bis(thiosemicarbazone) ligand 
containing a Boc-protected amino group has been described following two strategies. In the work by 
Donnelly et al., the Boc-protected ethylenediamino group was introduced by transamination of a 
reactive dimethyl thiosemicarbazone (denoted A in Scheme 2.1). The corresponding Cu(II) complex 
was formed from the protected derivative and deprotected with TFA.7 Differently, Dilworth et al. 
prepared a thiosemicarbazide species containing the terminal Boc-protected amino group. The 
thiosemicarbazide was condensed with a mono(substituted) derivative based on the 2,3-butanedione 




Scheme 2.1: Different synthetic strategies to a bis(thiosemicarbazone) ligand including a protected 
amino group. 
 
Consequently, three different thiosemicarbazides containing a terminal NHBoc group were prepared 
following the procedure described by Dilworth et al. from protected diamines. The only example 




described in the literature was the one prepared from ethylenediamine but the procedure was 
successfully generalised to the novel derivatives 8 and 9.  
 
The synthesis started with the corresponding protected diamines 1 – 3 and followed the same strategy 
(Scheme 2.2). The reaction proceeded through the condensation of the amine with carbon disulphide in 
a basic ethanolic medium. The addition of methyl iodide to the reaction mixture formed the 




Scheme 2.2: Synthetic route for the preparation of protected thiosemicarbazides. i) Et3N, CS2, CH3I, 
EtOH, 25 ºC, 3 h; ii) H2NNH2, EtOH, 78 ºC, 3 h. 
 
The reaction continued with the hydrazinolysis of the intermediate by reflux in ethanol to obtain the 
corresponding thiosemicarbazides (7 – 9) in moderate yields. The preparation of 4,4-dimethyl-3-
thiosemicarbazide was also attempted to explore the alternative route to prepare functional 
thiosemicarbazones by transamination. The methyl dithiocarbamate intermediate could be isolated in 
high yield as a crystalline solid. However, the hydrazinolysis step did not proceed as expected and the 
product was obtained as a complex mixture, likely due to known cyclisation issues which were 
encountered and reported before for other thiosemicarbazone derivatives, that could not be purified 
hereby. Therefore, 4,4-dimethyl-3-thiosemicarbazide was obtained from a commercial source. 
 
The synthesis of acenaphthenequinone bis(thiosemicarbazonato) metal complexes has been reported by 
heating the metal, generally Zn(OAc)2, with the bis(substituted) ligand9, the mono(substituted) ligand 
and an excess of thiosemicarbazide10 or acenaphthenequinone and an excess of thiosemicarbazide6. 
However, all these reported examples corresponded to symmetrical complexes. In this work, two 
synthetic strategies were attempted: forming the zinc(II) metal complex from the mono(substituted) 
ligand with an excess of the second thiosemicarbazide in a one-pot reaction (Scheme 2.3, dashed line) 
and preparing the complex from the unsymmetrical bis(substituted) ligand (Scheme 2.3). The route 
involving the preparation of the unsymmetrical bis(thiosemicarbazone) ligand is envisaged to offer more 
control over the entire process as the complexation is a separate step and its conditions can be optimised 
independently hence this route would be preferred.   






Scheme 2.3: Possible synthetic routes attempted to form an unsymmetrical Zn(II) 
acenaphthenequinone bis(thiosemicarbazonato) complex. 
 
Nevertheless, different mono(thiosemicarbazone) acenaphthenequinone ligands were prepared with 
commercial thiosemicarbazides, namely 4-methyl, ethyl, allyl or phenyl thiosemicarbazides, in order to 
explore the possible alternative route through a templated process from the alkylic or arylic 
mono(thiosemicarbazones). Furthermore, these mono(thiosemicarbazone) derivatives were used to 
evaluate the reaction conditions in the preparation of unsymmetrical ligands. The synthesis of 
mono(thiosemicarbazone) ligands from acenaphthenequinone was conducted by heating an equimolar 
amount of the diketone and thiosemicarbazide in an acidic ethanolic solution as previously described by 
our group.11  
 
The synthesis of the unsymmetrical ligand from the alkylic derivative mono(4-ethyl-3-
thiosemicarbazone) acenaphthenequinone and compound 7 was attempted but proved unsuccessful in 
an acidic solution of ethanol by refluxing 3.5 or 7 h although a small proportion of the product (ca. 3% 
as calculated by 1H NMR integration) was observed in the second case. In the same way, the formation 
of the unsymmetrical complex in a one-pot templated process was attempted from the same ethyl-
substituted acenaphthenequinone derivative, compound 7 and Zn(OAc)2 but led to a mixture of products. 
Different solvents (ethanol, toluene or acetic acid) and times were tested hereby but in all cases a 
complex mixture of products was obtained. 
 
 
Scheme 2.4: Reaction conditions for the preparation of a mono(thiosemicarbazone) ligand with 
a 2-aminoethyl group. 




Therefore, the preparation of the mono(thiosemicarbazone) ligands with thiosemicarbazides 4 – 6 
followed. However, the optimisation of the conditions was necessary to obtain the desired product. The 
formation of thiosemicarbazones from carbonylic compounds is an example of the formation of an imine 
from a carbonylic compound and an amine. This reaction is generally performed via acid catalysis that 
results in the elimination of water. Despite the Boc protecting group being sensitive to acidic conditions, 
the small amount of HCl used in the formation of acenaphthenequinone thiosemicarbazones (1 – 2 drops 
of conc. HCl) was not expected to affect the protecting group as observed in similar syntheses previously 
described from 2,3-butanedione8. Unfortunately, when the reaction was performed in the 
aforementioned conditions, the protecting group was completely removed and the deprotected derivative 
obtained (Scheme 2.4). This was easily confirmed by 1H NMR spectroscopy observing the 
disappearance of the tert-butyl resonance from the Boc group that is a characteristic singlet at 




Scheme 2.5: Synthesis of mono(thiosemicarbazone) acenaphthenequinone ligands with a protected 
amino group. 
 
The deprotection of the Boc group with just a few drops of conc. HCl indicated that the protecting group 
in the thiosemicarbazone in acenaphthenequinone derivatives was particularly labile in the presence of 
strong acids even at low concentrations in opposition of what was described in the literature for 
2,3-butanedione thiosemicarbazones. Therefore, the use of a weak acid as a catalyst for the reaction to 
avoid the deprotection of the Boc group was attempted. The reaction was repeated in the same conditions 
but using acetic acid at a 10% concentration in ethanol instead of conc. HCl. In this case, the desired 
product was obtained with no deprotection of the amino group (Scheme 2.5, 11). The compounds 
containing the hexyl or 2,2′-(ethylenedioxyl) chains (12 and 13 in Scheme 2.5) were successfully 
obtained by applying the same reaction conditions. 
 
The presence of the hexyl chain or a PEG unit as a spacer in the last two mono(thiosemicarbazone) 
examples significantly changed the physical properties of the product. These derivatives (12 and 13) 




were initially obtained as oils that could be separated from the starting materials by column 
chromatography in CH2Cl2 / MeOH, as opposed to the limited solubility of this class of 
acenaphthenequinone-based compounds in certain organic solvents. The ligands could, however, be 
precipitated by stirring in pentane and drying on standing at room temperature. 
 
All NHBoc mono(substituted) thiosemicarbazones were characterised by 1H and 13C NMR spectroscopy 
and mass spectrometry. The 1H NMR spectra of these compounds are comparable with the alkylic or 
arylic mono(substituted) ligands described in the literature.6, 10  
 
The first characteristic hydrazinic proton resonance appears at 12 – 13 ppm while the second 
characteristic amino proton appears upfield with respect to it at 9 – 10 ppm. This last amino group 
develops multiplicity due to the coupling with the neighbouring group, appearing as a triplet in contrast 
to most amino protons that usually appear as broad singlets. The substituent resonances are in the 1 – 4 
ppm region with the presence of the characteristic t-butyl resonance for the Boc protecting group at 1.31 
ppm. The 1H NMR spectrum of compound 12 is represented in Figure 2.2. The resonances in the NMR 





Figure 2.2: 1H NMR spectrum (d6-DMSO) of compound 12. [*Residual deuterated solvent signals 
























The NH signals can be differentiated because the amino proton shows a correlation peak with an alkylic 
proton (H-9). The six aromatic protons can be distinguished and appear as four doublets (H-5, H-6, H-3, 
H-8) and two doublet of doublets (H-4, H-7). In contrast, only three resonances of the alkylic chain can 
be observed independently. The more deshielded methylene groups correspond to the ones adjacent to 
the amino groups (H-9, H-14). The protected amino group presents a correlation peak with H-14 that 
allows to identify that methylene group. The H-10 methylene group is more deshielded and can be 
observed as a multiplet at 1.67 ppm while the resonances for H-11, H-12 and H-13 overlap with the 




Figure 2.3:1H-1H COSY NMR spectrum (d6-DMSO) of compound 12. [*Residual deuterated solvent 
signals and water; **residual solvents and impurities traces] 


















In addition, in the case of 11 and 12, suitable crystals for single-crystal X-ray crystallography were 
obtained by the vapour diffusion method, dissolving the ligands in THF and using hexane as a co-
solvent. The structures were obtained and are displayed in Figure 2.4.  
The presence of an intramolecular hydrogen bond between the oxygen and nitrogen (N1) atoms can be 
observed in 12. However, this interaction is not present for 11. The absence of the intramolecular 
hydrogen bond and the different conformation can be explained due to the presence of a water molecule 
that presents hydrogen bonding with the oxygen (O) and nitrogen (N1) in 11. 
 
Table 2.1: Selected bond distances and angles for compounds 11, 12 and mono(4-ethyl-3-
thiosemicarbazone) acenaphthenequinone. 
 
 11 12 R: Et10 
O-C1 (Å) 1.233 (4) 1.225 (2) 1.223 (2) 
C1-C2 (Å) 1.504 (5) 1.514 (2) 1.515 (2) 
N1-C2 (Å) 1.285 (5) 1.296 (2) 1.294 (2) 
O-C1-C2 (º) 124.9 (4) 126.24 (17) 125.6 (2) 













A selection of bond distances an angles for 11 and 12 can be seen in Table 2.1. The corresponding 
parameters for the mono(4-ethyl-3-thiosemicarbazone) acenaphthenequinone derivative have been 
included for comparison purposes. It can be observed that bond distances are in the same range for the 
three compounds although the distances are more alike between 12 and mono(4-ethyl-3-
thiosemicarbazone) acenaphthenequinone. The same situation is observed for the O-C1-C2 angle being 
the smaller value the one corresponding to 11 and all of ca. 125º which is in accordance with a sp2 
hybridisation of the carbon atom. In the case of the C1-C2-N1 angle the values are more dispersed with 
11 presenting the lower value with just 115.9º while 12 and the ethyl derivative are close to 128 º.  
 
The molecular structure showing the packing of 12 in the unit cell is shown in Figure 2.5. The CO in 
the acenaphthenequinone units are facing each other in a zig-zag disposition with short contacts between 
the sulphur and C2. The presence of the intermolecular hydrogen bonds between the CO group of the 
Boc moiety and the NH of the NHBoc moiety of another molecule are represented with a dashed grey 
line in Figure 2.5. The intramolecular hydrogen bonding between O and N1 is not visible with the view 




Figure 2.5: Molecular structure of 12 showing the unit cell along the b axis. Hydrogen bonds are 
showed as dashed grey lines. 
 
Once the functional mono(substituted) ligands were obtained and characterised, the synthesis of 
unsymmetrical bis(substituted) ligands or complexes was attempted. In the case of the bis(substituted) 
ligands, the reaction of 10 with thiocarbohydrazide did not provide the desired products when the 
previously described reaction conditions were applied (i.e. refluxing in EtOH). Either using 10 and 
thiocarbohydrazide or an alkyl thiosemicarbazide, mainly the starting material was recovered. 




The incapability of acetic acid to catalyse the reaction or the need for harsher conditions was 
hypothesised as the cause of the synthetic difficulties. In this sense, a two-sided approach was adopted, 
first, the application of microwave-assisted heating that allows to work at higher temperatures and 
pressures was evaluated and second the effect of the acid catalyst in the reaction was studied. 
In order to obtain a model for the reactivity for mono(thiosemicarbazone) acenaphthenequinone ligands 
and to optimise the reaction conditions, several mono(substituted) ligands were prepared from 
commercially available thiosemicarbazides with different substituents in position 4-, namely methyl, 
ethyl, allyl, and phenyl. The derivative including the N,N-dimethyl-3-thiosemicarbazone was obtained 
with minor impurities as confirmed by 1H NMR. The separation of the impurities proved especially 
challenging for this species and the use of this specific derivative was not considered hereby. 
 
2.3 Synthesis attempts of unsymmetrical bis(substituted) ligands 
The alkylic mono(substituted) ligands can be obtained in good yields by conventional synthesis as 
described in the literature.10 The mentioned derivatives can be prepared applying conventional 
conditions as in the previous section but also by applying microwave heating. There were no examples 
of the application of microwave-assisted synthesis to the preparation of acenaphthenequinone 
thiosemicarbazones so the optimisation of the reaction conditions was required (vide infra). Once the 
conditions were optimised, both the mono and bis(substituted) derivatives were obtained just varying 
the number of equivalents of thiosemicarbazide added. The reaction times were dramatically reduced 
and comparable yields to the conventional synthesis obtained. The acenaphthenequinone mono methyl 
(14), ethyl (15), allyl (16) or phenyl (17) thiosemicarbazones were prepared and used as a model to 




Scheme 2.6: General reaction conditions and parameters evaluated in the synthesis of symmetrical 
bis(substituted) BTSC ligands. The resonances of the NH protons (1, 2 and 1’, 2’, 3, 4) were used to 
follow the reaction evolution and to calculate conversions. 
 




The methyl or ethyl derivatives were indistinctly used in the synthesis of the symmetrical species 
(Scheme 2.6). The resonances of the hydrazinic and amino NH protons that appear between 8 and 13 
ppm were used to monitor the reaction and calculate the proportion of compound obtained in each 
reaction. The different conditions tested are summarised in Table 2.2. The initial temperature and time 
conditions for the microwave reaction (21 min, 140 ºC) were extracted from the microwave reactor’s 
manufacturer documents and correspond to 8 h refluxing in ethanol by conventional heating according 
to an approximation of the Arrhenius equation.12  
From the information summarised in Table 2.2 different conclusions can be drawn: 1) the effect of the 
acid catalysis on the reaction is crucial: the addition of just one equivalent of conc. HCl resulted in a 
100% conversion (entry 2) while the use of acetic acid yielded a mixture of products and only achieved 
a 50% conversion with extended reaction times and an excess of thiosemicarbazide (entry 5). 2) The 
temperature increase did not seem to provide a significant improvement in the reaction output and 
variations in time had a limited effect. Furthermore, there was a colour change in the product from 
yellow to light orange when 140 ºC were applied resulting in darker colours in the products. 3) The use 
of solvents other than ethanol in conventional heating as described in entries 11 and 12 did not seem to 
vary the reactivity. Furthermore, the substitution of the solvent is not desirable as the work-up, isolation 
and purification of this class of compounds in ethanol is considerably simpler. 4) The use of an excess 
of thiosemicarbazide seemed to help to increase the conversion as observed in entry 5.  
 






t / min 
T / °C, type 
of heating 
Acid Solvent Conversion 
1 Me 1.1 21 140, µw HCl, 50 µL EtOH 100% 
2 Et 4 21 140, µw HCl, 1 eq. EtOH 100% 
3 Me 1.1 21 140, µw AcOH, 10% (v/v) EtOH 13% 
4 Me 1.1 5+5 160, µw AcOH, 10% (v/v) EtOH 4% 
5 Me 4 21+21 140, µw AcOH, 10% (v/v) EtOH 50% 
6 Et 4 60 140, µw AcOH, 10% (v/v) EtOH Decomposition 
7 Et 4 21 140, µw AcOH, 20% (v/v) EtOH 3% 
8 Et 4 30 150, µw AcOH, 50% (v/v) EtOH Decomposition 
9 Et 4 21 140, µw AcOH AcOH Decomposition 
10 Me 1 240 78, conv.l AcOH, 10% (v/v) EtOH 5% 
11 Et 1.1 360 65, conv. AcOH, 10% (v/v) THF - 
12 Et 4 300 65, conv. AcOH, 10% (v/v) MeOH - 




An excerpt of the aromatic and aliphatic regions of the 1H NMR spectrum for the product isolated in 
entry 5 can be observed in Figure 2.6. In the aromatic region (Figure 2.6, left), the NH protons do not 
overlap despite the similar chemical shifts and all of them can be identified independently. The 
hydrazinic protons appear at 12.64 and 12.60 ppm corresponding to 1 and 1’ respectively. The additional 
hydrazinic proton in the bis(substituted product) appears at 11.25 ppm. The three amino protons appear 
upfield in the 8.7 – 9.5 ppm region as quadruplets. The resonances for the methyl groups appear in the 
aliphatic region (Figure 2.6, right). In this case, one of the signals overlap and only two doublets are 
observed for the three methyl groups. The methyl group of the mono(substituted) ligand (14) appears at 
3.12 ppm along with a methyl group of 18. The second methyl group of 18 appears at 3.10 ppm. The 
integration ratio between the two signals is 2:1 which confirms that the 14 and 18 are present in a 1:1 
ratio. 
 
The completion of the reaction using a weak acid as catalyst seemed unlikely so the use of conc. HCl 
was considered. Furthermore, it was observed that the synthesis of the mono(substituted) ligand with 
thiosemicarbazide 9 and one equivalent of conc. HCl yielded the desired product and maintained intact 




Figure 2.6: 1H NMR spectrum (d6-DMSO) detail of the aromatic (left) and aliphatic (right) regions of 
the product isolated for entry 5 in Table 2.2. 
1 1’ 
3 















For this reason, the improvement of the reaction conditions was continued using conc. HCl as a catalyst. 
The temperature in the microwave conditions applied in the last experiment was reduced when possible 
due to the observed colour change in the products from bright yellow to dark orange which can point to 
the presence of decomposition products. Consequently, the preparation of unsymmetrical 
bis(thiosemicarbazone) ligands was attempted applying the same alkylic model and HCl as an acid 
catalyst (Scheme 2.7, top).  
 
Surprisingly, the starting material and desired product were accompanied by the thiosemicarbazone 
exchange or metathesis products (Scheme 2.7, bottom). Therefore, the symmetrical products were also 
observed in the isolated mixture. Dynamic combinatorial exchange behaviour has been well studied for 
imines and hydrazones13 but less for thiosemicarbazones.14 The presence of this type of 
thiosemicarbazone exchange in acenaphthenequinone derivatives has never been reported to the best of 




Scheme 2.7: Synthesis attempt of an alkyl unsymmetrical bis(thiosemicarbazone). 
 
The results detailed in Table 2.3 revealed that heating the starting materials with just one equivalent of 
conc. HCl can lead to the observation of exchange products (entries 1 and 2). The temperature increase 
seems to have a positive effect for the conversion into the desired product although the proportion of 
exchange products increases as well (entries 4 and 5). The starting material is not consumed until 
relatively high temperatures (110 – 130 ºC, entries 4 – 6), which can lead to possible decomposition 
products. The addition of an excess of thiosemicarbazide along with an increase in the temperature of 
the reaction does not seem to help to increase the conversion into the desired product. Furthermore, the 
exchange products, particularly 19, are more favoured than the desired product in that case. 





Table 2.3: Conditions tested in the synthesis attempt of unsymmetrical bis(thiosemicarbazones). 
 
Entry Eq. TSC HCl t / min T / ºC 
Product proportion 
15 : P : 19 : 18 
1 1 1 eq., 25 µL 2.5 90 0.65 : 0.09 : 0.21 : (*) 
2 1 1 eq., 25 µL 5 90 0.60 : 0.10 : 0.24 : 0.06 
3 1.2 1.2 eq., 30 µL 10 90 0.35 : 0.12 : 0.36 : 0.16 
4 1.2 1.2 eq., 30 µL 10 110 - : 0.26 : 0.50 : 0.24 
5 1.2 1.2 eq., 30 µL 10 130 - : 0.28 : 0.45 : 0.27 
6 3 1.2 eq., 30 µL 10 120 - : 0.39 : 0.34 : 0.27 
 
(*) Present in the mixture but below 5% according 1H NMR integration 
 
 
In this case, the product identification and quantification was performed by observing the characteristic 
NH resonances in 1H NMR spectra as in the previous case but also looking at the resonance of the methyl 
and ethyl groups.  
 
The 1H NMR spectra of the regions where the methyl groups for the different ligands appear are 
displayed in Figure 2.7. It can be observed how in the mono(substituted) derivative the methyl group 
appears as a doublet (top) and the bis(substituted) ligand as a pair of doublets (middle) with a 1:1 
integration ratio. Differently, the mixture of products corresponding to entry 5 in Table 2.3 where the 
ethyl-methyl, bis(methyl) and bis(ethyl) products are represented should give place to three resonances 
for the three inequivalent methyl groups. However, the methyl resonance from the ethyl-methyl 
derivative (P) overlaps with the methyl resonances of the bis(methyl) product (18) originating a pair of 
doublets (Figure 2.7, bottom) as occurred in the mixtures of the mono(methyl) and bis(methyl) 
thiosemicarbazone derivatives (Figure 2.6).  
 
In the case of entry 5, P and 18 are present in a 1.04 : 1 ratio as can be observed by the integration of 
the doublets. Despite the convenience in the use of the NH protons to calculate the proportion of 
products, the resonances of the methyl group can be employed as well as they can be observed and 
integrated independently. The proportion of the remaining product (19) could be also estimated using 
the resonances in the alkylic region by observing at the ethyl resonances and subtracting the 
corresponding contribution of the ethyl-methyl derivative, P. 
 






Figure 2.7: 1H NMR spectra of the methyl resonances for mono(4-methyl-3-thiosemicarbazone) (top), 
bis(4-methyl-3-thiosemicarbazone) (middle) and isolated product of entry 5 in Table 2.3 (bottom). 
 
The same experiment was repeated using 4-phenyl-3-thiosemicarbazide instead of 4-methyl-3-
thiosemicarbazide to ascertain if the same reactivity was observed (Scheme 2.8) and to evaluate if the 
distribution of products was dependant on the thiosemicarbazide species. In this case, the temperature 
was limited to 90 ºC in order to avoid any possible decomposition. The amount of thiosemicarbazide 
was also limited to 1 equivalent as the presence of an excess did not have a dramatic effect in the results 
of previous experiments. The results are summarised in Table 2.4. 
 
The differences are evident in this case, when the thiosemicarbazide is 4-phenyl-3-thiosemicarbazide, it 
can be observed that the starting material is still present in a high proportion but the exchange products 
are obtained in a much reduced proportion, being the desired product with one substituent of each class 
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Scheme 2.8: Microwave heating experiment using 4-phenyl-3-thiosemicarbazide and mono(4-ethyl-3-
thiosemicarbazone) acenaphthenequinone. 
 
The addition of an excess of HCl catalyst (entry 4) did not produce a significant variation in the 
distribution of products. The application of a longer reaction time seemed to displace the equilibrium 
towards the products but unfortunately the proportion of exchange products increased equally (entries 
5 – 6). The greater proportion of the starting material followed by the desired product seems to indicate 
that the process is, in fact, thiosemicarbazide-dependant and bulkier groups as the phenyl group are more 
difficult to exchange upon heating. In addition, during this experiment the starting material was never 
consumed. 
 
Table 2.4: Conditions tested in the synthesis of asymmetric Et-Ph BTSC. 
 
Entry HCl t / min 
Product proportion 
15 : P’ : 19 : 21 
1 1 eq., 16.8 µL 2.5 0.78 : 0.19 : (*) : - 
2 1 eq., 16.8 µL 5 0.71 : 0.26 : (*) : - 
4 3 eq., 50 µL 5 0.71 : 0.25 : (*) : (*) 
5 1 eq., 16.8 µL 10 0.59 : 0.34 : (*) : (*) 
6 1 eq., 16.8 µL 15 0.52 : 0.39 : (*) : (*) 
 
(*) Present in the mixture but below 5% according 1H NMR integration 
 




2.4 Synthesis of unsymmetrical bis(thiosemicarbazonato) acenaphthenequinone 
complexes 
The results obtained in the experiments towards the synthesis of unsymmetrical bis(thiosemicarbazone) 
acenaphthenequinone derivatives indicate that the synthesis of a functional unsymmetrical 
acenaphthenequinone bis(thiosemicarbazone) ligand would be an incredibly challenging process, 
considering that the optimisation of the reaction conditions is possible. The problems to purify the 
resulting mixture add difficulty to the preparation of the product. Consequently, other strategies for the 
use of thiosemicarbazones needed to be applied to obtain a suitable compound to functionalise the 
nanoprobe. 
 
The synthesis of unsymmetrical acenaphthenequinone bis(thiosemicarbazonato) complexes including a 
free NH2 group has been described by applying a one-pot templating process with a mono(substituted) 
ligand and thiocarbohydrazide, so this approach was followed (Scheme 2.9).  
 
The Zn(II) complex was obtained in a templated process refluxing mono(4-allyl-3-thiosemicarbazone) 
acenaphthenequinone (16) in acetic acid with thiocarbohydrazide and Zn(OAc)2 for 30 h. The 
product (22) was precipitated with diethyl ether, filtered, washed with more diethyl ether and dried. The 
corresponding Ga(III) complex was obtained by reaction with GaCl3 heating in methanol by 
transmetallation of Zn(II) with Ga(III). The incorporation of gallium improves the fluorescence 
properties of the complex and constitutes a cold complex that could undergo potential radiolabelling 
with 68Ga. The gallium complex (23) was precipitated with dichloromethane, washed with diethyl ether 




Scheme 2.9: Synthesis of a Ga(III) acenaphthenequinone bis(thiosemicarbazonato) complex with a 
free amino group. 
 
The presence of a free amino group in this novel Ga(III) complex makes possible its incorporation in 
the nanoprobe forming an amide bond by simple carboxylic acid activation chemistry. 
  




2.5 Investigations into other aromatic dicarbonyl starting materials 
The difficulties encountered in the synthesis of unsymmetrical bis(thiosemicarbazone) ligands and 
complexes leading to mixtures, decomposition or metathesis-like exchanges can be attributed to the 
system’s inherent rigidity and planarity that makes impossible the free rotation of the C-C bond between 
the keto groups. All these factors hinder the incorporation of the second thiosemicarbazone to the ligand. 
In addition, the templated synthesis of metal complexes of acenaphthenequinone 
mono(thiosemicarbazone) ligands can compete with other processes as the formation of 
mono(thiosemicarbazonato) metal complexes in a distorted octahedral geometry when the ligand reacts 
with the metal centre in a 2:1 fashion. This behaviour of a thiosemicarbazone moiety acting as a 
tridentate ligand has been extensively observed in the literature but never exploited with 
acenaphthenequinone backbones for imaging. 
For these reasons, other aromatic dicarbonylic starting materials were explored in the formation of metal 
complexes. The synthesis of mono(thiosemicarbazonato) complexes was also explored with 
1,2-dicarbonylic compounds while the reactivity of others towards the synthesis of unsymmetrical 
ligands and complexes was evaluated. Furthermore, it was anticipated that the extended aromaticity of 
some of the examples may help to enhance the fluorescence yield. 
 
On a first basis, the cleavage of the C-C bond connecting the carbonyl groups of acenaphthenequinone 
was attempted. The oxidative cleavage of acenaphthene-1,2-diol to give the dialdehyde has been 
reported in the literature.15 This reaction would yield an aldehyde, a much more reactive starting material 
where the rigidity would no longer be a restraint and unsymmetrical ligands could be prepared as long 
as the condensation with the thiosemicarbazides can be controlled stoichiometrically. Therefore, 
acenaphthenequinone was reduced to obtain acenaphthene-1,2-diol using sodium borohydride 




Scheme 2.10: Synthesis attempt of naphthalene-1,8-dicarbaldehyde. 
 
The reaction was conducted as described in the literature and the product obtained as a beige solid.16 
The oxidative cleavage, however, did not work as expected. The oxidative procedure, first described by 
Criegee et al., consisted in the reaction of acenaphthene-1,2-diol with lead acetate in benzene to give 
the corresponding dialdehyde.15, 17 The original reaction conditions were tested with the exception of 




benzene that was substituted for toluene. However, the isolated solid did not contain the desired product 
as demonstrated by 1H NMR. The reaction was repeated varying different parameters as solvent (using 
benzene as in the original reference), a fresh batch of lead acetate and prolonging the reaction time. 
However, in our hands, the isolated solid contained a mixture of aromatic compounds, none of them 
being the desired product as the characteristic aldehyde resonance at ca. 10 ppm was not observed by 
1H NMR spectroscopy. 
 
The oxidative cleavage of 1,2-diols has also been described with other oxidative agents. One of the most 
popular is sodium metaperiodate, which can be supported on silica to allow its use in organic solvents.18, 
19 Therefore, the reaction was attempted using NaIO4 supported on silica and the diol in 
dichloromethane. Despite stirring the reaction mixture for several hours and heating to reflux in CH2Cl2, 
the isolated and purified product was not the expected naphthalene-1,8-dicarbaldehyde. The attempts to 
obtain the dialdehyde from the oxidative cleavage of acenaphthene-1,2-diol were not pursued any further 




Scheme 2.11: Synthetic protocols for phenanthroline 2,9-bis(thiosemicarbazone) derivatives. 
 
Alternatively, a related aromatic aldehyde derivative was obtained from neocuproine by oxidation with 
SeO2 (Scheme 2.11, first step). In this case, the dialdehyde was readily obtained by refluxing 
neocuproine hydrate in the presence of SeO2 in dioxane. The residues of SeO2 were removed by filtration 
through celite first and dissolving the dry product in DMF to be precipitated with water. The effect was 
rapidly observed as the pink colour disappeared to obtain the product as an off-white solid. 
The use of 1,10-phenanthroline-2,9-dicarbaldehyde for the preparation of unsymmetrical ligands was, 
however, limited due to the enhanced reactivity of the aldehyde groups compared to the keto groups that 
yielded the bis(substituted) compounds in all the cases (Scheme 2.11). The attempt to control the 
substitution stoichiometrically, controlling the equivalents of HCl or by addition at low temperatures 
failed and the reaction always resulted with the bis(thiosemicarbazone) as the product.  
 




The reaction was extended to all the commercially available thiosemicarbazides mentioned in the 
previous section that resulted in the bis(thiosemicarbazone) ligands obtained in moderate to high yields. 
These compounds may present interest as imaging agents in the case that the complexation reaction with 
different metals like Zn(II), Fe(III) and Ga(III) is possible. Accordingly, the reactivity of this new class 
of symmetrical bis(thiosemicarbazone) ligands was explored with different metals. The preliminary 
results with zinc(II) and gallium(III) proved unsuccessful. The reaction with copper(II) acetate in DMF 
resulted in a colour change from yellow to light brown but the isolated product turned out to be just the 
starting material. Differently, the addition of FeCl3 caused a colour change and the coordination could 
be detected by mass spectrometry. However, the geometry of the product could not be confirmed as 
Fe(III) is paramagnetic and NMR techniques could not be employed. A plausible coordination mode 
considering the exact mass obtained in mass spectrum, indicating the loss of 4 protons with respect to 
the ligand, could indicate towards the binding through the hydrazinic nitrogens and the sulphur atoms 
(after the thione-thiol equilibrium is displaced to the thiol form). Unfortunately, the poor solubility of 
this class of ligands and the lack of reactivity towards metals in the preliminary experiments were not 
encouraging to investigate their reactivity in more detail during this project. 
In the search for different aromatic dicarbonylic compounds and looking into the possibility of preparing 
mono(thiosemicarbazonato) metal complexes, two related derivatives to acenaphthenequinone are 




Scheme 2.12: Structures of aceanthrenequinone (left) and phenanthrenequinone (right). 
 
The similarity of these diketones to acenaphthenequinone encouraged us in the search for novel aromatic 
compounds to form thiosemicarbazones and thiosemicarbazonato metal complexes. Considering the 
success in the use of microwave-assisted heating for the synthesis of thiosemicarbazones in the previous 
section, this method in both the synthesis of the ligands and the synthesis of the complexes was explored 
as it has demonstrated to reduce dramatically the needed reaction time and to improve the yield in some 
cases. In addition, another aromatic 1,2-diketone was prepared from pyrene. The aromatic starting 
material was oxidised with RuCl2 to obtain 4,5-pyrenedione (Scheme 2.13). The product was purified 
by column chromatography and re-crystallised from CH2Cl2 / hexane. 
 
 





Scheme 2.13: Preparation of pyrene-4,5-dione from pyrene. 
 
The preparation of mono(thiosemicarbazones) with the four different aromatic diketones was conducted 
applying the optimised reaction conditions for microwave synthesis described in the previous section. 
The general method involved the addition of the 1,2-diketone and the thiosemicarbazide to a small 
volume of ethanol (ca. 5 mL), the sonication for 2 – 3 min to homogenise the mixture, the addition of 
2 – 3 drops of conc. HCl and heating under microwave irradiation for 10 min at 90 ºC (Scheme 2.14). 
The suspensions were filtered, washed with methanol or ethanol and diethyl ether to give the pure 
ligands in most cases. The reactions proceeded with good yields for all derivatives in the range of 




Scheme 2.14: Preparation of mono(thiosemicarbazone) ligands with different aromatic backbones. 
 
 




The reaction with 9 was also conducted to evaluate the applicability of the method and to obtain a 
derivative with a free amino group that could be further functionalised. The reaction proceeded with 
good yields and the desired product was obtained with the deprotection occurring along the formation 
of the thiosemicarbazone in a one-pot process that did not seem to affect the selectivity in the 
thiosemicarbazone formation or to produce side-products in an observable proportion. This 
methodology allows the condensation and deprotection to be performed in a one-pot reaction saving one 
synthetic step.  
 
The novel ligands were characterised by routine spectroscopic methods. The 1H NMR spectra were 
comparable to acenaphthenequinone derivatives. The resonances of the aromatic region are 
characteristic of each backbone and are all present as the symmetry of the starting material is lost with 




Figure 2.8: Aromatic region of the 1H NMR spectrum (d6-DMSO) of the mono(4-ethyl-3-
thiosemicarbazone) ligands. 1) Aceantrenequinone derivative, 2) acenaphthenequinone derivative, 3) 
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The resonances that changed in a more significant manner were the corresponding to the NH groups that 
were considerably deshielded compared to acenaphthenequinone in certain cases. The hydrazinic NH 
resonances appear as a singlet between 14 – 15 ppm for phenanthrenequinone and pyrene-5,6-dione 
thiosemicarbazones while acenaphthenequinone and aceanthrenequinone thiosemicarbazones present 
the corresponding resonances between 12 – 13 ppm (first signal in spectra 1 – 4 in Figure 2.8). The 
amino NH resonances, in contrast, did not change significantly between species and appear at 9 – 10 
ppm presenting the multiplicity that results of the interaction with the neighbouring substituent (second 
resonance (triplet) in spectra 1 – 4 in Figure 2.8 for ethyl substituted derivatives).  
 
In the case of pyrene-4,5-dione thiosemicarbazones with methyl (40), ethyl (41), allyl (42) and phenyl 
(43) substituents, suitable crystals for X-ray diffraction could be obtained and the structures resolved 
(Figure 2.9). The crystals were obtained by the vapour diffusion method, dissolving the compound in 
CH2Cl2 and using hexane as co-solvent. It can be observed in Figure 2.9 that all the members in this 
family of compounds in the solid phase present intramolecular hydrogen bonds between the hydrazinic 
proton and the oxygen from the ketone group.  






Figure 2.9: ORTEP representations of pyrene-4,5-dione mono(substituted) ligands (left) and 
molecular structures showing the unit cells (right). a) Methyl derivative, b) ethyl derivative, c) allyl 













A selection of parameters of the mono(substituted) ligands are summarised in Table 2.5. It can be seen 
how the C1-C2 distance does not vary much among the ligands and has an average value of 1.48 – 1.49 
Å. The increase seems to be related to the bulkiness of the substituent in the R group of the 
thiosemicarbazone. The angles comprised between the O-C1-C2 atoms have a value of 121º for all the 
compounds in accordance with a sp2 carbon atom. The tendency observed is opposite to the distance and 
decreases with the size of the substituent. The complementary angle between the C1-C2-N1 atoms have 
a value of ca. 124º and a trend to increase as the C1-C2 distance as mentioned above.  
The molecules are highly planar with the thiosemicarbazone, the R substituent in the terminal amino 
group and the backbone in the same plane with small deviations. The exception is the phenyl derivative 
where the Ph aromatic ring is out of the plane formed by the backbone and the thiosemicarbazone unit 
by an angle of 56.62º. The distance between planes in the solid packing is close to 3.2 Å except for the 
Ph derivative where this distance is larger, with a value of 3.556 Å. This difference can be explained by 
the displacement of the Ph ring out of the plane as already mentioned above.  
 
Table 2.5: Selected bond distances and angles for pyrene-4,5-dione thiosemicarbazones derivatives in 
Figure 2.9. 
 Me (40) Et (41) Allyl (42) Ph (43) 
O-C1 (Å) 1.2537 (3) 1.2373 (1) 1.2355 (17) 1.2328 (15) 
C1-C2 (Å) 1.4806 (4) 1.487 (2) 1.4899 (18) 1.4968 (16) 
N1-C2 (Å) 1.3172 (3) 1.3113 (1) 1.3078(17) 1.3043 (16) 
O-C1-C2 (º) 121.0 (6) 120.99 (14) 120.74 (12) 120.63 (11) 
C1-C2-N1 (º) 123.1 (6) 123.50 (14) 123.65 (12) 124.04 (11) 
Distance between 
planes (Å) 
3.141 3.257 3.175 3.556 
 
The same distances and bond angles have been summarised in Table 2.6 for mono(4-allyl-3-
thiosemicarbazones) with different backbones (one aliphatic and four aromatic), specifically 
butane-2,3-dione, acenaphthenequinone (16), phenanthrenequinone (38), aceanthrenequinone (34) and 
pyrene-4,5-dione (42). The crystallographic data for the mono(4-allyl-3-thiosemicarbazone) butane-2,3-
dione were obtained from the literature20, for 42 was obtained during this project and for 16, 34 and 38 
the crystal structures were provided by Dr S.I. Pascu. The distances in the aliphatic derivatives are 
similar to the ones found for thiosemicarbazones with aromatic backbone. The O-C1-C2 and C1-C2-N1 
angles are, however, smaller than in any of the aromatic analogues. This can be attributed to the E 
disposition of the keto and imino group along the C1-C2 bond as the free rotation is allowed in the 
butane-2,3-dione derivative. 




Table 2.6: Comparison of selected crystallographic parameters for mono(4-allyl-3-





16 34 38 42 
O-C1 (Å) 1.223 (2) 1.23 (1) 1.227 (2) 1.238 (2) 1.2355 (17) 
C1-C2 (Å) 1.494 (3) 1.50 (1) 1.518 (2) 1.491 (2) 1.4899 (18) 
N1-C2 (Å) 1.297 (2) 1.30 (1) 1.293 (2) 1.308 (2) 1.3078(17) 
O-C1-C2 (º) 119.2 (2) 127.1 (7) 124.6 (1) 121.0 (1) 120.74 (12) 
C1-C2-N1 (º) 115.4 (2) 128.8 (7) 128.2 (1) 123.9 (1) 123.65 (12) 
Distance between 
planes (Å) 
4.357 - 3.067 2.935 3.175 
 
 
The different aromatic backbones present equally similar values for bonds and distances. The distance 
O-C1 increases in the fashion: 34 < 16 < 42 < 38 and so does the N1-C2 distance. The C1-C2 distance 
follows a different trend decreasing as in 42 < 38 < 16 < 34. The O-C1-C2 and C1-C2-N1 angles follow 
a trend as in 42 < 38 < 34 < 16. Despite the change in order for some of the compounds, an underlying 
trend can be observed and related to structural characteristics. The derivatives presenting a five-
membered ring fused to the aromatic core (acenaphthenequinone and aceanthrenequinone) are grouped 
and so are the derivatives with a six-membered ring attached to the aromatic core when considering 
structural parameters. The O-C1 and N1-C2 distances are larger in species presenting the six-membered 
ring while the C1-C2 distance is shorter compared to the five-membered containing compounds. 
Furthermore, the O-C1-C2 and C1-C2-N1 angles are larger in derivatives presenting the six-membered 
cyclic ring fused to the aromatic group.  
 
The packing arrangements can be observed in the right column of Figure 2.9. All the ligands are arranged 
in the solid state in zig-zags and present interactions with molecules in the planes above and below the 
aromatic core. The solid packing of these compounds revealed the presence of short contact interactions 
between the different molecules. The distance between planes and the aromatic character of these 
compounds point to the presence of π – π interactions and observing the structures, the character could 
be attributed to parallel displaced π – π interactions with the exception of the phenyl derivative (43) that 
also presents perpendicular y-shaped interactions. This fact can be seen as a promising feature as pyrene 
derivatives have been used to attach groups of interest to carbon nanomaterials and to target specific 
biological structures like the cell nucleus or intercalators in DNA.21-23 
  




2.5 Synthesis of novel mono(thiosemicarbazonato) metal complexes 
The formation of unsymmetrical bis(substituted) complexes with acenaphthenequinone has revealed 
challenging and even the formation of bis(substituted) ligands utilising phenanthrenequinone, 
aceanthrenequinone or pyrene-4,5-dione proved unsuccessful applying the microwave conditions 
optimised for acenaphthenequinone.  
A possible route to avoid the difficulties observed when trying to obtain the bis(substituted) ligands 
and/or complexes is to prepare the mono(thiosemicarbazonato) complexes. In this class of compounds, 
the thiosemicarbazone acts as a tridentate ligand with the oxygen being an additional donor atom. There 
are numerous examples of tridentate thiosemicarbazones binding to different metals in the literature. 
Even the preparation of mono(thiosemicarbazonato) acenaphthenequinone complexes has been 
described. In the work by Rodriguez-Argüelles et al., the ligand mono(thiosemicarbazone) 
acenaphthenequinone was prepared and the Fe(II), Ni(II), Cu(II) and Zn(II) mono(thiosemicarbazonato) 
complexes formed.24  
The preparation of the complexes was carried out refluxing the chlorides or acetates of the metals in 
ethanol. The reaction time varied between 3 and 7 h depending on the metal. The interest of the authors 
in these compounds was motivated by the biological properties of similar thiosemicarbazones. However, 





Figure 2.10: Structure of Ni(II) mono(thiosemicarbazonato)2 complex. Figure reproduced from ref. 24 
with permission from the publisher. 




Initially, the formation of Zn(II) mono(thiosemicarbazonato) complexes with Zn(OAc)2 was attempted. 
The derivatives containing an allyl substituent of all aromatic backbones were selected as a model. The 
described synthetic methods consisted in refluxing in ethanol for several hours, as mentioned above, but 
after the success of microwave-assisted synthesis on the preparation of the ligands, the suitability of 
microwave heating to the synthesis of the complexes was assessed. The temperature was kept constant 
at 90 ºC as this temperature has shown to enhance the reaction speed without the products showing signs 
of decomposition. It was found that the Zn(II) mono(4-allyl-3-thiosemicarbazonato)2 complexes could 
be successfully obtained in just 1 h applying microwave heating thus avoiding prolonged heating times 
(Scheme 2.15). The products were isolated by filtration, washed with diethyl ether and dried under 




Scheme 2.15: Synthetic conditions for Zn(II) mono(thiosemicarbazonato)2 complexes. The proposed 
coordination mode to the metal is based on X-ray structures of similar species present in the 
literature.24, 25 
 
The normalised HPLC chromatograms of the Zn(II) complexes can be seen on Figure 2.11. The 
complexes were obtained in high purity with the presence of minor impurities. The retention times are 
in the 10 – 13 min range using HPLC method A (see Chapter 7 for details).  
The 1H NMR spectra of the complexes were also acquired and the disappearance of the characteristic 
resonance of the hydrazinic proton was observed when compared to the ligand, supporting the proposed 
coordination mode showed in Scheme 2.15. The spectra were complex to interpret, probably due to the 
presence of isomers, the two ligand units being inequivalent and to long-range couplings between 
protons. 
 






Figure 2.11: Normalised HPLC chromatogram of Zn(II) mono(4-allyl-3-thiosemicarbazonato)2 
complexes 45, 46, 47 and 48. 
 
The exact mass could be obtained for most of the complexes using ESI-TOF ionisation in positive mode 
and the masses corresponded to the protonated molecular ions, which is in accordance with the 
coordination mode proposed above.  
 
Table 2.7: Spectral properties of BTSC complexes in DMSO solutions. 
 
Compound λmax-abs (nm) λmax-em (nm) Δλ (nm) Φf 
23 482 638 156 0.022 
45 360 628 268 4.48x10-5 
47 517 610 93 3.83x10-5 
48 538 621 83 6.34x10-5 
46 427 542 115 4.81x10-5 
 
The UV-vis and fluorescence spectra were studied to evaluate their potential as optical imaging agents. 
The summary of the UV-vis and fluorescence properties such as maximum absorption wavelength, 
maximum emission wavelength, Stokes shift (Δλ) and quantum yield (Φ), are summarised in Table 2.7. 
The properties of Ga(III) complex 23 have also been included for comparison. All the complexes but 

























Figure 2.12: Normalised UV-vis spectrum (black line) and fluorescence spectrum (blue line) of 23 in 
DMSO. 
 
The emission wavelengths are in the visible region at ca. 600 nm except for the complex including the 
pyrene-4,5-dione backbone (46) which is at 542 nm. The Stokes shifts are large for all the complexes. 
The quantum yields are low for all the mono(thiosemicarbazonato) complexes with respect to other 
inorganic fluorophores. Despite being a different thiosemicarbazonato species, it can be observed how 
in the Ga(III) bis(thiosemicarbazonato) complex (23) the quantum yield increases in several orders of 
magnitude compared to the Zn(II) mono(thiosemicarbazonato) complexes. 
 
In an attempt to generalise the synthetic approach to other metals, the same microwave-assisted 
conditions were applied with Cu(OAc)2. However, the reaction outcome was not as straightforward as 
with Zn(II). A colour change was observed from the starting materials and the products were observed 
by mass spectrometry but the reaction mixture contained decomposition products observed as dark 
residues in the crude reaction mixture and several peaks in the mass spectra. This result indicates that 
the synthetic method is metal-dependant and would need to be optimised for every metallic species. In 
the case of gallium, a colour change was initially observed in the reaction when GaCl3 was added to a 
suspension of the thiosemicarbazone in ethanol but only the starting material was recovered after 
heating. The preparation of this metal complexes is most certainly possible based on the results shown 
above and the precedents in the literature. However, the optimisation of the reaction conditions for 


















2.6 Extended mono(thiosemicarbazone) ligands 
Due to the nature of many targeting molecules, like peptides, it is common that the coupling with the 
fluorophore would be made via an amide bond. This fact highlights the need of the presence of a 
carboxylic acid in the thiosemicarbazonato complex. There are some examples in the literature regarding 
the introduction of a carboxylic acid moiety into a thiosemicarbazonato complex. Dilworth et al. 
functionalised a 2,3-butanedione molecule to have a benzoic acid in the backbone. This benzoic acid 
was then employed to couple the complex to a targeting peptide, namely octreotide.8 Following another 
strategy, an amino functionalised ligand was reacted with succinic anhydride. The product of the ring-
opening reaction after work-up was the corresponding 4-oxobutanoic acid. However, the efficiency of 
the reaction was not outstanding producing mixtures of difficult separation. In the same work, a more 
successful alternative was described to introduce the desired carboxyl functionality that consisted in the 
coupling with a protected glutamine derivative forming an amide bond. This way, the desired group was 
obtained from an amino-functionalised thiosemicarbazone and additionally, two protected side groups 
were added obtaining a bipodal linker that could be selectively deprotected. In this project, the last 
approach was adopted as the functionalisation of the aromatic backbone can produce selectivity 
problems and a variety of amino-functionalised thiosemicarbazone ligands has already been synthesised. 
 
The coupling of the protected glutamine derivative was evaluated as a proof of principle for 
thiosemicarbazones based on aromatic backbones. Fmoc-Glu(OtBu)-OH, a commercial derivative, was 
activated with pyBOP in DMF. The role of pyBOP in carboxylic acid activation is detailed in the 
following chapter. The deprotected amino-functionalised thiosemicarbazone derivative was added and 
the reaction mixture stirred at room temperature overnight (Scheme 2.16). The introduction of the amino 
acid further improves the solubility properties of the thiosemicarbazone ligand in organic solvents and 




Scheme 2.16: Coupling of amino-functionalised thiosemicarbazone with Fmoc-Glu(OtBu)-OH. 
 




The success of the coupling with the protected amino acid expands the reactivity towards 
mono(thiosemicarbazonato) complexes and opens the way for the attachment to biomolecules or 
nanomaterials. 
  




2.7 Evaluation of novel complexes in vitro 
The complexes prepared in the previous two sections proved to be fluorescent and based on the 
promising results of acenaphthenequinone thiosemicarbazones in imaging in the past, the complexes 
were tested in vitro in PC-3 prostate cancer cells. 
The compounds were added in 100 µM final concentration dissolved in serum free medium (1% DMSO) 
and incubated in living prostate cancer, PC-3, cells for 15 min at 37 ºC. After washing the excess of 
compounds from the cells’ dish with PBS and restoring the serum-free medium, the single photon 




Figure 2.13: Single photon confocal microscopy images of compounds 45 (1), 46 (2), 47 (3) and 48 
(4) in PC-3 cells after 15 min incubation at 37 ºC where a) DIC image, b) blue channel, c) green 
channel, d) red channel and e) overlay of a)-d). Scalebar: 50 µm. 
 
4. a) b) c) d) e) 
2. a) b) c) d) e) 
1. a) b) c) d) e) 
3. a) b) c) d) e) 




The results can be observed in Figure 2.13 for compounds 45 to 48 and Figure 2.14 for compound 23. 
The complexes showed a certain degree of precipitation when the DMSO solutions were added to the 
serum-free medium, especially 45. Consequently, in further in vitro imaging experiments with this 
family of compounds the working concentration needs to be under 100 µM. 
 
The uptake of the complexes by the cells was observed and the complexes were concentrated into the 
cytoplasm with no access to the cell nucleus. Despite no toxicity tests being performed during this initial 
in vitro testing, the acenaphthenequinone based complex 45, the phenanthrenequinone based complex 
47 and the gallium complex 23 seemed to induce cytotoxicity as the shape of the cells varied after 
incubation with the compound as observed in the confocal images. This can be attributed to cytotoxic 
effects causing cell death by mitochondrial disruption as it has been reported before for Zn(II) 
bis(thiosemicarbazonato) acenaphthenequinone complexes.26 The fluorescence response showed 
activity in all channels (blue, green and red) due to the broad fluorescence emission profile of the 




Figure 2.14: Single photon confocal microscopy images of compound 23 in PC-3 cells after 15 min 
incubation at 37 ºC where a) DIC image, b) blue channel, c) green channel, d) red channel and 
e) overlay of a)-d). Scalebar: 50 µm. 
 
The fluorescence emission profile of 23, however, is narrower and there is virtually no fluorescence 
response in the blue and red channels. The fluorescence intensity of Zn(II) mono(thiosemicarbazonato) 
compounds in vitro seemed to be higher for complex 48. However, no direct correlations can be made 
with the photophysical properties of the complex, as the quantum yield, because the comparison between 
confocal images is not quantitative and other factors as precipitation problems may have a considerable 
effect in the actual concentration of the complex entering the cells. 
The distribution of the complexes in the cells seems to be favoured in small vesicles observed as highly 
fluorescent points. This could indicate the uptake of the complexes into the lysosomes or mitochondrias 
as this preference has been described before for other acenaphthenequinone bis(thiosemicarbazonato) 
complexes in the literature.6, 26 However, co-localisation experiments are needed to ascertain the 
distribution of these compounds inside the cell.   
a) b) c) d) e) 





In this chapter, several novel thiosemicarbazides bearing a protected amino group have been synthesised 
from protected diamines. The corresponding acenaphthenequinone thiosemicarbazones were prepared 
in an acidic ethanolic solution with acetic acid as it was observed that the protecting group was labile in 
the presence of small amount of conc. HCl. This constitutes the first example of functional 
acenaphthenequinone thiosemicarbazone ligands. 
The use of conventional heating of the mono(thiosemicarbazone) ligands to obtain the bis(substituted) 
species in an acidic solution with acetic acid proved unsuccessful so the use of microwave-assisted 
heating was explored. The results indicated that a strong acid was necessary in the formation of the 
bis(thiosemicarbazone) ligands. The use of microwave heating enhanced the reaction speed and the 
deprotection of the product could be controlled by adding an equimolar amount of conc. HCl. Therefore, 
for the first time in the chemistry of thiosemicarbazones containing aromatic backbones, microwave-
assisted heating was applied, demonstrating to be an advantageous technique reducing reaction time 
from hours to minutes and obtaining improved or comparable yields with reported protocols. The 
mono(thiosemicarbazone) and symmetrical bis(thiosemicarbazone) ligands were obtained using this 
method in yields typically above 70%. 
However, the synthesis and purification of unsymmetrical bis(substituted) ligands and complexes 
proved incredibly challenging. The application of microwave-assisted heating to the preparation of the 
bis(substituted) ligands to overcome the lack of reactivity under conventional conditions led to an 
unreported metathesis exchange of thiosemicarbazone groups that yielded a statistical mixture of 
products. The synthesis of the complex in a template process did not produce reproducible results. 
Despite these difficulties, unsymmetrical bis(thiosemicarbazonato) complexes of Zn(II) and Ga(III) with 
a free amino groups were obtained in a one-pot process from the mono(4-allyl-3-thiosemicarbazone) 
ligand and thiocarbohydrazide. 
 
In addition, a number of novel aromatic dicarbonyl compounds, namely phenanthrenequinone, 
aceanthrenequinone, pyrene-4,5-dione and 1,10-formyl-2,9-phenanthroline, have been explored as 
starting materials for the synthesis of novel thiosemicarbazone ligands. All of them produced the desired 
products in good yields applying microwave conditions optimised during this work. In the case of the 
phenanthroline group, the bis(substituted) product was obtained due to the enhanced reactivity of the 
aldehyde groups. The mono(substituted) ligands obtained with novel aromatic groups have been used 
for the synthesis of mono(thiosemicarbazonato) metal complexes. The derivatives were reacted with 
Zn(II) and the complexes were obtained in reduced times with respect to the literature under microwave 
heating conditions. Additional work is needed to expand the chemistry of these ligands to other metals, 
such as for example, Cu(II) or Ga(III). 




The preparation of extended thiosemicarbazone ligands bearing carboxylic acid groups for the coupling 
with biologically active amines, as peptides, was explored and a promising result was obtained with a 
protected glutamine derivative. 
 
The fluorescent complexes obtained were tested in vitro in prostate cancer PC-3 cancer cells showing 
good uptake and the stronger emission, generally, in the green channel. The specific localisation of the 
complexes into the cell and the assessment of cytotoxicity to cancer cells require of further experiments. 
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Chapter 3 : Synthesis of bifunctional BODIPY fluorophores 
3.1 Overview 
Despite the unique characteristics of bis(thiosemicarbazonato) compounds (e.g. versatile chelators, 
potential multimodality, possible hypoxia selectivity), the metal complexes present a series of 
drawbacks, as challenging purification processes, reduced fluorescence intensity, poor solubility in 
biological media or difficulty in introducing reactive functional groups, when compared to organic dyes. 
Furthermore, the chemistry to produce functional unsymmetrical derivatives proved to be considerably 
challenging due to exchange reactions as described in Chapter 2. Therefore, the chemistry of a series of 
well-known organic dyes was explored to produce a functional fluorophore. BODIPY (4,4-difluoro-4-
bora-3a,4a-diaza-s-indacene) dyes have been profusely applied as labelling reagents, chemosensors, 
laser dyes or switches.1 A wide range of BODIPY derivatives are commercially available for the 




Scheme 3.1: General synthetic route for BODIPY fluorophores with the numbering of the BODIPY 
core in the final product. 
 
The chemistry of BODIPY derivatives is varied and depending on the substitution, the versatility can 
be enhanced. These derivatives can undergo electrophilic reactions, substitution reactions or metal-
catalysed coupling reactions (e.g. Sonogashira, Heck, Stille, Suzuki) when halogenated atoms are 
present.3, 4 The advantageous properties attributed to BODIPY dyes include their photophysical 
properties. BODIPY dyes are generally strong UV-vis absorbents and emit sharp fluorescence peaks 
with high quantum yields. Regarding their stability, these species are generally not affected from 
changes in polarity or pH in the medium and are moderately stable under physiological conditions. 
Furthermore, the modification of the structure provides enhanced stability, water solubility or tunable 
fluorescence properties.5 In addition, BODIPY dyes can also act as multimodal imaging probes. The 
possibility to construct a multimodal probe by functionalising the BODIPY group with a chelator has 
been explored and different metals used (examples can be observed in Table 1.2). However, this is not 
necessary if the BODIPY core is radiolabelled by isotopic substitution of the fluorine atoms connected 
to the boron by 18F. 
 




The aim of this chapter was to obtain a series of functional BODIPY dyes able to be introduced in the 
nanoprobe, linking the nanomaterial and the targeting peptide. The possibility of obtaining derivatives 
emitting at different wavelengths, especially in the near infrared, were also explored. 
 
3.2 Synthesis of a bifunctional BODIPY derivative 
Fluorophores based on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) core were 
investigated taking in consideration all the properties cited above and with the target to obtain a 
fluorescent nanoprobe. Between the advantages described for BODIPYs probably the most important 
are the high quantum yields, broad range of substitution that can be obtained by modifying the starting 
materials, the varied reactivity (electrophilic reactions, coupling reactions, substitution reactions), their 
reasonable stability in different conditions and the possibility of varying their fluorescence properties 
by varying the core or substitution. 
 
BODIPY dyes are generally synthesised from the corresponding pyrroles in a condensation with 
aldehydes, acyl chlorides and acid anhydrides although the use of aromatic aldehydes is considerably 
more common in the literature. This condensation is followed by the boron complexation by the 
dipyrromethane intermediate, performed in most cases with BF3·OEt2. The dipyrromethane species is 
not generally isolated. Tetramethyl substitution in positions 1, 3, 5 and 7 tends to stabilise the BODIPY 




Scheme 3.2: Reaction conditions for the synthesis of 8-carboxyphenyl BODIPY (52). 
 
In this case, a literature procedure was followed to obtain a 4-carboxyphenyl group in position 8 of the 
BODIPY core by using 4-formylbenzoic acid and 2,4-dimethylpyrrole (Scheme 3.2).6 According to the 
authors of this work, the introduction of methyl groups in the 1, 3, 5, and 7 positions leads to an increase 
in quantum yield and extinction coefficient. The observed twenty fold increase in quantum yield 
compared to the species without substitution was related to a ‘push-pull’ electronic factor of the methyl 
groups, and steric hindrance that limits the free rotation of the phenyl group hence avoiding the 




intramolecular vibrational relaxation. The photostability of the compound was measured by irradiation 
with a 500 W lamp with 80% of the original absorption remaining after 16 h.6  
 
The carboxylic acid group will be the centre of all the following reactivity. The product obtained was 
purified by flash column chromatography and posterior recrystallisation. The yield could be improved 
if the crystallisation process was repeated. 
 
 
Scheme 3.3: One-pot synthesis attempt for compound 53. 
 
The following step was to functionalise 50 in a way that acted as a bifunctional dye. In order to achieve 
this goal, a protected lysine derivative (Fmoc-Lys(Boc)-OH) was employed. One of the protecting 
groups needed to be removed to use the free amine in the amino acid in the coupling to the fluorophore. 
Initially, the Fmoc group was removed by treating the amino acid with piperidine in DMF, resulting in 
the amino acid Lys(Boc)-OH (51). The activation of the carboxylic acid using N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl) and 1-hydroxybenzotriazole 




Scheme 3.4: Reaction conditions for the synthesis of 53 through the succinimidyl activated BODIPY. 






Figure 3.1: Two ORTEP representations of compound 52. Thermal ellipsoids represented at 50% 
probability. Hydrogen atoms have been omitted for clarity. 
 
However, the outcome of the reaction did not provide successful results even after increasing the 
reaction time (Scheme 3.3). Therefore, another activation strategy was followed where the activation of 
the carboxylic acid and the coupling were performed in a stepwise manner. The carboxylic acid in the 
BODIPY unit was reacted with EDC·HCl and N-hydroxysuccinimide following similar reaction 
conditions found in the literature (Scheme 3.4).7 The activated ester (52) was isolated and purified by 
flash column chromatography.  
 
Crystals suitable for single crystal X-ray crystallographic analysis were obtained for 52. ORTEP 
representations of the molecule in two different orientations can be seen in Figure 3.1 and the packing 
arrangement in Figure 3.2. A selection of bonds and angles are presented in Table 3.1. A selection of 
bonds and distances for the precursor (50) obtained from a crystal structure in a literature reference have 
been included for comparison. 




Table 3.1: Selected bond angles and distances for compound 50 and 52. Plane 1 is formed by the 
atoms of the dipyrromethene core excluding the methyl groups and fluorine atoms. Plane 2 is formed 
by the atoms in the phenyl substituent. Plane 3 is formed by the atoms of the succinimide group. 
 
Distance / angle 508 52 
N1-B (Å) 1.5486 (6) 1.5483 (18) 
B-F1 (Å) 1.397 (5) 1.3910 (19) 
B-F2 (Å) 1.398 (5) 1.3845 (19) 
N1-C5 (Å) 1.342 (5) 1.3465 (19) 
N1-C10 (Å) 1.407 (4) 1.3988 (17) 
O1-C24 (Å) 1.292 (5) 1.1854 (19) 
O2-C24 (Å) 1.253 (5) 1.4000 (19) 
O2-N3 (Å) - 1.3848 (15) 
F1-B-F2 (º) 108.1 (3) 109.52 (12) 
N2-B-N1 (º) 107.7 (3) 106.82 (11) 
N1-B-F1 (º) 109.9 (3) 110.18 (12) 
N1-B-F2 (º) 110.0 (3) 109.90 (12) 
O1-C24-O2 (º) 121.7 (4) 122.41 (14) 
C24-O2-N3 (º) - 112.50 (11) 
Angle planes 1 - 2 (º) 81.15 86.03 
Angle planes 1 - 3 (º) - 17.46 
Angle planes 2 - 3 (º) - 76.52 
 
 
The planarity of the BODIPY core is evident just by observing the representations of the structure in 
Figure 3.1. It is also evident that the phenyl substituent is almost perpendicular to the BODIPY core. 
This fact can be easily observed in Figure 3.1 but also confirmed by measuring the angle between the 
plane formed by the atoms in the dipyrromethene unit (excluding methyl groups and fluorine atoms, 
plane 1) and the plane formed by the carbon atoms in the phenyl group (plane 2) that is 86.03º. This 
angle increases from the carboxyphenyl BODIPY 50, where this angle has a value of 81.15º, as an effect 
of the substitution of the COOH group. The plane formed by the atoms in the succinimide substituent 
forms an angle of 17.46º with the dipyrromethene core and an angle of 76.52º with the phenyl group 
respectively. 
 







Figure 3.2: Molecular structure of 52 showing the unit cell. View along the c axis. Thermal ellipsoids 
represented at 50% probability. Hydrogens have been omitted for clarity.  
 
The F1-B-F2 angle has a value of 109.52º for 52 and it increases 1.42º compared to the starting material. 
The dihedral angle formed by F1-B-N1-C5 has a value of 61.35º respectively. The angles formed by N1 
with the boron atom and the two fluorine atoms (F1, F2) are very similar, differing in less than 1º. 
Similarly, the bond distances in the BF2 moiety, both are basically identical with a small difference of 
0.01 Å. In a different manner, the bond distances of N1 with the carbon atoms in the pyrrole group in 
50 and 52 are not equal. The N1-C10 distance in 52 is 1.3988 Å while the N1-C5 distance is considerably 
shorter, 1.3465 Å. Lastly, it can be observed how the O2-C24 distance increases with the formation of 
the ester bond from the starting material (1.253 and 1.292 Å) to the activated intermediate (1.4000 Å). 
The O1-C24-O2 angle, however, is kept relatively unchanged at ca. 122º. 
 
After the activated BODIPY was characterised, some reaction conditions were tested in the synthesis of 
53 (Scheme 3.4, second step). Initially, dichloromethane was used as a solvent and different reactions 
and times were tested but the observed conversion was not optimal. Therefore, the solvent was replaced 
for DMF and the best conditions resulted from heating compound 52 and the amino acid Lys(Boc)-OH 
to 60 ºC. The BODIPY-Lys derivative 53 was purified by flash column chromatography and obtained 
in good yield. Full characterisation was carried out for this compound although no crystals suitable for 
single crystal X-ray crystallography were obtained using the conditions previously employed for 52 
neither changing solvents nor crystallisation method. 







Figure 3.3: 1H NMR spectrum (CD3OD) of compound 53. [*Traces of residual solvents]. 
 
The 1H NMR spectrum of 53 can be observed in Figure 3.3. The characteristic pattern for the BODIPY 
group is conserved unchanged with respect to the starting materials including the resonances for the 
p-substituted aromatic group, the methyl groups and β protons as singlets. The resonances for the lysine 
group are observed upfield, being H-5 the most deshielded the resonance. 
 
The assignation of the 1H NMR spectrum was carried out using a 2D 1H-1H COSY spectrum 
(Figure 3.4). In this spectrum, the correlations corresponding to vicinal protons are displayed. However, 
in some cases, long range correlations can be observed. This is the case of β protons (H-15) and the 
methyl groups (H-14 and H-16) where a 4J correlation is observed. The resonance of H-5 has correlations 
with two resonances, corresponding to H-4 (highlighted in red in Figure 3.4). This is explained because 
the methylene group in H-4 is diastereotopic. The two geminal H-4 protons give separate resonances 
(multiplets at ca. 1.9 and 1.7 ppm) due to the presence of the adjacent chiral centre in position 5.  
 
H-1 can be identified as a terminal methylene because it has just one correlation with the overlapping 
resonances of H-2 and H-13. The singlets present in the aliphatic region correspond to the methyl and 
to the tert-butyl groups respectively. The assignation of H-8, H-9 and H-14, H-16 were realised based 
on chemical shift values encountered in the literature and in a 2D NOESY spectrum (see Appendix). 
 
 
H-8 H-9 H-15 




















Figure 3.4: 1H-1H COSY (CD3OD) spectrum of compound 53. 
  














3.3 Investigations into NIR emitting BODIPY fluorophores 
The window of the electromagnetic spectrum going from the near infrared (600 nm) to the far infrared 
(3 to 100 µm) has a series of advantages that the UV-vis region lacks, as a deep penetration in the tissues 
or the reduced biological processes/molecules emitting in this region. The absorption of haemoglobin, 
deoxy-haemoglobin and water has a minimum just above 600 nm. The absorption of water and 
haemoglobin starts to increase again at 1200 nm (Figure 3.5).9 Based on these advantages for 




Figure 3.5: Different optical windows in biological tissues against the effective attenuation 
coefficient. The first NIR window (pink shading) and second NIR window (grey shading) are 
represented. Figure reproduced from ref. 9 with permission from the publisher. 
 
The shift of the fluorescence emission maximum to the red has been achieved in BODIPY dyes by 
modifying the structure of the BODIPY core. This shift is also observed in aza-BODIPYS, where the 
carbon atom in the meso position has been substituted by a nitrogen atom (Figure 3.6, I, II). The 
preparation of extended aza-BODIPYS have also been explored although, no dramatic change in the 
maximum emission wavelength was observed. The extension of aromaticity is one example as in 
di(iso)indomethene dyes (Figure 3.6, III). The strategies mentioned so far imply the modification of the 
synthetic strategy and structure of the BODIPY to obtain rigid products that imply challenging synthesis 
and purification processes and limit further reactivity. However, the acidity of the methyl positions in 
the tetramethylated derivatives can lead to an alternative functionalisation strategy to obtain NIR 
emitting derivatives. Following a Knoevenagel-type reaction, the methyl groups can be condensed with 




an aldehyde, generally a benzaldehyde derivative, to extend the conjugation (Figure 3.6, IV).10 The 
introduction of 1, 2, 3 or 4 styryl moieties can be forced by changing the reaction conditions although 
the purification of reaction mixtures containing more than two derivatives has been described to be 
challenging. Tetrasubstituted derivatives can be obtained prolonging the reaction time11 although 
stepwise condensations has also been described12. The degree of red-shift observed in the fluorescence 




Figure 3.6: Structures of different BODIPY derivatives with NIR fluorescence emission maxima.1  
 
In spite of providing a smaller red-shift, the introduction of styryl groups has a number of advantages as 
conserving the majority of the structure of the BODIPY and other functionalities, being a post-synthetic 
modification in the BODIPY preparation and not requiring complex starting materials. In addition, a 
pair of similar fluorophores (before and after modification) with different absorption and emission 
wavelengths are obtained. Therefore, the acidity of the methyl groups was exploited in a Knoevenagel-
type reaction with p-dimethylaminobenzaldehyde. No examples of this reaction in the presence of a 
carboxylic acid group were found in the literature to the best of our knowledge thus no information 
about possible synthetic difficulties was available in advance. 




The reaction was attempted using the carboxylic acid derivative, 50, as starting material under 
Knoevenagel conditions except molecular sieves were used instead of a Dean-Stark apparatus 
(Scheme 3.5). The purification of the reaction mixture, however, proved difficult as the starting material 
and products had very similar retention factor and co-eluted under column chromatography conditions. 
Interestingly, only the mono(substituted) derivative was identified. This fact can be probably explained 
on the basis of the concentration of the reagents in the reaction mixture. 
 
 
Scheme 3.5: Reaction conditions attempted on the synthesis of a styryl-substituted BODIPY. 
 
Consequently, another strategy was attempted to obtain the red-shifted derivative. The final target of 
this modification was to obtain a bimodal ligand applying an approach of identical characteristics as the 
one described above. Following this reasoning, the intermediate ester was considered due to the reduced 
polarity, which may help during the purification, and the presence of examples of carboxyphenyl esters 




Scheme 3.6: Reaction of activated ester 52 under Knoevenagel conditions. 




However, when the previously attempted conditions were applied, BODIPY 52 reacted with the excess 
of piperidine forming an amide bond (Scheme 3.6). This derivative was nonetheless, isolated by flash 
column chromatography on silica and characterised. 
The possibility of purifying 54 from the reaction mixture was encouraging to further use 52 as a starting 
material. In order to overcome the undesired reactivity of the activated succinimide group, other non-
nucleophilic bases were tested (i.e. DIPEA and Et3N). Unfortunately, only the starting material was 
recovered in these reactions. The basicity of all amines is in the same range and although they should 
subtract the protons of the methyl group, the role of piperidine in the mechanism of the reaction is not 
trivial. As studied by Thelakkat et al., piperidine plays a principal role in the mechanism of the 




Scheme 3.7: Proposed mechanisms in a Knoevenagel-type condensation for BODIPYs. 
 




Two possible mechanisms have been described for a Knoevenagel reaction, namely the Hann-
Lapworth16 and the organocatalytic (Knoevenagel)17 mechanisms. In the first one, the base deprotonates 
the methyl group creating a methylene active intermediate that attacks the aldehyde forming a β-hydroxy 
intermediate (Scheme 3.7, top). This intermediate generates the vinylidene product by the loss of a water 
molecule.  
However, in the organocatalytic mechanism, piperidine also reacts with the aldehyde to produce a 
hemiaminal that can further react with another piperidine molecule to generate the aminal or the iminium 
ion by dehydration (Scheme 3.7, bottom). A β–amino intermediate results of the reaction with the acidic 
methyl group in the BODIPY that gives the vinylidene product by elimination of piperidine.15, 17  
 
The isolation by the corresponding aminal by Thelakkat et al. in their work about BODIPYs confirmed 
the idea that Knoevenagel-type reactions in these species occur through an organocatalytic mechanism. 
The lack of reactivity of 52 with tertiary amines indicates that this specific derivative obeys the same 
principle as the examples described in the literature hence piperidine plays a crucial role in the formation 
mechanism of the vinylidene product. Therefore, the use of the activated ester 52 in Knoevenagel 




Scheme 3.8: Reaction conditions for the preparation of the styryl-substituted BODIPY from 53. 
 
In light of these difficulties, the reaction was attempted with the BODIPY species 53, including the 
lysine moiety. The reaction was conducted under the same conditions using piperidine as a base in 
toluene with molecular sieves (Scheme 3.8). The product was isolated and purified by column 
chromatography followed by recrystallisation. The major observed product was the mono(styryl) 
derivative (55). The trans geometry of the styryl unit can be confirmed by looking at the characteristic 
coupling constant of the double bond resonances in the 1H NMR spectrum (3J = 16.2 Hz).  







Figure 3.7: Experimental (top) and predicted mass isotopic pattern (bottom) for 55. 
 
The ESI mass spectrum of the reaction product after column chromatography can be observed in 
Figure 3.7 along with the representation of the theoretical isotopic pattern. The base peak of the spectrum 
corresponds to the product [M–H]-. The photophysical properties of 54 and 55, including fluorescence 
emission maxima and quantum yields will be commented on in Section 3.6. 
 
  




3.4 Synthesis attempt of a BODIPY – thiosemicarbazone fluorophore 
The coupling of BODIPY 52 with a mono(thiosemicarbazone) ligand derivative was also attempted. 
The attachment of a BODIPY fluorophore to bis(thiosemicarbazonato) metal complexes has been 
described before in order to allow for the study of the thiosemicarbazonato aliphatic derivatives in vitro. 
Dilworth et al. reported the preparation of Ni(II), Zn(II) and Cu(II) complexes with different alkylic 
thiosemicarbazone backbones linked to a BODIPY fluorophore to study the stability of the compounds 
in vitro by two-photon fluorescence lifetime imaging measuring the lifetime distribution of the 
compounds in cells. 
 
In the case of the compounds prepared herein, the attachment of a BODIPY fluorophore to the ligand 
could help to enhance the fluorescence signal of the ligands or complexes for their use in vitro. 
Furthermore, the synthesis of mono(thiosemicarbazonato) complexes could be attempted following the 




Figure 3.8: Synthesis conditions applied for the synthesis of 59. 
 
The synthesis attempt of 59 was carried out applying the conditions evaluated in this chapter for the 
preparation of bifunctional derivatives. However, the starting material was not totally consumed as 
observed by TLC, even with prolonged reaction times. The application of microwave conditions heating 
the reaction mixture in DMF at 100 ºC for 20 min yielded the better conversion towards the product. 
The product could be detected by mass spectrometry in negative ESI mode as the molecular peak of the 
spectrum with a chlorine atom [M+Cl]- and a m/z value of 739.2696 with respect to the theoretical m/z 
value of 739.2605.  
 
The optimisation of the reaction conditions and evaluation of purification strategies constitutes a 
fundamental part of the future work needed prior of the potential application of these compounds as 
potential imaging probes.  




3.5 Deprotection attempts for the bifunctional BODIPY derivatives 
The next step in the preparation of the targeted nanoprobe involved the coupling of the fluorophore to 
the bombesin targeting peptide before the final step of supporting both on the functionalised SWNT. 
The mentioned final step requires the deprotection of the NHBoc group in the bombesin-BODIPY 
conjugate and the coupling with the terminal carboxylic acid functionalised nanotubes. 
 
In order to explore and optimise the deprotection reaction conditions, some tests were carried out using 
only the fluorophore. The removal of Boc protecting groups might be challenging in BODIPY species 
but it has been described to occur successfully using HCl 4 M in dioxane. The presence of minor 
decomposition was observed but the by-products were easily separated by chromatography.18 However, 
depending on the structure of the BODIPY dye, the deprotection was not achieved with protic acids as 
HCl, TFA or p-toluenesulfonic acid under mild conditions and the application of harsher conditions lead 
to the decomplexation of the BF2 moiety.19 Furthermore, the use of protic acids as HCl or TFA has been 
described as an efficient method to remove the BF2 moiety yielding the corresponding dipyrrins in 
quantitative yields depending on the substituents.20 The use of Lewis acids is an alternative to the use of 
Brønsted acids in the deprotection of tertbutoxycarbonyl groups.21, 22 The same reagent used in the last 
step of the synthesis of BODIPY dyes, BF3·OEt2, has been applied to the deprotection of Boc groups in 




Scheme 3.9: Conditions attempted in the deprotection of the Boc group in BODIPY 53. 
 
Unfortunately, in the case of 53, the use of these conditions proved unsuccessful (Scheme 3.9). The use 
of HCl 4 M in AcOEt lead to the decomposition of the starting material and only a pyrrole by-product 
was detected by 1H NMR. The use of BF3·OEt2 did not work as described in the literature and only a 
small conversion was observed by TLC even with large excesses of boron trifluoride and long reaction 
times. 




Furthermore, sodium iodide is another reagent that has been described to deprotect Boc groups in amino 
acids by the catalytic production of HI. However, in this case only the starting material was recovered.  
Surprisingly, neat TFA did not produce the removal of the BF2 group, and deprotected the starting 
material but the conversion was not complete, the reaction required long reaction times and the presence 
of decomposition products was also observed.  
 
In light of the difficulties encountered to remove the protecting group from the BODIPY fluorophore 
53, a different modification was pursued for the BODIPY dye. It was necessary that the deprotection of 
the amino group was conducted under mild conditions in order to avoid decomposition or racemisation 
of the peptide once the conjugate was obtained. Therefore, the complementary analogue of the amino 
acid was prepared by deprotecting the Boc group of the protected lysine instead of the Fmoc. The 
deprotection was achieved by stirring the amino acid in a solution of CH2Cl2 / TFA (1:1) for 3 h at room 
temperature, yielding the Fmoc-Lys-OH species 56. The subsequent coupling with activated BODIPY 
52 was successfully conducted following similar reaction conditions as previously described 
(Scheme 3.10). 
 
In this case, the deprotection did not present any problems and the reaction proceeded smoothly using 
piperidine (25% in DMF) as a base and stirring at room temperature for 3 h until the starting material 




Scheme 3.10: Synthesis and deprotection of a BODIPY dye with a bifunctional linker. 
 
The new BODIPY fluorophores were characterised using routine spectroscopic techniques. The 
1H NMR spectrum of 57 presented the characteristic aromatic resonances for the Fmoc protecting group 
along with the phenyl resonances of the BODIPY core in addition to the aliphatic resonances 
corresponding to the amino acid. 




The 1H NMR spectrum of 58 can be observed in Figure 3.9. The aspect of the spectrum is comparable 
to the one presented by 53 excluding the Boc group. It can be observed how the two protons attached to 
C-3 are diastereotopic due to the presence of the adjacent chiral centre. The multiplicity of H-2 is a 




Figure 3.9: 1H NMR spectrum (CD3OD) of compound 58 [*Traces of non-deuterated/partially 
deuterated solvents]. 
 
The observed deprotection problems for the Boc group, limited the introduction of the near-IR derivative 
55 in the targeted nanoprobe. However, a red-emitting targeted fluorescence conjugate can be prepared 
incorporating the targeting peptide. The details of the conjugation of the fluorophores with the targeting 
peptide are described in Chapter 5. 
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3.6 Spectral characterisation of prepared BODIPY fluorophores and preliminary tests 
in vitro 
The photophysical characterisation of compounds 53 to 58 was carried out by UV-vis and flurorescence 
spectroscopies. A summary of the spectral properties for compounds 53 to 58 can be found in Table 3.2. 
The quantum yields have been calculated according to the Equation 3.1 using [Ru(bipy)3]Cl2 as a 
reference. The characteristics of the starting material (50) have been included for comparison purposes. 
It can be observed how the modification of the starting material, 50, with the protected amino acid, either 
with the Boc or Fmoc protecting groups (53 and 57 respectively) does not change considerably the 
maximum absorption or emission wavelengths. These parameters remain virtually unchanged for the 
deprotected derivative 58. The λmax-abs  is observed at ca. 500 nm with the λmax-em at ca. 510 nm thus 
presenting a Stokes shift of only 10 nm. However, the quantum yields present considerable variations 
from the carboxyphenyl BODIPY to the species incorporating the amino acid, and these differences are 





Equation 3.1: Expression used to calculate quantum yield (where r refers to the reference 
[Ru(bipy)3]Cl2 in water, s refers to the compound of interest, A is the absorbance of the solution, E is 
the corrected emission intensity, I is the relative intensity and n is the refractive index of the 
solutions). 
 
The quantum yield of the starting material decreases when the Boc-protected lysine is introduced into 
the fluorophore (from 0.59 to 0.46). Surprisingly, the quantum yield when the Fmoc protected amino 
acid is introduced increases with respect to the starting material (from 0.59 to 0.85). The rationale behind 
this increase might be attributed to the bulky aromatic protecting group that makes the molecule more 
rigid and hinders the non-radiative relaxation from the excited state.  
 
However, this explanation is no longer applicable to the deprotected product 58, where the quantum 
yield decreases (0.81 vs. 0.85) but is still considerably higher compared to the starting material. 
Therefore the increase in quantum yield may be attributed to different factors and to the position of the 
carboxylic acid in the substituent could be one of them. In the second derivative, the carboxylic acid of 
the amino acid is separated from the BODIPY by a chain of five carbon atoms which can act in favour 
of intramolecular hydrogen bonding interactions enhancing the rigidity of the molecule. 
 












   




Table 3.2: Spectral properties of BODIPY derivatives in DMSO solutions. Data for 50 have been 
extracted from ref. 6 where the measurements were conducted in EtOH. 
 
Compound λmax-abs (nm) λmax-em (nm) Δλ (nm) Φf 
  506 500 509 9 0.59 
53 500 510 10 0.46 
54 601 694 93 0.03 
55 602 752 150 0.009 
57 499 510 11 0.85 
58 500 510 10 0.81 
 
 
In the case of the two derivatives incorporating N,N-dimethylstyryl units, it can be observed how the 
maximum absorption and emission wavelengths are effectively shifted to the NIR region of the spectra. 
The λmax-abs is pushed 100 nm until the 600 nm and the fluorescence emission maximum is shifted to 
almost 700 nm for 53 and to a longer wavelength (752 nm) for 55. It is worth mentioning that the 
quantum yields of these two species drop dramatically compared to the BODIPYs emitting in the visible 
range. The derivative presenting the Boc-Lys moiety, 55, presents the lowest quantum yield. The UV-vis 





Figure 3.10: Normalised UV-vis absorption spectra for 58 (black line) and 55 (blue line) and 























It can be clearly observed in Figure 3.10 how the visible emitting derivative, 58, has a sharp absorption 
and emission spectra while the Stokes shift is small. In the case of 55, the absorption and emission 
spectra are broad and the resulting Stokes shift is larger in the order of hundreds of nm. 
 
After the spectral characterisation of the dyes was conducted, the efficiency of as-prepared BODIPY 
compounds as imaging agents in PC-3 cells was evaluated. The compounds were added to PC-3 cells in 
serum free medium (1% DMSO) at a 20 µM final concentration and incubated for 15 min. The images 
were acquired immediately after in a confocal microscope. 
  
Derivatives 53 and 58 were strongly fluorescent in the green channel with excitation at 488 nm and 
emission at 518 nm (Figure 3.11). The two derivatives showed similar characteristics despite the 
differences in the configuration of the lysine linker. The uptake in the cells was concentrated in the 
cytoplasm and organelles with no apparent preference or uptake in the nucleus. BODIPY dyes are 
compounds known for targeting the cells endoplasmic reticulum (ER) and mitochondria. In fact, there 
are commercial dyes for ER staining based on the BODIPY core. However, in this case, the dye seems 
to be distributed over the cytoplasm although punctuation is observed around the nuclei. Co-localisation 




Figure 3.11: Single-photon confocal microscopy images of 53 (top) and 58 (bottom) in PC-3 cells 
after 15 min incubation, 20 µM 1% DMSO at 37 ºC where a) DIC image, b) green channel, excitation 
at 488 nm, emission at 518 nm and c) overlay of a) and b). Scalebar: 50 µm. 
 
a) b) c) 
a) b) c) 




Derivative 55 showed, however, an intense emission in the green and red channel due to the broader 
emission profile and the shift of the λmax-em towards the near infrared. In this case, the dye is also 
distributed in the cytoplasm with no nuclear uptake. However, the higher concentration seems to be 
displayed in the organelles, probably ER, around the nuclear membrane. Similarly, co-localisation 





Figure 3.12: Single-photon confocal microscopy images of 55 in PC-3 cells after 10 min incubation, 
20 µM 1% DMSO at 37ºC where a) DIC image, b) green channel, excitation at 488 nm, emission at 
518 nm and c) red channel, excitation at 561 nm, emission 785 nm d) overlay of a), b) and c). 











BODIPY fluorophores have a number of advantages compared to other organic or inorganic dyes as 
high quantum yields, narrow fluorescence emission peaks and possibility to tune their characteristics. 
In this chapter a BODIPY derivative bearing a carboxyphenyl function was used as a starting material 
to obtain bifunctional derivatives. The synthesis of a bifunctional derivative was achieved using a 
protected lysine with orthogonal amino protected groups. The compounds were obtained from the 
BODIPY N-succinimide ester after exploring other activation strategies for the acid that did not provide 
satisfactory results. 
The shift of the fluorescence emission wavelength from the visible to the NIR was also explored. This 
can be achieved in BODIPY dyes taking advantage of the acidic methyl groups in a Knoevenagel-type 
reaction that introduces one or more styryl groups. Under the reaction conditions tested, only the species 
with one styryl group was observed. The purification of these family of compounds proved especially 
challenging and the best results were obtained using the BODIPY-Lys(Boc) derivative as starting 
material. 
The removal of the Boc protecting group in the BODIPY-lysine compound was explored in order to 
optimise the reaction conditions and to avoid problems once the peptide-dye conjugate was prepared. 
Despite several examples being described in the literature, the deprotection of the Boc group included 
in the BODIPY resulted problematic. The most promising results were obtained where acids such as 
TFA were used and it was found that the long reaction times needed could compromise the integrity of 
the peptide by decomposition or racemisation. 
Consequently, the complementary BODIPY derivative with an Fmoc protecting group was prepared. In 
this case, the removal of the protecting group proceeded successfully in a short time using piperidine 
(25% in DMF).  
The spectral properties of the as-prepared BODIPY dyes were evaluated and the quantum yields 
measured. The carboxyphenyl starting material and all the compounds incorporating the amino acid 
showed identical absorption and emission properties and small Stokes shifts. However, the quantum 
yields varied, being considerably higher in the last derivatives prepared with the Fmoc protecting group. 
The red-emitting species showed shifted absorption maxima wavelengths in the order of 100 nm 
compared to the visible derivatives and emission maxima wavelengths shifted more than 200 nm. 
Unfortunately, in this case, the quantum yields were reduced several orders of magnitude.  
Finally, the most promising derivatives were tested in prostate cancer cells (PC-3) by confocal 
microscopy showing good uptake in the cellular cytoplasm and organelles and promising properties as 
fluorescence optical dyes. The specific location of the dyes in the cellular organelles requires of 
additional imaging experiments and co-localisation experiments.  
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Chapter 4 : Functionalisation of Single Walled Carbon Nanotubes 
4.1 Overview of functionalisation strategies 
Single walled carbon nanotubes (SWNT) have unique properties which make them promising probes 
for their use in biomedical and sensing fields.1-3 Their outstanding electrical and mechanical properties 
make them an excellent scaffold for the building of biosensors.3 Furthermore, the possibility of 
performing surface functionalisation, as well as filling functionalisation, has triggered a lot of interest 
for their application as delivery vectors with drugs or as part of imaging probes.  
Much research effort has been devoted to the purification of as-prepared SWNT after synthesis to 
remove residues of metallic impurities from the catalyst, fullerenes or amorphous carbon. The initial 
purification methodologies included washing with organic solvents to remove any soluble material such 
as fullerenes or treatment with acids to remove catalyst particles and amorphous carbon.4-6 Advanced 
purification methods were further developed including annealing or steam purification steps in order to 
remove the oxygen functionalities introduced during purification.7, 8 The development of these methods 
allowed for the production of high purity SWNT that are now available from advanced materials 
companies. Furthermore, the use of SWNT for biomedical applications requires of a functionalisation 
strategy to allow for the introduction of the molecules of interest, improve stability, and reduce the 
toxicity of pristine SWNT.9 In general, this process reduces the SWNT length, reduce their tendency to 




Scheme 4.1: Typical defects found in a SWNT: a) presence of COOH groups in the open end of the 
nanotube. Other groups as NO2, OH, H or =O have been reported, b) sp3 carbon atoms where R: H or 
OH, c) oxidative damage of the sidewall that generates a hole and the presence of COOH groups, d) 
presence of five or seven membered rings. Figure adapted from ref. 10. 




The chemistry and functionalisation strategies for SWNT have been covered in numerous reviews to 
date.11-14 The functionalisation methods for SWNT are generally classified in two categories: covalent 
and non-covalent modifications. 
Non-covalent functionalisation strategies are based on Van der Waals or electrostatic interactions and 
are normally conducted under mild conditions in standard organic solvents, or even aqueous media. 
Furthermore, this method presents the advantage of maintaining the integrity of the carbon lattice hence 
not affecting the intrinsic electrical or mechanical properties of the nanotube. The non-covalent 
functionalisation of SWNT is generally achieved by polymer wrapping, interaction with biomolecules, 
as DNA, or adsorption of small molecules, in most cases aromatic molecules where a π-π interaction is 
possible.15 However, non-covalently functionalised probes give rise to concerns of potential hazardous 
effects of the nanomaterial in case the interactions with the functional group are broken or displaced in 




Scheme 4.2: Examples of covalent functionalisation of SWNT. 
 
On the other hand, covalent functionalisation strategies create defects in the graphitic structure to 
introduce functionalities or to take advantage of the defects already present in the SWNT. A wide range 
of covalent functionalisation strategies have been described for SWNT.13, 16 The covalent 
functionalisation, however, is more robust and offers the advantage of controlling the degree of 




functionalisation to a greater extent and facilitating the characterisation of the produced nanomaterial 
compared to non-covalent methods. The most common strategies reported to covalently functionalise 
SWNT include oxidation, dipolar cycloadditions, halogenation, ozonolysis, acylation, etc. A selection 
of these strategies is displayed in Scheme 4.2. The functionalisation via 1,3-dipolar cycloadditions of 
SWNT has been especially popular for biomedical purposes.17 One of the disadvantages of 1,3-dipolar 
cycloadditions is that it requires a multistep synthesis to obtain the required starting material that reacts 
with the SWNT.18 
 
4.2 Initial functionalisation tests for SWNT 
All SWNT used were of advanced purity (Ellicarb® provided by Thomas Swan) which have been 
purified using a rigorous steam purification method, known to remove 98% of all metallic impurities.  
In this work, covalently modified SWNT were prepared for their integration in the imaging nanoprobe.  
Two initial functionalisation strategies were selected to obtain the nanoprobe: the oxidation with mineral 
acids and a modified version of the Tour reaction. These methods were selected as they have been well 
described in the literature, including their use for biomedical applications, and they are simple and 
efficient processes.19, 20 In addition, convenient functional groups as amines or carboxylic acids can be 
incorporated so the introduction of linkers in the nanomaterial can be conducted via amide chemistry. 
The two methods can be regarded as complementary since the first method has been described to 
functionalise preferentially SWNT tips while the second acts on the SWNT walls. 
 
Table 4.1: Selected oxidation strategies for SWNT described in the literature. 
 
Acid / mixture T (ºC)  Effect on SWNT Ref. 
HNO3 (2.6 M) 120 Effect on pre-existing defects only 21, 22 
HNO3 (conc.) 120 
Introduction of new functional groups, 
shortening 
23 
H2SO4 / HNO3 
(conc. v/v 3:1) 
100 New defects generated. Shortening observed 21, 24 
H2SO4 / H2O2 
(conc. v/v 4:1) 
22 
Shortening by action on pre-exisiting defects. 
Minimal carbon loss 
25 
70 
Shortening proportional to reaction time. 
Considerable carbon loss 
KMnO4 100 









The treatment of SWNT in acidic conditions has been applied to their purification in order to remove 
catalyst particles and amorphous carbon, and it is known to introduce oxygen-containing groups on the 
surface.6, 23 In some cases, the purification processes included an annealing step at high temperatures to 
remove the oxygen functionalities and close the nanotubes ends produced as a consequence of the 
treatment with strong acids. On the contrary, the functionalisation of SWNT by oxidation can in itself 
aim for the introduction of oxygen functionalities, especially carboxylic acids, to modify covalently the 
nanomaterial in further synthetic steps.  
 
The use of mineral acids as hydrochloric acid, nitric acid, sulphuric acid, a mixture of them or the 
inclusion of additives as H2O2 (in a 3:1 mixture with H2SO4 to produce piranha) or K2Cr2O7 (to increase 
the oxidative power) have been reported.26 A range of conditions for the oxidation of SWNT and their 
effects on the nanotubes are presented in Table 4.1. It has also been described that depending on the 
chemical treatment in acidic conditions the length of the nanotube can be reduced. This shortening is 
produced by an oxidative cutting mechanism that follows different steps: 1) attack on active sites of the 
SWNT (i.e. CH2 groups or CH groups on seven membered rings); 2) electrophilic addition that produces 
new defects with the introduction of –OH groups; 3) collapse of the graphitic structure around the active 
sites in strong oxidation conditions and cut of the nanotube in two shorter fragments.11 The disruption 
of the graphitic network can lead to the loss of the inherent characteristics of the carbon nanotubes so it 
is vital to consider the final application of the functionalised nanomaterial before applying aggressive 
conditions (e.g. if the final application of the nanohybrid is in the production of an electronic material a 
mild oxidation method would be preferred). Dilute concentrations of nitric acid or the use of piranha 
type mixtures at low temperatures were reported to reduce the length of the SWNT but only by action 
on pre-existing defects while no new oxygen functionalities were introduced (the oxidative mechanism 
had mainly the effect described in (1)).21, 22, 25 The use of a mixture of sulphuric and nitric acid, as well 
as the use of piranha, at high temperatures resulted in the introduction of new oxygen functionalities and 
a drastic shortening of the nanotubes, parameter that could be controlled and was proportional to the 
reaction time. Finally, the use of KMnO4 generated new defects but the oxidative cutting of the SWNT 




Scheme 4.3: Initial functionalisation of pristine SWNT by oxidation. 




Therefore, a compromise must be reached between the degree of functionalisation and the shortening of 
the tubes and distortion of the graphitic network. The use of mild oxidation conditions as 2.6 M HNO3 
seemed insufficient to reduce the length of the tubes and to introduce enough COOH groups in the 
nanoprobe.21 On the other hand, the use of a mixture of H2SO4 and HNO3 has been described to cut the 
entangled groups of nanotubes resulting in nanotubes with open tips and oxygen functionalities.21, 24  
 
As stated above, the nanotubes used in this work were high purity Elicarb® single walled nanotubes 
with low residue obtained from Thomas Swan. The selected oxidation strategy applied herein consisted 
on heating the nanotubes at 100 ºC for 30 min in a 1:3 mixture of concentrated sulphuric and nitric acids 
(Scheme 4.3).27 This treatment produced a shortening of the SWNT while introducing oxygen containing 
functional groups. The modification of the SWNT could be observed during the course of the reaction 
as the dispersibility of the nanomaterial increased considerably producing a black dispersion in contrast 
to the black precipitate observed at the beginning of the reaction. The crude reaction mixture was diluted 
with water and the nanomaterial was isolated by centrifugation to remove the acidic supernatant. The 
oxidised nanotubes (60) were then filtered through a 0.2 µm hydrophilic membrane and washed with 
plenty of water and ethanol until the pH of the filtrate was neutral. The product was dried in a 60 ºC 
oven to yield the oxidised product with a mass loss of 22% with respect to the pristine SWNT, probably 




Scheme 4.4: Radical addition reaction of an aryl compound to the SWNT sidewall in a Tour reaction. 
 
The second functionalisation strategy used hereby was based on a modification of the Tour reaction.28 
This process was first described in SWNT as a functionalisation method of the sidewall of the nanotubes 
by Tour et al.29 The authors functionalised electrochemically SWNT supported on paper using different 
aryl diazonium salts that were converted into the aryl radical that reacted with the nanotube wall. The 
functionalisation was demonstrated by using several techniques (Raman, TGA, TEM) and the 
functionalisation degree proved to be as high as one functionality every 20-30 carbons in the nanotube.29 
The same group demonstrated shortly after that the reaction worked not only electrochemically but also 
thermally and that the diazonium species could be formed in situ, simplifying greatly the process as 




anilines can be easily synthesised and stored.19 This strategy have been generalised for the 
functionalisation of SWNT. The reaction conditions evolved and Tour et al. successfully conducted this 
reaction in water by heating a series of aniline derivatives with isopentyl nitrite at 80 ºC, generating the 
diazonium species in situ.30 The reactivity in water has advantages as the reduced production of waste, 
the reduction of reaction times and the increase in the functionalisation degree.  
 
In this work, the reactivity “on water” was applied to SWNT using a procedure described in the 
literature.28 The functionalisation procedure was applied using tert-butyl (4-aminobenzyl)carbamate and 
the reaction time was extended in order to increase the functionalisation degree. The p-SWNT, the 
protected amine (61) and isopentyl nitrite were heated in water at 80 ºC for 48 h (Scheme 4.5, first step). 
The product was isolated and washed, similarly to 60, by cycles of centrifugation/re-dispersion and 
finally by filtration through a 0.2 µm polycarbonate membrane to be washed again with water, ethanol 
and isopropanol. The product was dried in a 60 ºC oven. Then, the Boc protecting group on the 
benzylamine moiety was deprotected by stirring 62 in HCl 4M in DMF at room temperature 
(Scheme 4.5, second step). The product was isolated in a similar manner as in previous steps: 
centrifuged, filtered and washed with water and ethanol until the pH of the filtrate was neutral. This 
deprotection method using HCl 4 M in DMF constituted the general procedure to deprotect Boc groups 
attached to SWNT throughout this work. The dried product 63 presented a weight increase of 22% 




Scheme 4.5: Initial functionalisation of pristine SWNT by a radicalic reaction with tert-butyl 
(4-aminobenzyl)carbamate (61). 
 




The products, 60 and 63, were characterised using Fourier transform infrared spectroscopy (FTIR), 
Raman spectroscopy and thermogravimetric analysis (TGA). The acquisition of FTIR spectra in SWNT 
is challenging due to the small amount of material, and the low functionalisation that renders most of 
the solid to be composed mainly by carbon. In addition, only a few characteristic functionalities with 
identifiable IR bands were introduced (e.g. carbonyl groups, amino groups). Nevertheless, the FTIR 
spectra can be obtained and the presence of indicative bands, identified. In this work, the FTIR spectra 
were obtained in attenuated total reflectance (ATR) mode. The FTIR spectra for 60 and 63 can be 
observed in Figure 4.1. The top spectrum corresponds to compound 60 while the spectrum at the bottom 
corresponds to compound 63. A baseline correction was applied to the spectra in order to help to identify 






































The oxidised SWNT (60) present the characteristic bands of the carboxylic acid moiety with the COO-H 
stretching at 3250 cm-1 and the C=O stretching at 1699 cm-1. The presence of C-H groups in the open 
tips of the SWNT can be deduced from the C-H stretching at 2900 cm-1. The bands at ca. 1100 cm-1 
could be attributed to the =CH rocking out of plane but the assignment is not as clear and bands from 
other moieties overlap in this area (aromatic rocking out of plane or OH rocking out of plane). 
In the case of 63, the degree of functionalisation seems to be lower than in 60 as the observed intensity 
of the bands is lower. The presence of the tert-butoxycarbonyl protecting group can be inferred from the 
presence of the N-H stretching at 3360 cm-1. The CO stretching is present at 1700 cm-1 (amide I) while 
the amide II band can be identified as a weaker band at 1527 cm-1. An intense band is observed at 
1044 cm-1 that in this case could be attributed to the skeletal vibrations of the CH3 group although this 
region is into the fingerprint area and the bands of different groups overlap.  
 
Raman spectroscopy is known to be a powerful technique for the characterisation of bulk carbon 
nanomaterials. No particular sample preparation is needed, the experiment is quick and non-destructive 
and the data can reveal essential characteristics of the nanomaterial or its functionalisation. The spectra 
of SWNT present a series of characteristic bands that help to characterise and elucidate the nature of the 
carbon nanomaterial, the presence of defects and degree of functionalisation. One of the characteristic 
bands of a SWNT are the radial breathing modes (RBM) that are present at low wavenumbers in the 
region of 50 – 300 cm-1. The RBM bands are of great importance in the characterisation of SWNT as 
they have been used for determining the diameter of the nanotubes and the optical transition energies in 
isolated tubes.31 The results of RBM frequencies found in the literature can be described according to 
Equation 4.1. This equation considers Van der Waals interactions with the environment and further 
environmental effects. The diameter of the tubes can, therefore, be estimated by Equation 4.2 where 
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Observing the RBM region in the Raman spectra of p-SWNT, 60 and 63 (Figure 4.2), it can be noted 
that the RBM bands appear at ca. 100 cm-1 to ca. 300 cm-1. The intensity of specific bands in the RBM 
region present maxima at ca. 160, 180 and 270 cm-1. This points to a polydisperse sample where these 
frequencies can be translated to the diameter of the tubes by applying Equation 4.2. The SWNT samples 
would contain a distribution of nanotubes with diameters ranging from 0.77 to 2.73 nm with a higher 
proportion of nanotubes of diameters of 1.51, 1.32 and 0.86 nm by considering the relative intensity of 
the bands. These results have to be taken with caution as the original equation was calculated only from 




Figure 4.2: Normalised Raman spectra of starting material p-SWNT (black line), 60 (blue line) and 





























































The G band in SWNT is attributed to the stretching of C-C bonds and is observed at ca. 1580 cm-1. In 
the case of p-SWNT, 60, and 63, the normalised Raman spectra can be observed in Figure 4.2 where the 
G band is the most intense band in all the spectra. The wavenumbers of characteristic bands for all 
functionalised SWNT derivatives are summarised in Table 4.2. The wavenumber of the G band for 
pristine SWNT is 1575 cm-1 while it is slightly shifted in the functionalised derivatives (1580 cm-1 for 
63 and 1584 cm-1 for 60). 
 
The D band is observed at lower wavenumbers than the G band (ca. 1340 cm-1) and is a disorder induced 
band. The disorder in the rolled graphene sp2 hybridized layer of a SWNT produces an increase of the 
D band thus constituting an ideal indicator of the success of a functionalisation strategy.  
 
Table 4.2: Summary of Raman spectroscopy data for p-SWNT, 60 and 63. 
 
Compound ν D (cm-1) ν G (cm-1) ν G’ (cm-1) ID/IG 
p-SWNT 1330 1575 2660 0.08 
60 1344 1584 2691 0.29 
63 1335 1580 2670 0.22 
 
 
Furthermore, the degree of functionalisation can be measured by comparing the ratio of intensities of 
the D and G bands. The ID/IG ratio constitutes an indicator of the disorder introduced in the nanotube by 
disruption of the sp2 graphene network to sp3 hybridised carbon. The subsequent comparison of the ID/IG 
ratios to the values obtained for pristine SWNT gives a perspective on the degree of functionalisation. 
The ID/IG ratios for p-SWNT, 60, and 63 were calculated and are summarised in Table 4.2. The values 
are expressed as an average from the Raman spectra acquired for each sample. In the case of p-SNWT, 
it can be noted how the ID/IG ratio is low, a fact that demonstrates the high purity of the p-SWNT. The 
functionalised samples present considerably higher ID/IG ratios (0.29 for 60 and 0.22 for 63). According 
to these values, the functionalisation degree is higher in the oxidised SWNT (60) which points to this 
strategy as the most effective to modify the pristine SWNT as a first step. 
 
Another inherently characteristic band on the SWNT is the G’ band. The G’ band is the first overtone 
of the D band and appears at ca. 2650 cm-1. For p-SWNT, 60, and 63 the G’ band is more intense than 
the D band and the wavenumber varies with the corresponding for the D band. In this way, the G’ band 
for p-SWNT is observed at 2660 cm-1 while the G’ band for 63 and 60 are observed at 2670 and 
2691 cm-1 respectively. The G’ band wavenumbers follow the same trend as in the D band. 
 
 




Table 4.3: TGA data showing the mass loss of pristine, and initially functionalised SWNT at 500 ºC. 
 






In addition, thermogravimetric analysis coupled to mass spectrometry (TGA-MS) was performed to the 
products. TGA measures the mass loss of the material during the application of a heating ramp under 
argon that generally ends around 1000 ºC. During this process, all organic functionalities that decorate 
the SWNT are decomposed and released in the form of different gases as CO2, N2, etc. The mass loss at 
500 ºC, when all the organic functional groups are decomposed, can be correlated to the functionalisation 
degree of the material. The MS results can be difficult to interpret as only low molecular weight species 
are detected and the contribution of moisture or argon from the gas flow can interfere with the results. 
The TGA curves can be observed in Figure 4.3 and the results of the mass loss at 500 ºC can be observed 
in Table 4.3. The pristine SWNT lose just 2% of their weight by 500 ºC probably due to adsorbed gases 
on the surface. The oxidised material, 60, loses 21% of its weight by 500 ºC and the higher degree of 





Figure 4.3: TGA curves for starting material, p-SWNT (black line), 60 (blue line) and 

































Another method of determining the loading in compounds containing amino groups is the Kaiser test. 
The Kaiser test is a colorimetric assay based on the reaction of ninhydrin with primary amines to 
generate an intense blue dye (Ruhemann’s purple). The reaction of amino acids and primary amines 
with ninhydrin was described in the beginning of the 20th century. The mechanism of formation of the 
coloured species and the applications of these reactions have been studied.32 Furthermore, the reaction 
of ninhydrin with amino acids constitutes an ideal qualitative tool to ascertain the effectiveness of a 
coupling reaction. This is routinely applied to the solid phase peptide synthesis (SPPS) developed by 
Merrifield et al. by the presence or absence of the blue colour.33 The reagents were slightly modified 
and the reaction conditions optimised to avoid common pitfalls as undesired side products or incomplete 
colour developing previously found in the literature in order to apply the method quantitatively by Sarin 
et al.34 The best results to estimate the amine loading in routine monitoring were obtained by heating 
the resin beads with a solution containing phenol, KCN and ninhydrin at 100 ºC. The optimal heating 
time was found to be 10 min when all the colour had developed but no decomposition was observed. 
The resulting colour was reported to be stable for more than 2 h.34 
 
 
Scheme 4.6: Application of the Kaiser test to probe the occurrence of an amino functionalised SWNT. 
 
The Kaiser test has also been applied to monitor the functionalisation of SWNT when amino groups 
were present due to the similarities between nanomaterials and resin beads as solid supports.35 Moreover, 
the possibility to apply this assay quantitatively in nanotubes has been explored and the loading 
expressed as mmol of NH2 per gram of material.36-38 The production of Ruhemann’s blue from an amino 
functionalised SWNT and ninhydrin is showed in Scheme 4.6.  
 
In this work, Kaiser tests were conducted using 0.5 – 2 mg of SWNT samples that were homogenised 
with the reagents described by Sarin et al.34 (120 µL of a first solution containing 0.36 g/mL phenol and 
0.012 mg/mL KCN in pyridine/ethanol (9:1) and 30 µL of a second solution containing 0.05 g/mL 




ninhydrin in ethanol). The SWNT and reagents were heated to 100 ºC for 10 min in capped vials. Then, 
the solution was filtered and diluted to 25 mL with ethanol/water (6:4). The absorbance of the solutions 
was measured within the next 30 min to avoid any possible colour fading. The concentration of amino 
groups was calculated using the Beer-Lambert law applying a molar extinction coefficient of 
ε = 1.3x105 M-1cm-1, and expressed as mmol(NH2) / g of material. In the case of 63 the estimated loading 
was 0.34 mmol (NH2) / g. The obtained values account for an approximation that allows comparison 
between samples when the same procedure is applied. However, to obtain a more accurate value of the 
concentration of amino groups, Merrifield et al. advised to find the specific molar extinction coefficient 
for each specific peptide/amino species.34  




4.3 Introduction of linkers used in the current synthetic strategy 
The functionalisation of the products obtained in Section 4.2 with organic linkers was performed by 
amide coupling with different functional molecules. In the case of oxidised nanotubes (60), protected 
diamines of different nature were coupled forming an amide bond via the in situ activation of the 
carboxylic acid in the SWNT using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) / 
1-hydroxybenzotriazole (HOBt) followed by the addition of the mono(protected) amine (Scheme 4.8, 
top, first step). The in situ activation of the carboxylic acids in functionalised nanotubes forming an 
activated ester has been applied in the literature and it resembles the conditions used in molecular 
chemistry with the exception that the reaction times are generally longer.39, 40 The addition of HOBt as 
an additive helps to reduce possible side reactions or epimerisation from the O-acylisourea intermediate 
formed with EDC (Scheme 4.7). The reaction was carried out dispersing the nanotubes in DMF by 
sonication and stirring with the coupling reagents and diamines at room temperature for 48 h. The 




Scheme 4.7: Activation of a carboxylic acid functionality using EDC/HOBt. 
 
In the case of the amino-functionalised nanotubes (63) the introduced linkers were protected long chain 
amino acids, namely 6-((tert-butoxycarbonyl)amino)hexanoic acid (64) and 
11-((tert-butoxycarbonyl)amino)undecanoic acid (65), where the amino group had been Boc protected. 
The reaction proceeded by the activation of the carboxylic acids in the protected amino acid with 
EDC/HOBt. The activated intermediate was added to a dispersion of amino-functionalised nanotubes in 
DMF and the reaction mixture stirred for 48 h (Scheme 4.8, bottom, first step). 
 
The introduction of protected diamines in CNT has been previously described in the literature. In 
particular, this group of diamines (tert-butyl 2-aminoethyl carbamate39, tert-butyl 6-aminohexyl 
carbamate41, 42 and tert-butyl-2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate43, 44, 45) have been previously 
applied to the functionalisation of SWNT and MWNT for biomedical applications. The couplings were 
performed through the acid halide or using activating agents as EDC or N-hydroxysuccinimide (NHS). 




The preparation of acid halides involves the use of oxalyl chloride or thionyl chloride that are 
comparatively much more toxic than diimide-based activating agents. Therefore, the conditions using 
EDC/HOBt for the coupling were preferred. The interest in these derivatives for biomedical applications 
was encouraging to apply similar reaction conditions to reproduce the results in the batch of high purity 
SWNT used herein. The use of 6-aminohexanoic acid and 11-aminoundecanoic acids as linkers for the 
decoration of SWNT and MWNT has been reported. However, the amino-functionalised SWNT were 
obtained from the fluorinated SWNT instead of the oxidised derivatives.46, 47 
 
 
Scheme 4.8: Reaction conditions for the modification with linkers of oxidised nanotubes, 60 (top) and 
amino-functionalised nanotubes 63 (bottom); i) EDC/HOBt, DMF, rt, 48 h, ii) HCl 4M, DMF, rt, 16 h. 
 
In both cases, the SWNT derivatives contained a Boc protected amino group as a terminal moiety. The 
next step consisted in the deprotection of the Boc group with HCl 4M in DMF (Scheme 4.8, second 
step). This way, the amino-terminated SWNT products 71, 72, 73, 74 and 75 were obtained. 
The novel amino-functionalised SWNT denoted 71 – 75 were characterised by applying the methods 
described in section 4.2 (i.e. FTIR and Raman spectroscopies). In addition, the Kaiser test was applied 
to the identification and quantification of amino groups as described above. The summary of the 
characterisation data containing results from the Kaiser test and Raman spectroscopy are given in 
Table 4.4 where the data obtained for compounds 60 and 63 have been included for comparison 
purposes.  




Table 4.4: Characterisation data for functionalised SWNT derivatives 71 – 75. 
 
Compound mmol NH2 / g  ν D (cm-1) ν G (cm-1) ID/IG 
60 - 1344 1584 0.29 
63 0.34 1335 1580 0.22 
71 0.19 1343 1582 0.15 
72 0.23 1344 1585 0.15 
73 0.17 1345 1587 0.22 
74  0.25 1334 1580 0.11 
75 0.24 1336 1580 0.16 
 
 
The wavenumbers corresponding to the D and G bands present in the Raman spectra do not appear to 
change appreciably with the introduction of the amino-terminated linkers. The D band of the 
functionalised SWNT derived from the oxidised nanomaterial (71, 72 and 73) is observed at 
ca. 1344 cm-1 similarly to the starting material while the same situation is encountered with the G band 
that appears at ca. 1584 nm. The scenario with the functionalised derivatives derived from 63 is repeated 
with the D and G bands (ca. 1335 and 1580 cm-1 respectively) appearing at very similar wavenumbers 
compared to 63.  
Interestingly, the ID/IG ratios were reduced in the compounds with the amino-terminated linkers when 
compared to the initially functionalised SWNT. This may be attributed to the loss of highly 
functionalised SWNT that might have suffered a dramatic shortening during the initial functionalisation 
treatment. This way, the disappearance of these SWNT, that contributed to increase notably the ID/IG 
ratio, results in an overall decrease of the ID/IG ratio for the new material. 
 
The results obtained from the quantitative Kaiser test showed a loading of ca. 0.20 mmol NH2 / g in the 
functionalised materials derived from the oxidised SWNT with the highest loading obtained for the 
probe including the hexyl linker (72). The functionalisation of 74 and 75 was slightly higher than in the 
previous derivatives and the loading reaches ca. 0.25 mmol NH2 / g. The existence of data from the 
starting material allowed to estimate the coupling efficiency in the introduction of the linker by 
comparing the two values and assuming the latest result is originated from the amino groups in the 
linkers. The coupling step of the benzylamine residue proved to be slightly more efficient with 
6-aminohexanoic acid (74%) than with 11-aminoundecanoic acid (70%). 
 
Due to the targeting nature of the peptide and the preferred coupling strategy to the fluorophore, a 
carboxylic acid group was necessary to support the conjugate on the nanotubes. Therefore, the amino-
terminated linkers were expanded by reaction with succinic anhydride. The opening of the succinic 




anhydride by the amine yields a 4-oxobutanoic acid at the end of the linker. This reaction has been 
reported to produce satisfactory results for MWNT.44 This reaction was performed using a general 
method for nanomaterials 71, 72, 73, 74 and 75. The procedure consisted in dispersing the nanomaterial 
by sonication in dry THF followed by the addition of succinic anhydride and stirring the reaction mixture 




Scheme 4.9: Introduction of a succinic acid moiety into the functionalised SWNT. Conditions: 
i) succinic anhydride, THF, rt, 16 h. 
 
The product was isolated by centrifugation, washed, filtered through a 0.2 µm polycarbonate membrane 
and dried in a similar manner as described for the initial functionalised products. The introduction of the 
carboxylic acid group was evident during the work-up. The improvement on the dispersibility of the 
samples can be observed in Figure 4.4, the image at the top corresponds to compounds 71, 72, 73, 74 
and 75 (from left to right) after a 20 min sonication period and 30 min standing at room temperature. 
The introduction of a polyethylene glycol (PEG) group in the linker chain improves dramatically the 
stability of the dispersion of functionalised nanotubes (73). The dispersibility improvement is 
generalised for all nanomaterials after the addition of N,N-diisopropylethylamine (DIPEA) as a base. 
The exception of 75 which offers a similar appearance can be attributed to the length of the alkylic chain 
that does not favour the suspension in a polar solvent as ethanol. The deprotonation of the terminal 
carboxylic acid proton by DIPEA improves significantly the dispersibility and serves as a confirmation 
of the success of the functionalisation reaction. 







Figure 4.4: Images of the dispersions emerging from sonication of 1 mg/mL functionalised SWNT 
dispersions in ethanol (left to right) of: 76, 77, 78, 79 and 80. a) Conditions: 20 min sonication and 30 
min standing at room temperature; b) the same dispersions after the addition of 50 µL of DIPEA. 
 
The final functionalised SWNT samples were characterised using techniques previously described in 
this chapter. Additionally, TGA was conducted in the samples as well as TEM for the derivatives 
terminated in the carboxylic acid (76 – 80) and the pristine SWNT in order to observe the morphology 
changes in the products after the functionalisation. A summary of the characterisation data can be 
observed in Table 4.5  
 
The variation in the D band wavenumber is greater in the functionalised SWNT derived from 60. The 
observed values go from 1333 to 1352 cm-1. The G band wavenumber is more constant through the 
different samples and in the same range of the starting materials within a 10 cm-1 difference.  
 
Table 4.5: Summary of characterisation data for functionalised SWNT 76 – 80. 
 
Compound Mass loss (500 ºC) D wavenumber G wavenumber ID/IG 
76 22 1352 1570 0.15 
77 22 1339 1574 0.15 
78 28 1333 1571 0.12 
79 17 1331 1573 0.10 











Figure 4.5: TGA curves for functionalised SWNT 76 – 80. a) Functionalised SWNT prepared from 60 
(76, 77 and 78) and b) functionalised SWNT prepared from 63 (79 and 80). The curves for the pristine 
SWNT used as a starting material have been included for comparison. 
 
In the case of 79 and 80, the values of D and G bands wavenumbers are similar for both nanomaterials 
and in accordance with the values obtained for the starting materials. 
The ID/IG ratios are kept in the same range of values when compared to the amino-functionalised SWNT 
for all samples (76 – 80) which indicates that the introduction of the succinic acid moiety did not affect 


























































Figure 4.6: TEM images of SWNT samples where a) pristine SWNT, b) 76, c) 77 and d) 78. 
Scalebar: 20 nm. 
 
The TGA curves for functionalised SWNT 76 – 78 present small steps in mass loss at low temperatures 
(100 – 300 ºC) and the mass loss is constant until 500 ºC. In the case of compounds 63, 79 and 80, the 
mass loss presents a big step before 350 ºC. In the case of 63, this step is more evident and the mass loss 
is constant at higher temperatures. Differently, 79 and 80 present a second step at ca. 500 ºC with the 
mass loss being constant at higher temperatures. 
a) b) 
c) d) 






Figure 4.7: TEM images of functionalised SWNT a) 79 and b) 80. Scalebar: 20 nm. 
 
 
The mass loss results obtained from TGA (Figure 4.5 and Table 4.5) indicate that, in general, the 
oxidative strategy proved more successful to introduce functional groups as it was demonstrated with 
the initial functionalisation of the SWNT. However, the overall increase from the initially functionalised 
SWNT is higher for the nanomaterial obtained in the radicalic reaction 63 with the mass loss starting at 
11% and the final products 79 and 80 presenting a value of 17 and 20% respectively. In comparison, in 
samples 76 – 78, obtained from oxidised nanotubes (60), the margin of mass loss increase is much 
narrower with a 1% increase for 76 and 77 and the bigger difference for 78 that presents a final 28% 
mass loss at 500 ºC. 
 
Transmission electron microscopy (TEM) is a powerful technique employed to characterise SWNT. 
TEM is especially useful as it allows to observe the surface functionalisation of the nanotubes, their 
morphological changes (shortening, bending) and other characteristics. The TEM samples were 
prepared by drop casting a suspension of the corresponding SWNT sample in ethanol on to a 400 mesh 
copper grid. 
 
The TEM image for pristine SWNT at 500k magnification can be observed in Figure 4.6, a). It can be 
seen that the pristine material is aggregated in ropes of several tubes as well as bundles that are 
distributed randomly. The surface of walls of the p-SWNT are generally smooth which confirms the 
absence of functional groups. 
b) a) 






Figure 4.8: TEM images and corresponding profiles (indicated by the dashed blue line in the images) 
for starting material p-SWNT (a), 78 (b) and 79 (c). 
 
The TEM images for 76, 77, and 78 are displayed in Figure 4.6, b), c) and d) respectively. The effect of 
the functionalisation is apparent as bumps on the surface of the SWNT with a darker contrast in the 
image. The tubes are still aggregated in ropes and bundles but the observation of individualised tubes or 
tubes in smaller groups is more frequent. The higher functionalisation degree is observed for the 
functionalised SWNT sample 78 where the tubes are dispersed to a greater extent, the irregular features 
on the sidewalls are more evident and occurrence of much shorter tubes can also be observed. 
 
The TEM images for 79 and 80 are displayed in Figure 4.7. In this case, the tubes are observed with a 

















































aggregation in form of ropes and bundles. The introduction of the phenyl and linker groups is observed 
as darkened areas on the nanotube surface and bumps on the sidewalls (more evident for 80). 
 
The initial functionalisation via the Tour reaction seems to produce a lower degree of shortening of the 
tube as well as less opening of the nanotubes ends. This is in accordance with the preferred sidewall 
functionalisation of the nanotubes. The SWNT in the images obtained for 76, 77, and 78 seemed to 
present a better dispersion on the grid as well. 
 
The height profiles obtained from selected TEM images for the starting material p-SWNT, 78 and 79 
are shown in Figure 4.8. The profile of the pristine SWNT shows the aggregation of the nanotubes in 
ropes with diameters going from 1.4 to 1.8 nm. In the case of the functionalised SWNT derivatives 78 
the length of the nanotubes was considerably reduced while the diameter is in the same range as for the 
p-SWNT although in the profile showed in the picture, examples of SWNT with wider diameters are 
observed with values going from 1.7 to 2.4 nm (Figure 4.8, b). A similar situation is observed for 79, 
where the functionalisation does not indicate a considerable increase in the coating around the nanotube. 
The diameters of the SWNT for 79 are kept in the range of 1.4 to 2.6 nm (Figure 4.8, c). The observed 
increase in the diameters in functionalised samples demonstrates the success of the functionalisation 
strategies applied to the starting pristine SWNT. 
 
  




4.4 Translation of the functionalisation strategy to graphene oxide 
Much research effort had been applied to obtain graphene but it was not until 2004 that individual 
graphene sheets could be isolated from graphite and characterised. The new material was described as 
stable and highly conductive, even at room temperature.48 The structure of graphene is that of a fused 
benzene-ring honeycomb lattice, but with only one atom thickness. One of the most common routes to 
the preparation of graphene derivatives is through the exfoliation of graphite oxide that produces 
graphene oxide (GO) (Figure 4.9). Graphene oxide presents many defects in the honeycomb structure, 
mainly oxygenated functions, that alter the unique properties of graphene as the high electrical 
conductivity. The preparation of graphene needs the final reduction of the GO structure. On the other 
hand, the presence of functional groups can be advantageous as it allows the introduction of groups of 




Figure 4.9: Structure of graphene oxide including its most common defects. 
 
Since the discovery of graphene, increasing attention has been dedicated to the application of this 
innovative carbon nanomaterial to the biomedical field with special attention to the fabrication of 
biosensors.49 Nevertheless, graphene and its derivatives have also been employed in biomedical 
imaging.2 The functionalisation strategies of graphene are similar to the ones typically applied to SWNT 




Figure 4.10: Representation of an imaging probe based on PEGylated rGO flakes where a Cy5 dye 
and the RGD targeting peptide have been introduced. Structure adapted from ref. 50. 




One example of non-covalent functionalisation of reduced graphene oxide to prepare a targeted imaging 
probe for integrin receptors can be observed in Figure 4.10. In this example, the authors used long PEG 
chains to functionalise reduced graphene oxide and introduce Cy5 dyes and the peptide RGD as targeting 
molecule. The imaging nanoprobe was biocompatible and could be detected in vitro thanks to the Cy5 
dye and in vivo thanks to the enhanced NIR absorbance of reduced GO compared to GO.50 
 
In this work, a PEG linker was introduced to graphene oxide via amidation, similarly to the strategy 
developed for 72, taking advantage of the presence of carboxylic acid groups in the structure. In this 
work, graphene oxide was synthesised in bulk in the group under the supervision of Dr Boyang Mao 
and used as received. The graphene oxide (GO) was obtained from graphite by a modification of the 
Hummers method following a described procedure.51 Shortly, graphite oxide was obtained from graphite 
powder by treatment with sodium nitrate and concentrated sulphuric acid. The dispersion was cooled to 
0 ºC and potassium permanganate added. When the suspension reached room temperature and had been 
stirring for another 30 min, hydrogen peroxide was added. The work-up of the reaction included dilution 
with water, filtration and washing of the precipitate and a final dialysis step to remove any remaining 
salts. Graphene oxide was obtained from the dried product by sonication periods. 
A TEM image for the same batch is showed in Figure 4.11 a). The crystallographic structure was 
obtained by selected area electron diffraction (SAED) and the resulting hexagonal diffraction pattern52 
is showed in Figure 4.11 b). The results of FTIR and Raman spectroscopies will be described later in 





Figure 4.11: a) TEM image of graphene oxide. Scalebar: 200 nm. b) SAED of graphene oxide. 
Scalebar: 2 nm. Figure reproduced from ref. 51. 
 
 







Scheme 4.10: Functionalisation route of GO to introduce an amino-terminated linker. i) EDC, HOBt, 
tert-butyl-2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate (6), DMF, rt, 48 h. 
 
The amidation of GO was conducted using EDC/HOBt as activating agents and 
tert-butyl-2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate (6) as a linker (Scheme 4.10, first step). The 
deprotection of the t-butoxycarbonyl group was achieved by treatment with HCl 4M in DMF to obtain 
83. In a similar way as for the strategy followed in the preparation of SWNT probes, the presence of 
terminal carboxylic acid was necessary to build the imaging nanoprobe. For this reason, the amino-
terminated GO species 83 was reacted with succinic anhydride in THF to produce 84. The product was 
isolated by centrifugation, the supernatant removed and the residue re-suspended and washed again. The 





Scheme 4.11: Reaction conditions for the preparation of carboxylic acid terminated GO. i) Succinic 
anhydride, THF, rt, 16 h. 
 
 
The nanohybrids were obtained as a brown powder that could be more easily dispersed in water or polar 
organic solvents compared to SWNT derivatives. The nanohybrids based on graphene oxide were 
characterised by FTIR and Raman spectroscopy as well as TGA. The characterisation data are 
summarised in Table 4.6. The initial characterisation data suggest that the introduction of functional 
groups in GO is comparatively low with respect to SWNT based derivatives. The performance of the 




Kaiser test in the amino functionalised derivative 83 offered an estimated loading of 0.02 mmol NH2/g 
which represents a reduced loading compared to the functionalised SWNT counterparts. 
 
The FTIR spectra of 81, 83 and 84 can be observed in Figure 4.12. The IR spectrum of the graphene 
oxide starting material (Figure 4.12, a)) shows characteristic bands of oxygenated functionalities 
introduced as defects in the honeycomb aromatic structure of graphene. The OH stretching is observed 
at 3300 cm-1 as a broad band. This band includes individual hydroxyl groups as well as COO-H groups. 
The band at 1043 cm-1 can be assigned to the corresponding C-O stretching bands of hydroxyl groups. 
The CO stretching can be observed at 1718 cm-1 next to the C=C stretching at 1620 cm-1. The bands 
observed at ca. 1200 cm-1 could be attributed to the C-O stretching in epoxide groups. 
 
The spectrum of 83 presents some essential differences to that of GO. The presence of a NH stretching 
can be inferred as a shoulder at 3370 cm-1 although the band is dominated by the OH stretching. 
 
 
Table 4.6: Summary of characterisation data for functionalised graphene oxide derivatives. 
 
Compound mmol NH2 / g  
Mass loss (%) 
at 500 ºC  
ν D (cm-1) ν G (cm-1) ID/IG 
81 (GO) - 42 1351 1600 0.97 
83 0.02 - 1379 1580 1.14 
84 - 37 1344 1580 0.98 
 






Figure 4.12: FTIR spectra of 81 (a), 83 (b) and 84 (c). 
 
The CO stretching is shifted to 1698 cm-1 for 83 that confirms the modification of the carboxylic acid to 
the amide. In the band at 1573 cm-1 the amide II band and the C=C stretching can overlap producing an 
















































The spectrum of 84 is similar to the one for 83. The zone of 3200 – 3300 cm-1 has the same profile and 
contains the bands corresponding to the stretching of OH and NH groups. The C-O stretching is observed 
as a sharp peak in this spectrum at 1058 cm-1. The band at 1561 cm-1 corresponds to the overlap of the 
amide II band at the C=C stretching. Interestingly, the introduction of the carboxylic acid terminated 
linker produces the appearance of a second CO stretching. The stretching corresponding to the amide, 
as observed in the previous spectrum, is slightly shifted herein and appears as 1708 cm-1 while the 
corresponding CO stretching for the carboxylic acid is present at 1643 cm-1. This splitting of the CO 




Figure 4.13: Normalised Raman spectra of starting material GO (black line) and 84 (blue line). 
 
The Raman spectrum for GO and 84 can be observed in Figure 4.13. The spectra of graphene oxide, 81, 
83 and 84 present the same appearance. The Raman spectra for GO derivatives are markedly different 
to the spectra for SWNT derivatives. Graphene oxide presents a much higher D band that equals in 
intensity the G band and can even have a higher intensity. The ID/IG ratios (Table 4.6) did not present 
much variation with the functionalisation. The ratio increased with the synthesis of 83 but remained 
practically the same of GO in the final product, 84. The wavenumbers of the D band change over the 
functionalisation of the GO with a trend that is not clear. The wavenumber of the G band remains more 
stable in the functionalised derivatives although it suffers a shift from the original graphene oxide. The 
blue shift of the G band in graphitic structures has been attributed to the merging with the D’ band as 
caused by defects which would be in accordance with the data observed for 83 and 84.53 The 2D band 


























Figure 4.14: TGA curves for graphene oxide starting material (black line) and 84 (blue line). 
 
The TGA curves for graphene oxide and 84 are shown on Figure 4.14. Both nanomaterials were dry as 
no mass loss due to dehydration was observed in the TGA experiment. The mass loss starts at 
approximately 130 ºC with a steep change that continues until 280 ºC for graphene oxide and to 180 ºC 
for 84. This dramatic mass loss is attributed to the pyrolysis of oxygenated functional groups that are 
released as CO, CO2 or steam.54 The change of slope and reduction of the dramatic mass change in 84 
demonstrates that the formation of the amide bonds confers thermal stability to the carbon lattice 
structure. This is proved by the overall mass loss by 500 ºC for GO that constitutes a 42% compared to 



























4.5  Conclusions 
In this chapter, the functionalisation of SWNT to produce novel biocompatible materials, able to be 
conjugated with fluorophores and targeting peptides, has been explored. The translation of the SWNT 
functionalisation strategy to graphene oxide was also evaluated and it was demonstrated that the 
methodologies are compatible.  
 
Initially, the SWNT were functionalised following two complementary strategies. One consisted in the 
oxidation of the SWNT with a mixture of concentrated acids to introduce oxygen functionalities 
(hydroxyl groups, carboxylic acids) and improve the dispersibility in solution. The oxidative strategy 
produced the functionalised SWNT (60). This strategy demonstrated to shorten the SWNT and open the 
ends as expected due to the increased reactivity of the carbon nanotube tips in acid mixtures. The second 
strategy was based on the Tour reaction where an aryl radical species, generated in situ from the diazo 
compound, reacts with the sidewall of the SWNT. This method allowed us to prepare SWNT with a 
benzylamine group in the sidewall, after deprotection (63). The nanoprobes were characterised by FTIR 
and Raman spectroscopies. FTIR provided the most representative bands for the introduced functional 
groups (as the CO stretching, the CH stretching or the COOH stretching) while Raman provided an 
indication of the degree of functionalisation by comparing the intensity of D and G bands (ID/IG ratio). 
The values of this relation in both cases demonstrated the success of the functionalisation reactions.  
 
The introduction of organic linkers/spacers in the SWNT was performed via amide formation chemistry. 
Oxidised SWNT were modified with diamines (71, 72, 73) while long chain amino acids were used for 
the amino-functionalised SWNT (74, 75). The couplings were performed using EDC and HOBt as 
activating agents and the protecting groups present in all linkers removed by treatment with HCl. The 
presence of free amines allowed us to perform the Kaiser test, a colorimetric assay, which provides a 
value for the loading of NH2 functional groups in the nanomaterial. The loading was slightly higher on 
derivatives containing amino acid linkers but was around 0.2 mmol NH2 / g for all samples. The Raman 
spectroscopy results for the SWNT functionalised with the linkers showed a decrease of the ID/IG ratio 
in the products. This can be attributed to the removal of highly functionalised SWNT during the reaction 
and work-up in the introduction of linkers. 
 
The amino terminated SWNT were reacted with succinic anhydride in order to obtain a terminal 
carboxylic acid group, necessary to build the imaging nanoprobe. The dispersibility of the COOH 
terminated SWNT was considerably enhanced compared to previous derivatives, especially in a basic 
medium, which confirmed the presence of the desired functional groups. The final products (76, 77, 78, 
79, 80) were characterised by TGA and TEM. TGA results proved the functionalisation and showed a 
higher amount of functional groups for initially oxidised SWNT probes but the greater variation in mass 




loss was for the SWNT derivatives containing amino acid linkers. The comparison of the TEM results 
for the pristine and functionalised SWNT demonstrated the successful functionalisation. The as 
functionalised tubes showed better dispersion, shorter lengths and open ends. The morphology of their 
sidewalls indicated that they were no longer smooth as indicated by TEM. The initially oxidised 
nanoprobes in ethanol showed better dispersion and shorter lengths although aggregation in bundles was 
still observed. The initially amino functionalised SWNT were aggregated in ropes, presented longer 
tubes and the functionalisation was evident in the sidewalls. 
 
The most promising SWNT functionalisation strategy in terms of stability in solution (amidation with 
PEG linker) was translated to the functionalisation of graphene oxide. The linkers introduced in GO 
allowed us to prepare a novel nanomaterial containing spacers and adequate functional groups to build 
a new nanohybrid that may be suitable for imaging applications. The characterisation of GO and GO 
nanohybrids was performed by FTIR and Raman spectroscopies and TGA. The functionalisation of the 
GO derivatives (81, 83, 84) was demonstrated by changes in FTIR bands, especially the splitting of the 
CO stretching bands in the final product. In addition, the introduction of the linker improved the thermal 
stability of the nanohybrid as observed by TGA. 
 
In summary, a range of novel functionalised carbon nanomaterials with promising properties for the 
building of the targeted imaging nanoprobe have been prepared and fully characterised. The most 
promising of these functional nanomaterials were taken forward to the assembly of fluorescent 
nanomaterials too, as described in Chapter 5. 
  





1. F. Cortezon-Tamarit, H. Ge, V. Mirabello, M.B.M. Theobald, D.G. Calatayud and S. I. Pascu, 
in Inorganic and Organometallic Transition Metal Complexes with Biological Molecules and 
Living Cells, Academic Press, 2017, pp. 245-327. 
2. G. Hong, S. Diao, A. L. Antaris and H. Dai, Chem. Rev., 2015, 115, 10816-10906. 
3. S. Liu, Q. Shen, Y. Cao, L. Gan, Z. Wang, M. L. Steigerwald and X. Guo, Coord. Chem. Rev., 
2010, 254, 1101-1116. 
4. A. G. Rinzler, J. Liu, H. Dai, P. Nikolaev, C. B. Huffman, F. J. Rodríguez-Macías, P. J. Boul, 
A. H. Lu, D. Heymann, D. T. Colbert, R. S. Lee, J. E. Fischer, A. M. Rao, P. C. Eklund and R. 
E. Smalley, Appl. Phys. A, 1998, 67, 29-37. 
5. A. C. Dillon, T. Gennett, K. M. Jones, J. L. Alleman, P. A. Parilla and M. J. Heben, Adv. Mater., 
1999, 11, 1354-1358. 
6. I. W. Chiang, B. E. Brinson, A. Y. Huang, P. A. Willis, M. J. Bronikowski, J. L. Margrave, R. 
E. Smalley and R. H. Hauge, J. Phys. Chem. B, 2001, 105, 8297-8301. 
7. G. Tobias, L. Shao, C. G. Salzmann, Y. Huh and M. L. H. Green, J. Phys. Chem. B, 2006, 110, 
22318-22322. 
8. B. Ballesteros, G. Tobias, L. Shao, E. Pellicer, J. Nogués, E. Mendoza and M. L. H. Green, 
Small, 2008, 4, 1501-1506. 
9. J. Wen, Y. Xu, H. Li, A. Lu and S. Sun, Chem. Commun., 2015, 51, 11346-11358. 
10. A. Hirsch, Angew. Chem. Int. Ed., 2002, 41, 1853-1859. 
11. D. Tasis, N. Tagmatarchis, A. Bianco and M. Prato, Chem. Rev., 2006, 106, 1105-1136. 
12. H.-C. Wu, X. Chang, L. Liu, F. Zhao and Y. Zhao, J. Mater. Chem., 2010, 20, 1036-1052. 
13. P. Singh, S. Campidelli, S. Giordani, D. Bonifazi, A. Bianco and M. Prato, Chem. Soc. Rev., 
2009, 38, 2214-2230. 
14. N. Karousis, N. Tagmatarchis and D. Tasis, Chem. Rev., 2010, 110, 5366-5397. 
15. M. A. Herranz and N. Martín, in Carbon Nanotubes and Related Structures, Wiley-VCH Verlag 
GmbH & Co. KGaA, 2010, pp. 103-134. 
16. F. Hauke and A. Hirsch, in Carbon Nanotubes and Related Structures, Wiley-VCH Verlag 
GmbH & Co. KGaA, 2010, pp. 135-198. 
17. A. Battigelli, C. Ménard-Moyon, T. Da Ros, M. Prato and A. Bianco, Adv. Drug Del. Rev., 
2013, 65, 1899-1920. 
18. K. Kordatos, T. Da Ros, S. Bosi, E. Vázquez, M. Bergamin, C. Cusan, F. Pellarini, V. Tomberli, 
B. Baiti, D. Pantarotto, V. Georgakilas, G. Spalluto and M. Prato, J. Org. Chem., 2001, 66, 
4915-4920. 
19. J. L. Bahr and J. M. Tour, Chem. Mater., 2001, 13, 3823-3824. 
20. V. Datsyuk, M. Kalyva, K. Papagelis, J. Parthenios, D. Tasis, A. Siokou, I. Kallitsis and C. 
Galiotis, Carbon, 2008, 46, 833-840. 




21. J. Zhang, H. Zou, Q. Qing, Y. Yang, Q. Li, Z. Liu, X. Guo and Z. Du, J. Phys. Chem. B, 2003, 
107, 3712-3718. 
22. M. N. Tchoul, W. T. Ford, G. Lolli, D. E. Resasco and S. Arepalli, Chem. Mater., 2007, 19, 
5765-5772. 
23. H. Hu, B. Zhao, M. E. Itkis and R. C. Haddon, J. Phys. Chem. B, 2003, 107, 13838-13842. 
24. J. Liu, A. G. Rinzler, H. Dai, J. H. Hafner, R. K. Bradley, P. J. Boul, A. Lu, T. Iverson, K. 
Shelimov, C. B. Huffman, F. Rodriguez-Macias, Y.-S. Shon, T. R. Lee, D. T. Colbert and R. E. 
Smalley, Science, 1998, 280, 1253-1256. 
25. K. J. Ziegler, Z. Gu, H. Peng, E. L. Flor, R. H. Hauge and R. E. Smalley, J. Am. Chem. Soc., 
2005, 127, 1541-1547. 
26. K. Esumi, M. Ishigami, A. Nakajima, K. Sawada and H. Honda, Carbon, 1996, 34, 279-281. 
27. M. S. P. Shaffer, X. Fan and A. H. Windle, Carbon, 1998, 36, 1603-1612. 
28. L. Maggini, F. M. Toma, L. Feruglio, J. M. Malicka, T. Da Ros, N. Armaroli, M. Prato and D. 
Bonifazi, Chem. Eur. J., 2012, 18, 5889-5897. 
29. J. L. Bahr, J. Yang, D. V. Kosynkin, M. J. Bronikowski, R. E. Smalley and J. M. Tour, J. Am. 
Chem. Soc., 2001, 123, 6536-6542. 
30. B. K. Price and J. M. Tour, J. Am. Chem. Soc., 2006, 128, 12899-12904. 
31. P. T. Araujo, I. O. Maciel, P. B. C. Pesce, M. A. Pimenta, S. K. Doorn, H. Qian, A. Hartschuh, 
M. Steiner, L. Grigorian, K. Hata and A. Jorio, Phys. Rev. B, 2008, 77, 241403. 
32. D. J. McCaldin, Chem. Rev., 1960, 60, 39-51. 
33. E. Kaiser, R. L. Colescott, C. D. Bossinger and P. I. Cook, Anal. Biochem., 1970, 34, 595-598. 
34. V. K. Sarin, S. B. H. Kent, J. P. Tam and R. B. Merrifield, Anal. Biochem., 1981, 117, 147-157. 
35. J. L. Stevens, A. Y. Huang, H. Peng, I. W. Chiang, V. N. Khabashesku and J. L. Margrave, 
Nano Lett., 2003, 3, 331-336. 
36. M. Quintana and M. Prato, Chem. Commun., 2009, 6005-6007. 
37. C. H. Villa, M. R. McDevitt, F. E. Escorcia, D. A. Rey, M. Bergkvist, C. A. Batt and D. A. 
Scheinberg, Nano Lett., 2008, 8, 4221-4228. 
38. V. Georgakilas, N. Tagmatarchis, D. Pantarotto, A. Bianco, J.-P. Briand and M. Prato, Chem. 
Commun., 2002, 3050-3051. 
39. D. He, Y. Peng, H. Yang, D. Ma, Y. Wang, K. Chen, P. Chen and J. Shi, Dyes and Pigments, 
2013, 99, 395-401. 
40. M. Á. Herranz, N. Martín, S. Campidelli, M. Prato, G. Brehm and D. M. Guldi, Angew. Chem., 
2006, 118, 4590-4594. 
41. X. Yang, Z. Zhang, Z. Liu, Y. Ma, R. Yang and Y. Chen, J. Nanopart. Res., 2008, 10, 815-822. 
42. Z. Zhang, X. Yang, Y. Zhang, B. Zeng, S. Wang, T. Zhu, R. B. S. Roden, Y. Chen and R. Yang, 
Clin. Cancer. Res., 2006, 12, 4933-4939. 
43. R. Marega, V. Aroulmoji, F. Dinon, L. Vaccari, S. Giordani, A. Bianco, E. Murano and M. 
Prato, J. Am. Chem. Soc., 2009, 131, 9086-9093. 




44. D. Iannazzo, A. Pistone, S. Galvagno, S. Ferro, L. De Luca, A. M. Monforte, T. Da Ros, C. 
Hadad, M. Prato and C. Pannecouque, Carbon, 2015, 82, 548-561. 
45. D. Iannazzo, A. Piperno, A. Ferlazzo, A. Pistone, C. Milone, M. Lanza, F. Cimino, A. Speciale, 
D. Trombetta, A. Saija and S. Galvagno, Org. Biomol. Chem., 2012, 10, 1025-1031. 
46. L. Zeng, L. B. Alemany, C. L. Edwards and A. R. Barron, Nano Research, 2008, 1, 72-88. 
47. L. Zeng, L. Zhang and A. R. Barron, Nano Lett., 2005, 5, 2001-2004. 
48. K. S. Novoselov, A. K. Geim, S. V. Morozov, D. Jiang, Y. Zhang, S. V. Dubonos, I. V. 
Grigorieva and A. A. Firsov, Science, 2004, 306, 666-669. 
49. W. Yang, K. R. Ratinac, S. P. Ringer, P. Thordarson, J. J. Gooding and F. Braet, Angew. Chem. 
Int. Ed., 2010, 49, 2114-2138. 
50. J. T. Robinson, S. M. Tabakman, Y. Liang, H. Wang, H. Sanchez Casalongue, D. Vinh and H. 
Dai, J. Am. Chem. Soc., 2011, 133, 6825-6831. 
51. B. Mao, D. G. Calatayud, V. Mirabello, B. J. Hodges, J. A. R. Martins, S. W. Botchway, J. M. 
Mitchels and S. I. Pascu, Adv. Funct. Mater., 2016, 26, 687-697. 
52. N. R. Wilson, P. A. Pandey, R. Beanland, R. J. Young, I. A. Kinloch, L. Gong, Z. Liu, K. 
Suenaga, J. P. Rourke, S. J. York and J. Sloan, ACS Nano, 2009, 3, 2547-2556. 
53. A. Alazmi, S. Rasul, S. P. Patole and P. M. F. J. Costa, Polyhedron, 2016, 116, 153-161. 
54. S. Stankovich, D. A. Dikin, R. D. Piner, K. A. Kohlhaas, A. Kleinhammes, Y. Jia, Y. Wu, S. T. 
Nguyen and R. S. Ruoff, Carbon, 2007, 45, 1558-1565. 
 




Chapter 5 : Synthesis and evaluation of novel targeted nanoprobes 
5.1  Overview 
To date, the state-of-the-art has generally focused on targeting aspects involving three main types of 
membrane receptors used by cells to detect environmental changes and to communicate with the 
extracellular environment: receptor tyrosine kinases (RTK), ion channel receptors and 
G protein-coupled receptors (GPCR). The study of ion channels and RTK in the progression of cancer 
has been extensively reported, being the best example the epidermal growth factor receptor (EGFR).1 
The targeting and study of GPCR receptors is now receiving increasing attention as these receptors have 
demonstrated to play an essential role in tumorigenesis, tumour progression, invasion and metastasis.1 
The gastrin releasing peptide receptor (GRPR) is a type of GPCR that has been found to be 
overexpressed in several types of cancers as non-small cell lung carcinoma2 and head and neck 
carcinoma3. Furthermore, the GRPR has been extensively applied for the detection of prostate 
adenocarcinoma, as the receptors are overexpressed in a large proportion of prostate cancer cases 
compared to the low expression found in healthy tissues or tissues affected by other prostatic affections 
such as BPH or prostatitis.4 The main type of agonists to target the GRP family of receptors is composed 
by small peptides like bombesin (14 amino acids).  
 
 
Figure 5.1: Schematic representation of the components of the imaging nanoprobe. 
 
Despite the fact that bombesin is a tetradecapeptide, it is currently believed that only 7 amino acids from 
the C-terminal are essential for its targeting role and the use of the [7-14] or [7-13] fragments have been 
widely applied in molecular imaging so far.5 In this work, the simpler [7-13] fragment was prepared via 
an adapted synthetic protocol, then coupled to a novel BODIPY fluorophore and further applied in the 
synthesis of diverse imaging probes, including optical imaging agents supported on the functionalised 
carbon nanomaterials (described in Chapter 4, Figure 5.1). Furthermore, the synthesis and 
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5.2 Synthesis of a bombesin [7-13] fragment 
As stated above, the selected targeting peptide sequence was a fragment of the bombesin peptide, 
specifically the [7-13] fragment. The complete amino acid sequence of bombesin is shown in Figure 5.2, 
with the [7-13] fragment highlighted in blue. This fragment has been successfully applied in imaging 
and drug design so far, and several studies by others have shown that the targeting nature for 
overexpressed gastrin releasing peptide receptors of the original peptide can be maintained.6, 7 
 
 
Figure 5.2: Structure of bombesin with the [7-13] fragment of bombesin (synthesised in this work) 
highlighted in blue. 
 
The peptide sequence was prepared by the widely used strategy of solid-phase peptide synthesis (SPPS). 
The use of microwave reactors in peptide synthesis is now a routine methodology with some fully 
automated systems.8  
 
 
Scheme 5.1: Role of 1-hydroxybenzotriazole (HOBt) in the activation mechanism of amino acids 
using N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide (HATU).9 





Scheme 5.2: Steps involved in the synthesis of the fragment [7-13] of bombesin applied hereby. 
 
The use of microwave radiation can increase the efficiency of the couplings and reduce substantially 
reaction times even if the systems are operated manually.9 In this case, a Rink amide resin (with a 
0.59 mmol/g substitution) was used as solid support and the couplings conducted using 
N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium 
hexafluorophosphate N-oxide (HATU) as activating reagent. The risk of undesired side reactions can 
be reduced and the optical integrity of the final product protected by the addition of 
1-hydroxybenzotriazole (HOBt) to the reaction mixture (Scheme 5.1).9, 10 A combination of HATU and 
HOBt were employed hereby as coupling reagents in a 1:1:1 stoichiometry with the amino acid.11 
N,N-diisopropylethylamine (DIPEA) was used as a base and the couplings carried out in DMF heating 
10 min at 75 ºC under microwave irradiation. The full synthetic methodology is depicted in Scheme 5.2 
and it involved five stages. The first was the deprotection of the resin after it had been swelled. This was 
achieved by heating the resin during three cycles in piperidine/DMF (1:4 v/v) at 60 ºC and 75 ºC. The 
resin was thoroughly washed with DMF and CH2Cl2 after each cycle. The deprotection was confirmed 
qualitatively in some resin beads by the reaction of the free amino groups with ninhydrin, yielding a 
deep blue solution (Kaiser test). The first coupling (step 2 in Scheme 5.2) was conducted with the first 
amino acid and the coupling reagents added in a three-fold excess with respect to the loading of the 




resin. The deprotection of the supported amino acid on the resin followed (step 3 in Scheme 5.2) and 
was performed by heating the resin with piperidine/DMF (1:4 v/v) for 10 min at 75 ºC. The success of 
the coupling and deprotection reactions were equally demonstrated with a qualitative Kaiser test. In case 
the result of the test was opposite to that expected, the coupling or deprotection step was repeated under 
the same conditions. 
The amino acid sequence was consequently elongated (step 4 in Scheme 5.2) by repeating steps 2 and 3 
with the remaining amino acids. Histidine was an exception as the coupling needed to be performed at 
room temperature to avoid racemisation reactions.12 
The final step in the synthetic process was the cleavage of the peptide from the resin (step 5 in 
Scheme 5.2), that was achieved by stirring the resin 2.5 h at room temperature with a cleavage cocktail 
containing trifluoroacetic acid, phenol, water and triisopropylsilane (88:5:5:2). The reaction was 
performed protected from light and the time was limited in order to avoid the potential oxidation or 
alkylation of the side chains of labile amino acids as His or Trp.13 The peptide was isolated as a white 
solid by precipitation in cold ether and posterior centrifugation. The crude peptide was purified by 





Figure 5.3: HPLC traces of the crude peptide after cleavage (a) and after purification by automated 




































The purified product was analysed by HPLC (Figure 5.3) demonstrating the efficacy of the purification 
process. The nature of the product was confirmed by mass spectrometry. The ESI-TOF technique in 
positive mode showed the radical cation [M]+· of the peptide as the molecular peak of the spectrum but 
the sodium salt [M-Na]+ was also observed. The mass spectrum and experimental isotopic patterns and 




Figure 5.4: ESI-TOF mass spectrum of 85 (a). Experimental isotopic patterns of [M]+· (b) and sodium 
salt (c). Theoretical isotopic patterns of [M]+· (d) and sodium salt (e). 
 
The 1H NMR spectrum of the peptide 85 was acquired in deuterium oxide and the resonances assigned 
thanks to the bidimensional 1H-1H COSY spectrum (see Appendix A). The chemical shifts of the 
resonances were in accordance with the values found in the literature.14  
The 1H resonances for amino acid residues incorporating aromatic groups (Trp and His) occur between 


























singlets with only one correlation peak in the 1H-1H COSY spectrum. In contrast, the tryptophan residue 
presents a singlet for H-2 and the pattern of a 1,2-disubstituted benzene ring. These resonances can be 
identified as two deshielded doublets, one triplet (H-6) and one multiplet (H-5). The resonance of the 
protons adjacent to the NH groups in the peptide backbone (αCH) are observed between 3.8 – 4.7 ppm, 
downfield in the aliphatic zone. The αCH resonances for His and Trp are the most deshielded 
(ca. 4.7 ppm) appearing as triplets although the resonances of αCH His and D2O overlap hence not 
showing a defined multiplicity. The only remaining αCH resonance with a clear multiplicity is that of 
Gln that appears as a triplet. The two protons of Gly also appear in this region as a multiplet overlapping 
with the αCH of Val. 
 
The resonances of the side groups of the amino acids appear in the 0.5 – 3.3 ppm region. The most 






































































The 1H resonance assignable to the γCH2 group of Gln follows, in a descending order of chemical shift, 
and appears as a triplet. The most characteristic and identifiable resonances are the methyl groups of 
Ala and isopropyl groups of Val and Leu that are helpful to assign the corresponding resonances. The 
methyl group of Ala appears as a doublet integrating for three protons while the isopropyl groups of Val 
and Leu are observed as four doublets. The resonances for the isopropyl group in Val are more 
deshielded and the doublets closer. The pair of doublets for Leu appear more separated and downfield.  




5.3 Preparation of a novel BODIPY-bombesin conjugate  
After the [7-13] fragment of bombesin was prepared and purified, the targeted fluorophore was prepared 
by coupling with BODIPY 57. Several conditions were evaluated following the reaction by TLC and 
HPLC and the best conversion was obtained by stirring the reaction mixture for 20 h at 60 ºC in DMF. 
The coupling proceeded by activation of the carboxylic acid in the side chain of the BODIPY linker 
with (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (pyBOP) for three hours 
when the peptide was added and the reaction mixture stirred overnight (Scheme 5.3).  
The solvent was concentrated under vacuum and the crude reaction mixture purified by automated flash 
column chromatography in a C18 cartridge. The product was subsequently deprotected using the same 
procedure as in the peptide synthesis (piperidine/DMF, 1:4 v/v) in just 1.5 h as followed by TLC. The 





Scheme 5.3: Reaction conditions for the coupling of BBN[7-13] and BODIPY 57 applied hereby. 
 
The product was fully characterised using spectroscopic techniques such as NMR or mass spectrometry. 
The mass spectrum of compound 87 is shown in Figure 5.6 (top). The radical cation of the product is 
observed as the molecular ion with a m/z value of 1287.6445 with the sodium salt also identified. The 
compared theoretical and experimental isotopic patterns for the two species can be observed under the 
spectrum in Figure 5.6 for the cation radical species (left) and the sodium salt (right). The experimental 
and isotopic patterns matched with a high level of accuracy demonstrating the nature of the product. 
 
The characterisation of 87 was also carried out with different NMR spectroscopies and all the resonances 
in the 1H NMR spectrum assigned. The 1H NMR spectrum can be observed in Figure 5.7 with expansions 
in Figure 5.8 for the aromatic (a) and aliphatic (b and c) regions. The assignment of the resonances for 
every group in the conjugate was possible thanks to the application of bidimensional techniques as 
1H-1H COSY, that shows vicinal correlation between H nuclei, TOCSY, that reveals long distance 
correlation between 1H nuclei or 1H-13C HSQC that shows 1J correlations between 1H and 13C nuclei. 






Figure 5.6: ESI-TOF mass spectrum of compound 87 (a). Experimental isotopic patterns of [M]·+ (b) 
and the sodium salt (c). Theoretical isotopic patterns for [M]·+ (d) and the sodium salt (e). 
 
The identification of the resonances for the BODIPY fluorophore in the 1H NMR spectrum of the 
conjugate was straightforward as they are similar to the starting material. The protons of the phenyl 
group appear as a doublet (H-3) and a multiplet (H-4) in the aromatic region. The methyl groups 
corresponding to H-8 and H-10 appear as singlets in the aliphatic region although a long distance 
correlation with H-9 is present. The fact that H-4 appears as a multiplet rather than a doublet and that 
H-9 is displayed as pair of singlets reveals that under the NMR experiment conditions, the rotation of 
the BODIPY group might not be totally free around the C-C bond linking the phenyl group to the boron 
dipyrromethene core which causes these protons to no longer be equivalent. The resonances of the Lys 
linker largely overlap with the rest of the amino acid residues in the peptide. 
 
The aromatic region of the spectrum also includes the resonances of the residues with aromatic groups 
(His and Trp) as in the original peptide, although the chemical shift was more deshielded (ca. 0.2 ppm) 









































Figure 5.7: 1H NMR spectrum (CD3OD) of BODIPY-bombesin conjugate 87. [*Traces of deuterated 
and non-deuterated solvents]. 
 
The Trp resonances appear as one doublet for H-7, a multiplet for H-4 (due to the overlap with His 
resonances), two triplets for H-5 and H-6 and a singlet for H-2. 
As in the starting material, the αCH resonances appear downfield between 3.8 and 4.7 ppm (Figure 5.8, 
b). The αCH resonances for His and Trp are the more deshielded and overlap in a pseudo doublet of 
doublets. The only αCH resonance that can be observed independently is the one for Val that appears as 
a doublet. The αCH resonances for Gln, Ala and Leu overlap in a multiplet and the one for the Lys 
residue overlaps with the Gly resonances. In this case, the two protons for Gly are observed as an AB 
system (2J = 16.7 Hz) with centre at 3.84 ppm.  
 
The 1H resonances assignable to the aliphatic side chains of the amino acids residues are observed 
upfield in the spectrum between 0.8 and 2.4 ppm (Figure 5.8, c). There are characteristic resonances that 
can be independently observed and develop a clear multiplicity and are helpful indicators in order to 
identify the amino acid residues. The γCH2 resonances for Gln, for example, appear as triplet with two 
correlation peaks in the 1H-1H COSY spectrum. Thanks to the correlation to the same carbon in the 
1H-13C HSQC spectrum for those two resonances, they are assignable to the adjacent βCH2 of Gln that 











Figure 5.8: Expansions of the aromatic (a) and aliphatic regions (b) and (c) of the 





























































































Another characteristic resonance is the CH3 group of Ala that appears as a doublet due to the coupling 
with the αCH group. The isopropyl groups of Val and Leu appear as a pair of doublets as in the starting 
material. The vicinal correlations in the 1H-1H COSY spectrum reveal that the resonances of the βCH2 
group of Leu are also diastereotopic giving two different multiplets. 
 
The assignment of the methylene groups in the Lys linker were conducted finally as the majority of  the 
resonances overlap with other groups. The use of the TOCSY spectroscopy (Appendix A) was helpful 
as it revealed long distance 1H-1H correlations and allowed the identification of the groups of resonances 
in the same spin system. 
 
Furthermore, UV-vis and fluorescence spectroscopic investigations were carried out, and the 
photophysical properties of the conjugate 87 will be discussed in Section 5.6. 
 
  




5.4 Preparation of functional SWNT nanoprobes for optical imaging 
In order to obtain SWNT nanoprobes, the functionalised derivatives presenting the most promising 
properties in terms of functionalisation and dispersion stability containing the terminal carboxyl linkers 
were selected to be functionalised with the fluorophore and fluorophore-peptide conjugate. The coupling 
to the different COOH-functionalised SWNT was performed similarly to the amide couplings described 
in previous sections. The carboxylic acid groups on the nanotubes were activated with pyBOP for 3 h 
in DMF. The excess activating reagent was removed in order to prevent any possible auto coupling 
reactions of the fluorophore by centrifuging the reaction mixture, removing the supernatant and 
re-suspending the carbon nanomaterial in fresh DMF. The fluorophore, 58, was coupled to the oxidised 




Scheme 5.4: Coupling procedure followed in order to incorporate the fluorophore 58 covalently onto 
the functionalised SWNT 78. 
 
The reaction mixture was stirred at room temperature for 48 h. Then, the nanohybrid was isolated by 
centrifugation of the reaction mixture, removing the supernatant and dispersing in fresh solvent. This 
process was repeated several times followed by a filtration step. The nanomaterial was filtered, washed 
with DMF, re-suspended in DMF by sonication and filtered again. This process was repeated several 
times, even if the filtrate was no longer coloured or fluorescent to ensure that all the fluorophore in 
excess had been discarded. The residue was dried under vacuum and lyophilised. 
 
 







Scheme 5.5: Reaction conditions applied hereby for the synthesis of targeted nanoprobes 89 and 90. 
 
Following the same principle, the BODIPY-bombesin conjugate, 87, was coupled to two functionalised 
SWNT derivatives, 78 and 79 yielding the targeted nanoprobes 89 and 90 as depicted in Scheme 5.5.  
 
In both cases, the dispersions containing the desired nanohybrid samples were centrifuged and washed 
with DMF and methanol until a clear supernatant was obtained before being filtered and washed with 
more DMF and methanol until no fluorescence response was observed in the filtrate. The nanoprobes 
were dried and stored at low temperature to prevent any possible decomposition of the peptide. 




In addition, an imaging probe based on a nanohybrid containing the gallium complex 23 was prepared 
(Scheme 5.6). The coupling was conducted in the same manner as the examples described in Scheme 5.4 
and Scheme 5.5. The carboxylic acid groups in the functionalised SWNT were activated with pyBOP 
and an amide bond formed taking advantage of the free amino groups in the Ga(III) complex. The 




Scheme 5.6: Reaction conditions in the preparation of desired imaging probe 91. 
 
The prepared nanohybrids were characterised by using the techniques already described in Chapter 4 
(e.g. FTIR and Raman spectroscopies and imaged by TEM).  
 
Table 5.1: Characterisation data for nanohybrids 87 – 90 obtained by solid state Raman spectroscopy. 
 
Compound ν D (cm-1) ν G (cm-1) ID/IG 
87 1336 1574 0.12 
88 1338 1579 0.11 
89 1334 1575 0.10 
90 1338 1576 0.13 
 






Figure 5.9: Solid state FTIR spectra of nanohybrids 88 (a), 89 (b) and 90 (c). 
 
A summary of the characterisation data obtained by Raman spectroscopy including the wavenumbers 
of the D and G bands and the ID/IG ratio are showed in Table 5.1. It can be observed how the wavenumber 
of the D and G bands only suffer slight changes with respect to the starting materials and between 
nanohybrids. The ID/IG ratios are maintained in the same scale as the values obtained for the 
functionalised SWNTimplying that the coupling steps with the fluorophores or conjugate do not affect 




























































Figure 5.10: TEM images of functionalised SWNT 78 (a and b) and nanohybrid 88 (c and d). 
Scalebar for images on the left: 50 nm. Scalebar for images on the right: 20 nm. 
 
The corresponding FTIR spectra for nanoprobes 88 – 90 can be observed in Figure 5.9. The FTIR spectra 
are similar among them with characteristic bands appearing in all three examples, probably due to the 
similarity of the functional groups introduced. A broad band at ca. 3300 cm-1 is visible in all of them and 
can be assigned to the NH stretching and OH stretching of the carboxylic acids. Another feature visible 
in all three spectra are the bands corresponding to the aliphatic CH stretching at ca. 2950 cm-1. At least 
two different C=O stretching bands (ca. 1710 and 1640 cm-1) are observed for 88 and 89 while only the 
a) b) 
c) d) 




most intense (1643 cm-1) is observable for 90. Other intense and sharp band observable in the three 
spectra is the corresponding to the C-O stretching at ca. 1030 cm-1.  
 
Transmission electron microscopy was performed for a selection of SWNT probes. The TEM images 




Figure 5.11: TEM images of targeted functional nanohybrids 89 (a and b) and 90 (c and d). 
Scalebar for images on the left: 50 nm. Scalebar for images on the right: 20 nm. 
a) b) 
c) d) 






Figure 5.12: TEM images and height profiles (over the dashed blue lines) for 88 (a and b) and 
89 (c and d). 
 
The TEM images of the oxidised SWNT with the carboxyl terminated linker (78) have been included in 
Figure 5.10 for comparison as 78 served as starting material for 88 and 89. In Figure 5.10 (left) the 
images of 78 and 88 at a lower magnification (300k and 250k respectively) can be observed. On the 
right column, a detailed picture at a higher magnification (500k) is showed. It can be observed how 78 
shows an even distribution of SWNT individual tubes or groups of a few tubes can be observed. The 
SWNT present functionalised walls and tips that appear as imperfections and areas of darker contrast 
on walls and tips. However no extensive coating is observed. This is in accordance with the 
functionalisation nature as 78 only contains an aliphatic linker terminating in a carboxylic acid. In the 
case of 88 it appears that the SWNT strands are more aggregated in fibres or ropes of several SWNT. 
Nevertheless it is still possible to observe individual tubes in regions of the sample. The observed 
functionalisation seems higher in this case displayed as a thick coating around the tube with some dotted 
areas of darker contrast. This is in accordance with the introduction of the fluorophore containing the 
amino acid linker. The superior aggregation with respect to 78 can be caused by further aromatic or 
electrostatic interactions facilitated by the BODIPY group. An image at a greater magnification can be 
observed in the right column of Figure 5.10, which in the case of 88 shows aggregation of tubes but also 












































In order to evaluate the increase in the thickness of the resulting nanohybrids, TEM profiles were 
measured and the examples for 88 and 89 are showed in Figure 5.12. For 88, the profile measured over 
two aggregated SWNT (Figure 5.12, top) shows an overall thickness of 7 nm and the measured distance 
in Figure 5.12 reveals a tube with a thickness of ca. 3.8 nm while the second one would have a thickness 
of around 3.2 nm. 
 
In the case of 89 and 90 (Figure 5.11) the situation is analogous although the coating around the SWNT 
is observed in a higher degree. The SWNT nanohybrid 89 can also be compared to 78, and in this case 
the variation is much more appreciable from the linker-containing tubes where the functionalisation is 
apparent in the presence of shorter tubes, imperfections and areas of darker contrast but the nanotube 
walls are still relatively smooth. This changes dramatically for 89 where the SWNT are aggregated in 
ropes and tangles and is difficult to observe individual tubes. The coating around the nanotubes’ wall is 
much thicker in this case and it covers the nanotube homogenously over the nanotube length with respect 
to 88. A detailed section at a higher magnification where the aggregation of the tubes in tangles, ropes 
as well as some individual tubes can be observed in Figure 5.11, top right. The TEM profile measured 
for 89 (Figure 5.12, bottom) also shows an increase in the SWNT thickness as a result of the 
functionalisation with the conjugate. The measured thickness is comparable to that of 88 (3.2 nm). The 
measured profile shows a range of values for SWNT thickness that goes from 2.4 to 3.5 nm. 
 
The case of nanohybrid 90 is similar to that of 89: the morphology of the SWNT observed suggests the 
presence of a coating around the walls, which are no longer “smooth”. However, in this particular case, 
the tubes seemed to be aggregated preferably in ropes that cross the grid in all directions. This is in 
accordance with the functionalisation strategy as the initially functionalised SWNT with benzylamine 
moieties presented a less damaged structure and aggregation into ropes with respect to the oxidised 
materials. 
 
The TEM microscopy results seem to suggest that the introduction of the fluorophore and conjugate has 
been successful by the increase in the functionalisation around the SWNT tubes. This is more apparent 
where the BODIPY-peptide compound was used.  




5.5 Preparation of GO nanoprobes 
The functionalisation strategy to introduce the BODIPY fluorophore, BTSC gallium complex or 
BODIPY-bombesin conjugate was translated to graphene oxide similarly to the strategy described in 




Scheme 5.7: Reaction conditions for the preparation of nanohybrids of GO (92, 93 and 94) 
(products shown schematically). 
 




In this case, the carboxylic acid groups in the functionalised GO were activated using pyBOP and the 
reaction mixtures stirred for 48 h. The nanohybrids were then isolated by centrifugation, the supernatant 
removed and the solid residue re-dispersed again in fresh solvent. These cycles of centrifugation and 
washing were repeated several times. The suspensions were finally filtered through a 0.2 µm membrane 
and further washed until no colouration or fluorescence was observed in the filtrate. The brown solid 
residue was dried under vacuum. 
 
The nanohybrids were characterised by applying the techniques described in the previous section (FTIR 
and Raman spectroscopies). A summary of data obtained by Raman spectroscopy including D and G 
wavenumbers and ID/IG ratios can be observed in Table 5.2. The D and G wavenumbers are comparable 
between nanohybrids and in the same range to the ones obtained for the functionalised GO derivative 
including the linker (84). In contrast, the ID/IG ratios are slightly lower than the ones observed for the 
starting material. This can be an indicative (as it also occurred in the case of functionalised SWNT) that 
a fraction of highly functionalised GO has been lost during the reaction and subsequent processing of 
the reaction mixtures. 
 
Table 5.2: Summary of Raman data for GO nanohybrids 92 – 94. 
 
Compound ν D (cm-1) ν G (cm-1) ID/IG 
92 1354 1589 0.92 
93 1347 1585 0.94 
94 1352 1587 0.87 
 
 
The FTIR spectra for the GO nanohybrids 93 and 94 are shown in Figure 5.13. The FTIR spectra present 
bands observed in the starting material. The broad band at ca. 3200 corresponds to the OH and NH 
stretching. Therefore, in this region overlap the hydroxyl groups of graphene oxide, the NH groups in 
the linker and fluorophore groups (amide bonds) and the hydroxyl groups in carboxylic acids. This can 
explain why this band is broader with respect to similar SWNT nanohybrids (Figure 5.9). The band for 
the CH stretching was observed as a shoulder of the aforementioned band at ca. 2930 cm-1. This band is 
indicative of saturation in the graphene oxide lattice and of methine, methylene and methyl groups in 
the linker and fluorophore moieties. There are at least two different C=O stretching bands with 
wavenumbers at ca. 1710 and 1630 cm-1 although the presence of a shoulder at slightly lower 
wavenumbers can be deduced by observing the spectra. The bands in this region correspond to the 
different C=O groups in the linker and fluorophore. The C-O stretching is also observed at lower 
wavenumber (ca. 1060 cm-1).  












































5.6 Photophysical characterisation of novel probes and nanoprobes 
The photophysical characterisation of the conjugate and all nanohybrids synthesised hereby was carried 
out by UV-vis and fluorescence spectroscopies. The maximum absorption and emission wavelengths 
and quantum yield in the derivatives presenting a strong enough fluorescence signal was calculated. 
 
 
Figure 5.14: Normalised UV-vis spectra of SWNT dispersions (ca. 0.05 mg/mL in DMSO). 



























































The UV-vis spectra for nanohybrids 88 – 90 are displayed in Figure 5.14. The spectra had been 
normalised and a baseline correction applied for clarity. In addition, the UV-vis spectra of the p-SWNT 
and the functionalised SWNT including the carboxyl terminated linkers were included for comparison. 
It can be observed how the pristine SWNT and linker functionalised SWNT present a single peak at 736 
nm that can be attributed to the first Van Hove transition due to metallic SWNT.15  
In contrast, the nanoprobes not only present the aforementioned peak but also others with the maximum 
absorption at ca. 500 nm although the specific wavelength depends on the compound. This peak can be 
attributed to the absorption of the BODIPY fluorophore in the case of 88 or the absorption of the 
BODIPY-bombesin conjugate in the case of 89 and 90. 
 
The spectral properties of the BODIPY-bombesin conjugate were evaluated, the excitation and emission 
spectra were acquired and can be observed in Figure 5.15. It is apparent how the excitation and emission 
profiles are identical to the BODIPY fluorophore. Therefore, in the case of 87 the conjugation to the 
peptide did not cause a variation in the properties of the fluorescent profile of the product. 
 
A summary of the spectral properties of 87 and different nanohybrids is presented in Table 5.3.  
Despite the conjugation to the peptide not causing a change in the excitation and emission profile of 87, 
it had a quenching effect. The quantum yield is affected in the product and decreases to 0.69 with respect 
to the BODIPY starting material. The Stokes shift of 10 nm is identical to the value found for the 
BODIPY starting materials described in Chapter 3. 
 
 
Figure 5.15: Fluorescence spectra of BODIPY-bombesin conjugate 87. Excitation spectrum 


















Table 5.3: Spectral properties of 87 and nanohybrids 88, 89 and 90 in DMSO dispersions. 
 
Compound λmax-abs (nm) λmax-em (nm) Δλ (nm) Φf 
87 500 510 10 0.69 
88 504 505 1 0.03 
89 502 505 3 0.05 
90 502 504 2 0.02 
92 504 505 1 0.04 
93 502 504 2 0.04 
 
 
The coupling of the BODIPY fluorophore to the functionalised SWNT or GO respectively had a strong 
quenching effect in the resulting nanohybrids (88 and 92). The quantum yields are reduced to 0.03 and 
0.04 respectively. Interestingly, the Stokes shift is also reduced and the nanohybrids only present a 1 nm 
difference between the excitation and emission spectra. In the case of the coupling with conjugate 87 
the situation is similar, a strong quenching is observed as a decrease in the quantum yields of the 
resulting SWNT and GO nanohybrids (89, 90 and 93). The quantum yields are in the same range 




Figure 5.16: iSIM super-resolution confocal image of 89 in the green channel (λex 488 nm, λem 525 
nm). The nanoprobe was deposited on a petri dish. Scalebar: 5 µm. Images recorded and processed by 
Colin Wright, Nikon Bioimaging UK, Ltd.16 




The instant structured illumination microscopy (iSIM) super-resolution confocal images of nanoprobe 
89 on the solid state are shown in Figure 5.16. The nanoprobe was deposited on a Petri dish with glass 
bottom (MatTek) from a 1 mg/mL DMSO solution and the solvent removed under vacuum. The 
fluorescence signals can be observed in isolated spots corresponding to aggregate particulate SWNT. 
However, it can also be observed how the SWNT nanoprobes seemed to undergo certain supramolecular 
interactions when the solvent was removed resulting in aggregation as micrometre long fibres. This is 
more apparent in long fibre-like aggregates in the corners of Figure 5.16 (pointed with red arrows). This 
interesting behaviour needs to be further explored using other derivatives, exploiting the available offer 
of fluorescence super-resolution microscopy techniques with nanometre spatial resolution as well as 
employing other techniques such as AFM and SEM. 
 
In addition to the UV-vis and fluorescence spectra, the fluorescence lifetime decays were acquired by 
2-photon time-correlated single photon counting (TCSPC) and the corresponding lifetimes calculated 
from the mathematical fitting of the decay. Fluorescence lifetime experiments were conducted in the 
Central Laser Facility at the Research complex at Harwell under the supervision of Prof Stan Botchway. 
The specific conditions used during fluorescence lifetime experiments are detailed in Chapter 7. 
 
The fluorescence lifetime (τ) is a measurement of the time that the fluorophore remains in the excited 
state. The fluorescence lifetime provides information about the environment of the fluorophore and it 
has the advantage of being independent of the fluorophore concentration.17, 18 The goodness of the fitting 
can be estimated with parameters such as χ2. The better the fitting, the closer χ2 is to unity. The 
fluorescence decay measured for a homogenous group of molecules can be expressed as a mono 
exponential function.19 A large difference of χ2 with the ideal value for a mono exponential fitting (χ2 > 




Figure 5.17: 2P-TCSPC fluorescence decay curves for 87 (left) and 89 (right) and corresponding 
fitting curves (red lines). 

























The fluorescence decays curves and corresponding fittings for 87 and 89 are shown in Figure 5.17. The 
fluorescence lifetimes were calculated in different solvents (DMSO, phosphate-buffered saline, PBS, 
and serum-free medium, SFM) in order to ascertain the effect of the solvent in the lifetime of the 
fluorophore (Table 5.4).  
 
In the case of 58, 87 – 90, one component or mono exponential fittings were valid and worked well for 
the compounds tested in all the solvents as 2 was close to unity with slight variations. The exception 
was compound 58 in DMSO and SFM where the 2 value was slightly higher but within the range of 
values allowed for a one-component fitting. 
 
The lifetime results indicate a trend for 58 and 87 where the longest lifetime is obtained in DMSO, 
followed by PBS and SFM. The use of DMSO has been reported to increase the lifetime of organic dyes 
with respect to aqueous solvents due to the decrease of hydrogen bonding and hence the reduction of 
non-radiative decay.20, 21 The lifetimes of 58 are ca. 3.5 ns and the lifetime differences are ca. 0.5 ns 
depending on the solvent. Differently, for 87 there is a larger difference (> 1 ns) between the lifetime in 
DMSO and in PBS or SFM. The lifetimes in PBS and SFM decreased with respect to 58 and increased 
in DMSO.  
 
Table 5.4: 2P-TCSPC fluorescence lifetime decay data for 58, 87 – 90 in DMSO, PBS and SFM. 
One component fitting. 
 
Compound Solvent P (mW) 2 a1 (%) t1 (ns) 
58 DMSO 0.64 1.26 100 4.00 
PBS 0.5 1.08 100 3.37 
SFM 2.2 1.35 100 3.35 
87 DMSO 0.98 1.18 100 4.03 
PBS 0.5 0.98 100 2.88 
SFM 2.2 0.99 100 2.67 
88 DMSO 13.7 1.04 100 2.93 
PBS 8.1 1.11 100 2.57 
SFM 5.8 1.11 100 3.23 
89 DMSO 7.1 1.11 100 3.21 
PBS 7.8 1.16 100 2.39 
SFM 5.8 1.17 100 3.02 
90 DMSO 8.2 1.10 100 3.04 
PBS 7.9 1.19 100 3.00 
SFM 7.9 1.15 100 3.49 
 




This could be explained by the extended presence of hydrogen bonding generated by the presence of the 
peptide residue in polar protic solvents. The lifetime of 87 was 4.03 ns in DMSO while is reduced to 
2.88 ns and 2.68 ns in PBS and SFM respectively. 
 
The lifetimes values observed herein for the BODIPY derivatives are in accordance with previously 
observed values for similar BODIPY species functionalised with small molecules. Dilworth et al. 
reported values in the range of 2 – 3 ns for BODIPYs functionalised with bis(thiosemicarbazone) ligands 
and the corresponding copper complexes.22 
 
In the case of the nanohybrids, the situation was analogous when the solvent was DMSO. The nanoprobe 
functionalised with the BODIPY fluorophore (88) showed a lifetime of 2.93 ns and was in a similar 
range for the corresponding nanohybrids containing the fluorophore-peptide conjugate: 3.21 ns and 
3.04 ns for 89 and 90 respectively. When the solvent was PBS or SFM the situation was more complex. 
In general, the lifetimes increased with respect to the conjugate 87. The trend observed for the molecular 
species was maintained for 89 where the lifetimes were shorter with respect to the derivative containing 
just the fluorophore, a fact that can be attributed to the higher degree of hydrogen bonding interactions 
in aqueous solvents that favour non-radiative decay processes and shorten the fluorescent lifetime in the 
excited state. However, in the case of 90 an increase of the lifetime in PBS and SFM was observed with 
respect to 88. Furthermore, the nanohybrids presented longer lifetimes in SFM and PBS with respect to 
87 which can be indicative that the SWNT are hindering the hydrogen bonding in aqueous solvents and 










5.7 Cell viability assays 
The use of tetrazolium salts have become a widely employed technique in cell biology to measure 
metabolic activity. In particular, the use of 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium 
bromide (MTT) is now an accepted method to measure cell viability.23, 24 The accepted mechanism for 
the action of MTT implies the cellular uptake of the MTT dye and its reduction by nicotinamide species 
(i.e. NAD(P)H) in the cytoplasm and mitochondria of the cells to form the formazan species 
(Scheme 5.8). The coloured formazan species is non-soluble in cellular media so it needs to be 
solubilised in order to measure the absorbance. The concentration can be calculated from the absorbance 




































In this work, MTT assays were performed in a range of concentrations to calculate the IC50 values of a 
selection of fluorophores and nanohybrids. The viability assays were carried out in PC-3 cells in 96 well 
plates incubated with the selected compounds in serum medium (1% DMSO) at different concentrations 
for 48 h at 37 ºC. Then, MTT was added and incubated for 2 h. The insoluble formazan species was 
solubilised with 100 µL DMSO and the corresponding absorbance measured using a plate reader. The 
MTT assays showed herein were carried out by Dr Haobo Ge at the University of Bath following 
previously validated protocols.26, 27 The detailed conditions can be found in Chapter 7. 
 
The IC50 values for a group of fluorophores can be observed in Figure 5.18 (IC50 values here refer to the 
concentration at which the number of viable cells is reduced 50%). It can be seen how the BODIPY 
fluorophore 58 presents a remarkable cytotoxicity in PC-3 cells in the µM range. The conjugation of the 
fluorophore with the bombesin peptide to form 87 results in a considerable reduction of the cytotoxicity 
with the conjugate’s IC50 in the mM range. Surprisingly, the IC50 value for the Ga(III) complex 23 is 
higher than for 58 being in the ten of mM range. Similar symmetrical Ga(III) complexes described in 
the literature proved to be considerably more toxic for HeLa cells with IC50 values in the micromolar 
range.28 In this case, the response of 23 can be strongly cell-dependent, showing a reduced cytotoxic 
effect in PC-3 cells or the introduction of a free amino group in the thiosemicarbazonato structure might 
have a considerable effect in the uptake and viability of this cell line. This result requires of further 
investigation into the properties of this compound to understand its effect in living PC-3 cells. 
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The cell viability results for a selection of functionalised SWNT can be observed in Figure 5.19. A clear 
trend can be observed where the functionalisation of the SWNT clearly reduces the cytotoxicity of the 
nanomaterial. The pristine SWNT show a high cytotoxicity with an IC50 value on the sub ngmL-1 scale. 
A drastic change is observed when the linkers are introduced in the SWNT and the cytotoxicity of the 
functionalised material with terminal carboxylic acids presents a reduction of four orders of magnitude 
being in the µgmL-1 scale. The functionalisation with the BODIPY or BODIPY-bombesin peptide in 
nanohybrids 88, 89 and 90 yields the lowest cytotoxicity in the functionalised SWNT family. This 
increase might be motivated for the action of the fluorophore and its linker in 88 and due to the enhanced 
biocompatibility generated because of the introduction of the peptide in 89 and 90. 
 
The cell viability results for graphene oxide and graphene oxide nanohybrids can be observed in 
Figure 5.20. The trend observed for SWNT derivatives is not observed herein. Graphene oxide has the 
lowest cytotoxicity with an IC50 value in the µgmL-1 scale, comparable to the linker functionalised 
SWNT (78). This can be rationalised on the basis that GO already contains numerous oxygenated 
functionalities and their number is reduced during the synthetic process. Surprisingly, the cytotoxicity 
increases for the GO derivatives containing the linker (84) with respect to the original GO. The highest 
cytotoxicity was observed for the nanohybrid containing the BODIPY-bombesin conjugate which is 
surprising and contradicts the trend observed in the SWNT case. In this case, the increase in cytotoxicity 
might be attributed to potential aggregation effects when the GO is functionalised with the conjugates. 
 
 




























A summary of the IC50 values for the fluorophores and nanomaterials described above can be observed 
in Table 5.5.  
 
Table 5.5: Summary of estimated IC50 values for a selection of fluorophores and SWNT and GO 
nanomaterials. The mean of at least six determinations is indicated with the corresponding SEM. 
 
Compound IC50 (mM) ± SEM 
58 0.0027 ± 0.0011 
87 0.75 ± 0.27 
23 13 ± 3 
Compound IC50 (µgmL-1) ± SEM 
p-SWNT 0.000036 ± 0.000004 
[78 0.18 ± 0.17] 
88 6.1 ± 0.4 
89 20 ± 2 
90 98 ± 1 
81 0.37 ± 0.12 
84 0.011 ± 0.004 
93 0.017 ± 0.006 
 
 
The cytotoxicity results for SWNT should be interpreted with caution. The cytotoxicity effects of single 
walled carbon nanotubes have revealed to be controversial as they are affected by a considerable number 
of factors as the presence of metallic or carbonaceous impurities, the type of functionalisation, the use 
of dispersants, the agglomeration or the cell line evaluated.29-33 Even the use of the MTT reagent has 
been questioned for the estimation cell viability with SWNT due to the insolubility of the formazan 
species and the authors advised to use at least two different techniques.34  
 
However, there seems to be an agreement about the effect of the functionalisation of SWNT on cell 
viability. The cytotoxicity of highly pure SWNT where no additives or dispersants were employed was 
reported to be higher with respect to other comparable functionalised samples.29 Furthermore, the 
increase in the degree of functionalisation could be related to the decrease in cytotoxicity.32, 35, 36 
 
The results observed in this work are in accordance with the mentioned behaviour and showed a clear 
tendency in the direction of the reduction of the cytotoxicity with each step of the functionalisation.   




5.8 In vitro imaging with new compounds synthesised and corresponding nanoprobes 
The imaging probes and nanoprobes synthesised hereby were proposed as optical imaging agents in 
living PC-3 cells and the cellular uptake observed by single-photon confocal microscopy. The cells were 
cultured by standard techniques and grown until ca. 70% confluency. In general, the compounds were 
incubated for periods of 15-20 min to verify the hypothesis that these systems presented a rapid uptake 




Figure 5.21: Single-photon confocal microscopy images of 58 (top) 87 (middle) and blocking 
experiment with 87 in PC-3 cells after 15 min incubation, 20 µM 1% DMSO at 37 ºC where a) DIC 
image, b) green channel, λex 488 nm, λem 518 nm and c) overlay of a) and b). Scalebar: 50 µm. 
a) b) c) 
c) a) b) 
a) b) c) 




The BODIPY 58 and BODIPY-bombesin conjugate 87 were tested in PC-3 cells. The compounds were 
added in a 20 µM concentration in serum-free medium (1% DMSO). The images obtained by single 
photon confocal microscopy are shown in Figure 5.21. The fluorophore 58 is displayed in the top row 
and it can be observed that the fluorescence signal is intense in the green channel and the compound is 
distributed in the cytoplasm with occasional location in organelles/micelles observed as punctuation. 
Interestingly, the conjugate 87 (Figure 5.21, middle) presents a very different distribution in the cell. 
It can be observed how for the conjugate, a fraction of the compound is present dispersed in the 




Figure 5.22: 3D representation of the iSIM confocal images of 58 (top) and 87 (bottom) in fixed PC-3 
cells. Both images show the green channel (λex 488 nm, λem 525 nm). Scalebar: 5 µm. Images recorded 
and processed by Colin Wright, Nikon Bioimaging UK, Ltd.16 
 






Figure 5.23: Single photon confocal microscopy images of SWNT nanoprobes 88 (top), 89 (middle) 
and 90 (bottom) in PC-3 cells after 15 min incubation, 10 µg/mL 1% DMSO at 37 ºC where a) DIC 
image, b) green channel, λex 488 nm, λem 518 nm and c) overlay of a) and b). Scalebar: 50 µm. 
 
However, the most intense fluorescence signal was observed around the cell membranes as well as 
localised in a dotted pattern inside the cytoplasm. This is in accordance with a targeted uptake directed 
by the GRP receptors in PC-3 cells. To further prove this observation, a blocking imaging experiment 
was conducted (Figure 5.21, bottom). In this experiment, the cells were first incubated in the presence 
of a high concentration of bombesin [7-13] (10 mM) for 30 min. After this time, the cells were washed 
with PBS, the serum free medium replaced and the cells incubated with conjugate 87. After washing the 
excess of compound, the images acquired showed a dispersed distribution of 87 in the cytoplasm with 
a) b) c) 
c) a) b) 
a) b) c) 




occasional concentration with a punctuated distribution but remarkably different to the uptake observed 
for 87. This result would point at a non-specific behaviour where the uptake under the evaluated 
conditions is governed not only by the targeting peptide, showing a preference for the GRP receptors 
and a targeted behaviour, but also by the BODIPY fluorophore that shows a distribution in the cytoplasm 
known to be typically in the ER. This has been observed before for BODIPYs or porphyrin derivatives.22 
This was further explored by the acquisition of 3D super-resolution confocal microscopy images (iSIM) 
for 58 and 87 in fixed PC-3 cells (Figure 5.22). In the case of the BODIPY fluorophore it can be observed 
how the maximum fluorescence intensity locations are observed in a punctuated pattern inside the 
cellular cytoplasm. On the contrary, the cells incubated with 87 showed a completely different aspect. 
In this case, the observed maximum fluorescence intensity is distributed over the exterior of the cell 
with points of aggregation around the membrane. This result would further confirm the observations 
made by single photon confocal microscopy in living cells. 
 




Figure 5.24: Single photon confocal microscopy images of GO nanoprobes 92 (top) and 93 (bottom) 
in PC-3 cells after 15 min incubation, 10 µg/mL 1% DMSO at 37 ºC where a) DIC image, b) green 
channel, λex 488 nm, λem 518 nm, and c) overlay of a) and b). Scalebar: 50 µm. 
 
a) b) c) 
a) b) c) 




In the case of the nanohybrids based on SWNT, it can be observed how 88, that contains only the 
BODIPY fluorophore, shows a more homogeneous distribution in the cytoplasm than 89 and 90. The 
targeted nanoprobes present a punctuated distribution, similar to 87, and a more intense fluorescence 
response inside the cellular cytoplasm in organelles or vesicles. This behaviour was especially noted for 
90. However, this effect compared to 88 could be attributed due to the enhanced dispersibility in DMSO 
thanks to the functionalisation with the peptide that can favour cell uptake, and further work on cellular 
co-localisation with dyes is needed in detailed in vitro studies beyond the scope of this thesis. 
 
Similarly, the imaging experiments conducted with GO nanoprobes can be observed in Figure 5.24. In 
this case, the response for the material containing the fluorophore alone (92) or the targeted derivative 
(93) present a similar response. The fluorescence response is widely distributed around the cell 
cytoplasm and the uptake seems to result in the nanohybrids located in small vesicles that are observed 
as a fluorescent punctuation.  
 
The imaging experiments performed for the nanohybrids containing the Ga(III) BTSC complex (Figure 
5.25) showed a completely different behaviour. In this case, the fluorescence response in the green 
channel was equivalent in the blue and red channels due to the broader emission spectrum of the 
thiosemicarbazonato complex. The distribution of the nanohybrids can be related to the original gallium 
complex, with the fluorescence signal mainly concentrated in a dotted pattern inside the cytoplasm 
mostly around the nuclei that can be attributed to localisation in the endoplasmic reticulum due to the 




Figure 5.25: Single photon confocal microscopy images of compounds 91 (top) and 94 (bottom) in 
PC-3 cells after 15 min incubation at 37 ºC where a) DIC image, b) blue channel, c) green channel, 
d) red channel and e) overlay of a)-d). Scalebar: 50 µm. 
a)  b) c) d) e) 
a)  b) c) d) e) 




5.9 Fluorescence lifetime imaging evolution of new BODIPY-functionalised probes 
The development of multi-photon and TCSPC systems opened the way for the development of 
fluorescence lifetime imaging that can be carried out using a confocal microscopy setup thus allowing 
study of living cells and biological interactions. Two-photon excitation consists of the process where a 
fluorophore absorbs two photons simultaneously at approximately double the wavelength of the 
one-photon absorption wavelengths. The emission, however, occurs at the same wavelength of the one-
photon emission allowing to perform the imaging experiments in the visible range. This allows to use 
excitation wavelengths in the NIR region of the spectrum that benefits of a number of advantages as 





Figure 5.26: FLIM maps in PC-3 cells with lifetime distribution plots and profiles for a) 58, b) 87, 










The use of FLIM techniques allows us to represent lifetime maps of the compounds of interest in living 
cells which give an insight in the interaction of the fluorophore with cellular environment and the effect 
that this environment produces in the fluorophore’s lifetime.38 The application of FLIM to study protein-
protein interactions in cells has been profusely reported.39 However, FLIM has not only been applied to 
the study of proteins but also to small molecules including organic fluorophores or coordination 
complexes such as thiosemicarbazonato species.22 Furthermore, this technique has revealed as a 
powerful tool to evaluate the interactions of fluorescent nanomaterials such as quantum dots, 
nanoparticles or carbon nanotubes in living cells.26 
 
In this work, FLIM experiments were conducted for a selection of probes and nanoprobes in PC-3 cells. 
The conditions applied were analogous to those used in the acquisition of lifetime decays and single-
photon confocal imaging experiments. The FLIM maps, lifetime distribution plots and lifetime profiles 
for 58, 87, 88 and 89 can be observed in Figure 5.26 while a summary of the calculated parameters is 
showed in Table 5.6. 
 
In this case, the lifetime decays were fitted to an exponential decay with two components. Therefore the 
fluorescence lifetime decays are fitted to a model where the intensity is presumed to decay as the sum 
of two individual single exponential decays. In the case of a sample containing only one fluorophore as 
in this case, assuming that no decomposition of the probes is being produced in vitro on the imaging 




Table 5.6: Two-photon Time Correlated Single Photon Counting data of compounds 58, 87, 88, 89 
and 90 incubated in PC-3 cells for 15 min, in SFM (1% DMSO), ex = 910 nm. 
 
Compound P (mW) 2 a1 (%) t1 (ps) a2 (%) t2 (ns) 
58 2.1 1.00 11.4 1403 88.6 4.50 
87 2.3 0.99 60.7 1057 39.3 4.42 
88 7.7 1.25 84.1 480 15.9 2.27 
89 7.3 1.26 73.9 327 26.1 2.11 









The fluorophore 58 and the conjugate 87 presented two lifetime components that were in the nanosecond 
range. The first component presented the shortest lifetime (ca. 1 ns). However, the weighting varied 
from the fluorophore, where the second and longest component is the principal (88.6%), to the conjugate 
where the situation was reversed and the first and shortest component is now dominant (60.7%). The 
second components present longer lifetimes with respect to the lifetimes of the free compounds in SFM 
but both are in the same range. In the case of the fluorophore 58 the lifetime of the major component is 
in the same range of the observed in the free species. However, the conjugate presents a major 
component with a much shorter lifetime to the observed for the free compound in SFM. This might be 
attributed to interactions in the cellular environment that quench the fluorescence decay in favour of 
alternative non-radiative process to dissipate the energy of the excited state. 
 
The situation for the nanohybrids is different to that described for the fluorophore and conjugate 
although the results are similar among the three nanohybrids (88, 89 and 90). The nanohybrids present 
a major component (ca. 80%) with the shortest estimated lifetime, in the picosecond scale and a second 
minor component with a lifetime in the nanosecond scale (ca. 2 ns). In this case, the second component 
is similar to the lifetimes observed for the nanoprobes in dispersion in PBS or SFM. However, the 
interactions in the cell environment produce a strong quenching effect for the nanoprobes that shortens 
considerably the time that the imaging nanohybrids based on SWNT spend in the excited state. 
 
The distribution for nanohybrids 88 and 89 in PC-3 cells can be observed in the lifetime maps depicted 











In this chapter, the [7-13] fragment of the bombesin peptide was synthesised via a modified route. The 
preparation of the peptide was conducted by solid-phase peptide synthesis using microwave-assisted 
heating. This peptide has been known to act as a targeting molecule for GRP receptors that are 
overexpressed in prostate cancer. The use of microwave radiation in peptide synthesis has a number of 
advantages such as the dramatic reduction of reaction times or providing access to sequences that are 
not accessible by conventional synthesis. The peptide was purified by automated flash column 
chromatography and the purity assessed by HPLC. The characterisation was carried out by common 
spectroscopic techniques such as 1H NMR or mass spectrometry. 
The peptide fragment was successfully coupled to a selected BODIPY fluorophore (58) described in 
Chapter 3. The purification in this case was performed by RP-HPLC. The conjugate was studied by 
mono and bidimensional 1H NMR and mass spectrometry. Furthermore, the photophysical properties 
were evaluated and the conjugate showed identical behaviour to the initial fluorophore in terms of 
fluorescence profiles and maximum excitation and emission wavelength. However, the incorporation of 
the peptide to the structure provoked a quenching of the fluorescence and the quantum yield was reduced 
with respect to the starting material.  
 
Different nanohybrids were prepared by coupling selected fluorophores described in Chapter 2 and 
Chapter 3, as well as the BODIPY-bombesin conjugated, with functionalised SWNT. The nanoprobes 
were prepared by amide chemistry activating the carboxylic acids present in the functionalised SWNT. 
Nanoprobes containing the BODIPY fluorophore and others containing a new aromatic Ga(BTSC) 
complex were obtained. In addition, targeted nanohybrids were prepared using the same procedure by 
coupling to the BODIPY-bombesin conjugate. All SWNT nanohybrids were thoroughly washed with 
different organic solvents to maximise the chances that all of the unbound excess reagents present being 
removed. The novel materials were characterised by FTIR and Raman spectroscopies and TEM was 
carried out for a subset of compounds. In this family, the photophysical properties were evaluated by 
UV-vis and fluorescence spectroscopy and the spectra revealed that a fluorescence response was still 
appreciable although the fluorescence was quenched due to the coupling to the nanomaterial as 
demonstrated by the reduction of the quantum yields. 
 
Furthermore, the procedures developed for the assembly of new SWNT probes were translated to 
functionalised graphene oxide species, as described in Chapter 4. This way, the GO derivative including 
the linker was coupled to the BODIPY fluorophore, the BTSC complex and the BODIPY-bombesin 
conjugate. The GO nanohybrids were equally characterised by FTIR and Raman spectroscopies and the 
photophysical properties evaluated. The GO nanoprobes emerging showed an appreciable fluorescent 
response which was encouraging towards their use for optical imaging purposes. 




The fluorescence of the nanohybrids containing BODIPY fluorophores showed similarities in their 
optical properties, i.e. in a similar excitation and emission profiles with respect to the starting materials 
although the emission profiles were slightly blue shifted and the Stokes shifts were smaller (in the order 
of 2 – 5 nm). The quenching of the fluorescence emission was evident by the coupling to the 
nanomaterials, as it was demonstrated by the reduction in the quantum yields and the fluorescence 
lifetimes. 
 
Cell viability experiments were performed to assess the cytotoxicity of these novel compounds. The 
experiments were carried out in PC-3 cells and the IC50 estimated. The values for the fluorophores 
showed how the formation of the BODIPY-peptide conjugate produced a reduction of the cytotoxicity 
of the BODIPY starting material. In the same way the Ga(III) thiosemicarbazonato complex showed a 
surprisingly low cytotoxicity compared with similar derivatives reported in the literature. For the SWNT 
series, a clear trend was observed in the direction of the reduction of cytotoxicity with subsequent 
functionalisation as expected. Pristine SWNT proved to be the most cytotoxic nanomaterial for cells, 
which is in accordance with literature data by this group and others, the initial functionalisation and 
introduction of linkers produced a dramatic reduction in cytotoxicity while the coupling with the 
fluorophore or the conjugate produced further reduction in the cytotoxicity.  
 
This trend was not observed for the GO and GO nanohybrids. In the case of GO, the lower cytotoxicity 
was observed for the starting material (GO) while the linker functionalised derivative was more toxic 
and the nanohybrid incorporating the fluorophore-peptide conjugate proved to be the more cytotoxic of 
the derivatives under the evaluated conditions. However, the IC50 values did not change as dramatically 
as in the case of the functionalisation of SWNT. 
 
The prepared fluorophores and nanohybrids were evaluated as optical imaging probes in living PC-3 
cells by confocal microscopy. When the behaviour of the BODIPY fluorophore was compared to the 
conjugate, it could be observed that the targeted conjugate showed a preference for the cell membranes 
and it entered the cell in the form of vesicles. This is in accordance with the targeted behaviour reported 
in the literature for similar bombesin derivatives. A blocking experiment was carried out to demonstrate 
this fact and it could be seen how the cellular distribution after the GRP receptors were blocked with an 
excess of bombesin was highly similar to the fluorophore alone. This suggests that a split uptake 
mechanism is taking place that is directed jointly by the peptide and also by the fluorophore.  
The SWNT nanohybrids were evaluated and demonstrated their applicability as imaging probes. A 
difference was also observed between the uptake and distribution of the derivatives containing only the 
fluorophore or the conjugate but more experiments are needed to demonstrate the targeted uptake of the 
SWNT nanohybrids.  
 




The GO nanohybrids proved useful as imaging agents although the difference between the derivatives 
containing just the BODIPY fluorophore or the targeted species was not as evident as in the last case. 
The cytotoxicity of these nanohybrids seemed higher in the imaging experiment timescale, which is in 
accordance with the results obtained in cell viability experiments. 
 
The SWNT and GO nanohybrids containing the Ga(III) thiosemicarbazonato complex were also tested 
in PC-3 cells. In this case, the fluorescence emission observed was broader and the fluorescence intensity 
reduced compared to the case of the probes containing BODIPY fluorophores in samples of comparable 
concentration. The uptake and localisation in the cells was comparable to that described for the 
fluorophore alone that might reveal a strong effect of the metal complex in the uptake mechanism of the 
nanoprobe. 
 
Furthermore, fluorescence lifetime imaging experiments were carried out for a selection of compounds. 
The FLIM experiments were conducted in living PC-3 cells and allowed to obtain the lifetime of the 
fluorophores and nanohybrids in vitro. In this case, the fluorescence lifetime decays were fitted to an 
exponential function with two fluorescent components. 
The fluorophore 58 presented a major component with a long lifetime, comparable to the observed for 
the species in solution. The second minor component presented a shorter lifetime in the picosecond 
scale. This situation was reversed for the conjugate 87 where the major component was the one that 
presented a shorter lifetime value in the picosecond scale. The minor component presented a lifetime 
comparable to the observed in solution. From these observations, it can be inferred that the conjugate 
undergoes interactions in vitro that result in a quenching process that shortens its lifetime. 
 
In the case of the nanohybrids, the major component is the first with a shorter lifetime in the picosecond 
scale. The second minor component, presents comparable lifetime values as the ones observed for 
suspensions in PBS or SFM. Therefore, the nanohybrids similarly to 87 present certain interactions in 
vitro that result in the quenching of the fluorescence through other non-radiative process as the lifetime 
in the excited state is shortened. 
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Chapter 6 : Summary and outlook 
The synthesis and characterisation of fluorescent nanohybrids based on carbon nanomaterials 
(i.e. functionalised SWNT and functionalised GO) for their application in optical imaging were 
described in this thesis. New nanohybrids incorporating a thiosemicarbazonato complex, a BODIPY 
fluorophore and/or a BODIPY-bombesin conjugate were evaluated in vitro in living prostate cancer 
PC-3 cells using different optical imaging techniques and it appears that they show promising prospects 
as imaging agents. The novel nanohybrids demonstrated their capability to enter into the cancer cells, 
reduced cytotoxicity with respects to the starting materials and possibilities of further functionalisation 
using non covalent or filling strategies to expand their applications. 
 
The chemistry of thiosemicarbazones and the formation of the zinc and gallium complexes for several 
different novel derivatives was described in Chapter 2. New synthetic routes for known, and novel 
functional thiosemicarbazides were explored, as necessary steps in order to apply them further to the 
synthesis of new unsymmetrical bis(thiosemicarbazonato) complexes. The preparation of 
unsymmetrical derivatives using the standard methods described in the literature proved challenging, so 
a novel set of conditions was explored by using microwave-assisted heating. The application of the 
microwave conditions to the synthesis of mono(thiosemicarbazone) and symmetrical 
bis(thiosemicarbazone) ligands proved successful leading to considerably reduced reaction times and 
enhanced yields. This emerged as a new desirable method to obtain this type of compound in the future. 
However, the synthesis of unsymmetrical ligands proved to be further complicated by the occurrence of 
a metathesis exchange between the thiosemicarbazone moieties, which was observed upon heating. This 
exchange yielded a statistical mixture of the starting material and all derivatives originated by exchange 
of the thiosemicarbazone groups. Although such synthetic difficulties were encountered, a zinc complex 
was successfully prepared by a one-pot templated method from the mono(substituted) ligand with 
thiocarbohydrazide and the desired free amino group was present in the final product as demonstrated 
by spectroscopic techniques. The corresponding gallium complex was obtained by transmetallation with 
gallium chloride and the final product proved to be a promising bis(thiosemicarbazonato) fluorophore. 
This was demonstrated and fluorescence spectroscopy data suggested its usefulness for further imaging 
applications. 
 
Furthermore, other aromatic dicarbonylic compounds were explored for the preparation of intrinsically 
fluorescent thiosemicarbazones. Four different starting materials were used in the preparation of 
thiosemicarbazones that had never been reported before. The structural investigations into these 
compounds were carried out by 1H and 13C NMR spectroscopies, mass spectrometry and, in the case of 
pyrene-4,5-dione mono(thiosemicarbazones), by single crystal X-ray crystallography. The mono(allyl) 




thiosemicarbazones ligands with acenaphthenequinone, aceanthrenequinone, phenanthtrenequinone and 
pyrene-4,5-dione backbones were evaluated as synthetic scaffolds for the preparation of the zinc 
thiosemicarbazonato species. The complexes were successfully obtained by microwave-assisted heating 
which considerably reduced the reaction time with respect of similar acenaphthenequinone examples 
already reported in the literature.  
A selection of compounds was tested in PC-3 cells showing cellular uptake and concentration in 
organelles but further work is needed to discern a preferred cellular localisation.  
The preparation of functional derivatives incorporating protected amino acids opens the way of coupling 
the thiosemicarbazone ligands or complexes to targeting molecules. The coupling to bombesin would 
be a logical next step as bombesin has been used as a targeting peptide for prostate cancer cells 
throughout this project. These targeted derivatives will be tested in vitro in PC-3 cells and other prostate 
cancer cell lines to evaluate their selectivity towards GRP receptors. Furthermore, the biological 
evaluation will be extended to explore the hypoxia selectivity of the novel thiosemicarbazonato 
complexes as it has been already described for certain compounds in this family. Imaging experiments 
of the prepared compounds at variable oxygen levels can provide valuable information about the 
potential hypoxia selectivity prior to further biological experiments.  
In addition, the radiolabelling of the distinct thiosemicarbazonato compounds by transmetallation of Zn 
or Ga with 68Ga would make their use possible in PET imaging. Preliminary results in the radiolabelling 
of mono(thiosemicarbazonato) compounds showing high incorporation and radiochemical yield are 
encouraging to study the possibilities of the radiolabelled compounds as in vivo imaging agents. 
 
The study of BODIPY fluorophores was described in Chapter 3. BODIPY fluorophores were selected 
due to their advantageous photophysical properties and stability under a wide range of conditions. A 
bifunctional derivative was prepared including a protected lysine residue. The preparation of derivatives 
emitting in the IR was also explored taking advantage of the possibility of the methyl groups in the 
BODIPY core to undergo a Knoevenagel-type reaction. This way, a styryl residue was introduced, 
extending the conjugation and shifting the fluorescence emission maximum towards the NIR region of 
the spectrum (λem-max 752 nm).  
The deprotection of the Boc group in the lysine residue was explored prior to the coupling of the 
fluorophore with the peptide, and some difficulties were found when treating the bifunctional BODIPY 
under acidic conditions. Several reaction conditions were tested but an efficient synthetic method, 
compatible with the presence of a peptide group, was not established. In order to overcome the 
deprotection difficulties, the equivalent bifunctional derivative was prepared by coupling the BODIPY 
with the Fmoc amino protecting group. This way, an equivalent bifunctional BODIPY derivative was 
obtained but in this case the deprotection could be achieved using piperidine in mild conditions and 
reduced reaction times. The characterisation of the BODIPY derivatives was carried out by 1H- and 13C 
NMR spectroscopies, single X-ray crystallography for one of the intermediate compounds and UV-vis 




and fluorescence spectroscopies to evaluate the photophysical properties. The absorption and emission 
of this family of compounds occurs in the visible region of the spectrum (λmax 500 nm) presenting high 
quantum yields (with the exception of the styryl BODIPY derivatives that had their emission in the NIR 
region of the spectrum and the quantum yield significantly reduced with respect to other BODIPY 
species). 
The novel BODIPY derivatives prepared hereby were tested in PC-3 cells proving as promising optical 
imaging dyes showing cell uptake and localisation in the cytoplasm. The understanding of the fate of 
these compounds in vitro is essential for their applicability and potential modification to target specific 
organelles inside the cell. Co-localisation experiments with specific dyes to ascertain the specific 
localisation in the cell (membranes, nuclei, endoplasmic reticulum, mitochondria, etc.) are being 
designed for this family of compounds. 
 
The preparation of carbon nanomaterials based on single walled carbon nanotubes for their use in 
biological systems was described in Chapter 4. Two initial functionalisation strategies were used herein: 
oxidation and a Tour reaction. The oxidation yielded carboxylic acid groups in the tips and sidewalls of 
the SWNT, while the Tour reaction provided a free amino group by functionalising the sidewalls of the 
SWNT. The introduction of linkers followed to improve the dispersibility and stability of the dispersions 
of the nanotubes. Different diamines or long chain amino acids were applied that resulted in terminal 
amino groups for the different nanoprobes. The introduction of terminal carboxylic acids was achieved 
by reaction with succinic anhydride that improved the dispersions’ stability and yielded a convenient 
functional group for the introduction of the fluorophores or fluorophore-peptide conjugate.  
The different functional SWNT prepared hereby were characterised by FTIR and Raman spectroscopies, 
the Kaiser test and by TGA and TEM for selected derivatives. The functionalisation could be 
demonstrated using these techniques and the functionalisation degree estimated by TGA and the Kaiser 
test. 
 
In addition, the functionalisation strategy applied hereby to SWNT was translated to graphene oxide 
(GO). In this case, one selected diamine compound was used as a linker taking advantage of the 
carboxylic acid groups in the graphene oxide structure. The GO nanohybrids were characterised using 
the techniques described above for SWNT (FTIR, Raman, Kaiser test, TGA) that demonstrated the 
functionalisation of the material. However, the functionalisation degree found for the GO derivatives 
proved to be lower than the observed for equivalent SWNT compounds, probably due to the lower 
concentration of functional groups in the starting material. 
 
The preparation and characterisation of bombesin, a targeting peptide towards prostate cancer cells was 
described in Chapter 5. The peptide was prepared by solid phase peptide synthesis (SPPS) using 
microwave heating. The crude peptide was purified by automated flash column chromatography and 




characterised by HPLC, mass spectrometry and 1H NMR spectroscopy. The resonances of the different 
amino acids could be assigned by applying different bidimensional NMR techniques revealing the 
correlation between coupled 1H-1H nuclei. Furthermore, the coupling of bombesin to the bifunctional 
BODIPY fluorophore was described hereby. The conjugate was purified by RP-HPLC and characterised 
by 1H NMR, mass spectrometry and UV-vis and fluorescence spectroscopies. The photophysical 
properties revealed that the conjugate presented identical fluorescence excitation and emission profiles 
with respect to the starting materials although the quantum yield was reduced. The fluorescence lifetime, 
acquired by time-correlated single photon counting, was also measured in solution and proved to be 
shorter than that found in the BODIPY starting material, revealing that the peptide changed the 
environment of the fluorophore and induced a process of quenching of the fluorescence. 
Different targeted nanohybrids, based on functionalised SWNT and functionalised GO, were prepared 
incorporating the conjugate. In addition, nanohybrids were also prepared incorporating the gallium 
thiosemicarbazonato complex and the BODIPY fluorophore. 
The evaluation of the conjugate and nanohybrids in vitro was carried out in PC-3 cells by confocal 
imaging microscopy. The different uptake presented by the fluorophore and the fluorophore-bombesin 
conjugate proved the targeting behaviour of the conjugate. This was further explored by performing a 
blocking experiment and acquiring super-resolution microscopy images. The nanohybrids showed good 
uptake and maintained the fluorescence probing as promising imaging probes. The fluorescence lifetime 
imaging (FLIM) of a selection of compounds was carried out and the existence of a quenching 
mechanism was demonstrated in the cellular environment whilst the environment of the fluorophores 
was clearly influenced by the interaction with cellular biomolecules. Cell viability studies (MTT assays) 
suggested that the reduction of toxicity of the SWNT nanohybrids with respect to the starting materials, 
that further points towards their advantageous properties as potential cellular imaging probes. 
 
The evaluation of the nanohybrids in vitro showed promising results that are encouraging to continue 
the study of their behaviour in other cancer cell lines especially the ones rich in GRP receptors. The 
preference of the nanohybrid for the overexpressed GRP receptors can be demonstrated by the 
performance of blocking experiments, similar to the experiments performed for the BODIPY 
fluorophore and the conjugate that revealed a preference of the conjugate for the cellular membranes. 
Co-localisation experiments are being designed as well to help understand the fate of the carbon 
nanomaterials in vitro and their presence in the cellular membrane, in vacuoles or near the endoplasmic 
reticulum. 
 
Furthermore, the excellent conducting properties of SWNT make them ideal candidates to form part of 
electrical sensing devices. The use of gold electrodes on a glass substrate opens the possibility of dual 
electrical and optical detection. Preliminary experiments for the deposition of pristine nanotubes 
between gold electrodes by dielectrophoresis showed promising results. Therefore, the building of a 




sensor towards the GRP receptor, overexpressed in different cancer cell lines, could be developed by 
depositing the obtained nanohybrids between gold electrodes.  
The application of functionalised GO towards the development of a sensor is also encouraging. 
However, an alternative functionalisation strategy will need to be applied in order to increase the 
functionalisation degree and a final reduction step introduced to obtain the reduced derivative in order 








Chapter 7 : Experimental section 
7.1 General information 
Reagents were obtained from commercial sources (Sigma Aldrich, Alfa Aesar, Acros Organics, Merck 
Chemicals, Fluorochem) and used as received unless otherwise specified. Solvents were reagent or 
HPLC grade obtained from Sigma Aldrich or VWR. Water was obtained from a Millipore milli-Q 
purification system and anhydrous solvents from a PS-400-7 Innovative technologies SPS system.  
 
Microwave reactions were conducted in 5 or 20 mL capped vessels in a Biotage Initiator 2.5 microwave 
reactor pre-stirring for 30 s and heating to the desired temperature by applying a maximum power of 
400 W that was reduced and kept constant once the target temperature was reached. 
Automated flash chromatography purification was performed in a Biotage Isolera Four system using 
10, 25 or 50 g Biotage SNAP silica cartridges. 
 
NMR spectra were acquired in a 300 MHz BRUKER Avance, 400 MHz Bruker Avance, 500 MHz 
Bruker Avance II+ or a 500 MHz Agilent automated system. Spectra were processed using MestReNova 
10.0.2 and referenced to the residual solvent peaks. Splitting patterns are identified as singlet (s), doublet 
(d), triplet (t), quartet (q) and multiplet (m). 
 
Mass spectra were acquired in a Bruker MicroTOF equipment. The mass spectra of 23 and 46 were 
acquired in a nano-ESI LTQ Orbitrap XL instrument. The mass spectra of 52 and 54 were acquired in 
an APCI Xevo-G2S equipment. The mass spectra for 23, 46, 52 and 54 were acquired at the EPSRC UK 
National Mass Spectrometry Facility at Swansea University. 
 
HPLC was performed in a Dionex Ultimate 3000 HPLC instrument with a UV-vis diode array detector 
measuring at eight wavelengths between 200 and 800 nm. Analytical HPLC chromatograms were 
acquired in RP mode using a Dionex C18 Acclaim column (5 µm, 4.6 x 150 mm). In this case, a 20 min 
gradient method (method A) was applied using MeCN / H2O containing 0.1% TFA as mobile phases 
with the following conditions: 0 min 5% MeCN; 1 min 5% MeCN; 6 min 95% MeCN, 13 min 95% 
MeCN, 16 min 5% MeCN; 20 min 5% MeCN. Alternatively, an 18 min gradient method (method B) 
was employed with the following conditions: 0 min 5% MeCN; 7.5 min 95% MeCN; 15 min 95% 
MeCN, 18 min 95% MeCN. Flow rate = 0.8 mL / min. Semi-preparative HPLC was performed using a 
C18 Nucleodur HTEC column (5 µm, 10 x 250 mm). The gradient method was extended to 37 min 
(method C) using the same mobile phases and the following conditions: 0 min 5% MeCN; 1 min 5% 
MeCN; 11 min 95% MeCN, 26 min 95% MeCN, 31 min 5% MeCN; 36 min 5% MeCN. Flow rate = 
1.8 mL / min. 




X-ray crystallography data were acquired by Dr Gabrielle Kociok-Kohn at the University of Bath. 
Intensity data for 12, 43 and 52 were collected at 150(2) K on an Agilent SuperNova Dual diffractometer, 
Cu at zero, EosS2 and using monochromated Cu-K radiation  = 1.54184 Å. Intensity data for 40, 41 
and 42 were collected at 150(2) K on a Rigaku New Xcalibur diffractmometer, EosS2 using graphite 
monochromated Mo-Kradiation = 0.71073 Å. All structures were solved with SHELXT and refined 
by a full-matrix least-squares procedure based on F2 (Shelxl-2014/7).1 All non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms were placed onto calculated positions and refined using a riding 
model except for the OH hydrogen atoms which have been located in the difference fourier map and 
were refined with bond lengths restraints. Additional programmes used for analysing data and their 
graphical manipulation included: SHELXle2 and ORTEP 3 for windows.3  
 
IR spectra were acquired in a Perkin Elmer Frontier FTIR machine in ATR mode. 
 
UV-vis spectra were acquired in 1 cm quartz cuvettes in a Perkin Elmer Lambda 35 UV-vis spectrometer 
controlled by UV-Winlab software.  
 
Fluorescence spectra were acquired in 1 cm quartz cuvettes in a Perkin Elmer LS55 luminescence 
spectrometer controlled by FL-Winlab 4.0 software.  
 





Raman spectra were acquired in a Renishaw inVia microscope equipped with a 532 nm excitation laser.  
 
TEM experiments were performed in a JEOL JEM1200EXII instrument with a maximum voltage of 
120 kV at the Microscopy and Analysis Suite at the University of Bath with the assistance of Dr David 
Gonzalez Calatayud. Samples were prepared by evaporation of a drop of a dispersion of the nanomaterial 
in ethanol onto a carbon-coated 200 Mesh copper grid (Aggar scientific). 
 
TGA experiments were performed in a Setaram Setsys Evolution TGA 16/18 instrument with an 
Omnistar GSD 320 MS detector equipped with a quadrupole mass analyser and a SEM detector. TG 
curves were acquired heating the sample between 100 and 1000 ºC under an argon atmosphere at a 












   




10 ºC / min rate. TGA data were collected by Dr Remi Castaing in the Chemical Characterisation and 
Analysis Facility at the University of Bath. 
 
Cells were cultured at 37 ºC in RPMI medium containing foetal calf serum (10%), 
penicillin/streptomycin (10,000 IU mL-1) and L-glutamine (200 mM). All steps were performed in the 
absence of phenol red. Cell culturing was carried out with the assistance of Dr Haobo Ge. 
 
Cell viability assays (MTT) were performed culturing cells as above in 96 well plates (ca. 5x104 cells 
mL-1). The cells were incubated for 48 h to adhere and then the compounds of interest added in different 
concentrations in RPMI medium (1% DMSO). The concentrations used were 1, 0.1, 0.05, 0.01, 1x10-3, 
1x10-4, 1x10-5, 1x10-6 mM for compounds 23, 58 and 87. The concentrations used for p-SWNT, 78, 88, 
89, 90, 81, 84 and 93 were 1, 0.25, 0.1, 0.01, 1x10-3, 1x10-4, 1x10-5, 1x10-6 mgmL-1. The compounds 
were incubated for 48 h at 37 ºC to be subsequently washed with PBS and MTT reagent added. The 
tetrazolium reagent was incubated for 2 h, the cell media removed by aspiration and DMSO added. The 
absorbance of the generated colour was measured using a Molecular Devices Versa Max ELISA plate 
reader. Data were calculated from at least six consistent results and IC50 values calculated from the fitting 
obtained with Origin 9.0. The error reported corresponds to the error of the mean. Cell viability studies 
were carried out by Dr Haobo Ge. 
 
Confocal microscopy images were acquired in a Nikon Eclipse Ti instrument equipped with 405 / 488 / 
561 excitation lasers. The images obtained were processed using the Nikon NIS elements-AR Analysis 
4.30.02 software. 
 
Fluorescence lifetimes and FLIM measurements were conducted at the Rutherford Appleton Laboratory 
(Central Lasers Facility, Research Complex at Harwell) with the assistance of Dr Vincenzo Mirabello 
and Dr Haobo Ge. A detailed description of the characteristics of FLIM measurements acquisition can 
be found in ref. 18. Lifetime calculations were processed using SPCImage software. 
 
Elemental analyses were carried out by Stephen Boyer at the Science Centre (London Metropolitan 
University) using a Thermo Scientific CE Flash 2000 Elemental Analyser configured for %CHN. 
  




7.2 Experimental procedures 
1. Tert-butyl (2-aminoethyl)carbamate (adapted from a literature procedure4) 
 
Di-tert-butyl dicarbonate (3.000 g, 13.7 mmol) in CHCl3 (100 mL) was added dropwise to a stirring 
solution of ethylenediamine (4.960 g, 82.5 mmol) dissolved in CHCl3 (100 mL) at 0 ºC over a period of 
2 h. The reaction mixture was allowed to reach room temperature and stirred for 16 h. The solvent was 
removed under vacuum, the white residue re-suspended in CHCl3 (150 mL) and washed with sat. 
aqueous sodium carbonate (150 mL) and brine (100 mL). The organic phase was dried over MgSO4 and 
concentrated under vacuum. The product was obtained as a yellowish oil (2.150 g, 98%).  
1H NMR (400 MHz, CDCl3, 25 ºC): δ 4.99 (brs, 1H, NH), 3.21 – 3.07 (m, 2H, H-1), 2.76 (t, 
3J = 5.9 
Hz, 3H, H-2), 1.42 (s, 9H, (CH3)3), 1.23 (s, 2H, NH2).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 156.5 (CO), 79.4 (C(CH3)3), 43.2 (C-1), 41.7 (C-2), 28.4 (CH3)3). 
Mass spectrum: ESI-MS calc. for C7H16N2NaO2 [M+Na]+: 183.1109; found: 183.1110.  
IR (solid): ν (cm-1) 3359, 2986, 1684, 1528, 1268, 1165. 
 
2. Tert-butyl (6-aminohexyl)carbamate (adapted from a literature procedure5) 
 
Hexamethylenediamine (39.930 g, 0.343 mol) was dissolved in CH2Cl2 (150 mL), triethylamine added 
(10 mL) and the reaction mixture cooled to 0 ºC. Di-tert-butyl dicarbonate (15.000 g, 68.7 mmol) 
dissolved in CH2Cl2 (150 mL) was then added dropwise over a 2 h period and the reaction mixture was 
allowed to warm-up to room temperature and stirred for another 16 h. The solvent was removed under 
vacuum to yield a white slurry that was re-dissolved in CH2Cl2 (150 mL) and washed with sat. sodium 
carbonate. The aqueous phase was extracted with CH2Cl2 (3x 100 mL), the organic layers collected, 
washed with brine, dried over MgSO4 and concentrated under vacuum. The resulting residue was 
dissolved in CH2Cl2 and purified by flash column chromatography using CH2Cl2 / MeOH (0 - 10%) as 
eluent. The product was obtained as a yellowish oil that solidified over time (14.289 g, 96%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 4.52 (brs, 1H, NH), 3.12 – 2.96 (m, 2H, H-1), 2.68 (t, 
3J = 7.0 
Hz, 2H, H-6), 1.49 – 1.37 (m, 13H, H-3, H-5, (CH3)3), 1.38 – 1.28 (m, 4H, H-3, H-4).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 156.1 (CO), 79.2 (C(CH3)3), 42.2 (C-6), 40.6 (C-1), 33.6 (C-5), 
30.2 (C-3), 28.6 ((CH3)3), 26.8 (C-4), 26.6 (C-3).  
Mass spectrum: ESI-MS calc. for C11H24N2NaO2 [M+Na]+: 239.1735; found: 239.1731.  
IR (solid): ν (cm-1) 3367, 2930, 1683, 1520, 1167. 




3. Tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (adapted from a literature procedure6) 
 
2,2’-(ethylenedioxy)bis(ethylamine) (20.507 g, 0.138 mol) was dissolved in 1,4-dioxane (40 mL) and 
cooled to 0 ºC. Di-tert-butyl dicarbonate (5.033 g, 0.023 mol) dissolved in 40 mL of 1,4-dioxane was 
added dropwise over a period of 2 h. The reaction mixture was allowed to warm to room temperature 
and left stirring for 16 h. The solvent was removed under vacuum to yield a white slurry that was re-
dissolved in CH2Cl2 (500 mL) and washed with water (3x 300 mL) and brine (3x 150 mL). The organic 
phase was dried over MgSO4 and concentrated under vacuum. The oil obtained was purified by flash 
column chromatography using CH2Cl2 / MeOH (0 – 10%) as eluent. The product was obtained as a 
yellowish oil (4.620 g, 81%).  
1H NMR (500 MHz, CDCl3, 25 ºC): δ 5.23 (s, 1H, NH), 3.60 (s, 4H, H-4, H-5), 3.55 – 3.49 (m, 4H, 
H-2, H-7), 3.29 (brs, 2H, H-1), 2.87 (t, 3J = 5.2 Hz, 2H, H-8), 1.42 (s, 9H, (CH3)3).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 156.2 (CO), 79.3 (C(CH3)3), 72.6, 70.3 (C-2, C-7), 70.3, 70.2 
(C-4, C-5), 41.5 (C-8), 40.4 (C-1), 28.5 (CH3)3).  
Mass spectrum: ESI-MS calc. for C11H24N2NaO4 [M+Na]+: 271.1634; found: 271.1614.  
IR (solid): ν (cm-1) 3351, 2974, 1695, 1516, 1365, 1103.  
 
4. Tert-butyl (2-(((methylthio)carbonothioyl)amino)ethyl)carbamate (adapted from a literature 
procedure7)  
 
To a stirring solution of Boc-protected ethylenediamine (1) (0.869 g, 5.42 mmol) and triethylamine (0.83 
mL, 5.96 mmol) in ethanol (20 mL) at 25 ºC in a water bath, carbon disulphide (0.36 mL, 5.96 mmol) 
was added dropwise. The reaction was stirred for 1.5 h and iodomethane (0.37 mL, 5.96 mmol) was 
added dropwise and the reaction mixture stirred for 2 h. The solvent was removed under vacuum and 
the resulting residue re-suspended in ethyl acetate (100 mL) and washed with, 1 M HCl (100 mL), aq. 
sat. NaHCO3 solution (100 mL) and water (100 mL). The organic fraction was dried over MgSO4 and 
the solvent removed under vacuum. The product was obtained as a yellowish solid (1.101 g, 81%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 8.43 (s, 1H, NHCS), 5.16 (s, 1H, CONH), 3.76 (d, 
3J = 5.0 Hz, 
2H, H-2), 3.39 (d, 3J = 5.0 Hz, 2H, H-1), 2.55 (s, 3H, SCH3), 1.41 (s, 9H, (CH3)3).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 199.2 (CS), 157.8 (CO), 80.4 (C(CH3)3), 49.4 (C-2), 39.1 (C-1), 
28.4 ((CH3)3), 18.0 (SCH3).  
Mass spectrum: ESI-MS calc. for C9H19N2O2S2 [M+H]+: 251.0888; found: 251.0875. 




5. Tert-butyl (6-(((methylthio)carbonothioyl)amino)hexyl)carbamate 
 
Carbon disulphide (1.73 mL, 28.8 mmol) was added dropwise to a stirring solution of tert-butyl 
(6-aminohexyl)carbamate (2) (4.150 g, 19.2 mmol) and triethylamine (5.3 mL, 38.3 mmol) in ethanol 
at 25 ºC. The reaction mixture was stirred for 1.5 h when iodomethane (1.8 mL, 28.8 mmol) was added 
dropwise. After the addition finished, the stirring continued for another 2.5 h. The solvent was removed 
under vacuum and the residue re-suspended in ethyl acetate (50 mL) and washed with 1M HCl (50 mL), 
aq. sat. NaHCO3 (50 mL) and water (50 mL). The organic fraction was dried over MgSO4 and the solvent 
removed under vacuum. The product was obtained as a yellowish oil that solidified on standing 
(4.414 g, 75%). 
1H NMR (400 MHz, CDCl3, 25 ºC): δ 7.72 (s, 1H, NHCS), 4.64 (s, 1H, CONH), 3.67 (q, 
3J = 6.7 Hz, 
2H, H-6), 3.05 (q, 3J = 6.7 Hz, 2H, H-1), 2.56 (s, 3H, SCH3), 1.67 – 1.57 (m, 2H, H-5), 1.48 – 1.36 (m, 
11H, H-2, (CH3)3), 1.34 – 1.28 (m, 4H, H-3, H-4).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 198.8 (CS), 156.2 (CO), 79.1 (C(CH3)3), 46.9 (C-6), 46.2, 40.1 
(C-1), 30.0 (C-2), 28.5 ((CH3)3), 28.4 (C-5), 26.3, 26.2 (C-3, C-4), 18.1 (SCH3).  
Mass spectrum: ESI-MS calc. for C13H26N2NaO2S2 [M+Na]+: 329.1333; found: 329.1313. 
 
6. Tert-butyl (3-thioxo-7,10-dioxa-2-thia-4-azadodecan-12-yl)carbamate 
 
Tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (3) (2.500 g, 10.1 mmol) and triethylamine 
(1.41 mL, 10.1 mmol) were dissolved in ethanol (50 mL) and warmed to 25 ºC. Carbon disulphide 
(0.606 mL, 10.1 mmol) was added dropwise and the reaction mixture stirred at 25 ºC for 2 h. Methyl 
iodide (0.63 mL, 10.1 mmol) was added to the reaction mixture further stirred for 2 h. The solvent was 
concentrated under vacuum, the residue dissolved in 50 mL AcOEt and washed with HCl 1M, sat. 
NaHCO3 and water. The organic phase was dried over MgSO4 and the solvent removed under vacuum. 
The resulting oil was passed through a silica plug using CH2Cl2 first and then a mixture 8:2 of CH2Cl2 / 
MeOH. The second fraction was concentrated and dried under vacuum. The product was obtained as an 
off-white solid (2.971 g, 87%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 8.02 (s, 1H, NHCS), 5.10 (s, 1H, CONH), 3.78 (brs, 2H, H-5), 
3.60 – 3.52 (m, 2H, H-6), 3.48 (s, 4H, H-8, H-9), 3.41 – 3.39 (m, 2H, H-11), 3.16 (brs, 2H, H-12), 2.45 
(s, 3H, SCH3), 1.28 (s, 9H).  




13C NMR (125 MHz, CDCl3, 25 ºC): δ 198.8 (CS), 170.8, 155.7 (CO), 78.9 (C(CH3)3), 69.9 (C-8, C-9), 
69.9 (C-11), 68.1 (C-6), 46.5 (C-5), 40.0 (C-12), 28.1 ((CH3)3), 17.8 (SCH3).  
Mass spectrum: ESI-MS calc. for C13H26N2NaO4S2 [M+Na]+: 361.1232; found: 361.1218.  
 
7. Tert-butyl (2-(hydrazinecarbothioamido)ethyl)carbamate 
 
A stirring solution of methyl-N-(2-t-butoxycarbonylaminoethyl)dithiocarbamate (4) (0.272 g, 
1.10 mmol) and hydrazine hydrate (73 µL, 1.5 mmol) in ethanol was heated under reflux for 2.5 h. The 
solvent was removed under vacuum and the residue re-dissolved in CHCl3. The product was passed 
through a silica plug, washed with CHCl3 and eluted with MeOH. The solvent was removed from the 
methanolic fraction and the product obtained as a yellowish oil that solidified over time (0.260 g, 95%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 8.33 (s, 1H, NHNH2), 7.89 (s, 1H, NHCS), 4.94 (s, 1H, CONH), 
3.86 – 3.71 (m, 2H, H-2), 3.47 – 3.27 (m, 2H, H-1), 1.43 (s, 9H, (CH3)3).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 178.6 (CS), 159.3 (CO), 83.0 (C(CH3)3), 45.0 (C-2), 40.2 (C-1), 
28.5 (CH3)3. 
Mass spectrum: ESI-MS calc. for C8H18N4NaO2S [M+Na]+: 257.1048; found: 257.1042.  
IR (solid): ν (cm-1) 3358, 3315, 3245, 2976, 2942, 1670, 1519, 1140.  
HPLC (Method A): Rt (min) 8.12. 
 
8. Tert-butyl (6-(hydrazinecarbothioamido)hexyl)carbamate 
 
Methyl-N-(2-t-butoxycarbonylaminohexyl)dithiocarbamate (5) (4.414 g, 14.4 mmol) and hydrazine 
hydrate (1.0 mL, 21.6 mmol) were heated under reflux in ethanol for 2.5 h. The solvent was removed 
under vacuum and the residue redissolved in CH2Cl2 (20 mL) and passed through a silica plug that was 
washed with CH2Cl2 and the product eluted with MeOH. The product was obtained as a yellowish oil 
that solidified on standing (3.756 g, 90%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 8.32 (brs, 1H, NHNH2), 7.43 (brs, 1H, NHCS), 4.53 (brs, 1H, 
CONH), 3.77 (brs, 2H, NHNH2), 3.62 (td, 
3,3J = 7.2, 5.8 Hz, 1H, H-6), 3.13 – 3.06 (m, 2H, H-1), 1.70 
– 1.57 (m, 1H, H-5), 1.52 – 1.43 (m, 2H, H-2), 1.43 (s, 9H, (CH3)3), 1.41 – 1.32 (m, 4H, H-3, H-4). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 177.9 (CS), 156.0 (CS), 79.2 (C(CH3)3), 44.0 (C-6), 40.3 (C-1), 
30.1 (C-2), 29.3 (C-5), 28.3 (CH3)3), 26.6, 26.5 (C-3, C-4). 




Mass spectrum: ESI-MS calc. for C12H27N4O2S [M+H]+: 291.1855; found: 291.1852.  
IR (solid): ν (cm-1) 3336, 3196, 2930, 2861, 1682, 1520, 1248, 1166.  
HPLC (Method A): Rt (min) 8.10. 
 
9. Tert-butyl (2-(2-(2-(hydrazinecarbothioamido)ethoxy)ethoxy)ethyl)carbamate 
 
Tert-butyl (3-thioxo-7,10-dioxa-2-thia-4-azadodecan-12-yl)carbamate (6) (2.776 g, 8.80 mmol) was 
dissolved in ethanol (60 mL), hydrazine hydrate (0.9 mL, 12.1 mmol) added and the reaction mixture 
heated under reflux for 3 h. The solution was left to cool and the solvent removed under vacuum. The 
residue was dissolved in CHCl3 and passed through a silica plug, washing with CHCl3 before eluting 
the product with MeOH. The methanolic fraction was concentrated under vacuum to yield the product 
as a grey solid (1.928 g, 68%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 7.98 (s, 1H, NHNH2), 7.69 (s, 1H, NHCS), 5.13 (s, 1H, CONH), 
3.92 (brs, 2H, NH2), 3.75 (appq, 
3J = 5.3 Hz, 2H, H-5), 3.57 (t, 3J = 5.1 Hz, 2H, H6), 3.54 (s, 4H, H-8, 
H-9), 3.45 (t, 3J = 5.2, 1H, H-11), 3.21 (appq, 3J = 5.7 Hz, 2H, H-12), 1.35 (s, 9H). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 181.8 (CS), 156.0 (CO), 79.2 (C(CH3)3), 70.1 (C-8, C-9), 70.1 
(C-11), 69.5 (C-6), 43.6 (C-5), 40.3 (C-12), 28.4 (CH3)3).  
Mass spectrum: ESI-MS calc. for C12H27N4O4S [M+H]+: 323.1753; found: 323.1734. 
IR (solid): ν (cm-1) 3333, 3193, 3126, 2980, 2869, 1692, 1679, 1530, 1278, 1120. 
HPLC (Method A): Rt (min) 7.74. 
 
10. Mono(4-(2-aminoethyl)-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 10 was synthesised under conventional mode (refluxing acenaphthenequinone (0.148 g, 
0.81 mmol) and the protected thiosemicarbazide (7) (0.200 g, 0.85 mmol) in ethanol with 2 – 3 drops 
conc. HCl for 3 h) or microwave mode (heating acenaphthenequinone (0.265 g, 1.45 mmol) and the 
protected thiosemicarbazide (0.340 g, 1.45 mmol) in ethanol with 2 – 3 drops conc. HCl under 
microwave irradiation for 10 min at 90 ºC). In both cases, the work-up included filtering the reaction 




mixture whilst hot and washing with methanol and diethyl ether. The product was obtained as a yellow 
solid (0.150 g, 62% by conventional synthesis; 0.258 g, 60% by MW synthesis). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.72 (s, 1H, NNH), 9.68 (t, 3J = 5.8 Hz, 1H, NHCH2), 8.39 
(dd, 3,4J = 8.2, 0.7 Hz, 1H, H-5), 8.29 – 8.19 (brs, 2H, NH2), 8.16 (dd, 
3,4J = 8.5, 0.7 Hz, 1H, H-6), 8.11 
(dd, 3,4J = 7.0, 0.7 Hz, 1H, H-3), 8.10 (dd, 3,4J = 7.0, 0.7 Hz, 1H, H-8), 7.89 (dd, 3,3J = 8.2, 7.1 Hz, 1H, 
H-4), 7.85 (dd, 3,3J = 8.4, 7.0 Hz, 1H, H-7), 3.95 (q, 3J = 6.3 Hz, 2H, NHCH2), 3.11 (s, 2H, CH2NH2).  
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.6 (CO), 178.0 (CS), 139.3 (C-5b), 137.6 (CN), 132.9 (C-
5), 130.4, 129.9 (C-5a, C-1a, C-2a), 129.9 (C-4), 128.9 (C-8), 128.6 (C-3), 127.2 (C-6), 122.5 (C-7), 
118.6 (C-4), 41.8 (NHCH2), 37.7 (CH2NH2).  
Mass spectrum: ESI-MS calc. for C15H15N4OS [M+H]+: 299.0967; found: 299.0959.  
IR (solid): ν (cm-1) 3280, 3204, 2836, 1693, 1523, 1467, 1452, 1050. 
HPLC (Method A): Rt (min) 7.42. 
 
11. Mono (4-(tertbutyl-(2-aminoethyl)carbamate)-3-thiosemicarbazone) acenaphthenequinone 
 
Acenaphthenequinone (0.125 g, 0.69 mmol) and tert-butyl (2-(hydrazinecarbothioamido)ethyl) 
carbamate (7) (0.160 g, 0.69 mmol) were heated to 78 ºC for 6 h in EtOH (10% acetic acid). The reaction 
mixture was filtered whilst hot and washed with methanol, diethyl ether and dried under vacuum. The 
product was obtained as a bright yellow solid (0.139 g, 51%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.61 (s, 1H, NNH), 9.41 (t, 3J = 5.6 Hz, 1H, NHCH2), 8.37 
(dd, 3,4J = 8.2, 0.7 Hz, 1H, H-5), 8.13 (dd, 3,4J = 8.4, 0.7 Hz, 1H, H-6), 8.09 (dd, 3,4J = 7.1, 0.7 Hz, 1H, 
H-3), 8.01 (d, 3J = 7.0 Hz, 1H, H-8), 7.87 (dd, 3,3J = 8.2, 7.0 Hz, 1H, H-4), 7.83 (dd, 3,3J = 8.3, 7.0 Hz, 
1H, H-7), 7.06 (t, 3J = 5.7 Hz, 1H, NHCO), 3.65 (q, 3J = 5.9 Hz, 2H, H-9), 3.25 (q, 3J = 6.2 Hz, 2H, H-
10), 1.38 (s, 9H, (CH3)3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.5 (CO), 177.6 (CS), 156.2 (NHCO), 139.5 (C-5b), 
137.2 (CN), 132.8 (C-5), 130.5, 130.0, 129.9 (C-1a, C-2a, C-5a), 128.9 (C-7), 128.4 (C-4), 127.1 (C-6), 
122.5 (C-3), 118.2 (C-8), 78.0 (C(CH3)3), 44.9 (C-9), 39.2 (C-10), 28.2 ((CH3)3). 
Mass spectrum: ESI-MS calc. for C20H22N4NaO3S [M+Na]+: 421.1310; found: 421.1329. 
IR (solid): ν (cm-1) 3384, 3326, 3260, 2980, 1719, 1685, 1670, 1512, 1480. 
HPLC (Method A): Rt (min) 10.04. 




12. Mono(4-(tertbutyl-(6-aminohexyl)carbamate)-3-thiosemicarbazone acenaphthenequinone 
 
Compound 12 was synthesised following the same synthetic procedure as in 11. Alternatively, it could 
be prepared from acenaphthenequinone (0.050 g, 0.27 mmol), tert-butyl (6-
(hydrazinecarbothioamido)hexyl)carbamate (8) (0.318 g, 1.10 mmol) and hydrochloric acid (0.010 g, 
0.27 mmol) heating in ethanol (5 mL) for 10 min at 90 ºC under microwave irradiation. The work-up 
followed the same experimental procedure of 11. The product was obtained as a bright yellow solid 
(0.112 g, 93%). 
1H NMR (300 MHz, d6-DMSO, 25 ºC): δ 12.60 (s, 1H, NNH), 9.39 (t, 3J = 5.9 Hz, 1H, NHCH2), 8.38 
(d, 3J = 8.2 Hz, 1H, H-5), 8.14 (d, 3J = 8.3 Hz, 1H, H-6), 8.09 (d, 3J = 7.0 Hz, 1H, H-3), 8.01 (d, 3J = 6.9 
Hz, 1H, H-8), 7.91 – 7.86 (m, 1H, H-4), 7.86 – 7.79 (m, 1H, H-7), 6.77 (t, 3J = 5.1 Hz, 2H, NHCO), 
3.63 (q, 3J = 6.8 Hz, 2H, H-9), 2.91 (q, 3J = 6.4 Hz, 2H, H-14), 1.70 – 1.63 (m, 2H, H-10), 1.45 – 1.34 
(m, 11H, H-13, (CH3)3), 1.34 – 1.27 (m, 4H, H-11, H-12). 
13C NMR (75 MHz, d6-DMSO, 25 ºC): δ 188.4 (CO), 177.1 (CS), 155.6 (NHCO), 139.0 (C-5b), 137.0 
(CN), 132.8 (C-5), 130.4, 130.0, 129.8 (C-5a, C-2a, C-1a), 128.8 (C-7), 128.6 (C-4), 127.0 (C-8), 122.4 
(C-6), 118.4 (C-3), 77.25 (C(CH3)3), 44.2 (C-9), 39.0 (C-14), 28.4 (C-10), 28.2 ((CH3)3), 26.0, 25.9 (C-
11, C-12), 25.6 (C-13). 
Mass spectrum: ESI-MS calc. for C24H29N4O3S [M-H]-: 453.1960; found: 453.1976.  











13. Mono(4-(tertbutyl (2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate)-3-thiosemicarbazone 
acenaphthenequinone 
 
Acenaphthenequinone (0.042 g, 0.22 mmol) and tert-butyl (2-(2-(2-
(hydrazinecarbothioamido)ethoxy)ethoxy)ethyl)carbamate (9) (0.071 g, 0.22 mmol) were heated to 
78 ºC for 3 h in ethanol (60 mL, 10% acetic acid). The work-up procedure followed the described for 
compound 11. The product was purified by column chromatography using CH2Cl2 / MeOH (0 – 20%) 
as eluent. The product was obtained as a dark yellow oil that solidified over time (0.856 g, 88%).  
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.62 (s, 1H, NNH), 9.29 (t, J = 5.7 Hz, 1H, NHCH2), 8.36 
(dd, 3,4J = 8.3, 0.7 Hz, 1H, H-5), 8.12 (dd, 3,4J = 8.4, 0.7 Hz, 1H, H-6), 8.07 (dd, 3,4J = 7.1, 0.7 Hz, 1H, 
H-3), 7.95 (dd, 3,4J = 7.0, 0.7 Hz, 1H, H-8), 7.86 (dd, 3,3J = 8.2, 7.0 Hz, 1H, H-4), 7.82 (dd, 3,3J = 8.3, 
7.0 Hz, 1H, H-7), 6.74 (t, 3J = 5.7 Hz, 1H, NHCO), 3.82 (q, 3J = 5.9 Hz, 2H, H-9), 3.69 (t, 3J = 5.9 Hz, 
2H, H-10), 3.63 – 3.52 (m, 4H, H-11, H-12), 3.40 (t, 3J = 6.1 Hz, 2H, H-13), 3.07 (q, 3J = 6.0 Hz, 2H, 
H-14), 1.34 (s, 9H, (CH3)3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.8 (CO), 178.6 (CS), 155.4, 140.2 (C-5b), 137.5 (CN), 
132.7 (C-5), 130.8, 130.5, 130.2 (C-1a, C-2a, C-5a) 128.9 (C-7), 128.5 (C-4), 127.4 (C-6), 122.8 (C-3), 
118.2 (C-8), 70.5, 70.5, 70.4 (C-11, C-12, C13), 69.4 (C-10), 44.6 (C-9), 40.5 (C-14), 28.6 ((CH3)3). 
Mass spectrum: ESI-MS calc. for C24H31N4O5S [M+H]+: 487.2015; found: 487.2041. 
Elem. Anal. (%). Found (calc.) for C24H30N4O5S: C, 59.24 (57.94); H, 5.75 (6.21); N, 11.14 (11.51). 
IR (solid): ν (cm-1) 3358, 3270, 2974, 2868, 1687, 1524, 1476, 1171. 












14. Mono(4-methyl-3-thiosemicarbazone) acenaphthenequinone 
 
Acenaphthenequinone (0.200 g, 1.10 mmol), 4-methyl-3-thiosemicarbazide (0.108 g, 1.00 mmol) and 
ethanol (10 mL) were added to a 20 mL microwave vial. The mixture was sonicated for 3 min to generate 
a homogeneous dispersion and then 3 drops of concentrated hydrochloric acid were added. A colour 
change to a brighter yellow colour was observed upon addition of the acid. The vial was capped and 
heated under microwave irradiation at 90 ºC for 10 min. The reaction mixture was filtered whilst hot, 
re-suspended in hot methanol (ca. 15 mL) and stirred for 15 min before filtering again, washing with 
methanol and diethyl ether and drying under vacuum. The product was obtained as a yellow solid (0.215 
g, 70%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.64 (s, 1H, NNH), 9.38 (q, 3J = 4.5 Hz, 1H, NHCH3), 8.37 
(d, 3J = 8.1 Hz, 1H, H-5), 8.13 (d, 3J = 8.3 Hz, 1H, H-6), 8.09 (d, 3J = 7.0 Hz, 1H, H-3), 7.97 (d, 3J = 7.0 
Hz, 1H, H-8), 7.88 (dd, 3,3J = 8.1, 7.0 Hz, 1H, H-4), 7.84 (dd, 3,3J = 8.3, 7.0 Hz, 1H, H-7), 3.11 (d, 3J = 
4.5 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.5 (CO), 177.9 (CS), 139.0 (C-5b), 137.1 (CN), 
132.8 (C-5), 130.4, 130.1, 129.9 (C-1a C-2a C-5a), 128.9 (C-7), 128.6 (C-4), 127.0 (C-6), 122.4 (C-3), 
118.1 (C-8), 31.4 (CH3). 
Mass spectrum: ESI-MS calc. for C14H11N3OS [M+H]+: 270.0701; found 270.0700. 
IR (solid): ν (cm-1) 3219, 1689, 1540, 1475, 1055, 1027. 
HPLC (Method A): Rt (min) 9.53. 
 
15. Mono(4-ethyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 15 was prepared following the experimental procedure for 14. Acenaphthenequinone (0.200 
g, 1.10 mmol), 4-ethyl-3-thiosemicarbazide (0.124 g, 1.00 mmol) and 3 drops of concentrated 




hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a yellow solid (0.215 g, 70%).  
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.60 (s, 1H, NNH), 9.42 (t, 3J = 5.7 Hz, 1H, NHCH2), 8.38 
(d, 3J = 8.2 Hz, 1H, H-5), 8.14 (d, 3J = 8.3 Hz, 1H, H-6), 8.10 (d, 3J = 7.0 Hz, 1H, H-3), 8.01 (d, 3J = 7.0 
Hz, 1H, H-8), 7.89 (dd, 3,3J = 8.2, 7.0 Hz, 1H, H-4), 7.84 (dd, 3,3J = 8.3, 7.0 Hz, 1H, H-7), 3.75 – 3.63 
(m, 2H, CH2), 1.23 (t, 
3J = 7.2 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.5 (CO), 176.9 (CS), 139.1 (C-5b), 137.1 (CN), 132.8 (C-
5), 130.4, 130.1, 129.9 (C-1a, C-2a, C-5a), 128.9 (C-7), 128.6 (C-4), 127.0 (C-6), 122.4 (C-3), 118.2 
(C-8), 39.5 (CH2), 14.0 (CH3). 
Mass spectrum: ESI-MS calc. for C15H14N3OS [M+H]+: 284.0857; found 284.0860. 
IR (solid): ν (cm-1) 3302, 3280, 2977, 1685, 1538, 1475, 1056, 1027. 
HPLC (Method A): Rt (min) 9.90. 
 
16. Mono(4-allyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 16 was prepared following the experimental procedure for 14. Acenaphthenequinone (0.200 
g, 1.10 mmol), 4-allyl-3-thiosemicarbazide (0.137 g, 1.00 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a yellow solid (0.225 g, 76%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.65 (s, 1H, NNH), 9.57 (t, 3J = 5.8 Hz, 1H, NHCH2), 8.38 
(d, 3J = 8.1 Hz, 1H, H-5), 8.14 (d, 3J = 8.2 Hz, 1H, H-6), 8.10 (d, 3J = 6.9 Hz, 1H, H-3), 8.01 (d, 3J = 6.8 
Hz, 1H, H-8), 7.88 (dd, 3,3J = 8.2, 7.1 Hz, 1H, H-4), 7.84 (dd, 3,3J = 8.3, 7.0 Hz, 1H, H-7), 6.04 – 5.89 
(m, 1H, CH), 5.24 (ddd, 3,2,4Jtrans, gem = 17.2, 3.1, 1.5 Hz, 1H, Ha), 5.17 (ddd, 
3,2,4Jcis,gem = 10.3, 3.1, 1.5 
Hz, 1H, Hb), 4.35 – 4.26 (m, 2H, NHCH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.5 (CO), 177.6 (CS), 139.1 (C-5b), 137.3 (CN), 
134.0 (CH), 132.8 (C-5), 130.4, 130.0, 129.9 (C-1a C-2a C-5a), 128.9 (C-7), 128.6 (C-4), 127.1 (C-6), 
122.4 (C-3), 118.3 (C-8), 116.3 (CH2), 46.4 (NHCH2). 
Mass spectrum: ESI-MS calc. for C16H13N3NaOS [M+Na]+: 318.0677; found: 318.0666. 
IR (solid): ν (cm-1) 3318, 3049, 1688, 1523, 1478, 1178, 773. 
HPLC (Method A): Rt (min) 11.38. 




17. Mono(4-phenyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 17 was prepared following the experimental procedure for 14. Acenaphthenequinone 
(0.102 g, 0.53 mmol), 4-phenyl-3-thiosemicarbazide (0.089 g, 0.53 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as an orange solid (0.137 g, 78%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.83 (s, 1H, NNH), 10.95 (s, 1H, CSNH), 8.40 (dd, 3,4J = 
8.3, 0.7 Hz, 1H, H-5), 8.16 (dd, 3,4J = 8.4, 0.7 Hz, 1H, H-6), 8.14 (d, 3J = 6.8 Hz, 1H, H-3), 8.12 (d, 3J = 
7.0 Hz, 1H, H-8), 7.90 (dd, 3,3J = 8.2, 7.0 Hz, 1H, H-4), 7.86 (dd, 3,3J = 8.3, 7.0 Hz, 1H, H-7), 7.65 (dd, 
3,4J = 8.5, 1.2 Hz, 2H, H-10), 7.45 (dd, 3,3J = 8.4, 7.4 Hz, 2H, H-11), 7.32 – 7.28 (m, 1H, H-12). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.6 (CO), 176.6 (CS), 139.4 (C-5b), 138.5 (C-9), 137.7 
(CN), 132.8 (C-5), 130.4, 129.9, 129.9 (C-1a, C-2a, C-5a), 128.9 (C-7), 128.6 (C-4), 128.4 (C-11), 
127.2 (C-6), 126.1 (C-12), 125.7 (C-10), 122.5 (C-3), 118.8 (C-8). 
Mass spectrum: ESI-MS calc. for C19H14N3OS [M+H]+: 332.0856; found: 332.0841. 
IR (solid): ν (cm-1) 3336, 3269, 3059, 1688, 1671, 1596, 1523, 1475. 
HPLC (Method A): Rt (min) 10.23. 
 
18. Bis(4-methyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 18 was prepared following the experimental procedure for 14. Acenaphthenequinone (0.200 
g, 1.00 mmol), 4-methyl-3-thiosemicarbazide (0.339 g, 3.10 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a dark yellow solid (0.384 g, 95%). 




1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.60 (s, 1H, NNH’), 11.23 (s, 1H, NNH), 9.12 (q, 3J = 4.5 
Hz, 1H, NHCH3’), 8.81 (q, 
3J = 4.6 Hz, 1H, NHCH3), 8.20 (d, 
3J = 7.1 Hz, 1H, H-3), 8.12 (d, 3J = 8.3 
Hz, 1H, H-5), 8.06 (dd, 3,4J = 7.1, 0.7 Hz, 1H, H-8), 8.02 (dd, 3,4J = 8.3, 0.7 Hz, 1H, H-6), 7.80 (dd, 3J = 
8.3, 7.2 Hz, 1H, H-4), 7.77 (dd, 3J = 8.3, 7.0 Hz, 1H, H-7), 3.13 (d, 3J = 4.6 Hz, 3H, CH3’), 3.11 (d, 
3J 
= 4.5 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 180.6 (CS), 178.1, (CS’) 146.5 (CN), 137.6 (CN’), 136.0 (C-
5b), 132.8 (C-5a), 129.9 (C-1a, C-2a), 128.8 (C-5), 128.5 (C-7), 128.2 (C-4), 127.8 (C-1a, C-2a), 126.6 
(C-6), 124.6 (C-3), 118.3 (C-8), 31.4 (CH3), 31.2 (CH3’). 
Mass spectrum: ESI-MS calc. for C16H15N6S2 [M-H]-: 355.0800; found: 355.0811. 
IR (solid): ν (cm-1) 3368, 3225, 1641, 1523, 1474. 
HPLC (Method A): Rt (min) 9.69. 
 
19. Bis(4-ethyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 19 was prepared following the experimental procedure for 14. Acenaphthenequinone (0.200 
g, 1.00 mmol), 4-ethyl-3-thiosemicarbazide (0.384 g, 3.10 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a yellow solid (0.359 g, 90%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.56 (s, 1H, NNH’), 11.18 (s, 1H, NNH), 9.17 (t, 3J = 5.9 
Hz, 1H, NHCH2’), 8.78 (t, 
3J = 5.5 Hz, 1H, NHCH2), 8.20 (d, 
3J = 7.2 Hz, 1H, H-3), 8.13 (d, 3J = 8.3 
Hz, 1H, H-5), 8.09 (dd, 3,4J = 7.1, 0.7 Hz, 1H, H-8), 8.03 (dd, 3,4J = 8.2, 0.8 Hz, 1H, H-6), 7.80 (dd, 3,3J 
= 8.3, 7.2 Hz, 1H, H-4), 7.78 (dd, 3,3J = 8.3, 7.0 Hz, 1H, H-7), 3.72 – 3.67 (m, 2H, CH2), 3.67 – 3.61 (m, 
2H, CH2’), 1.26 (t, 
3J = 7.2 Hz, 3H, CH3’), 1.22 (t, 
3J = 7.1 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 179.9 (CS), 177.5 (CS’), 146.9 (CN), 138.1 (CN’), 136.5 (C-
5b), 133.3 (C-5a), 130.4 (C-1a, C-2a), 128.9 (C-5), 128.6 (C-7), 128.3 (C-4), 127.5 (C-1a, C-2a), 127.1 
(C-6), 125.1 (C-3), 118.9 (C-8), 39.5 (CH2), 39.2 (CH2’), 14.8 (CH3), 14.6 (CH3’). 
Mass spectrum: ESI-MS calc. for C18H20N6NaS2 [M+Na]+: 407.1089; found: 407.1127. 
IR (solid): ν (cm-1) 3366, 3303, 2971, 1685, 1533, 1473. 
HPLC (Method A): Rt (min) 10.51. 
 




20. Bis(4-allyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 20 was prepared following the experimental procedure for 14. Acenaphthenequinone (0.200 
g, 1.00 mmol), 4-allyl-3-thiosemicarbazide (0.410 g, 3.10 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a yellow solid (0.402 g, 94%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.61 (s, 1H, NNH’), 11.24 (s, 1H, NNH), 9.29 (t, 3J = 5.8 
Hz, 1H, NHCH2’), 9.00 (t, 
3J = 5.3 Hz, 1H, NHCH2), 8.21 (d, 
3J = 7.2 Hz, 1H, H-3), 8.14 (d, 3J = 8.6 
Hz, 1H, H-5), 8.12 (d, 3J = 7.4 Hz, 1H, H-8). 8.01 (d, 3J = 8.2 Hz, 1H, H-6), 7.81 – 7.73 (m, 2H, H-7, 
H-4), 6.05 – 5.91 (m, 1H, CH, CH’), 5.32 (dd, 3,4Jtrans = 17.2, 1.7 Hz, 1H, Ha, Ha’), 5.23 (dd, 
3,4Jtrans = 
17.2, 1.8 Hz, 1H, Ha, Ha’), 5.20 – 5.12 (m, 2H, Hb, Hb’), 4.35 – 4.21 (m, 4H, CH2, CH2’). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 180.1 (CS), 177.8 (CS’), 137.8 (CN), 136.1 (CN’), 
134.5 (C-5b), 134.0 (CH, CH’), 132.8 (C-5a), 129.9 (C-5a), 128.9 (C-1a, C-2a), 128.5 (C-5), 128.2 
(C-1a, C-2a), 127.8 (C-4, C-7), 126.7 (C-6), 124.5 (C-3), 118.5 (C-8), 116.4, 115.9 (CHaHb, CHaHb’), 
46.7, 46.1 (CH2, CH2’). 
Mass spectrum: ESI-MS calc. for C20H20N6NaS2 [M+Na]+: 431.1089; found: 431.1067. 
IR (solid): ν (cm-1) 3365, 3220, 1641, 1521, 1473. 
HPLC (Method A): Rt (min) 10.75. 
 
21. Bis(4-phenyl-3-thiosemicarbazone) acenaphthenequinone 
 
Compound 21 was prepared following the experimental procedure for 14. Acenaphthenequinone (0.103 
g, 0.53 mmol), 4-phenyl-3-thiosemicarbazide (0.269 g, 1.61 mmol) and 3 drops of concentrated 




hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as an orange solid (0.216 g, 85%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.95 (s, 1H, NNH’), 11.55 (s, 1H, NNH), 10.74 (s, 1H, 
NHPh’), 10.68 (s, 1H, NHPh), 8.32 (d, 3J = 7.2 Hz, 1H, H-3), 8.29 (dd, 3,4J = 7.1, 0.7 Hz, 1H, H-8), 8.18 
(d, 3J = 8.3 Hz, 1H, H-5), 8.08 (dd, 3,4J = 8.3, 0.7 Hz, 1H, H-6), 7.89 – 7.84 (m, 1H, H-4), 7.84 (d, 3J = 
7.5 Hz, 2H, H-10), 7.83 – 7.78 (m, 1H, H-7), 7.67 (dd, 3,4J = 8.6, 1.2 Hz, 2H, H-10’), 7.46 – 7.39 (m, 
4H, H-11. H-11’), 7.30 – 7.25 (m, 2H, H-12, H-12’). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 178.4 (CS), 176.5 (CS’), 138.9 (CN), 138.4 (CN’), 136.3 (C-
5b), 132.7 (C-5a), 130.0 (C-1a, C-2a), 129.1 (C-5), 128.6 (C-9, C-9’), 128.3 (C-1a, C-2a), 128.3 (C-11, 
C-11’), 128.2 (C-7), 127.7 (C-4), 126.9 (C-6), 125.8 (C-12’), 125.6 (C-10), 125.4 (C-12), 124.7 (C-3), 
124.2 (C-10), 119.2 (C-8). 
Mass spectrum: ESI-MS calc. for C26H20N6NaS2 [M+Na]+: 503.1089; found: 503.1105. 
IR (solid): ν (cm-1) 3377, 3346, 3280, 3049, 1596, 1530, 1474. 
HPLC (Method A): Rt (min) 11.38. 
 
22. Zinc(II) 4-allyl-4’-hydrazino-3,3’-bis(thiosemicarbazonato) acenaphthenequinone 
 
Mono(4-allyl-3-thiosemicarbazone) acenaphthenequinone (0.400 g, 1.40 mmol) and zinc acetate (0.990 
g, 5.40 mmol) were suspended in acetic acid (30 mL) and homogenised by sonication for 3 min. The 
mixture was heated to 60 ºC and thiocarbohydrazide (0.575 g, 5.40 mmol) added. The suspension was 
heated to 120 ºC for 24 h. The reaction mixture was filtered whilst hot, washed with THF (20 mL) and 
diethyl ether (100 mL) and dried under vacuum. The product was obtained as a brown solid (0.528 g, 
87%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 9.59 (brs, 1H, NHNH2), 8.58 (brs, 1H, H-3), 8.20 (s, 1H, 
NHCH2), 8.09 (brs, 1H, H-3), 7.95 (d, 
3J = 8.2 Hz, 1H, H-5), 7.90 (d, 3J = 7.2 Hz, 1H, H-6), 7.66 (t, 
3J = 7.3 Hz, 1H, H-4), 7.63 (t, 3J = 7.1 Hz, 1H, H-7), 6.43 (brs, 2H, NH2), 6.03 (s, 1H, CH), 5.29 (d, 
3Jtrans = 17.9 Hz, 1H, Ha), 5.14 (d, 
3Jcis = 10.8 Hz, 1H, Hb), 4.18 (brs, 2H, CH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 134.7 (CH), 127.8 (C-4), 127.5 (C-7), 126.8 (C-5), 125.9 (C-
6), 125.5 (C-3), 115.4 (CHaHb), 45.0 (CH2). 
Mass spectrum: ESI-MS calc. for C17H14N7S2Zn [M+H]+: 444.0044; found: 444.0102.  




Elem. Anal. (%). Found (calc.) for C17H15N7S2Zn·CH2Cl2: C, 41.09 (40.66); H, 3.45 (3.22); N, 17.40 
(18.44). 
IR (solid): ν (cm-1) 3305, 3254, 3136, 2935, 1627, 1578, 1392, 1242, 1137. 
HPLC (Method B): Rt (min): 8.74. 
 
23. Gallium(III) 4-allyl-4’-hydrazino-3,3’-bis(thiosemicarbazonato) acenaphthenequinone 
 
A suspension of zinc(II) 4-allyl-4’-hydrazino-3,3’-bis(thiosemicarbazonato) acenaphthenequinone (22) 
(0.250 g, 0.56 mmol) in dry methanol (30 mL) was added dropwise to gallium(III) chloride (1.480 g, 
8.40 mmol) and the reaction mixture heated to 65 ºC for 6 h. The majority of the solvent was removed 
under vacuum and diethyl ether added dropwise to the residue until a precipitate appeared. The 
precipitate was filtered and the filtrate was concentrated under vacuum and the process repeated adding 
CH2Cl2. The product was obtained as a red-orange solid (0.239, 94%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 10.23 (s, 1H, NHNH2), 8.75 (s, 1H, NHCH2), 8.62 (d, 
3J = 7.1 
Hz, 1H, H-5), 8.15 (d, 3J = 8.3 Hz, 1H, H-3), 7.99 (d, 3J = 8.2 Hz, 1H, H-8), 7.86 (d, 3J = 6.9 Hz, 1H, 
H-6), 7.82 (t, 3J = 7.8 Hz, 1H, H-4), 7.76 (t, 3J = 7.6 Hz, 1H, H-7), 7.59 (s, 2H, NH2), 6.09 – 5.93 (m, 
1H, CH), 5.33 (d, 3Jtrans = 17.3 Hz, 1H, Ha), 5.19 (d, 
3Jcis = 10.4 Hz, 1H, Hb), 4.22 (s, 2H, CH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 185.2, 170.7, 147.0, 135.3 (CN, CN’, CS, CS’), 134. 6 (CH), 
134.2, 130.4 (C-5b, C-5a), 129.8 (C-5), 129.4, 129.0 (C-4, C-7), 129.0, 128.6 (C-2a, C-1a), 127.1 (C-3), 
125.7 (C-8), 117.8 (C-6), 116.2 (CHaHb), 45.2 (CH2). 
Mass spectrum: nanoESI-MS calc. for C17H15GaN7NaS2 [M+Na]+: 450.0086; found: 450.0074. 
IR (solid): ν (cm-1) 3202, 2997, 1607, 1508, 1412, 1140, 1107. 
HPLC (Method B): Rt (min) 7.15. 
 
24. 1,2-Dihydroacenaphthylene-1,2-diol (adapted from a literature procedure8) 
 
To a stirred suspension of acenaphthenequinone (3.000 g, 16.0 mmol) in methanol (50 mL) sodium 
borohydride (1.250 g, 33.0 mmol) was added portion wise over 15 min at 0 ºC. Once the addition 




finished, the brown reaction mixture was stirred at room temperature for 1.5 h. The solvent was removed 
under vacuum, the solid washed with water and filtered. The product was obtained as a light brown solid 
(1.287 g, 42%).  
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 7.76 (d, 3J = 8.2 Hz, 2H, H-3), 7.57 (dd, 3,3J = 8.2, 6.8 Hz, 
2H, H-4), 7.44 (d, 3J = 6.8 Hz, 2H, H-5), 5.81 (brs, 2H, OH), 5.19 (brs, 2H, H-2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 143.8 (C-5b), 135.4 (C-5a), 130.2 (C-2a), 128.2 (C-4), 
123.8 (C-3), 119.9 (C-5), 82.5 (C-2). 
Mass spectrum: ESI-MS calc. for C12H10NaO2 [M+Na]+: 209.0578; found: 209.0577. 
IR (solid): ν (cm-1) 3229, 3049, 1336, 803, 771. 
HPLC (Method A): Rt (min) 7.17. 
 
25. 1,10-phenanthroline-2,9-dicarbaldehyde (adapted from a literature procedure 9) 
 
2,9-dimethyl-1,10-phenanthroline (3.530 g, 16.9 mmol) was dissolved in hot dioxane (100 mL), 
selenium dioxide (4.681 g, 42.4 mmol) added portion wise and the reaction mixture heated under reflux 
for 2 h. The heating was stopped and activated charcoal was added to the reaction mixture that was 
stirred for 5 – 10 min. The resulting suspension was filtered through celite and washed with hot dioxane. 
The solvent was removed under vacuum and the resulting pink solid dissolved in DMF, the solution was 
cooled to 0 ºC and filtered. Water was added dropwise to the filtrate yielding a white precipitate that 
was isolated by filtration. The product was obtained as an off-white solid (1.248 g, 31%).  
1H NMR (300 MHz, d6-DMSO, 25 ºC): δ 10.34 (s, 2H, CHO), 8.78 (d, 3J = 8.2 Hz, 2H, H-3), 8.30 (d, 
3J = 8.2 Hz, 2H, H-4), 8.27 (s, 2H, H-5). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 193.7 (CO), 152.2 (C-2), 145. 2 (C-1a), 138.4 (C-3), 131.4 
(C-4a), 129.2 (C-5), 120.1 (C-4). 
Mass spectrum: ESI-MS calc. for C14H8N2NaO2 [M+Na]+: 259.0483; found: 259.0460. 
IR (solid): ν (cm-1) 3064, 2860, 1699, 1596, 1555, 1279, 1237. 









26. Bis(4-methyl-3-thiosemicarbazone) 1,10-phenanthroline-2,9-dicarbaldehyde 
 
Compound 26 was prepared following the experimental procedure for 14. 1,10-Phenanthroline-2,9-
dicarbaldehyde (0.050 g, 0.21 mmol), 4-methyl-3-thiosemicarbazide (0.056 g, 0.53 mmol) and 3 drops 
of concentrated hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The 
product was obtained as a bright yellow solid (0.087 g, 99%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.15 (s, 2H, NNH), 8.95 (q, 3J = 4.4 Hz, 2H, NHCH3), 8.79 
(d, 3J = 8.6 Hz, 2H, H-3), 8.65 (d, 3J = 8.6 Hz, 2H, H-4), 8.50 (s, 2H, H-5), 8.09 (s, 2H, CHN), 3.08 (d, 
3J = 4.5 Hz, 6H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 178.0 (CS), 153.4 (C-2), 141.0 (CHN), 138.8 (C-4), 128.8 
(C-1a), 127.0 (C-4a), 120.1 (C-3), 31.0 (CH3). 
Mass spectrum: ESI-MS calc. for C20H22N8NaS2 [M+Na]+: 461.1307; found: 461.1290. 
IR (solid): ν (cm-1) 3355, 2934, 1744, 1544, 1511, 1494, 1214. 
HPLC (Method A): Rt (min) 7.68. 
 
27 Bis(4-ethyl-3-thiosemicarbazone) 1,10-phenanthroline-2,9-dicarbaldehyde 
 
Compound 27 was prepared following the experimental procedure for 14. 1,10-Phenanthroline-2,9-
dicarbaldehyde (0.200 g, 0.85 mmol), 4-ethyl-3-thiosemicarbazide (0.260 g, 2.12 mmol) and 3 drops of 
concentrated hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The 
product was obtained as a bright yellow solid (0.322, 88%). 
1H NMR (300 MHz, d6-DMSO, 25 ºC): δ 12.08 (s, 2H, NNH), 9.00 (t, 3J = 5.9 Hz, 2H, NHCH2), 8.79 
(d, 3J = 8.5 Hz, 2H, H-3), 8.64 (d, 3J = 8.5 Hz, 2H, H-4), 8.49 (s, 2H, H-5), 8.09 (s, 2H, CHN), 3.78 – 
3.55 (m, 4H, CH2), 1.20 (t, 
3J = 7.1 Hz, 6H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 177.0 (CS), 153.3 (C-2), 142.9 (C-1a), 140.7 (C-5), 137.6 
(C-4), 128.9 (C-4a), 127.0 (CHN), 120.4 (C-3), 38.5 (CH2), 14.5 (CH3). 




Mass spectrum: ESI-MS calc. for C20H22N8NaS2 [M+Na]+: 461.1307; found: 461.1290. 
IR (solid): ν (cm-1) 3354, 2972, 1623, 1537, 1488, 1132. 
HPLC (Method A): Rt (min) 8.18. 
 
28. Bis(4-allyl-3-thiosemicarbazone) 1,10-phenanthroline-2,9-dicarbaldehyde 
 
Compound 28 was prepared following the experimental procedure for 14. 1,10-Phenanthroline-2,9-
dicarbaldehyde (0.200 g, 0.84 mmol), 4-allyl-3-thiosemicarbazide (0.280 g, 2.13 mmol) and 3 drops of 
concentrated hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The 
product was obtained as a bright yellow solid (0.290 g, 75%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.15 (s, 2H, NNH), 9.14 (t, 3J = 5.9 Hz, 2H, NHCH2), 8.81 
(d, 3J = 8.5 Hz, 1H, H-3), 8.63 (d, 3J = 8.5 Hz, 1H, H-4), 8.52 (s, 1H, H-5), 8.09 (s, 1H, CHN), 6.02 – 
5.90 (m, 1H, CH), 5.21 (dq, 3,4Jtrans = 17.2, 1.6 Hz, 1H, Ha), 5.14 (dq, 
3,4Jcis = 10.2, 1.4 Hz, 1H, Hb), 
4.32 – 4.26 (m, 2H, NHCH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 177.5 (CS), 153.5 (C-2), 142.2 (C-5), 141.7 (C-1a), 137.0 
(C-4), 134.8 (CH), 128.8 (C-4a), 127.0 (CHN), 120.1 (C-3), 115.7 (CHaHb), 45.9 (NHCH2). 
Mass spectrum: ESI-MS calc. for C22H21N8S2 [M-H]-: 461.1331; found: 461.1393. 
IR (solid): ν (cm-1) 3357, 3315, 3191, 1489, 1272, 1185. 
HPLC (Method A): Rt (min) 8.37. 
 
29 Bis(4-phenyl-3-thiosemicarbazone) 1,10-phenanthroline-2,9-dicarbaldehyde  
 
Compound 29 was prepared following the experimental procedure of 14. 1,10-Phenanthroline-2,9-
dicarbaldehyde (0.114 g, 0.48 mmol), 4-phenyl-3-thiosemicarbazide (0.201 g, 1.20 mmol) and 3 drops 
of conc. HCl were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was obtained 
as a yellow solid (0.238 g, 92%). 




1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.41 (s, 2H, NNH), 10.47 (s, 2H, CSNH), 8.93 (d, 3J = 8.6 
Hz, 2H, H-3), 8.61 (d, 3J = 8.6 Hz, 2H, H-4), 8.59 (s, 2H, H-5), 8.08 (s, 2H, CHN), 7.57 (d, 3J = 7.2Hz, 
2H, H-12), 7.45 – 7.38 (m, 2H, H-13), 7.27 – 7.23 (m, 2H, H-14). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 176.6 (CS), 149.0 (C-2), 146.5 (C-1a), 142.2 (CHN), 137.1 
(C-4), 128.8 (C-4a), 128.1 (C-13), 127.2 (C-2), 126.4 (C-12), 125.9 (C-14), 120.2 (C-3). 
Mass spectrum: ESI-MS calc. for C28H22N8NaS2 [M+Na]+: 557.1307; found: 557.1427. 
IR (solid): ν (cm-1) 3657, 3344, 3256, 2968, 1633,97, 1542, 1509, 1187, 1176. 
HPLC (Method A): Rt (min) 8.95. 
 
30. 4,5-Pyrenedione (adapted from a literature procedure10) 
 
Sodium metaperiodate (22.050 g, 0.10 mol) and RuCl3·xH2O (0.480 g, 2.32 mmol) were added to pyrene 
(4.780 g, 23.2 mmol) in CH2Cl2 (150 mL), THF (150 mL) and H2O (200 mL). The reaction mixture was 
stirred at room temperature for 3 h. The reaction mixture was poured in 1 L of water and the phases 
separated. The aqueous phase was extracted with CH2Cl2 (3x 150 mL). The collected organic phases 
were washed with water (3x 150 mL), dried over MgSO4 and the solvent removed under vacuum. The 
product was purified by flash column chromatography using CH2Cl2 as eluent. The product was obtained 
as an orange solid after re-crystallisation from CH2Cl2 / hexane (1.538 g, 29%). 
1H NMR (300 MHz, CDCl3, 25 ºC): δ 8.45 (dd, 
3,4J = 7.4, 1.1 Hz, 2H, H-3), 8.15 (dd, 3,4J = 8.0, 1.1 Hz, 
2H, H-1), 7.82 (s, 2H, H-9), 7.73 (appt, 3J = 7.5 Hz, 2H, H-2). 
13C NMR (75 MHz, CDCl3, 25 ºC): δ 180.6 (CO), 135.9 (C-1), 132.1 (C-8a), 130.3 (C-3), 130.2 (C-3b), 
128.5 (C-2), 128.1 (C-3a)), 127.4 (C-9). 
Mass spectrum: ESI-MS calc. for C16H9O2 [M+H]+: 233.0602; found: 233.0601. 
IR (solid): ν (cm-1) 3048, 2892, 1667, 1614, 1336, 1089. 











31. Mono(4-(N-(2-(2-(2-aminoethoxy)ethoxy)ethyl))-3-thiosemicarbazone) acenaphthenequinone 
 
Acenaphthenequinone (14 mg, 71 µmol) and 4-(N-(2-(2-(2-aminoethoxy)ethoxy)ethyl))-3-
thiosemicarbazide (9) (23 mg, 71 µmol) were suspended in ethanol and homogenised by sonication for 
3 min. Concentrated HCl (3 drops) was added and the reaction mixture heated to 90 ºC for 10 min. The 
solvent was removed under vacuum, the residue re-suspended in CH2Cl2 and passed through a silica 
plug. The product was eluted with CH2Cl2 / MeOH (9:1). The solvent was removed under vacuum and 
the product obtained as a yellow solid (10 mg, 37%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.66 (s, 1H, NNH), 9.42 (t, 3J = 5.8 Hz, 1H, NHCH2), 8.39 
(d, 3J = 8.1 Hz, 1H, H-5), 8.15 (d, 3J = 8.3 Hz, 1H, H-6), 8.10 (d, 3J = 7.0 Hz, 1H, H-3), 8.05 (s, 2H, 
NH2), 8.04 (d, 
3J = 6.9 Hz, 2H, H-8), 7.93 – 7.86 (m, 1H, H-4), 7.85 (dd, 3,3J = 8.3, 7.0 Hz, 1H, H-7), 
3.83 (q, 3J = 6.0 Hz, 2H, H-9), 3.70 (t, 3J = 6.1 Hz, 2H, H-10), 3.66 – 3.58 (m, 6H, H-11, H-12, H-13), 
2.94 (q, 3J = 5.5 Hz, 2H, H-14). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.5 (CO), 177.5 (CS), 139.2 (C-5b), 137.5 (CN), 132.8 (C-
5), 130.4, 130.0, 129.9 (C-1a, C-2a, C-5a), 128.9 (C-7), 128.6 (C-4), 127.1 (C-6), 122.5 (C-3), 118.4 
(C-8), 69.7, 69.5 (C-11, C-12), 68.0 (C-10), 66.6 (C-13), 43.8 (C-9), 38.5 (C-14). 
Mass spectrum: ESI-MS calc. for C19H23N4O3S [M+H]+: 387.1491; found: 387.1561. 
IR (solid): ν (cm-1) 3300, 1659, 1496, 1388, 1097, 1066. 
HPLC (Method A): Rt (min) 11.84. 
 
32. Mono(4-methyl-3-thiosemicarbazone) aceanthrenequinone 
 
Compound 32 was prepared following the experimental procedure for 14. Aceanthrenequinone (0.208 g, 
0.86 mmol), 4-methyl-3-thiosemicarbazide (0.086 g, 0.82 mmol) and 3 drops of concentrated 




hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a red-brown solid (0.207 g, 79%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.89 (s, 1H, NNH), 9.41 (q, 3J = 4.0 Hz, 1H, NHCH3), 9.11 
(s, 1H, H-6), 8.95 (d, 3J = 8.5 Hz, 1H, H-10), 8.38 (d, 3J = 8.4 Hz, 1H, H-7), 8.23 (d, 3J = 8.6 Hz, 1H, 
H 5), 7.97 (d, 3J = 6.6 Hz, 1H, H-3), 7.95 – 7.89 (m, 1H, H-9), 7.81 (dd, 3,3J = 8.6, 6.6 Hz, 1H, H-4), 
7.78 – 7.72 (m, 1H, H-8), 3.15 (d, 3J = 4.6 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.5 (CO), 178.0 (CS), 140.9 (C-5b), 137.1 (CN), 134.7 
(C-6), 132.8 (C-6a), 130.5 (C-9), 130.2 (C-7), 129.5 (C-2a), 128.0 (C-4), 127.5 (C-10a), 127.4 (C-5a), 
127.2 (C-5), 126.9 (C-8), 123.6 (C-10b),123.3 (C-10), 118.1 (C-3), 31.4 (CH3). 
Mass spectrum: ESI-MS calc. for C18H13N3NaOS [M+Na]+: 342.0677, found: 342.0658. 
Elem. Anal. (%). Found (calc.) for C18H13N3OS: C, 66.81 (67.69); H, 4.25 (4.10); N, 12.96 (13.16). 
IR (solid): ν (cm-1) 3373, 3250, 1661, 1542, 1479, 1048. 
HPLC (Method A): Rt (min) 11.08. 
 
33. Mono(4-ethyl-3-thiosemicarbazone) aceanthrenequinone 
 
Compound 33 was prepared following the experimental procedure for 14. Aceanthrenequinone (0.208 
g, 0.86 mmol), 4-ethyl-3-thiosemicarbazide (0.098 g, 0.82 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as an orange solid (0.243 g, 89%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.81 (s, 1H, NNH), 9.41 (t, 3J = 5.6 Hz, 1HNHCH2), 9.06 
(s, 1H, H-6), 8.90 (d, 3J = 8.6 Hz, 1H, H-10), 8.35 (d, 3J = 8.5 Hz, 1H, H-7), 8.20 (d, 3J = 8.6 Hz, 1H, 
H-5), 7.96 (d, 3J = 6.7 Hz, 1H, H-3), 7.93 – 7.86 (m, 1H, H-9), 7.78 (dd, 3,3J = 8.6, 6.7 Hz, 1H, H-4), 
7.76 – 7.70 (m, 1H, H-8), 3.80 – 3.63 (m, 2H, CH2), 1.25 (t, 
3J = 7.1 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.4 (CO), 177.0 (CS), 140.8 (C-5b), 137.0 (CN), 134.6 (C-
6), 132.7 (C-6a), 130.5 (C-9), 130.1 (C-7), 129.4 (C-2a), 127.9 (C-4), 127.5 (C-10a), 127.3 (C-5a), 127.1 
(C-5), 126.9 (C-8), 123.5 (C-10b), 123.3 (C-10), 118.2 (C-3), 39.0 (CH2), 14.1 (CH3). 
Mass spectrum: ESI-MS calc. for C19H15N3NaOS [M+Na]+: 356.0833; found: 356.0801. 
Elem. Anal. (%). Found (calc.) for C19H15N3OS: C, 68.51 (68.45); H, 4.47 (4.53); N, 12.48 (12.60). 
IR (solid): ν (cm-1) 3373, 3220, 2967, 1665, 1527, 1482, 1193, 1147, 1072. 
HPLC (Method A): Rt (min) 11.57. 




34. Mono(4-allyl-3-thiosemicarbazone) aceanthrenequinone 
 
Compound 34 was prepared following the experimental procedure of 14. Aceanthrenequinone (0.208 g, 
0.86 mmol), 4-allyl-3-thiosemicarbazide (0.107 g, 0.82 mmol) and 3 drops of concentrated hydrochloric 
acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was obtained as an 
orange solid (0.229 g, 81%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.89 (s, 1H, NNH), 9.59 (t, 3J = 5.9 Hz, 1H, NHCH2), 9.09 
(s, 1H, H-6), 8.93 (d, 3J = 8.8 Hz, 1H, H-10), 8.37 (d, 3J = 8.5 Hz, 1H, H-7), 8.22 (d, 3J = 8.7 Hz, 1H, 
H-5), 8.00 (d, 3J = 6.4 Hz, 1H, H-3), 7.91 (ddd, 3,3,4J = 8.4, 6.7, 1.3 Hz, 1H, H-9), 7.79 (dd, 3,3J = 8.1, 
6.7 Hz, 1H, H-4), 7.75 (ddd, 3,3,4J = 8.3, 6.7, 1.3 Hz, 1H, H-8), 6.07 – 5.84 (m, 1H, 1H, CH), 5.26 (d, 
3Jtrans = 17.1 Hz, 1H, Ha), 5.19 (d, 
3Jcis = 10.2 Hz, 1H, Hb), 4.33 (brs, 2H, NHCH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.4 (CO), 177.6 (CS), 140.9 (C-5b), 137.3 (CN), 134.7 
(C-6), 134.0 (CH), 132.8 (C-6a), 130.5 (C-9), 130.2 (C-7), 129.4 (C-2a), 127.9 (C-4), 127.5 (C-10a), 
127.3 (C-5a), 127.2 (C-5), 126.9 (C-8), 123.6 (C-10b), 123.3 (C-10), 118.3 (C-3), 116.3 (CHaHb), 46.4 
(NHCH2). 
Mass spectrum: ESI-MS calc. for C20H15N3NaOS [M+Na]+: 368.0833; found: 368.0824. 
Elem. Anal. (%). Found (calc.) for C20H15N3OS: C, 69.64 (69.54); H, 4.21 (4.38); N, 12.09 (12.17). 
IR (solid): ν (cm-1) 3360, 3217, 3066, 1664, 1526, 1485, 1190, 1149, 1075. 
HPLC (Method A): Rt (min) 11.59. 
 
35. Mono(4-(N-(2-(2-(2-aminoethoxy)ethoxy)ethyl))-3-thiosemicarbazone) aceanthrenequinone 
 
Aceanthrenequinone (0.104 g, 0.86 mmol) and thiosemicarbazide 9 (0.132 g, 0.41 mmol) were 
suspended in ethanol (5 mL) and homogenised by sonication for 3 min. Concentrated HCl (3 drops) was 




added and the reaction mixture heated to 90 ºC for 10 min by microwave irradiation. The solvent was 
removed under vacuum and the product re-suspended in CH2Cl2 and passed through a silica plug. After 
washing with CH2Cl2, the product was eluted with CH2Cl2 / MeOH (9:1). The solvent was removed 
under vacuum and the product obtained as an orange solid (0.094 g, 53%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.86 (s, 1H, NNH), 9.40 (t, 3J = 5.8 Hz, 1H, NHCH2), 9.06 
(s, 1H, H-6), 8.88 (dt, 3,4J = 8.5, 1.0 Hz, 1H, H-10), 8.35 (dd, 3,4J = 8.3, 1.0 Hz, 1H, H-7), 8.20 (d, 3J = 
8.6 Hz, 1H, H-5), 8.00 (brs, 2H, NH2), 7.96 (dd, 
3,4J = 6.7, 0.7 Hz, 1H, H-3), 7.89 (ddd, 3,3,4J = 8.4, 6.7, 
1.2 Hz, 1H, H-9), 7.78 (dd, 3,3J = 8.6, 6.7 Hz, 1H, H-4), 7.74 (ddd, 3,3,4J = 8.1, 6.6, 1.2 Hz, 1H, H-8), 
3.86 (q, 3J = 6.0 Hz, 2H, H-11), 3.73 (t, 3J = 6.0 Hz, 2H, H-12), 3.68 – 3.61 (m, 6H, H-13, H-14, H-15), 
2.96 (q, 3J = 5.4 Hz, 2H, H-16). 
Mass spectrum: ESI-MS calc. for C23H23N4O3S [M+H]+: 435.1491; found: 435.1453. 
Elem. Anal. (%). Found (calc.) for C23H24N4O3S·HCl·C3H7NO: C, 58.05 (57.19); H, 6.34 (5.91); N, 
12.69 (12.82). 
IR (solid): ν (cm-1): 3367, 3324, 2870, 1630, 1598, 1538, 1485, 1446. 
HPLC (Method A): Rt (min) 11.84. 
 
36. Mono(4-methyl-3-thiosemicarbazone) phenanthrenequinone 
 
Compound 36 was prepared following the experimental procedure of 14. Phenanthrenequinone (0.210 
g, 0.96 mmol), 4-methyl-3-thiosemicarbazide (0.096 g, 0.91 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a yellow solid (0.249 g, 92%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.59 (s, 1H, NNH) 9.56 (q, 3J = 4.5 Hz, 1H, NHCH3), 8.66 
(dd, 3,4J = 8.0, 1.3 Hz, 1H, H-8), 8.43 (d, 3J = 8.0 Hz, 1H, H-4), 8.34 (dd, 3,4J = 7.9, 0.5 Hz, 1H, H-5), 
8.26 (dd, 3,4J = 7.9, 1.4 Hz, 1H, H-1), 7.85 (ddd, 3,3,4J = 8.0, 7.2, 1.4 Hz, 1H, H-3), 7.60 – 7.57 (m, 1H, 
H-2), 7.57 – 7.54 (m, 1H, H-6), 7.49 (ddd, 3,3,4J = 8.0, 7.1, 1.2 Hz, 1H, H-7), 3.16 (d, 3J = 4.5 Hz, 3H, 
CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.2 (CO), 178.1 (CS), 136.0 (C-4a), 135.3 (C-3), 130.5 
(C-2a), 129.8, 129.7 (CN, C-1a), 129.4 (C-6), 128.8 (C-5a), 128.8 (C-7), 128.4 (C-2), 128.2 (C-1), 125.0 
(C-8), 123.8, 123.7 (C-4, C-5), 31.8 (CH3). 
Mass spectrum: ESI-MS calc. for C16H13N3NaOS [M+Na]+: 318.0677; found: 318.0718. 




Elem. Anal. (%). Found (calc.) for C16H13N3OS: C, 65.17 (65.07); H, 4.28 (4.44); N, 14.13 (14.23). 
IR (solid): ν (cm-1) 3324, 2976, 1638, 1595, 1552, 1448, 1040. 
HPLC (Method A): Rt (min) 8.83. 
 
37. Mono(4-ethyl-3-thiosemicarbazone) phenanthrenequinone 
 
Compound 37 was prepared following the experimental procedure of 14. Phenanthrenequinone (0.210 
g, 0.96 mmol), 4-ethyl-3-thiosemicarbazide (0.109 g, 0.91 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a red solid (0.214 g, 76%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.55 (s, 1H, NNH), 9.65 (t, 3J = 5.8 Hz, 1H, NHCH2), 8.66 
(dd, 3,4J = 8.0, 1.3 Hz, 1H, H-8), 8.44 (d, 3J = 8.1 Hz, 1H, H-4), 8.35 (d, 3J = 7.3 Hz, 1H, H-5), 8.27 (dd, 
3,4J = 7.9, 1.4 Hz, 1H, H-1), 7.86 (ddd, 3,3,4J = 8.1, 7.3, 1.5 Hz, 1H, H-3), 7.61 – 7.58 (m, 1H, H-2), 7.58 
– 7.55 (m, 1H, H-6), 7.51 (ddd, 3,3,4J = 8.0, 7.1, 1.3 Hz, 1H, H-7), 3.77 – 3.67 (m, 2H, CH2), 1.24 (t, 
3J 
= 7.1 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.2 (CO), 177.2 (CS), 136.0 (C-4a), 135.3 (C-3), 130.5 
(C-2a), 129.8 (CN, C-1a), 129.4 (C-6), 128.9 (C-5a), 128.8 (C-7), 128.4 (C-2), 128.3 (C-1), 125.1 (C-8), 
123.8, 123.7 (C-4, C-5), 39.0 (CH2), 13.8 (CH3). 
Mass spectrum: ESI-MS calc. for C17H15N3NaOS [M+Na]+: 332.0833; found: 332.0822. 
Elem. Anal. (%). Found (calc.) for C17H15N3OS: C, 65.94 (66.00); H, 4.78 (4.89); N, 13.44 (13.58). 
IR (solid): ν (cm-1) 3339, 2977, 1682, 1600, 1595, 1482. 
HPLC (Method A): Rt (min) 8.46. 
 
38. Mono(4-allyl-3-thiosemicarbazone) phenanthrenequinone 
 
Compound 38 was prepared following the experimental procedure of 14. Phenanthrenequinone (0.210 g, 
0.96 mmol), 4-allyl-3-thiosemicarbazide (0.120 g, 0.91 mmol) and 3 drops of concentrated hydrochloric 




acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was obtained as a 
yellow solid (0.253 g, 86%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.59 (s, 1H, NNH), 9.79 (t, 3J = 5.8 Hz, 1H, NNH), 8.67 (dd, 
3,4J = 8.0, 1.4 Hz, 1H, H-8), 8.42 (d, 3J = 8.1 Hz, 1H, H-4), 8.33 (d, 3J = 8.0 Hz, 1H, H-5), 8.26 (dd, 3,4J 
= 7.9, 1.3 Hz, 1H, H-1), 7.87 – 7.82 (m, 1H, H-3), 7.61 – 7.57 (m, 1H, H-2), 7.57 – 7.54 (m, 1H, H-6), 
7.52 – 7.47 (m, 1H, H-7), 6.02 – 5.92 (m, 1H, CH2CH), 5.24 (dd, 
3,4Jtrans = 17.2, 1.2 Hz, 1H, H-a), 5.17 
(dd, 3,4Jcis = 10.3, 1.1 Hz, 1H, H-b), 4.33 (t, 
3J = 5.6 Hz, 2H, CH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.3 (CO), 177.9 (CS), 136.0 (C-4a), 135.3 (C-3), 133.7 
(CH2CH), 130.4 (C-2a), 130.0, 129.8 (CN, C-1a), 129.4 (C-2), 128.9 (C-5a), 128.8 (C-7), 128.4 (C-2), 
128.3 (C-1), 125.2 (C-8), 123.8, 123.7 (C-4, C-5), 116.3 (CHaHb), 46.6 (CH2). 
Mass spectrum: ESI-MS calc. for C18H15N3NaOS [M+Na]+: 344.0833; found: 344.0815. 
Elem. Anal. (%). Found (calc.) for C18H15N3OS: C, 67.22 (67.27); H, 4.61 (4.70); N, 12.98 (13.07). 
IR (solid): ν (cm-1) 3311, 2977, 1645, 1599, 1588, 1449. 
HPLC (Method A): Rt (min) 11.02. 
 
39. Mono(4-(N-(2-(2-(2-aminoethoxy)ethoxy)ethyl))-3-thiosemicarbazone) phenanthrenequinone 
 
Phenanthrenequinone (0.105 g, 0.48 mmol) and thiosemicarbazide 9 (0.147 g, 0.46 mmol) were 
suspended in ethanol (5 mL) and homogenised by sonication for 3 min. Concentrated HCl (3 drops) was 
added and the reaction mixture heated to 90 ºC for 10 min by microwave irradiation. The solvent was 
removed under vacuum and the product re-suspended in CH2Cl2 and passed through a silica plug. After 
washing with CH2Cl2, the product was eluted with CH2Cl2 / MeOH (9:1). The solvent was removed 
under vacuum and the product obtained as an orange solid (0.109 g, 58%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.57 (s, 1H, NNH), 9.60 (t, 3J = 5.9 Hz, 1H, NHCH2), 8.64 
(dd, 3,4J = 8.1, 1.4 Hz, 1H, H-8), 8.43 (d, 3J = 7.8 Hz, 1H, H-4), 8.34 (dd, 3,4J = 8.2, 1.2 Hz, 1H, H-5), 
8.26 (dd, 3,4J = 7.9, 1.5 Hz, 1H, H-1), 7.97 (brs, 2H, NH2), 7.85 (ddd, 
3,3,4J = 8.4, 7.2, 1.5 Hz, 1H, H-3), 
7.60 – 7.54 (m, 2H, H-3, H-2, H-6), 7.50 (ddd, 3,3,4J = 8.2, 7.1, 1.2 Hz, 1H, H-7), 3.86 (q, 3J = 6.1 Hz, 




2H, H-11), 3.70 (t, 3J = 6.2 Hz, 2H, H-12), 3.64 – 3.56 (m, 6H, H-13, H-14, H-15), 2.92 (q, 3J = 5.4 Hz, 
2H, H-16). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.4 (CO), 177.9 (CS), 136.0 (C-4a), 135.4 (C-3), 130.4 
(C-2a), 130.1, 129.8 (CN, C-1a), 129.5 (C-6), 129.0 (C-7), 128.5 (C-2, C-5a), 128.3 (C-1), 125.1 (C-8), 
123.8 (C-4, C-5), 69.7, 69.5 (C-13, C-14), 67.8 (C-12), 66.7 (C-15), 44.0 (C-11), 38.5 (C-16). 
Mass spectrum: ESI-MS calc. for C21H25N4NaO3S [M+Na]+: 435.1467; found: 435.1542. 
IR (solid): ν (cm-1) 3300, 1659, 1496, 1388, 1097, 1066. 




Compound 40 was prepared following the experimental procedure for 14. 4,5-Pyrenedione (0.200 g, 
0.86 mmol), 4-methyl-3-thiosemicarbazide (0.086 g, 0.82 mmol) and 3 drops of concentrated 
hydrochloric acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was 
obtained as a red solid (0.217 g, 83%).  
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.70 (s, 1H, NNH), 9.65 (q, 3J = 4.4 Hz, 1H, NHCH3), 8.93 
(dd, 3,4J = 7.7, 1.2 Hz, 1H, H-3), 8.54 (dd, 3,4J = 7.5, 1.3 Hz, 1H, H-6), 8.42 (dd, 3,4J = 7.8, 1.3 Hz, 1H, 
H-8), 8.13 (dd, 3,4J = 7.8, 1.1 Hz, 1H, H-1), 8.02 (d, 4J = 1.2 Hz, 2H, H-9, H-10), 7.92 (t, 3J = 7.7 Hz, 
1H, H-7), 7.84 (t, 3J = 7.8 Hz, 1H, H-2), 3.19 (d, 3J = 4.6 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.9 (CO), 178.1 (CS), 134.9 (C-8), 134.4 (CN), 131.2, 
131.0 (C-5a, C-3a), 129.8 (C-10a), 129.0 (C-8a), 128.6 (C-5b), 128.5 (C-5a), 128.1 (C-1), 127.9 (C-7), 
127.6 (C-10, C-2), 127.3 (C-6), 127.1 (C-7), 126.4 (C-9), 123.1 (C-3), 31.8 (CH3). 
Mass spectrum: ESI-MS calc. for C18H13N3NaOS [M+Na]+: 3042.0677; found: 342.0658. 
IR (solid): ν (cm-1) 3299, 3053, 2932, 1667, 1616, 1543, 1481, 1174. 












Compound 41 was prepared following the experimental procedure for 14. 4,5-Pyrenedione (0.200 g, 
0.86 mmol), 4-ethyl-3-thiosemicarbazide (0.098 g, 0.82 mmol) and 3 drops of concentrated hydrochloric 
acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was obtained as a 
red solid (0.236 g, 86%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.64 (s, 1H, NNH), 9.72 (t, 3J = 5.8 Hz, 1H, NHCH2), 8.90 
(dd, 3,4J = 7.7, 1.1 Hz, 1H, H-3), 8.52 (dd, 3,4J = 7.5, 1.2 Hz, 1H, H-6), 8.42 (dd, 3,4J = 7.8, 1.2 Hz, 1H, 
H-8), 8.13 (dd, 3,4J = 7.8, 1.1 Hz, 1H, H-1), 8.01 (s, 2H, H-9, H-10), 7.92 (t, 3J = 7.7 Hz, 1H, H-7), 7.84 
(t, 3J = 7.8 Hz, 1H, H-2), 3.86 – 3.67 (m, 2H, CH2), 1.27 (t, 
3J = 7.1 Hz, 3H, CH3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.82 (CO), 177.22 (CS), 134.42 (C-8), 131.2, 131.1 (C-5a, 
C-3a, C-3b), 130.5 (CN), 129.7 (C-10a), 129.0 (C-8a), 128.6 (C-1), 128.1 (C-5b), 127.7 (C-10, C-2), 
127.3 (C-6), 127.1 (C-7), 126.4 (C-9), 123.1 (C-3), 39.02 (CH2), 13.93 (CH3). 
Mass spectrum: ESI-MS calc. for C19H15N3NaOS [M+Na]+: 356.0834; found: 356.0833. 
IR (solid): ν (cm-1) 3338, 2976, 1670, 1619, 1485, 1416, 1037. 




Compound 42 was prepared following the experimental procedure for 14. 4,5-Pyrenedione (0.200 g, 
0.86 mmol), 4-allyl-3-thiosemicarbazide (0.107 g, 0.82 mmol) and 3 drops of concentrated hydrochloric 
acid were heated in ethanol at 90 ºC 10 min by microwave irradiation. The product was obtained as a 
red solid (0.233 g, 82%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.72 (s, 1H, NNH), 9.89 (t, 3J = 6.0 Hz, 1H, NHCH2), 8.95 
(dd, 3,4J = 7.8, 1.1 Hz, 1H, H-3), 8.55 (dd, 3,4J = 7.5, 1.3 Hz, 1H, H-6), 8.43 (dd, 3,4J = 7.8, 1.3 Hz, 1H, 




H-8), 8.14 (dd, 3,4J = 7.8, 1.1 Hz, 1H, H-1), 8.03 (d, 4J = 1.1 Hz, 2H, H-9, H-10), 7.93 (t, 3J = 7.7 Hz, 
1H, H-7), 7.85 (t, 3J = 7.8 Hz, 1H, H-2), 6.04 – 5.93 (m, 1H, CH), 5.27 (dd, 3,4Jtrans = 17.2, 1.7 Hz, 1H, 
Ha), 5.19 (dd, 3,4Jcis = 10.3, 1.7 Hz, 1H, Hb), 4.41 – 4.33 (m, 2H, CH2). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.5 (CO), 177.8 (CS), 134.2 (C-8), 133.8 (CH), 131.0, 
130.9 (C-3a, C-3b, C-5a), 130.3 (CN), 129.5 (C-10a), 128.7 (C-8a), 128.4 (C-1), 127.8, 127.5 (C-10, 
C-2), 127.4 (C-6), 127.1 (C-7), 126.2 (C-9), 123.0 (C-3), 116.3 (CHaHb), 46.7 (CH2). 
Mass spectrum: ESI-MS calc. for C20H15N3NaOS [M+Na]+: 368.0834; found: 368.0829. 
Elem. Anal. (%). Found (calc.) for C20H15N3OS: C, 69.37 (69.54); H, 4.51 (4.38); N, 12.01 (12.17). 
IR (solid): ν (cm-1) 3354, 1618, 1532, 1484, 1035. 




Mono(4-phenyl-3-thiosemicarbazone)-4,5-pyrenedione was prepared following the experimental 
procedure for compound 14. Pyrene-4,5-dione (0.200 g, 0.86 mmol) and 4-phenyl-3-thiosemicarbazide 
(0.432 g, 2.58 mmol) were heated 10 min at 90 ºC in a microwave reactor. The product was obtained as 
a red solid (0.274 g, 83%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 14.82 (s, 1H, NNH) 11.12 (s, 1H, CSNH), 8.97 (d, 3J = 7.8 
Hz, 1H, H-3), 8.48 (dd, 3,4J = 7.5, 1.3 Hz, 1H, H-6), 8.38 (dd, 3,4J = 7.8, 1.3 Hz, 1H, H-8), 8.08 (dd, 3,4J 
= 7.8, 1.2 Hz, 1H, H-1), 7.98 (s, 2H, H-9, H-10), 7.89 (t, 3J = 7.7 Hz, 1H, H-7), 7.77 (t, 3J = 7.7 Hz, 1H, 
H-2), 7.65 (dd, 3,4J = 8.5, 1.3 Hz, 2H, H-11), 7.52 – 7.46 (m, 2H, H-12), 7.37 – 7.32 (m, 1H, H-13). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 181.9 (CO), 177.2 (CS), 138.6 (C-11a), 134.5 (C-8), 131.2, 
131.0 (C-2a, C-3b, C-5a), 130.9 (CN), 129.5 (C-10a), 128.8 (C-8a), 128.7 (C-1), 128.5 (C-5b), 127.6 
(C-10, C-2), 127.3 (C-6), 127.0 (C-7), 126.5 (C-13), 126.3 (C-11), 126.2 (C-9), 123.7 (C-3). 
Mass spectrum: ESI-MS calc. for C23H15N3NaOS [M+Na]+: 404.0833; found: 404.0830. 
IR (solid): ν (cm-1) 3295, 3053, 1638, 1619, 1499, 1130. 
HPLC (Method A): Rt (min) 12.61. 
 




44. Mono(4-N(2-(2-(2-aminoethoxy)ethoxy)ethyl))-3-thiosemicarbazone pyrene-4,5-dione 
 
Pyrene-4,5-dione (0.100 g, 0.43 mmol) and thiosemicarbazide 9 (0.132 g, 0.41 mmol) were suspended 
in ethanol (5 mL), homogenised by sonication for 3 min and heated 10 min at 90 ºC in the microwave 
reactor. The solvent was removed under vacuum and the residue re-suspended in CH2Cl2 and passed 
through a silica plug washing with CH2Cl2 and eluting with CH2Cl2 / MeOH (9:1). The solvent was 
removed under vacuum and the product was obtained as a red solid (0.121 g, 68 %). 
1H NMR (400 MHz, CDCl3, 25 ºC): δ 14.67 (s, 1H, NNH), 9.68 (t, 
3J = 5.9 Hz, 1H, NHCH2), 8.92 (dd, 
3,4J = 7.7, 1.1 Hz, 1H, H-3), 8.54 (dd, 3,4J = 7.5, 1.3 Hz, 1H, H-6), 8.44 (dd, 3,4J = 7.9, 1.3 Hz, 1H, H-8), 
8.15 (dd, 3,4J = 7.9, 1.1 Hz, 1H, H-1), 8.04 (d, 4J = 0.8 Hz, 2H, H-9, H-10), 7.93 (t, 3J = 7.7 Hz, 1H, H-
7), 7.89 (brs, 2H, NH2), 7.85 (t, 
3J = 7.8 Hz, 1H, H-2), 3.91 (q, 3J = 6.1 Hz, 2H, H-11), 3.75 (t, 3J = 6.2 
Hz, 2H, H-12), 3.68 – 3.60 (m, 6H, H-13, H-14, H-15), 2.98 – 2.91 (m, 2H, H-16). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 182.0 (CO), 178.0 (CS), 134.6 (C-8), 131.3, 131.1, 131.0 (C-3a, 
C-3b, C-5a), 129.7 (CN), 129.0 (C-10a), 128.7 (C-1), 128.1 (C-5b), 127.7 (C-10, C-2), 127.4 (C-6), 
127.2 (C-7), 126.4 (C-9), 123.2 (C-3), 69.7, 69.6 (C-13, C-14), 67.9 (C-12), 66.7 (C-15), 44.1 (C-11), 
38.6 (C-16). 
Mass spectrum: ESI-MS calc. for C23H25N4O3S [M+H]+: 437.1647; found: 437.1656. 
IR (solid): ν (cm-1) 3300, 1659, 1496, 1388, 1097, 1066. 












45. Zn(II)[mono(allyl-thiosemicarbazonato) acenaphthenequinone]2 
 
Mono(4-allyl-3-thiosemicarbazone) acenaphthenequinone (0.286 g, 0.97 mmol) and anhydrous zinc 
acetate (0.177 g, 0.97 mmol) were suspended in ethanol (5 mL) and homogenised by ultrasonication. 
The reaction mixture was heated 1 h at 90 ºC under microwave irradiation. The reaction mixture was 
filtered whilst hot, washed with ethanol and dried under vacuum. The solid was dissolved in CH2Cl2 and 
purified using a silica plug, washing with CH2Cl2 and eluting with CH2Cl2 / MeOH (8:2). The solvent 
was concentrated under vacuum. The product was obtained as an orange solid (0.288 g, 91%). 
Mass spectrum: ESI-MS calc. for C32H25N6O2S2Zn [M+H]+: 653.0772; found: 653.0804. 
Elem. Anal. (%). Found (calc.) for C32H24N6O2S2Zn·CHCl3: C, 50.53 (51.25); H, 3.15 (3.26); N, 10.90 
(10.87). 
IR (solid): ν (cm-1) 3321, 3059, 1675, 1484, 1247, 1090, 1026. 
HPLC (Method A): Rt (min) 9.98.   
 
46. Zn(II) [mono(allyl-thiosemicarbazonato) aceanthrenequinone]2 
 
Compound 46 was synthesised following the experimental procedure of 45. Mono(4-allyl-3-
thiosemicarbazone) aceanthrenequinone (0.060 g, 0.14 mmol) and anhydrous zinc acetate (0.027 g, 0.14 
mmol) were heated in ethanol for 1 h at 90 ºC under microwave irradiation. The product was obtained 
as a red solid (0.059 g, 91%). 




Mass spectrum: nanoESI-MS calc. for C40H29N6O2Zn [M+H]+: 753.1085; found: 753.1079. 
IR (solid): ν (cm-1) 3300, 1659, 1496, 1388, 1097, 1066.  
HPLC (Method A): Rt (min) 11.84. 
 
47. Zn(II) [mono(allyl-thiosemicarbazonato) phenanthrenequinone]2 
 
Compound 47 was synthesised following the experimental procedure of 45. Mono(4-allyl-3-
thiosemicarbazone) phenanthrenequinone (0.050 g, 0.16 mmol) and anhydrous zinc acetate (0.028 g, 
0.16 mmol) were heated in ethanol for 1 h at 90 ºC under microwave irradiation. The product was 
obtained as a red solid (0.046 g, 84%). 
Mass spectrum: ESI-MS calc. for C36H29N6O2S2Zn [M+H]+: 705.1085; found: 705.1200.  
Elem. Anal. (%). Found (calc.) for C36H28N6O2S2Zn·C6H14: C, 64.11 (63.67); H, 5.27 (5.34); N, 9.18 
(10.61). 
IR (solid): ν (cm-1) 3313, 2961, 2925, 1486, 1078, 1014.  
HPLC (Method A): Rt (min) 11.26. 
 
48. Zn(II) [mono(allyl-thiosemicarbazonato) pyrene-4,5-dione]2 
 
Compound 48 was synthesised following the experimental procedure of 45. Mono(4-allyl-3-
thiosemicarbazonato) pyrene-4,5-dione (0.050 g, 0.14 mmol) and anhydrous zinc acetate (0.026 g, 




0.14 mmol) were heated in ethanol for 1 h at 90 ºC under microwave irradiation. The product was 
obtained as a dark red solid (0.057 g, 99%). 
Mass spectrum: ESI-MS calc. for C40H29N6O2S2Zn [M+H]+: 753.1085; found: 753.1186. 
IR (solid): ν (cm-1) 3355, 2918, 1679, 1484, 1075, 1026.  





A solution of Fmoc-Glu(OtBu)-OH (0.214 g, 0.50 mmol), pyBOP (0.262 g, 0.50 mmol) and DIPEA 
(0.11 ml, 0.63 mmol) were stirred for 2 h at room temperature in DMF (5 mL). 
Mono(thiosemicarbazone) 10 (0.125 g, 0.42 mmol) was added to the reaction mixture dissolved in DMF 
(5 mL) and the reaction mixture stirred at room temperature for 20 h. The solvent was removed under 
vacuum, the crude re-dissolved in CH2Cl2 and purified by column chromatography using CH2Cl2 / 
MeOH (0-10%) as solvent system. The solvent was concentrated under vacuum to yield a yellow solid 
(0.147 g, 49%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 12.61 (s, 1H, NNH), 9.36 (t, 3J = 5.4 Hz, 1H, CSNH), 8.35 
(d, 3J = 8.2 Hz, 1H, H-5), 8.20 (t, 3J = 6.0 Hz, 1H, C-10-NH), 8.10 (d, 3J = 8.5 Hz, 1H, H-6), 8.07 (d, 3J 
= 7.1 Hz, 2H, H-3), 8.02 (d, 3J = 7.0 Hz, 1H, H-8), 7.90 – 7.86 (m, 1H, H-4), 7.86 – 7.81 (m, 2H, H-19, 
H-19’), 7.78 (dd, 3,3J = 8.9, 7.0, 2H, H-7), 7.70 (d, 3J = 7.5 Hz, 2H, H-16, H-16’), 7.66 (d, 3J = 7.7 Hz, 
1H, H-17, H-17’), 7.54 (d, 3J = 7.4 Hz, 1H, C-11-NH), 7.38 (t, 3J = 7.5 Hz, 2H, H-18, H-18’), 7.29 (t, 
3J = 7.5 Hz, 2H, H-17, H-17’), 4.36 – 4.11 (m, 3H, H-14, H-16), 4.09 – 3.94 (m, 2H, H-11), 3.77 – 3.64 
(m, 2H, H-9), 3.51 – 3.38 (m, 2H, H-10), 2.23 (t, 3J = 7.7 Hz, 3H, H-13), 2.05 – 1.87 (m, 1H, H-12), 
1.87 – 1.70 (m, 2H, H-12). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 188.9 (C-2aCO), 178.1 (CS), 172.6 (COC11), 172.0 
(COOtBu), 156.4 (COOFmoc), 144.3, 144.1, 141.1, 139.6 (Cq Fmoc), 137.6 (CN), 133.3 (C-5), 130.8 




(C-5a), 130.4, 130.3, 129.3 (C-1a, C-2a, C-5a), 129.1 (C-7), 129.0 (C-4), 128.0 (C-18, C-18’), 127.5, 
127.4 (C-4, C-17, C-17’), 125.7 (C-16, C-16’), 122.9 (C-3), 120.5 (C-19, C-19’), 118.8 (C-8), 66.1 (C-
14), 54.5 (C-11), 47.1 (H-15), 44.9 (C-9), 38.1 (C-10), 31.8 (C-13), 28.1 ((CH3)3), 27.7 (C-12). 
Mass spectrum: ESI-MS calc. for C39H39N5NaO6S [M+Na]+: 728.2518; found: 728.2580. 
HPLC (Method A): Rt (min) 10.96. 
 
  




50. 4,4-Difluoro-8-(4’-carboxyphenyl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene (adapted 
from a literature procedure 11) 
 
2,4-dimethylpyrrole (5.000 g, 52.6 mmol) and 4-formylbenzoic acid (3.718 g, 22.5 mmol) were 
dissolved in CH2Cl2 (2 L) and 10 drops of TFA added. The reaction mixture was allowed to stir at room 
temperature for 1.5 h. 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (5.098 g, 22.5 mmol) was 
added portion wise followed by triethylamine (50 mL) and BF3·OEt2 (50 mL) added dropwise. The 
reaction was quenched by the addition of water (1 L). The aqueous phase was extracted with CH2Cl2 
(3x 600 mL). The organic fractions were collected, dried over MgSO4 and the solvent removed under 
vacuum. The crude was purified by flash column chromatography using CH2Cl2 / MeOH (0 – 20%) as 
eluent. After recrystallisation from THF/hexane, the product was obtained as a red solid (3.147 g, 38%). 
1H NMR (500 MHz, d8-THF, 25 ºC): δ 8.19 (d, 3J = 8.2 Hz, 2H, H-3), 7.48 (d, 3J = 8.2 Hz, 2H, H-4), 
6.03 (s, 2H, H-2, H-10), 2.49 (s, 6H, H-12), 1.38 (s, 6H, H-9). 
13C NMR (125 MHz, d8-THF, 25 ºC): δ 167.2 (COOH), 156.7 (C-11), 143.6 (C-5), 142.1 (C-8), 140.6 
(C-6), 132.9 (C-7), 132.0 (C-2), 131.5 (C-3), 129.5 (C-4), 122.1 (C-10), 14.8, 14.7 (C-9, C-12). 
Mass spectrum: ESI-MS calc. for C20H18BF2N2O2 [M-H]-: 367.1429; found: 367.1435. 
Elem. Anal. (%). Found (calc.) for C20H19BF2N2O2: C, 64.05 (65.24); H, 5.18 (5.20); N, 7.21 (7.61). 
IR (solid) ν (cm-1): 2974, 1678, 1544, 1076, 1043, 972, 738. 
HPLC (Method A): Rt (min) 10.22. 
 
51. N6-(tert-butoxycarbonyl)lysine (adapted from a literature procedure 12) 
 
Piperidine (2.5 mL) was added to a stirring solution of N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-
(tert-butoxycarbonyl)lysine (1.000 g, 2.13 mmol) in DMF (10 mL) at 25 ºC. The reaction mixture was 
allowed to stir at room temperature for 2 h. The solvent was removed under vacuum and the residue 
re-suspended in water (20 mL) and washed with petroleum ether (3x 25 mL). The aqueous phase was 
concentrated under vacuum and freeze dried. The product was obtained as a white solid (0.499 g, 95%). 




1H NMR (500 MHz, D2O, 25 ºC): δ 3.66 (t, 
3J = 6.1 Hz, 1H, H-2), 3.01 (t, 3J = 6.7 Hz, 2H, H-6), 1.89 
– 1.73 (m, 2H, H-3), 1.52 – 1.41 (m, 2H, H-5), 1.36 (s, 9H, (CH3)3), 1.34 – 1.20 (m, 2H, H-4). 
13C NMR (125 MHz, D2O, 25 ºC): δ 174.7 (COOH), 158.3 (CO), 54.7 (C-2), 39.56 (C-6), 30.1 (C-3), 
28.6 (C-5), 27.6 (CH3)3, 21.6 (C-4). 
Mass spectrum: ESI-MS calc. for C11H22N2NaO4 [M+Na]+: 269.1477; found: 269.1476. 





8-carboxyphenyl BODIPY (50) (0.100 g, 0.27 mmol), N-hydroxysuccinimide (0.065 g, 0.27 mmol) and 
EDC·HCl (0.107 g, 0.56 mmol) were dissolved in CH2Cl2 (60 mL). The reaction mixture was stirred at 
room temperature for 3 h. The solvent was removed under vacuum and the residue purified by flash 
column chromatography using hexane / ethyl acetate (1:1) as eluent. The product was obtained as a 
crystalline orange solid (0.135 g, 99%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 8.27 (d, 
3J = 8.4 Hz, 2H, H-4), 7.50 (d, 3J = 8.4 Hz, 2H, H-6), 
6.01 (s, 2H, H-12), 2.94 (s, 4H, H-1), 2.56 (s, 6H, H-14), 1.38 (s, 6H, H-11). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 169.3 (C-2), 161.4 (C-3), 156.5 (C-13), 143.0 (C-10), 142.2 
(C-8), 139.4 (C-7), 131.4 (C-5), 130.8 (C-4), 129.2 (C-6), 125.9 (C-9), 121.8 (C-12), 25.8 (C-1), 14.9 
(C-14), 14.8 (C-11). 
Mass spectrum: ESI-MS calc. for C25H25BF2N3O5 [M-H]-: 496.1855; found: 496.1867. 
Elem. Anal. (%). Found (calc.) for C24H22BF2N3O4: C, 61.78 (61.96); H, 4.88 (4.77); N, 8.89 (9.03). 
IR (solid): ν (cm-1) 2921, 2852, 1802, 1778, 1737, 1542, 1065, 721. 












To a solution of NHS-activated BODIPY (52) (0.600 g, 1.29 mmol) and N,N-DIPEA (2.5 mL, 12.9 
mmol) in DMF (50 mL) at 60 ºC, N-6-(tert-butoxycarbonyl)lysine (0.950 g, 3.86 mmol) was added 
portion wise and the reaction mixture stirred at 60 ºC for 7 h. The solvent was removed under vacuum 
and the residue dissolved in CH2Cl2 and washed with water (3x50 mL). The organic layer was dried 
over MgSO4 and the solvent removed under vacuum. The purification was performed by automated 
flash column chromatography using CH2Cl2 / MeOH (0 – 10%) as eluent. The product was obtained as 
a red solid (0.699 g, 91%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 7.95 (d, 
3J = 8.2 Hz, 2H, H-8), 7.31 (d, 3J = 8.2 Hz, 2H, H-9), 
5.93 (s, 2H, H-15), 4.83 (s, 1H, H-5), 4.76 (s, 1H, NHCO), 3.07 (brs, 2H, H-4), 2.48 (s, 6H, H-17), 2.05 
– 1.93 (m, 1H, H-3), 1.90 – 1.79 (m, 1H, H-3), 1.56 – 1.41 (m, 4H, H-1, H-2), 1.36 (s, 9H, (CH3)3), 1.29 
(s, 6H, H-14).  
13C NMR (125 MHz, CDCl3, 25 ºC): δ 156.1 (NHCO), 143.0, 128.7 (C-9), 128.3 (C-8), 121.6 (C-15), 
66.0, 53.0 (C-5), 36.8, 31.7 (C-3), 30.0 (C-1, C-2), 28.6 (CH3)3, 22.8 (C-1, C-2), 14.8 (C-14, C-17). 
Mass spectrum: ESI-MS calc. for C31H39BF2NaN4O5 [M+Na]+: 619.2879; found 619.2908. 
IR (solid): ν (cm-1) 3327, 2929, 1646, 1542, 1508, 1154, 974. 


















NHS-activated BODIPY (52) (0.108 g, 0.23 mmol) and 4-(N,N-dimethylamino)benzaldehyde (0.138 g, 
0.93 mmol) were dissolved in toluene and piperidine (206 µL, 2.08 mmol) and acetic acid (158 µL, 2.77 
mmol) added. The reaction mixture was heated at 110 ºC for 6 h. The solvent was removed under 
vacuum, the residue re-dissolved in CH2Cl2 and washed with water. The organic layer was dried over 
MgSO4 and the solvent removed under vacuum. The purification was carried out by automated flash 
column chromatography using an increasing concentration of THF / MeOH (20 – 40%) as eluent. The 
product was obtained as a blue solid (0.030 g, 22%). 
1H NMR (500 MHz, 500 MHz, CDCl3) δ 7.55 (d, 
3J = 7.8 Hz, 2H, H-6), 7.52 (d, 3J = 8.6 Hz, 2H, H-
26), 7.49 (d, 3Jtrans = 15.7 Hz, 1H, H-23), 7.39 (d, 
3J = 7.9 Hz, 2H, H-7), 7.23 (d, 3Jtrans = 15.7 Hz, 1H, 
H-24), 6.69 (d, 3J = 8.6 Hz, 2H, H-27), 6.61 (s, 1H, H-13), 5.97 (s, 1H, H-20), 3.75 (s, 4H, H-3), 3.36 
(s, 4H, H-2), 3.03 (s, 6H, N(CH3)2), 2.59 (s, 3H, H-19), 2.05 (s, 2H, H-1), 1.45 (s, 3H, H-12), 1.40 (s, 
3H, H-22). 
Mass spectrum: APCI-MS calc. for C34H37BF2N4O [M+H]+: 567.3113; found: 567.3102. 
IR (solid): ν (cm-1) 2962, 1615, 1596, 1258, 1012. 
















BODIPY 53 (56 mg, 94 µmol) and 4-(N,N-dimethylamino)benzaldehyde (56 mg, 0.37 mmol) were 
dissolved in toluene. Piperidine (93 µL, 0.94 mmol) and acetic acid (32 µL, 0.56 mmol) were added and 
the reaction mixture heated to 110 ºC for 7 h. The solvent was removed under vacuum, the resulting 
residue re-suspended in CH2Cl2 and washed with water. The organic layer was dried over MgSO4 and 
the solvent removed under vacuum. The purification was carried out by automated flash column 
chromatography using CH2Cl2 / MeOH (0 – 10%) as eluent. The product was obtained as a dark blue 
solid. 
1H NMR (500 MHz, CD3OD) δ 8.06 (d, 
3J = 8.2 Hz, 2H, H-8), 7.50 (d, 3J = 8.3 Hz, 2H, H-9), 7.49 (d, 
3J = 8.9 Hz, 2H, H-28), 7.42 (d, 3Jtrans = 16.2 Hz, 1H, H-25), 7.35 (d, 
3Jtrans = 16.2 Hz, 1H, H-26), 6.78 
(d, 3J = 8.9 Hz, 2H, H-29), 6.08 (s, 1H, H-15, H-22), 6.04 (s, 1H, H-15, H-22), 4.60 (s, 1H, H-5), 3.09 
– 3.05 (m, 2H, H-1), 3.03 (s, 6H, N(CH3)2), 2.52 (s, 3H, H-24), 2.10 – 1.97 (m, 2H, H-3), 1.96 – 1.83 
(m, 2H, H-4), 1.61 – 1.50 (m, 5H, H-2, H-21), 1.48 (s, 3H, H-14), 1.42 (s, 9H, (CH3)3). 
Mass spectrum: ESI-MS calc. for C40H47BF2N5O5 [M+H]+: 726.3638; found: 726.3643. 
IR (solid): ν (cm-1) 3352, 2920, 1703, 1663, 1524, 1479, 1072. 




Fmoc-Lys(Boc) (1.058 g, 2.15 mmol) was dissolved in a 1:1 mixture of TFA and CH2Cl2 (20 mL) and 
the reaction mixture was stirred at room temperature for 3 h. The solvent was removed under vacuum 




and the remaining TFA removed by adding diethyl ether and concentrated under vacuum repeatedly. 
The product was obtained as a white solid (0.638 g, 80%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 12.63 (s, 1H, COOH), 7.89 (dd, 
3,4J = 7.6, 1.0 Hz, 2H, H-15), 
7.71 (ddd, 3,4,5J = 7.5, 4.9, 1.0 Hz, 2H, H-12), 7.60 (d, 3J = 8.3 Hz, 1H, CONH), 7.42 (t, 3J = 7.5 Hz, 2H, 
H-13), 7.33 (td, 3,4J = 7.5, 1.1 Hz, 2H, H-14), 4.34 – 4.28 (m, 1H, CHCH2O), 4.27 – 4.18 (m, 2H, 
CH2O), 3.99 – 3.86 (m, 1H, CHCOOH), 2.82 – 2.71 (m, 2H, H-1), 1.76 – 1.67 (m, 1H, H-4), 1.66 – 
1.54 (m, 1H, H-4), 1.57 – 1.45 (m, 1H, H-2), 1.42 – 1.30 (m, 2H, H-3). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 175.6 (COOH), 158.7 (CONH), 145.3 (C-11), 145.1 (C-16), 
128.8 (C-13), 128.2 (C-14), 126.2 (C-12), 120.9 (C-15), 67.9 (CH2O), 54.9 (CHCOOH), 48.5 
(CHCH2O), 40.5 (C-1), 40.4, 32.2 (C-4), 28.0 (C-2), 23.8 (C-3). 
Mass spectrum: ESI-MS calc. for C21H24N2NaO4 [M+Na]+: 391.1634; found: 391.1631. 
IR (solid): ν (cm-1) 3077, 2946, 1670, 1634, 1516, 1180. 





To a solution of NHS-activated BODIPY (52) (0.210 g, 0.45 mmol) and N,N-DIPEA (0.78 mL, 4.50 
mmol) in DMF (15 mL), (((9H-fluoren-9-yl)methoxy)carbonyl)lysine (0.652 g, 1.35 mmol) was added 
portion wise. The reaction mixture was stirred at room temperature for 2 h until the starting material 
was consumed as confirmed by TLC. The solvent was removed under vacuum, the residue re-dissolved 
in CH2Cl2 and washed with water. The organic layer was collected, dried over MgSO4 and the solvent 
removed under vacuum. The purification was performed by automated flash column chromatography 
using CH2Cl2 / MeOH (0 – 15%) as eluent. The product was obtained as an orange solid (0.024 g, 75%). 
1H NMR (500 MHz, CD3OD, 25 ºC): δ 7.93 (d, 
3J = 8.3 Hz, 2H, H-8), 7.74 (d, 3J = 7.8 Hz, 2H, H-23, 
H-23’), 7.70 (d, 3J = 7.4 Hz, 1H, H-20), 7.65 (d, 3J = 7.3 Hz, 1H, H-20’), 7.39 – 7.29 (m, 4H, H-22, 
H-22’, H-23, H-23’), 7.28 (d, 3J = 8.3 Hz, 2H, H-9), 6.04 (s, 2H, H-15), 4.43 – 4.25 (m, 2H, H-18), 4.24 
– 4.16 (m, 2H, H-2, H-19), 3.47 – 3.37 (m, 2H, H-6), 1.99 – 1.88 (m, 1H, H-3), 1.83 – 1.72 (m, 1H, H-
3), 1.73 – 1.62 (m, 2H, H-5), 1.60 – 1.47 (m, 2H, H-4). 




13C NMR (125 MHz, CD3OD, 25 ºC): δ 175.9 (COOH), 169.5 (C-7), 158.8 (OCONH), 157.0 (C-16), 
145.4 (C-13), 145.0, 144.4, 142.5, 142.3 (Cq Fmoc), 139.4 (C-11), 136.8 (C-10), 132.3 (C-7), 129.6 
(C-9), 129.3 (C-8), 128.8, 128.2, 128.1 (C-21, C-21’, C-22, C-22’), 126.4, 126.2 (C-20, C-20’), 122.4 
(C-15), 121.0 (C-23, C-23’), 68.1 (C-18), 55.2 (C-2), 48.2 (C-19), 40.8 (C-6), 32.5 (C-3), 29.9 (C-5), 
24.4 (C-4), 14.7, 14.6 (C-14, C-17). 
Mass spectrum: ESI-MS calc. for C41H40BF2N4O5 [M-H]-: 717.3060; found: 717.3103. 
Elem. Anal. (%). Found (calc.) for C41H41BF2N4O5·C3H7NO: C, 65.94 (66.75); H, 5.68 (6.11); N, 7.63 
(8.85). 
IR (solid): ν (cm-1) 3268, 2931, 1713, 1655, 1541, 1507, 1189. 





Compound 57 (36 mg, 46 µmol) was dissolved in a solution of CH2Cl2 / piperidine (1:4) (7.5 mL) and 
the reaction mixture stirred at room temperature until consumption of the starting material (1 h). Water 
was added to the reaction mixture, the organic phase washed with HCl (1M), brine, dried over MgSO4 
and concentrated under vacuum. The residue was purified by flash column chromatography using 
CH2Cl2 / MeOH (0 – 15%) as an eluent. The product was obtained as a red solid (19 mg, 82%). 
1H NMR (500 MHz, CD3OD, 25 ºC): δ 8.02 (d, 
3J = 8.5 Hz, 2H, H-8), 7.46 (d, 3J = 8.5 Hz, 2H, H-9), 
6.08 (s, 2H, H-15), 3.55 (dd, 3,3J = 6.9, 5.2 Hz, 1H, H-2), 3.49 – 3.39 (m, 2H, H-6), 2.49 (s, 6H, H-16), 
1.99 – 1.82 (m, 2H, H-3), 1.75 – 1.65 (m, 2H, H-5), 1.58 – 1.49 (m, 2H, H-4), 1.41 (s, 6H, H-14). 
13C NMR (125 MHz, CD3OD, 25 ºC): δ 174.2 (COOH), 169.4 (CONH), 157.1 (C-16), 144.4 (C-13), 
139.5 (C-11), 136.7 (C-10), 132.3 (C-7), 129.7 (C-9), 129.4 (C-8), 122.4 (C-15), 56.1 (C-2), 40.7 (C-6), 
32.0 (C-3), 30.2 (C-5), 23.8 (C-4), 14.7 (C-16), 14.6 (C-14). 
Mass spectrum: ESI-MS calc. for C26H31BF2N4NaO3 [M+Na]+: 519.2355; found: 519.2383. 
IR (solid): ν (cm-1) 3296, 2968, 1707, 1640, 1543, 1508, 1191, 1156. 
HPLC (Method A): Rt (min) 7.71.  
 
 







Activated BODIPY 52 (6 mg, 13 µmol), mono(4-(6-aminohexyl)-3-thiosemicarbazone) 
acenaphthenequinone (24 mg, 67 µmol) and DIPEA (12 µL, 67 µmol) were charged in a microwave 
vial and dissolved in DMF (1 mL). The reaction mixture was heated to 100 ºC for 20 min. The solvent 
was removed under vacuum to yield the crude as a red solid.  
Mass spectrum: ESI-MS calc. for C39H39BF2N6O2SCl [M+Cl]-: 739.2605; found: 739.2696. 
 
  




60. Oxidised single-walled carbon nanotubes (adapted from a literature procedure13) 
 
Elicarb® pristine SWNT (0.300 g) were added to a Schlenk flask under inert atmosphere. Sulphuric acid 
(15 mL) and nitric acid (5 mL) were added to the solid. The reaction mixture was heated to 100 ºC for 
30 minutes and cooled down to be diluted with water. The dark suspension was transferred to centrifuge 
tubes and centrifuged 30 min at 4000 rcf. The yellow supernatant was removed, the solid pellet 
re-suspended in water and the suspension filtered through a 0.2 µm polycarbonate membrane. The 
oxidised nanotubes were washed with plenty of water and ethanol until the filtrate’s pH was neutral. 
The nanotubes were dried in the oven at 60 ºC overnight to yield 0.234 g of material. 
IR (solid): ν (cm-1) 3250, 1699, 1060. 
Raman: ν (cm-1) 198, 277, 1344, 1583, 2656, 2684. 
TGA, mass loss at 500 ºC: 21%. 
 
61. Tert-butyl (4-aminoben zyl)carbamate  
 
To a solution of 4-aminobenzylamine (1.016 g, 8.32 mmol) in dry THF (30 mL) at room temperature, 
di-tert-butyl dicarbonate (1.994 g, 9.14 mmol) was added dropwise dissolved in 20 mL THF over 15 
min. The reaction mixture was stirred for 2.5 h. The solvent was removed under vacuum and the product 
was purified by flash column chromatography using hexane / ethyl acetate 3:2 as eluent. The product 
was isolated as a yellow solid (1.593 g, 86%). 
1H NMR (500 MHz, d6-DMSO, 25 ºC): δ 7.03 (d, 3J = 8.2 Hz, 2H, H-2), 6.59 (d, 3J = 8.2 Hz, 2H, H-3), 
4.87 (brs, 1H, NH), 4.15 (d, 3J = 4.9 Hz, 2H, CH2), 3.68 (brs, 2H, NH2), 1.43 (s, 9H, (CH3)3). 
13C NMR (125 MHz, d6-DMSO, 25 ºC): δ 156.0 (CO), 145.8 (C-4), 129.0 (C-2), 128.8 (C-1), 115.3 
(C-3), 79.3 (C(CH3)3), 44.4 CH2, 28.5 ((CH3)3). 
Mass spectrum: ESI-MS calc. for C12H18N2NaO2 [M+Na]+: 245.1266; found: 245.1270. 
IR (solid): ν (cm-1) 3452, 3365, 2973, 1688, 1514, 1245, 1156. 
 




62. Boc-benzylamine modified SWNT (adapted from a literature procedure14) 
 
Elicarb® pristine SWNT (0.300 g) were added to a Schlenk flask under inert atmosphere. Tert-butyl 
(4-aminobenzyl)carbamate (61) (1.140 g, 5.1 mmol) was added and the mixture sonicated in milliQ 
water (25 mL) for 15 min. Isopentyl nitrite (0.901 g, 7.7 mmol) was added and the mixture heated to 
80 ºC for 48 h. The reaction mixture was transferred to a centrifuge tube, centrifuged 15 min. at 4000 
rcf, the supernatant removed and the residue re-suspended in water. The process was repeated three 
more times and finally the nanotubes were re-dispersed in water, filtered through a 0.2 µm polycarbonate 
membrane, washed with water, methanol and isopropanol until the filtrate was clear. The SWNT were 
dried in the oven at 60 ºC overnight to yield 0.423 g of material. 
IR (solid): ν (cm-1) 3200, 2901, 1870, 996.  
Raman: ν (cm-1) 179, 258, 1337, 1577, 2668.  
 
63. Benzylamine modified SWNT 
 
Compound 62 was dispersed in DMF by sonication (15 min) before adding concentrated HCl to a final 
concentration of 4 M (25 mL). The reaction mixture was stirred overnight. The nanotubes were 
centrifuged 15 min at 4000 rcf, the supernatant removed, the residue re-dispersed in water and the 
process repeated three times. Finally, the residue was re-dispersed in water, filtered through a 0.2 µm 
membrane and washed with water and methanol until the pH of the filtrate was neutral. The SWNT were 
dried in the oven at 60 ºC overnight to yield 0.368 g of material.  
IR (solid): ν (cm-1) 3360, 1527, 1434, 1044.  
Raman: ν (cm-1) 169, 261, 1336, 1580, 2668.  
TGA, mass loss at 500 ºC: 11%.  
Kaiser test: 0.34 mmol/g. 




64. 6-((Tert-butoxycarbonyl)amino)hexanoic acid (adapted from a literature procedure15) 
 
6-Aminohexanoic acid (1.312 g, 10 mmol) and sodium hydroxide (0.400 g, 10 mmol) were dissolved in 
a 2:1 solution of dioxane and water. The reaction mixture was cooled to 0 ºC. Di-tert-butyl dicarbonate 
(2.400 g, 11 mmol) was added portion wise and the reaction mixture stirred for 4 h. The solvent was 
removed under vacuum and the residue re-dissolved in water (30 mL) and extracted with ethyl acetate 
(2x 25 mL). The aqueous phase was acidified until pH 1-2 with 1M aq. HCl and extracted again with 
ethyl acetate (3x 25 mL). The combined organic layers were dried over MgSO4 and concentrated under 
vacuum. The product was obtained as a white solid (1.742 g, 75%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 9.59 (brs, 1H, COOH), 4.61 (brs, 1H, NH), 3.08 (brs, 2H, H-6), 
2.32 (t, 3J = 7.4 Hz, 2H, H-2), 1.62 (m, 2H, H-3), 1.51 – 1.44 (m, 2H, H-5), 1.42 (s, 9H, (CH3)3), 1.38 – 
1.31 (m, 2H, H-4). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 178.9 (COOH), 156.2 (CO), 79.4 (C(CH3)3), 40.5 (C-6), 34.0 
(C-2), 29.8 (C-5), 28.5 ((CH3)3), 26.3 (C-4), 24.5 (C-3). 
Mass spectrum: ESI-MS calc. for C11H21NNaO4 [M+Na]+: 254.1368; found: 254.1339.  
IR (solid): ν (cm-1) 3364, 2945, 2872, 1684, 1516, 1248, 1164. 
 
65. 11-((Tert-butoxycarbonyl)amino)undecanoic acid 
  
Compound 65 was prepared following the experimental procedure of 64. 11-Aminoundecanoic acid 
(1.000 g, 4.97 mmol) and sodium hydroxide (0.199 g, 4.97 mmol) were dissolved in dioxane / water 
(2:1), cooled to 0 ºC and di-tertbutyl dicarboante (1.193 g, 5.47 mmol) added portion wise. The product 
was obtained as a white solid (1.123 g, 75%). 
1H NMR (500 MHz, CDCl3, 25 ºC): δ 10.57 (brs, 1H, COOH), 4.55 (s, 1H, NH), 3.08 (m, 2H, H-11), 
2.32 (t, 3J = 7.5 Hz, 2H, H-2), 1.65 – 1.56 (m, 2H, H-3), 1.43 (m, 11H, H-10, (CH3)3), 1.36 – 1.20 (m, 
12H, H-4, H-5, H-6, H-7, H-8, H-9). 
13C NMR (125 MHz, CDCl3, 25 ºC): δ 179.4 (COOH), 156.2 (CO), 79.2 (C(CH3)3), 40.8 (C-11), 34.2 
(C-2), 30.1 (C-10), 29.5 (C-3), 29.4, 29.3, 29.3, 29.2 (C-4, C-5, C-8, C-9), 28.6 ((CH3)3), 26.9, 24.8 (C-
6, C-7). 
Mass spectrum: ESI-MS calc. for C16H32NO4 [M+H]+: 302.2331; found: 302.2314. 
IR (solid): ν (cm-1) 3365, 2918, 1684, 1520, 1169. 




66. Ox-Boc-ethylenediamine SWNT (adapted from a literature procedure16) 
 
Oxidised nanotubes (60) (40 mg) were suspended in 10 mL dry DMF by sonicating for 20 min until a 
homogenous dispersion was observed. EDC·HCl (40 mg, 0.26 mmol) and HOBt (40 mg, 0.30 mmol) 
were added and the reaction mixture was stirred for 30 min when tert-butyl (2-aminoethyl)carbamate 
(1) (60 mg, 0.37 mmol) was added dissolved in 5 mL DMF. The reaction mixture was stirred at room 
temperature for 48 h. The suspension was transferred to centrifuge tubes and centrifuged at 3000 rcf for 
20 min, the supernatant discarded and the residue re-suspended in ethanol. The suspension was filtered 
through a 0.2 µm polycarbonate membrane, the solid washed with methanol and dried under vacuum. 
The SWNT were further dried in the oven at 60 ºC, yielding 34 mg of material. 
IR (solid): ν (cm-1) 3270, 1705, 1689.  
Raman: ν (cm-1) 206, 1345, 1585, 2690.  
 
67. Ox-Boc-hexylenediamine SWNT 
 
The experimental procedure followed was the same as in 66. Oxidised nanotubes (40 mg) suspended in 
DMF, EDC·HCl (40 mg, 0.26 mmol) and HOBt (40 mg, 0.30 mmol) added and the reaction mixture 
was stirred for 30 min before the addition of tert-butyl (6-aminohexyl)carbamate (2) (80 mg, 0.37 
mmol). The product was isolated and dried to yield 41 mg of material. 
IR (solid): ν (cm-1) 3300, 1636, 1506. 
Raman: ν (cm-1) 165, 1344, 1580, 2658. 




68. Ox-Boc-pegdiamine SWNT 
  
The experimental procedure followed was the same as in 66. Oxidised nanotubes (41 mg) suspended in 
DMF, EDC·HCl (40 mg, 0.26 mmol) and HOBt (40 mg, 0.30 mmol) added and the reaction mixture 
stirred for 30 min before the addition of  tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (3) 
(90 mg, 0.37 mmol). The product was isolated and dried to yield 43 mg of material. 
IR (solid): ν (cm-1) 3226, 1680, 1078. 
Raman: ν (cm-1) 160, 1344, 1582, 2665. 
 
69. Bz-Boc-hexylaa SWNT 
 
6-((Tert-butoxycarbonyl)amino)hexanoic acid (64) (0.050 g, 0.22 mmol) was dissolved in DMF (10 
mL), EDC·HCl (0.034 g, 0.22 mmol) and HOBt (0.035 g, 0.26 mmol) added. The reaction mixture was 
stirred for 30 min at room temperature. In parallel, functionalised SWNT 63 were suspended in DMF 
(10 mL) by sonicating 10 min. The activated amino acid solution was added to the SWNT solution and 
the resulting suspension was stirred at room temperature for 48 h. The reaction mixture was centrifuged 
at 3000 rcf for 20 min, the supernatant removed, the resulting residue resuspended in ethanol and the 
process repeated three times. The solid was resuspended one more time in ethanol and filtered through 
a 0.2 µm membrane, washed with ethanol and dried under vacuum. The isolated product yielded 54 mg 
of material. 
IR (solid): ν (cm-1) 3478, 2910, 1633, 1340. 
Raman: ν (cm-1) 183, 1335, 1577, 2653. 
 




70. Bz-undecaa SWNT 
 
The same experimental procedure as in 69 was followed. 11-((Tert-butoxycarbonyl)amino)undecanoic 
acid (65) (0.050 g, 0.17 mmol), EDC·HCl (0.026 g, 0.17 mmol) and HOBt (0.027 g, 0.20 mmol) were 
used in the activation of the amino acid. The amino acid solution was added to functionalised SWNT 63 
(0.050 g) and the reaction mixture stirred for 48 h. The isolated product yielded 53 mg of material. 
IR (solid): ν (cm-1) 3500, 2911, 1699, 1647, 1151. 
Raman: ν (cm-1) 177, 1333, 1582, 2658. 
 
71. Ox- ethylenediamine SWNT 
 
The deprotection of product 71 was conducted in the same way as in 63. Shortly, product 66 was 
dispersed in DMF before the addition of conc. HCl (3.28 mL) to a 4 M final concentration. The 
dispersion was stirred at room temperature overnight. The suspension of SWNT was centrifuged for 30 
min at 3000 rcf, the supernatant removed, the solid re-suspended and filtered through a 0.2 µm 
membrane. The residue was washed with DMF and methanol. After drying in the oven overnight 32 mg 
of material were obtained.  
IR (solid): ν (cm-1) 3264, 1705, 1519. 
Raman: ν (cm-1) 277, 1343, 1583, 2660. 








72. Ox-hexylenediamine SWNT 
 
The experimental procedure followed was the same as in 71. Functionalised nanotubes 67 were stirred 
at room temperature overnight in a solution of 4 M HCl in DMF. The dried product yielded 40 mg of 
material. 
IR (solid): ν (cm-1) 3220, 1711, 1067. 
Raman: ν (cm-1) 181, 1344, 1585, 2670. 
Kaiser test: 0.23 mmol/g. 
 
73. Ox- pegdiamine SWNT 
 
The experimental procedure followed was the same as in 71. Functionalised nanotubes 68 were stirred 
at room temperature overnight in a solution of 4 M HCl in DMF. The dried product yielded 34 mg of 
material. 
IR (solid): ν (cm-1) 3106, 1863, 1699, 1586, 1006. 
Raman: ν (cm-1) 198, 1345, 1587, 2674. 









74. Bz-hexylaa SWNT 
 
The same experimental procedure as in 71 was followed. Functionalised nanotubes 69 were dispersed 
in HCl 4 M in DMF (10 mL) and stirred overnight at room temperature. The isolated product yielded 
42 mg of material.  
IR (solid): ν (cm-1) 3300, 1696, 1041. 
Raman: ν (cm-1) 166, 1334, 1580, 2653. 
Kaiser test: 0.25 mmol/g. 
 
75. Bz-undecaa SWNT 
 
The same experimental procedure as in 71 was followed. Isolated material 52 mg. 
IR (solid): ν (cm-1) 3367, 2889, 1672, 1062. 
Raman: ν (cm-1) 166, 1336, 1580, 2653. 
Kaiser test: 0.24 mmol/g. 
 
76. Ox-ethylenediamine-COOH SWNT17 
 
Ethylenediamine-functionalised SWNT (71) (20 mg) were dispersed in 15 mL dry THF by 30 min. 
sonication. Succinic anhydride (40 mg, 0.40 mmol), DMAP (0.049 g, 0.40 mmol) and triethylamine 




(0.040 g, 0.04 mmol) were added to the mixture and the solution stirred at room temperature for 24 h. 
The dispersion was centrifuged at 3000 rcf for 20 min., the supernatant discarded and the residue 
re-suspended in water and filtered through a 0.2 µm membrane. The solid was washed with water, 1 M 
HCl aq. and methanol. The product was dried in the oven yielding 18 mg of material.  
IR (solid): ν (cm-1) 3257, 2900, 1695, 1624, 1042.  
Raman: ν (cm-1) 188, 1352, 1570, 2670, 3139.  
TGA, mass loss at 500 ºC: 21.7%.  
 
77. Ox-hexylenediamine-COOH SWNT 
 
The same experimental procedure as in 76 was followed. Hexamethylenediamine-functionalised SWNT 
(72) (20 mg) were dispersed in dry THF (15 mL) and succinic anhydride (40 mg, 0.40 mmol), DMAP 
(0.049 g, 0.40 mmol) and triethylamine (0.040 g, 0.04 mmol) added. The dried product yielded 16 mg 
of material. 
IR (solid): ν (cm-1) 3200, 1705, 1702, 1050. 
Raman: ν (cm-1) 171, 1339, 1574, 2680, 3146. 
TGA, mass loss at 500 ºC: 22.0%.  
 
78. Ox- pegdiamine-COOH SWNT 
 
The same experimental procedure as in 76 was followed. 2,2′-(Ethylenedioxy)bis(ethylamine)-
functionalised SWNT (73) (20 mg) were dispersed in dry THF (15 mL) and succinic anhydride (40 mg, 
0.40 mmol), DMAP (0.048 g, 0.40 mmol) and triethylamine (0.040 g, 0.04 mmol) added. The dried 
product yielded 16 mg of material. 




IR (solid): ν (cm-1) 1705, 1634, 1521. 
Raman: ν (cm-1) 167, 1334, 1571, 2641, 3145. 
TGA, mass loss at 500 ºC: 28.2%.  
 
79. Bz-hexylaa-COOH SWNT 
 
The same experimental procedure as in 76 was followed. Functionalised SWNT 74 (20 mg) were 
dispersed in dry THF (15 mL) and succinic anhydride (40 mg, 0.40 mmol), DMAP (0.048 g, 0.40 mmol) 
and triethylamine (0.040 g, 0.040 mmol) added. The dried product yielded 15.4 mg of material. 
IR (solid): ν (cm-1) 3254, 1700, 1001. 
Raman: ν (cm-1) 183, 1331, 1573, 2656, 3167. 
TGA, mass loss at 500 ºC: 17.3%. 
 
80. Bz-Boc-undecaa SWNT 
 
The same experimental procedure as in 76 was followed. Functionalised SWNT 75 (20 mg) were 
dispersed in dry THF (15 mL) and succinic anhydride (40 mg, 0.40 mmol), DMAP (0.048 g, 0.40 mmol) 
and triethylamine (0.040 g, 0.04 mmol) added. The dried product yielded 19 mg of material. 
IR (solid): ν (cm-1) 3200, 1685, 1644, 1050. 
Raman: ν (cm-1) 165, 1337, 1578, 2663, 3164. 
TGA, mass loss at 500 ºC: 19.6%.  
 
 




81. Graphene oxide (GO) 
 
Graphene oxide was prepared by Dr Boyang Mao following a procedure reported in the literature from 
graphite powder converted in graphite oxide following a modified Hummers method.18 Shortly, graphite 
powder and sodium nitrate were stirred in sulphuric acid. The mixture was cooled to 0 ºC, potassium 
permanganate added and the temperature allowed to rise to room temperature to be diluted with water. 
Hydrogen peroxide was added to the dispersion and the suspension was filtered through a 0.2 µm 
polycarbonate membrane. A dialysis process was used to remove any remaining salts before further 
filtering, washing and drying the resulting graphite oxide. Graphene oxide was subsequently prepared 
by sonication cycles. The non-dispersed material was removed by centrifugation. 
IR (solid): ν (cm-1) 3200, 1718, 1620, 1177, 1043. 




Graphene oxide (56 mg) was dispersed in DMF by 5 min sonication. EDC·HCl (0.100 g, 0.60 mmol), 
HOBt (0.104 g, 0.77 mmol) followed by protected amine 3 (0.191 g, 0.77 mmol). The reaction mixture 
was stirred at room temperature for 48 h. The resulting suspension was filtered through a 0.2 µm 
polycarbonate membrane and washed with DMF and MeOH. The solid was dried at 60 ºC. The product 
was obtained as a black solid (60 mg). 
IR (solid): ν (cm-1) 3544, 3130, 1698, 1573, 1002. 











Product 82 was dispersed in a solution of HCl 4 M in DMF and stirred at room temperature during 16 h. 
The resulting suspension was filtered through a 0.2 µm membrane and washed with DMF. The solid 
was re-suspended by sonication, filtered and washed with a large amount of water until the pH of the 
filtrate was neutral. The solid was further washed with methanol and dried under vacuum and at 60 ºC. 
The product was obtained as a black solid (46 mg). 
IR (solid): ν (cm-1) 3200, 1708, 1618 1350, 1235. 
Raman: ν (cm-1) 1379, 1580. 




Product 83 (30 mg) was dispersed in a 5:1 mixture of dry DMF and dry THF. Succinic anhydride (0.060 
g, 0.60 mmol), triethylamine (83 µL, 0.60 mmol) and DMAP (0.073 g, 0.60 mmol) were added and the 
reaction mixture was stirred for 24 h at room temperature. The reaction mixture was filtered through a 
0.2 µm membrane and washed with THF, DMF and methanol. The product was dried under vacuum 
and in the oven at 60 ºC. The product was isolated as a black solid (27 mg). 
IR (solid): ν (cm-1) 3230, 1708, 1643, 1561, 1348, 1214. 











85. Bombesin [7-13] (L-glutaminyl-L-tryptophyl-L-alanyl-L-valylglycyl-L-histidyl-L-leucine) 
 
The [7-13] fragment of bombesin was synthesised by SPPS using a Biotage Initiator 2.5 microwave 
reactor and a rink amide resin as a solid support (1.011 g, 0.60 mmol). First, the resin was swelled in 
dichloromethane and DMF. The deprotection of the resin was carried out in piperidine/DMF 1:4 in three 
cycles heating at 75 ºC for 10 minutes, 3 minutes and 3 minutes. The resin was washed between steps 
with dichloromethane and DMF. The coupling steps were carried out with an excess of the amino acid 
(1.79 mmol, 3 eq.), HATU (1.79 mmol, 3 eq.), HOBt (1.79 mmol, 3 eq.) in DIPEA (4.18 mmol, 7 eq.) 
and DMF (5 mL). The reaction mixture, once homogenised, was heated at 75 ºC for 10 minutes except 
in the case of His that was coupled at room temperature for 2 h. The deprotection after each coupling 
step was carried out in piperidine/DMF heating at 75 ºC for 10 minutes. The resin was washed with 
dichloromethane and DMF after each coupling and deprotection step and the efficiency of the coupling 
assessed by the Kaiser test using some resin beads. Finally, the cleavage of the peptide from the resin 
was performed using a cleavage cocktail containing TFA/phenol/H2O/TIPS (88:5:5:2). The reaction 
mixture was stirred for 2.5 h at room temperature and the peptide precipitated in cold diethyl ether and 
dried. The crude was purified by automated flash column chromatography using a C18 cartridge 
(method C) and lyophilised from acetic acid to yield a white solid. 
1H NMR (500 MHz, D2O, 25 ºC): δ 8.51 (brs, 1H, H-2, His), 7.64 (d, 
3J = 7.9 Hz, 1H, H-7, Trp), 7.51 
(d, 3J = 8.2 Hz, 1H, H-4, Trp), 7.29 – 7.24 (m, 1H, H-5, Trp), 7.20 (brs, 1H, H-4, His), 7.17 (t, 3J = 7.6 
Hz, 1H, H-6, Trp), 4.72 (t, 3J = 7.1 Hz, 1H, αCH, His), 4.65 (t, 3J = 7.2 Hz, 1H, αCH, Trp), 4.35 – 4.25 
(m, 2H, αCH, Ala, Leu), 4.02 (t, 3J = 6.7 Hz, 1H, αCH, Gln), 3.99 – 3.89 (m, 3H, CH2 Gly, αCH Val), 
3.36 – 3.20 (m, 2H, βCH2, His), 3.20 – 3.11 (m, 2H, βCH2, Trp), 2.40 (t, 
3J = 7.5 Hz, 2H, γCH2, Gln), 
2.18 – 2.07 (m, 2H, βCH2, Gln), 2.05 – 1.98 (m, 1H, βCH, Val ), 1.70 – 1.61 (m, 1H, βCH2, γCH, Leu), 
1.62 – 1.53 (m, 2H, βCH2, γCH, Leu), 1.30 (d, 
3J = 7.2 Hz, 3H, CH3¸Ala), 0.97 (d, 
3J = 6.7 Hz, 3H, 
CH3¸Val), 0.95 (d, 
3J = 6.7 Hz, 3H, CH3’, Val), 0.92 (d, 
3J = 5.7 Hz, 3H, CH3, Leu), 0.86 (d, 
3J = 5.7 
Hz, 3H, CH3’, Leu). 
HPLC (Method B): Rt (min) 6.80. 
Mass spectrum: ESI-MS calc. for C38H55N11NaO9 [M+Na]+: 831.4004; found: 831.4242. 
 








BODIPY 57 (46 mg, 65 µmol) was dissolved in DMF (0.5 mL) and DIPEA (15 µL, 86 µmol) added 
followed by pyBOP (39 mg, 75 µmol). The reaction mixture was stirred at room temperature for 2 h and 
[7-13]-bombesin (17 mg, 22 µmol) dissolved in 0.5 mL DMF, added. The temperature was raised to 
60 ºC and the reaction stirred for 20 h. The crude was purified by semi-preparative HPLC using method 
C. The product was obtained as a red solid (14 mg, 44%). 
HPLC (Method B): Rt (min) 8.76. 





Compound 86 (19 mg, 12 µmol) was dissolved in piperidine/DMF 1:4 (total volume: 2 mL) and the 
reaction mixture stirred at room temperature for 1 h until the reaction was completed as confirmed by 
HPLC. The reaction mixture was washed with hexane and the DMF crude purified by semi-preparative 
HPLC (method C). The product was obtained as a red powder (16 mg, quant.).  
1H NMR (500 MHz, CD3OD, 25 ºC): δ 8.73 (d, 
4J = 1.4 Hz, 1H, H-2 His), 8.02 (d, 3J = 8.4 Hz, 2H, H-
3 BD), 7.56 (dt, 3,4J = 7.9, 1.0 Hz, 1H, H-7 Trp), 7.46 – 7.43 (m, 2H, H-4 BD), 7.34 – 7.32 (m, 1H, H-4 




His), 7.30 (dt, 3,4J = 8.1, 0.9 Hz, 1H, H-4 Trp), 7.21 (s, 1H, H-2 Trp), 7.05 (ddd, 3,3,4J = 8.1, 7.0, 1.2 Hz, 
1H, H-5 Trp), 6.97 (ddd, 3,3,4J = 8.1, 7.0, 1.1 Hz, 1H, H-6 Trp), 6.09 (s, 2H, H-9), 4.68 (dd, 3,3J = 7.4, 
5.5 Hz, 2H, αCH His, Trp), 4.43 – 4.33 (m, 3H, αCH Gln, Ala, Leu), 4.00 (d, 3J = 7.3 Hz, 1H, αCH Val), 
3.90 (d, 2J = 16.8 Hz, 1H, Gly), 3.85 (t, 3J = 6.6 Hz, 1H, αCH Lys), 3.79 (d, 2J = 16.8 Hz, 1H, Gly), 3.41 
– 3.35 (m, 2H, εCH2 Lys), 3.22 – 3.09 (m, 2H, βCH, His, Trp), 2.49 (s, 6H, H-8 BD), 2.30 (t, 
3J = 7.6 
Hz, 2H, γCH2 Gln), 2.09 – 1.95 (m, 2H, βCH2 Gln), 1.86 – 1.76 (m, 2H, βCH2 Lys), 1.73 – 1.65 (m, 1H, 
γCH Leu), 1.64 – 1.55 (m, 3H, δCH2 Lys, βCH Leu), 1.49 – 1.38 (m, 2H, γCH2 Lys), 1.39 (s, 6H, H-10 
BD), 1.26 (d, 3J = 7.1 Hz, 3H, CH3 Ala), 0.98 – 0.95 (m, 6H, iPr Val). 0.94 (d, 
3J = 6.5 Hz, 3H, CH3 
Leu), 0.91 (d, 3J = 6.4 Hz, 3H, CH3’ Leu). 
Mass spectrum: ESI-MS calc. for C64H84BF2N15O11 [M+H]+: 1287.6536; found: 1287.6445. 




Functionalised SWNT 78 (3 mg) were dispersed in DMF (1.5 mL) and DIPEA (25 µL) by sonication 
for 15 min. PyBOP (21 mg, 40 µmol) was added and the reaction mixture stirred at room temperature 
for 4 h. The dispersion was filtered through a 0.2 µm polycarbonate membrane to remove excess of 
pyBOP and re-suspended in DMF (1.5 mL). BODIPY 58 (4 mg, 8 µmol) was added to the dispersion 
dissolved in DMF (0.5 mL) and the reaction mixture stirred at room tempereature for 48 h. The 
suspension was centrifuged for 10 min at 14,000 rpm, the supernatant removed, the solid residue 
re-suspended in MeOH, sonicated for 3 min and the process repeated several times. The dispersion was 
filtered through a 0.2 µm membrane, washed with DMF, MeOH, re-suspended in MeOH, sonicated for 
3 min and filtered again. This process was repeated at least 4 times. In the last step, the solid was left 
drying under vacuum. The product was obtained as a black solid (4 mg). 
IR (solid): ν (cm-1) 3286, 2949, 1713, 1643, 1022. 











Nanoprobe 89 was prepared following the experimental procedure of 88. Functionalised SWNT 78 
(3 mg) were dispersed in DMF (1.5 mL) and DIPEA (25 µL). PyBOP (6 mg, 12 µmol) was added and 
the reaction mixture stirred at room temperature for 4 h. After removing the excess of pyBOP, conjugate 
87 (3 mg, 2 µmol) was added. The product was obtained as black solid (5 mg). 
IR (solid): ν (cm-1) 3299, 2948, 1713, 1638, 1032. 
Raman: ν (cm-1) 149, 1339, 1579, 2660. 
 
90. BOD-BBN-SWNT 2 
 
Nanoprobe 90 was prepared following the experimental procedure of 88. Functionalised SWNT 79 
(4 mg) were dispersed in DMF and DIPEA (25 µL) by sonication. PyBOP (6 mg, 12 µmol) added and 




the reaction mixture stirred for 4 h. The excess of pyBOP was removed by filtration and conjugate 87 
(3 mg, 2 µmol) was added. The product was obtained as a black solid (4 mg).  
IR (solid): ν (cm-1) 3356, 2947, 1643, 1032. 
Raman: ν (cm-1) 183, 1333, 1575, 2651. 
 
91. SWNT Ga(III)BTSC 
 
Nanoprobe 91 was prepared in a similar way as 88. Functionalised SWNT 78 (5 mg) and DIPEA (25 µL) 
were dispersed in DMF (1 mL) by sonication. PyBOP (37.4 mg, 72 µmol) was added and the reaction 
mixture stirred at room temperature for 2 h. Gallium complex 23 (7 mg, 14 µmol) was added to the 
reaction mixture dissolved in DMF (1 mL) and the reaction mixture stirred at room temperature for 48 h. 
The product was obtained as a black solid (3 mg). 




Graphene oxide derivative 84 (4 mg) and DIPEA (25 µL) were suspended in DMF and the mixture 
homogenised by sonication for 3 min. PyBOP (0.026 g, 50 µmol) was added and the reaction mixture 
stirred at room temperature for 4 h. BODIPY 58 (5 mg, 10 µmol) was added and the resulting suspension 
was stirred at room temperature for 48 h. The excess of fluorophore was removed by various cycles of 
centrifugation at 10,000 rpm for 15 min and washing with DMF. The solid was then re-suspended in 
DMF and filtered through a 0.2 µm membrane to be washed with DMF and MeOH before being dried 




under vacuum. The product was obtained as a black solid (1 mg). 
IR (solid): ν (cm-1) 3200, 1721, 1619, 1353, 1062. 




Graphene oxide derivative 84 (3 mg) and DIPEA (25 µL) were suspended in DMF and the mixture 
homogenised by sonication for 3 min. PyBOP (0.010 g, 19 µmol) was added and the reaction mixture 
stirred at room temperature for 4 h. Conjugate 87 (3 mg, 2 µmol) was added and the resulting suspension 
was stirred at room temperature for 48 h. The excess of conjugate was removed by various cycles of 
centrifugation at 10,000 rpm for 15 min and washing with DMF. The solid was then re-suspended in 
DMF and filtered through a 0.2 µm membrane to be washed with DMF and MeOH before being dried 
under vacuum. The product was obtained as a black solid (1 mg). 
IR (solid): ν (cm-1) 3200, 1618, 1354, 1218, 1062. 




Graphene oxide derivative 84 (4 mg) and DIPEA (25 µL) were suspended in DMF and the mixture 




homogenised by sonication for 3 min. PyBOP (0.026 g, 51 µmol) was added and the reaction mixture 
stirred at room temperature for 4 h. Ga(III) bis(thiosemicarbazonato) complex 23 (5 mg, 10 µmol) was 
added and the resulting suspension was stirred at room temperature for 48 h. The excess of complex was 
removed by various cycles of centrifugation at 10,000 rpm for 15 min and washing with DMF. The solid 
was then re-suspended in DMF and filtered through a 0.2 µm membrane to be washed with DMF and 
MeOH before being dried under vacuum. The product was obtained as a black solid (4 mg). 
IR (solid): ν (cm-1) 3200, 1711, 1646, 1386, 1060. 
Raman: ν (cm-1) 1352, 1586. 
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Figure 27: NOESY (CD3OD) spectrum of 53. 
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Appendix B. X-ray crystallography data 
 
Intensity data for 12, 43 and 52 were collected at 150(2) K on an Agilent SuperNova Dual, Cu at zero, 
EosS2 diffractometer and using monochromated Cu-K radiation  = 1.54184 Å. 
Intensity data for 40, 41 and 42 were collected at 150(2) K on a Rigaku New Xcalibur, EosS2 
diffractometer using graphite monochromated Mo-Kradiation = 0.71073 Å. 
 
Intensity data for 11 were collected at the National Crystallography Service (University of Southampton) 
at 293(2) K on a AFC-12 diffractometer equipped with a Rigaku Saturn 724 CCD detector using 
monochromated Mo-Kα radiation α = 0.71073 Å. 
 
All structures were solved with SHELXT and refined by a full-matrix least-squares procedure based on 
F2 (Shelxl-2014/7).1 All non-hydrogen atoms were refined anisotropically.  
 
Hydrogen atoms were placed onto calculated positions and refined using a riding model except for the 
OH hydrogen atoms which have been located in the difference Fourier map and were refined with bond 
lengths restraints.  
 
Additional programmes used for analysing data and their graphical manipulation included: SHELXle2 
and ORTEP 3 for windows3. 
  
  
                                                     
1 Sheldrick, Acta Crystallographica Section C, 2015, 71, 3-8. 
2 C. B. Hubschle, G. M. Sheldrick and B. Dittrich, J. Appl. Crystallogr., 2011, 44, 1281-1284. 
3 Farrugia, J. Appl. Crystallogr., 1997, 30, 565 




Crystal Data and structure refinement for 11 
 
Identification code  FCT090 
Empirical formula  C20 H23 N4 O3.5 S 
Formula weight  407.48 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2/n 
Unit cell dimensions a = 17.9444(13) Å = 90° 
 b = 5.6177(4) Å = 104.650(3)° 
 c = 20.2368(14) Å  = 90° 
Volume 1973.7(2) Å3 
Z 4 
Density (calculated) 1.371 Mg/m
3
 




Crystal size 0.350 x 0.060 x 0.010 mm
3
 
Theta range for data collection 4.16 to 55.1° 
Index ranges -23<=h<=23, -7<=k<=6, -26<=l<=26 
Reflections collected 22629 
Independent reflections 4542 [R(int) = 0.0845] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Multi-scan 
Max. and min. transmission 1.000 and 0.456 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4542 / 0 / 274 
Goodness-of-fit on F2 1.369 
Final R indices [I>2sigma(I)] R1 = 0.1044, wR2 = 0.3248 
R indices (all data) R1 = 0.1433, wR2 = 0.3647 
Extinction coefficient n/a 












Crystal Data and structure refinement for 12 
 
Identification code  s15sip1 
Empirical formula  C24 H30 N4 O3 S 
Formula weight  454.58 
Temperature  150(2) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 21.7348(4) Å = 90° 
 b = 11.8244(2) Å = 91.497(2)° 





Density (calculated) 1.278 Mg/m
3
 




Crystal size 0.250 x 0.200 x 0.010 mm
3
 
Theta range for data collection 4.257 to 72.189°. 
Index ranges -26<=h<=26, -13<=k<=14, -11<=l<=7 
Reflections collected 17176 
Independent reflections 4588 [R(int) = 0.0451] 
Completeness to theta = 67.684° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.61870 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4588 / 0 / 304 
Goodness-of-fit on F2 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0512, wR2 = 0.1354 
R indices (all data) R1 = 0.0584, wR2 = 0.1426 
Extinction coefficient n/a 













Crystal Data and structure refinement for 40 
 
Identification code  e15sip4 
Empirical formula  C36 H26 N6 O2 S2 
Formula weight  638.75 
Temperature  150.00(10) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 7.378(2) Å = 90° 
 b = 21.882(7) Å = 94.82(3)° 





Density (calculated) 1.439 Mg/m
3
 




Crystal size 0.200 x 0.100 x 0.050 mm
3
 
Theta range for data collection 3.339 to 25.385°. 
Index ranges -8<=h<=8, -26<=k<=24, -11<=l<=5 
Reflections collected 5780 
Independent reflections 2692 [R(int) = 0.1250] 
Completeness to theta = 25.242° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.98133 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 2692 / 2 / 218 
Goodness-of-fit on F2 0.978 
Final R indices [I>2sigma(I)] R1 = 0.0906, wR2 = 0.1092 
R indices (all data) R1 = 0.2388, wR2 = 0.1613 
Extinction coefficient n/a 










Crystal Data and structure refinement for 41 
 
Identification code  e15sip3 
Empirical formula  C19 H15 N3 O S 
Formula weight  333.40 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 7.8711(4) Å  = 90° 
 b = 21.9365(13) Å = 99.273(5)° 
 c = 9.3107(6) Å   = 90° 
Volume 1586.62(16) Å 
Z 4 
Density (calculated) 1.396 Mg/m
3
 




Crystal size 0.400 x 0.220 x 0.180 mm
3
 
Theta range for data collection 3.561 to 29.378°. 
Index ranges -10<=h<=10, -28<=k<=29, -12<=l<=12 
Reflections collected 14236 
Independent reflections 3839 [R(int) = 0.0309] 
Completeness to theta = 25.242° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.90874 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3839 / 12 / 244 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0494, wR2 = 0.1126 
R indices (all data) R1 = 0.0664, wR2 = 0.1210 
Extinction coefficient n/a 









Crystal Data and structure refinement for 42 
 
Identification code  e15sip2 
Empirical formula  C20 H15 N3 O S 
Formula weight  345.41 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.1032(3) Å  = 79.553(3)° 
 b = 9.0297(3) Å  = 87.125(3)° 





Density (calculated) 1.430 Mg/m
3
 




Crystal size 0.300 x 0.300 x 0.200 mm
3
 
Theta range for data collection 3.512 to 29.244°. 
Index ranges -10<=h<=10, -12<=k<=12, -14<=l<=15 
Reflections collected 20946 
Independent reflections 4026 [R(int) = 0.0291] 
Completeness to theta = 25.242° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.97450 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4026 / 0 / 234 
Goodness-of-fit on F2 1.102 
Final R indices [I>2sigma(I)] R1 = 0.0437, wR2 = 0.1141 
R indices (all data) R1 = 0.0508, wR2 = 0.1180 
Extinction coefficient n/a 










Crystal Data and structure refinement for 43 
 
Identification code  s15sip8 
Empirical formula  C23 H15 N3 O S 
Formula weight  381.44 
Temperature  150(2) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 5.84390(10) Å = 90° 
 b = 25.4324(3) Å = 98.9650(10)° 





Density (calculated) 1.429 Mg/m
3
 




Crystal size 0.300 x 0.150 x 0.080 mm
3
 
Theta range for data collection 3.476 to 72.591°. 
Index ranges -7<=h<=7, -31<=k<=30, -12<=l<=14 
Reflections collected 19536 
Independent reflections 3525 [R(int) = 0.0325] 
Completeness to theta = 67.684° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.72375 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3525 / 0 / 261 
Goodness-of-fit on F2 1.064 
Final R indices [I>2sigma(I)] R1 = 0.0314, wR2 = 0.0813 
R indices (all data) R1 = 0.0334, wR2 = 0.0827 
Extinction coefficient n/a 










Crystal Data and structure refinement for 52 
 
Identification code  s16sip6 
Empirical formula  C24 H22 B F2 N3 O4 
Formula weight  465.25 
Temperature  150.00(10) K 
Wavelength  1.54184 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.7311(2) Å = 98.686(3)° 
 b = 10.4072(3) Å = 96.430(3)° 





Density (calculated) 1.429 Mg/m
3
 




Crystal size 0.150 x 0.150 x 0.040 mm
3
 
Theta range for data collection 2.772 to 73.489°. 
Index ranges -5<=h<=8, -12<=k<=12, -20<=l<=20 
Reflections collected 12844 
Independent reflections 4336 [R(int) = 0.0256] 
Completeness to theta = 67.684° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.73067 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4336 / 0 / 311 
Goodness-of-fit on F2 1.040 
Final R indices [I>2sigma(I)] R1 = 0.0386, wR2 = 0.0974 
R indices (all data) R1 = 0.0466, wR2 = 0.1027 
Extinction coefficient n/a 
Largest diff. peak and hole 0.288 and -0.222 e.Å
-3
 
 
 
 
